<SEC-DOCUMENT>0001610618-22-000042.txt : 20220511
<SEC-HEADER>0001610618-22-000042.hdr.sgml : 20220511
<ACCEPTANCE-DATETIME>20220511160620
ACCESSION NUMBER:		0001610618-22-000042
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220511
DATE AS OF CHANGE:		20220511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		22913701

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cdtx-20220331.htm
<DESCRIPTION>CIDARA THERAPEUTICS, INC. FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:8627cbaf-6f66-4b32-bb14-4a9dea57dc11,g:21d3a7c8-7ecf-40b1-a09c-92da8f218d01,d:12928d5708484b01a3ce462a99216eeb--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cdtx="http://cidara.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdtx-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF8zLTEtMS0xLTMwMzUx_4a6b0b4e-8a05-4003-bba1-fc48bb5209f6">false</ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF80LTEtMS0xLTMwMzUx_1c7ff4c0-19a8-4cee-bcbd-954ec3704db2">2022</ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF81LTEtMS0xLTMwMzUx_2fb96d12-edbe-41dc-ab84-746e20e87c74">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF82LTEtMS0xLTMwMzUx_8e10f395-0e29-412a-84f6-86f77eea7d93">0001610618</ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF83LTEtMS0xLTMwMzUx_1d4cdba9-d15f-4ec2-9640-9319f81b9fa8">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_86037227-b16d-461a-8143-948ba4f1025f">http://cidara.com/20220331#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_8a3b3de7-da47-4d52-a743-ea2ee0014004">http://cidara.com/20220331#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_9cd6c1ef-ede4-4be7-85be-696217c96ca5">http://cidara.com/20220331#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_ae2b0c7e-d3fd-4c73-b2ea-1dbaad18b7f6">http://cidara.com/20220331#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="iae0fb3f8928942308d937ccfcd35d926_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTIzNw_5527d6f8-bbd7-4b20-ac44-ff096fb03762">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="iebf1af9bc014431a9d173becef761d0e_D20150301-20150331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTQ2NQ_7675637d-1608-4a23-aa34-7b6bb8a8e302">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i051d9f3eac064cabb12542bb0d83033e_D20190903-20190903" decimals="INF" name="cdtx:CollaborativeArrangementCostSharingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81Mi9mcmFnOmM0OTY0MmFlOGVlOTQzOWU5NTdjNzAwM2UxZjdhNjZlL3RleHRyZWdpb246YzQ5NjQyYWU4ZWU5NDM5ZTk1N2M3MDAzZTFmN2E2NmVfNTM_2a567704-bb7c-44ac-a6c2-12446c599271">0.50</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdtx-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c51335a81484dfb9629cbe37cd15f71_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic36326a3df014b8d992c03bd0101de68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca662309536454c8fc2ec20aa598bfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed4d780fa7c4657ace1ca39915c5db9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i594ac01243ff48a294a5691f8bb16ec7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae401fe1ec94508a4c3bc1de6b123a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29d0679e5a849fd8f0b328b0047051f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01e075b04cda432ea3e0bb290da8aa76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5be7deff5c45d58b2dabd268641ffa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie249caef64f94171b3f97f31b1702323_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffef7cfce9f74e188e663bb9b9e5a2b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90d7c5734cb4948aae78ef94bf77084_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078bfa49848346d5a1e3ebef80a9bf83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98e2da648634bd2abb09e30b07febad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbfbe505a42456b8b907a1ce48ce8f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2d9cef5eea4c869286d364c1fc6da0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75db0cf998d34c4f90645b2615a44ae4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib20007356f9d4ba5be34c0e5c7493ff3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f61e4e8ab114e4e8fa4705c380ffc10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52015336fa754888b0567c048a6a08cd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51fadbb95d64d119839876c70af802f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf01e9ab4d5447ae8695372ee5c96045_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie313ed150dbb4af980047e1f2ca2e27c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3325f5645b9b4b7f988048d9368cbd44_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i570e663b09344feb9ff09e6ddb45fead_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cdtx:segment</xbrli:measure></xbrli:unit><xbrli:context id="iae0fb3f8928942308d937ccfcd35d926_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21169da961a642269defd386e1909c8e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i95f5fe2a729b4d4b88d79c8b9f71926b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a37a66cd6249378b32ab50166895a0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa023587c32497cbf47ee68d3cbfb01_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900152b8dae048ce8a4acda17d7bcb77_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c94bb11270499696b1406f63c1b83d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5153e1e8ab48e49acff0d1756e5388_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c6cdf33b80446aa3a77138caa526a0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i041a511ce516484886b5ffe0acef8f8e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa38f920be7245f686abc0a371da8a87_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b73da715794f18af42e513a2842fb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic713e533dda046afa29b8024f40c66d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795c9fa22a224d2bbd52d8f2fe81648b_I20161003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46940802d05a44c78644bacf035f8ab4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6621b987d56742bdb57725ac1faabdbb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c8f58bd982422a986ef78bf58fc3ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0195058d79fa431882538deea9d40134_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc4656677c945bea6a7f93277e0065d_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51f2518f48844149c35fadeee45c717_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0b0517b28c459d84c79bff7bdcb54e_I20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0df47124083a4f99a0e151684e8f154c_I20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1eb42daf54d4b668a360dcc81934f30_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55bdd2d5589d4fe7b0309fed8211b8a8_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69448e0c7d0b4165bc50aaf98eb14d71_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280b1d43fcd44cc3b820c5ccce18586b_D20200812-20200812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-12</xbrli:startDate><xbrli:endDate>2020-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc285ca9fc0947889305e6be663b5ce3_D20200812-20200812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-12</xbrli:startDate><xbrli:endDate>2020-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1567b76bf14270856d0e77828b3edd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>cdtx:vote</xbrli:measure></xbrli:unit><xbrli:context id="i1202dce605be4c82a0a70d95af7a8593_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5971b45c3a7c412c88e46aa2b80a5a6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f8aa79b2a034ff484490a0f9ed5005a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic27040cee9f64227942f86974dfc7e07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67507a3641814df4b10e074a32b49c2e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd0f0932ef8490bb6c1d6b126581749_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0d4f2214a74513a73c71607fd17646_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id49a49faa40b4317b2251637999b3844_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3394b2a276ce4f24a740ba07a69873e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef9aeb2eaab46cf8f2dc459329f1dab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6500728b40904350a970627b377ddbb0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieab45868d7b34980921f34867b165abc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71eefcf9d68457782ef30c211def3a7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378b0ff196374173acefdb91629cc588_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a0dd60e595d4d90b99db4dfcc03e925_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf1af9bc014431a9d173becef761d0e_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6dd61a92f24717a10f0e25c4e1a31f_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720b8558f3114a66b3afb7ddb6acfbda_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b84d00a866d4c51b68551b7e95373d5_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fbce54647a341fba1a08f3e3d01f687_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64417209e6a7431e9641d70ebaa9d805_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720f7ca4cb4d47c797738cd1efd27be0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7725d535d6df481ba4eb64e1f9497bb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36320806fa3c4b5f9432d569a7254fb3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d982e5d0cc6497c854d56be2b7a9838_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if93aa19e1f944c0c881474a93809cb2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i228ae513e4d048c1b3d1b4222fab3750_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f64292f9a6949a8b73b0d21cbeefa6a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0284b9283584c6a98c2cf36c7b67635_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4d20a797ca4520be3b7156f337e50f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2950f3ff64498ea4482c1111550256_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1f47cfaf864b5b8449cf27f8903001_D20190903-20190903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-03</xbrli:startDate><xbrli:endDate>2019-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1b832c3bcc45ec9f16fa3306e87d89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59db54d089334f80bfc2bf1d019c720c_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68f5f47ae533474f9d58f357b7560076_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2c214fd2d34166a98231e78e89cb57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4961bcc2a42459fbdcff0f5d4ffbff3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857d96ec633a44e1b0ea653816686201_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be4c76c948d42acabc01f60c0e15d14_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:RDFundingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8dadaa504524767be44ca25b519478f_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41dc4db26c7d45a799666fc33080b4f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37c7f2020504762b3c04bc8f40f0ede_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbcdd3cc2a2e4827a4681f970f6d7389_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b63e51f2fb46699aee3fdf1e54a345_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79dab98a8e3e4d89a66719d5a46c5f73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie02b09de693048bc9accc5d0a7f832d4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4458c0ab6aa4e3aa31bee9f21e043b2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443dc61676d64544abd994b78e8e6267_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a1639fe6204e6f9c15a4b4242bfe9e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c53ce77870a41f5beea59ecd239000c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dad60c0f2e040f5b0673a6393394e63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87caf4dd1d234587aa8a86b0e5f01f6c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837f36bd31f84edca1439985d38c4717_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c225bd22cb4a8094a6e4710a63e69c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba15d9175213445a9632cc6854819319_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ce9e60ff6584997b9bbb0384ed6d8f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2edbac57ce84f7b9906d418d840a9f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57264f734480431092220a6ede4796c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615ceceeaed5466fb85286d706d29b85_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716d135486924cee81e022c6ac2e5d44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5e6adc3fef490dbca284a3b1c6289d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ba2d8537d1401aa4d567fbd40f5201_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie796a038ce0e48ce994e533569bf1dff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1fea76ca9d480da5ec1b4279d7de92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic368059479da424f931465560c9ec6ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8326f1cfdd2e45bda044cbe96cfa6825_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a7f4f7d381047d6b390662bf856366c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c0da6f182649489b0466ee3d5e1e90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e055b607f746a7bb4d400492c18aae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051d9f3eac064cabb12542bb0d83033e_D20190903-20190903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-03</xbrli:startDate><xbrli:endDate>2019-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida2575eac8b54cbd9b8d91895a8f0d63_I20210714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d38d95a623e4c7db64c6031f9fbdbde_D20210714-20210714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>cdtx:option</xbrli:measure></xbrli:unit><xbrli:context id="i7ab61c4680194901bbce5f08a8fd1c4c_I20220420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-20</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i12928d5708484b01a3ce462a99216eeb_1"></div><div style="min-height:30.6pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODgx_e79ea0a7-212c-482a-bd44-f994abd3f5aa">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6ZWY4ZmE5M2M4MjE0NGY2M2EyZjgxOGFjNmFkNjNkYjMvdGFibGVyYW5nZTplZjhmYTkzYzgyMTQ0ZjYzYTJmODE4YWM2YWQ2M2RiM18wLTAtMS0xLTMwMzUx_706a7d44-1a98-4654-9c09-90a1d26591e1">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xMzU_f9180fe2-5d31-4c61-8b6d-691f153954b7">MARCH&#160;31, 2022</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6MGIwYTg3OTEwYmE4NDk1Y2JlOThiNWNjNTUwMjIwODAvdGFibGVyYW5nZTowYjBhODc5MTBiYTg0OTVjYmU5OGI1Y2M1NTAyMjA4MF8wLTAtMS0xLTMwMzUx_5b9a3081-35c7-4303-87ec-744009650dbb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODc3_31d8eee7-dac4-4e96-b54a-1a6b0a9a7efe">001-36912</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODgz_64b2ca14-058c-4a78-9959-7197099a81d9">CIDARA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8wLTAtMS0xLTMwMzUx_43c1ae04-c697-4b81-b6c6-79fc824a5d5f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8wLTUtMS0xLTMwMzUx_04b541c2-13df-445a-a5ab-26a100090735">46-1537286</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8zLTAtMS0xLTMwMzUx_9dcc38e8-d7d5-4182-b585-f7e2fbd4769e">6310 Nancy Ridge Drive,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8zLTMtMS0xLTMwMzUx_2ca57ff4-138d-4da0-95c0-1f9647bca35c">Suite 101</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTAtMS0xLTMwMzUx_cb579e33-3c40-470a-bf46-0ed1a5abcaa9">San Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTEtMS0xLTMwMzUx_82512724-3e6e-42f7-8a21-3fbcbf59a3ab">CA</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTItMS0xLTMwMzUx_bad7e71d-9619-4be7-8566-b06772a62bd1">92121</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTUtMS0xLTMwMzUx_6133b653-da89-48c1-a693-ee218812462b">(858)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTYtMS0xLTMwMzUx_1ad196c2-3089-432b-81e3-f547cc80f3f6">752-6170</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices, including Zip Code)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:38.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6M2FhMDAwZDNhYzY2NDU2MzgyZWUxNWMxYjc4YjhjZjUvdGFibGVyYW5nZTozYWEwMDBkM2FjNjY0NTYzODJlZTE1YzFiNzhiOGNmNV8xLTAtMS0xLTMwMzUx_5561ba2c-ae8c-425e-b682-197a03ca3c8b">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6M2FhMDAwZDNhYzY2NDU2MzgyZWUxNWMxYjc4YjhjZjUvdGFibGVyYW5nZTozYWEwMDBkM2FjNjY0NTYzODJlZTE1YzFiNzhiOGNmNV8xLTItMS0xLTMwMzUx_f6bf048d-754f-4fef-957d-d38ae8e4eeb4">CDTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6M2FhMDAwZDNhYzY2NDU2MzgyZWUxNWMxYjc4YjhjZjUvdGFibGVyYW5nZTozYWEwMDBkM2FjNjY0NTYzODJlZTE1YzFiNzhiOGNmNV8xLTQtMS0xLTMwMzUx_03694a31-3e53-4ffa-9dd5-62690ee1aafc">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODg0_863d9a22-ae5a-43a6-907b-3b2dc113e5da">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODc4_2d747890-e4bd-4432-aac2-35cc0a66e3df">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6OWVkNzZiYWI1MDY4NGNlZmI2ZDVhZjUzYTE4ZTdlN2YvdGFibGVyYW5nZTo5ZWQ3NmJhYjUwNjg0Y2VmYjZkNWFmNTNhMThlN2U3Zl8yLTAtMS0xLTMwMzUx_df6f5289-e7b6-4b50-abe5-68230e1a0943">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6OWVkNzZiYWI1MDY4NGNlZmI2ZDVhZjUzYTE4ZTdlN2YvdGFibGVyYW5nZTo5ZWQ3NmJhYjUwNjg0Y2VmYjZkNWFmNTNhMThlN2U3Zl8yLTQtMS0xLTMwMzUx_193c67c4-1bf0-413a-8c41-66c0b024ce46">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6OWVkNzZiYWI1MDY4NGNlZmI2ZDVhZjUzYTE4ZTdlN2YvdGFibGVyYW5nZTo5ZWQ3NmJhYjUwNjg0Y2VmYjZkNWFmNTNhMThlN2U3Zl80LTQtMS0xLTMwMzUx_ca67f5a8-dcce-42e7-b71f-4b24354d742a">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODgw_57fcccde-25a4-44c0-9b3b-a0609b775cd0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of April&#160;29, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i3c51335a81484dfb9629cbe37cd15f71_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODIy_2d37c7f5-1b98-49f1-83ad-66b43e503bf8">69,049,497</ix:nonFraction> shares of Common Stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODUw_8b478aae-549a-4e2d-a19f-5136389dba24"><ix:nonFraction unitRef="usdPerShare" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODUw_d12bf858-1794-49fb-9a77-0ab91deae01e">0.0001</ix:nonFraction></ix:nonFraction> par value) outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:30.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_16">Condensed Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_22">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_25">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity for the three months ended March 31, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_61">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_61">23</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_82">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_82">33</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_85">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_85">33</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_88">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_85">33</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_91">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_91">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_94">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_94">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_127">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_127">72</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_130">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_130">73</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_133">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_133">73</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_136">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_136">73</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_139">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_139">74</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_142">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i12928d5708484b01a3ce462a99216eeb_142">75</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i12928d5708484b01a3ce462a99216eeb_13"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1. FINANCIAL STATEMENTS</span></div><div id="i12928d5708484b01a3ce462a99216eeb_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNC0xLTEtMS0zMDM1MQ_cb194f26-c0cf-41cf-bc0c-dc9aee4faf12">36,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNC0zLTEtMS0zMDM1MQ_81e8889b-01a5-437d-9bfe-c29379b7b3be">59,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNS0xLTEtMS0zMDM1MQ_16fe966c-9de2-4a55-bfc4-7b68f4baf91b">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNS0zLTEtMS0zMDM1MQ_ff1199f9-7bba-4a93-82a0-f39e6a44db0a">2,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNi0xLTEtMS0zMDM1MQ_63a8f60d-134e-4ffb-953a-e44aafebdf8b">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNi0zLTEtMS0zMDM1MQ_e9c9dabb-c211-411d-bf63-94bdd8d5d894">5,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNy0xLTEtMS0zMDM1MQ_22b96ac9-ebc2-40a7-8143-d7c2024eff14">5,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNy0zLTEtMS0zMDM1MQ_9df4bd79-47e2-4279-ad8b-ebcb0f28ff02">4,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOC0xLTEtMS0zMDM1MQ_afa18d15-b5f6-415b-955e-4220450047cb">52,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOC0zLTEtMS0zMDM1MQ_02c165a9-5070-4ef7-9f1f-c5a81349d0a1">71,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOS0xLTEtMS0zMDM1MQ_b4c52575-8021-4f12-922a-37ebf886db41">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOS0zLTEtMS0zMDM1MQ_9c196d4a-c020-4e46-aa42-f0fbb53489ff">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTAtMS0xLTEtMzAzNTE_aecc2adf-5fcf-464e-b460-b0339e4adb0e">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTAtMy0xLTEtMzAzNTE_74461d08-5b5f-41c2-9e8d-68053b37ed0b">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTEtMS0xLTEtMzAzNTE_8ce4bd22-d0e3-4dc2-b71f-acb835ef0db9">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTEtMy0xLTEtMzAzNTE_4f3fe3e7-0b51-4243-96ab-cadeef995807">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTItMS0xLTEtMzAzNTE_c00a4ebc-4695-4a3f-93bf-c1ffb9f2ed27">55,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTItMy0xLTEtMzAzNTE_e01e2a77-8261-4614-93a4-786d8e954764">75,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTYtMS0xLTEtMzAzNTE_2e0f5c95-8ec5-4559-8489-82b80fe897d3">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTYtMy0xLTEtMzAzNTE_fc418efc-e148-489c-8293-68328c3273d5">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTctMS0xLTEtMzAzNTE_2da19e45-185c-4ed1-9652-a6c76bfda4e0">9,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTctMy0xLTEtMzAzNTE_b0fbc6ec-33fc-4572-8f1f-4191b574c934">10,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTgtMS0xLTEtMzAzNTE_f57af066-6177-42a1-b64f-bb6019015587">3,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTgtMy0xLTEtMzAzNTE_7d8a96e0-0995-4702-8e73-254e817d71f9">4,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current deferred revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTktMS0xLTEtMzAzNTE_0c3c6009-d83d-4853-9936-3be8232de0c1">14,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTktMy0xLTEtMzAzNTE_cebe6857-1604-495f-851b-7028d3f177d9">13,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of term loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjAtMS0xLTEtMzAzNTE_0e7acc5e-ece7-478d-bf1b-670090241884">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjAtMy0xLTEtMzAzNTE_40451592-a9fb-4165-9af3-3aa7b9abcd57">2,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjEtMS0xLTEtMzAzNTE_be559129-a09b-4814-a45a-390462aa3027">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjEtMy0xLTEtMzAzNTE_ba1b1891-8057-463f-a192-9e57e8cafa88">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjItMS0xLTEtMzAzNTE_e5271e1f-e370-4550-93e5-28ec391f8d12">32,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjItMy0xLTEtMzAzNTE_e640380e-55bc-4a15-aacf-a658cf4e0b9e">34,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjMtMS0xLTEtMzAzNTE_59eea6c8-601b-467d-989b-a04a16ecb048">17,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjMtMy0xLTEtMzAzNTE_d25211dd-1220-4468-8a06-a8f8f188cf07">18,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjQtMS0xLTEtMzAzNTE_16d46831-eeb0-4bde-8691-97ba3bb635d1">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjQtMy0xLTEtMzAzNTE_05c123c5-26bc-4841-b75c-935077436b47">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjUtMS0xLTEtMzAzNTE_4f4b6ab4-6bf9-496b-9b0a-86cf51c829b0">50,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjUtMy0xLTEtMzAzNTE_b295fd02-b113-4341-bfc8-43fa6d2d7a03">53,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjYtMS0xLTEtMzAzNTE_bb54ff32-3b52-4956-b9b8-f3852310dfc3"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjYtMy0xLTEtMzAzNTE_ba465a02-1b38-4bb9-9121-c26f07fa6951"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8yMg_17e63a39-17e2-468f-a78d-8c0bdf28ba73"><ix:nonFraction unitRef="usdPerShare" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8yMg_913586a8-3037-47ce-b923-7c0b1ee5243b">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8zNg_6d7c0e02-0d2f-4ad2-b2b5-6c066992e6c9"><ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8zNg_d08600a8-f01c-4ed5-b764-983f24cd1511">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2022 and December&#160;31, 2021:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" xsi:nil="true" name="us-gaap:PreferredStockValue" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMS0xLTEtMzAzNTE_b84e5f52-e6ba-4c53-b930-3bc9ad4b863c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" xsi:nil="true" name="us-gaap:PreferredStockValue" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMy0xLTEtMzAzNTE_ef0939b3-6307-4ad8-8f28-4bcd299eaf6d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV80Mw_31585d79-6243-4eb4-931f-68608afa4692"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV80Mw_f1a756a0-b22b-4d18-bca1-d15371abedaa">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV81Nw_909fa249-6047-486e-b101-415737f4c5a9"><ix:nonFraction unitRef="shares" contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV81Nw_d19122d3-7b00-4772-a86d-fde3b6f836c1">4,947,759</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85Mg_1ad696a3-a2a1-4ed4-92bb-507acb278854"><ix:nonFraction unitRef="shares" contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85Mg_c084c67a-3d6e-45a0-af99-221a0948d269">1,870,713</ix:nonFraction></ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85OQ_6b2b6d45-2f14-428b-9cb9-49baf025e80c"><ix:nonFraction unitRef="shares" contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85OQ_def10892-c6ff-4887-bc72-3b4379966082">1,818,472</ix:nonFraction></ix:nonFraction> shares outstanding at March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMS0xLTEtMzAzNTE_16dd5a22-1b7c-4a28-8942-5304ca30324a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMy0xLTEtMzAzNTE_ab21dc09-ac25-4710-9ea4-6c9ea9ed1074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8xOQ_8b478aae-549a-4e2d-a19f-5136389dba24"><ix:nonFraction unitRef="usdPerShare" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8xOQ_d12bf858-1794-49fb-9a77-0ab91deae01e">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8zMw_5a169051-9e96-448d-9425-f5c0e111b370"><ix:nonFraction unitRef="shares" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8zMw_9679fbbf-a0fa-4913-a38b-edc2a8e0534c">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl82OA_2add9378-913f-47da-b591-b73708de97b9"><ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl82OA_72fd81c9-9fbb-4a8c-a347-53dfc48af7d3">69,049,247</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl83NQ_f76bbf6d-f964-4b18-82f7-b7efb0e57048"><ix:nonFraction unitRef="shares" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl83NQ_f9ed5a62-e3e2-4dad-b9c4-85226773871a">67,863,674</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMS0xLTEtMzAzNTE_fa1ca59f-a7f0-41ff-8bdf-00ed81934ff5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMy0xLTEtMzAzNTE_25bbc6d7-eade-4f4a-a503-46551b8d0810">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzEtMS0xLTEtMzAzNTE_c0950811-ecc5-41b4-8a74-232dce5b6b92">400,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzEtMy0xLTEtMzAzNTE_997d83b7-daaf-4846-a1f6-89f4b496216d">398,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzItMS0xLTEtMzAzNTE_89bfc192-e3e5-4324-8114-acbbfb62cd9f">395,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzItMy0xLTEtMzAzNTE_29476c60-d760-4069-822c-ba121e6efa62">377,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stockholders' equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzMtMS0xLTEtMzAzNTE_c2414242-914f-42de-a06b-92c840337b86">4,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzMtMy0xLTEtMzAzNTE_a428e279-62c5-4645-ac63-178e4faf53be">21,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzQtMS0xLTEtMzAzNTE_daaf0b7d-b94a-44d2-be64-6925143cc24d">55,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzQtMy0xLTEtMzAzNTE_696f99cd-5433-4480-880c-8ae5286c276e">75,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_86037227-b16d-461a-8143-948ba4f1025f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_8a3b3de7-da47-4d52-a743-ea2ee0014004"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_9cd6c1ef-ede4-4be7-85be-696217c96ca5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_ae2b0c7e-d3fd-4c73-b2ea-1dbaad18b7f6">Collaboration revenue</span></span></span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0xLTEtMS0zMDM1MQ_66937767-38b5-4c67-be75-3be7c6d36a35">7,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0zLTEtMS0zMDM1MQ_c9e7d640-1deb-482f-87df-052652e89340">2,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNC0xLTEtMS0zMDM1MQ_baffd04d-ee02-441f-9341-a21c4d97cd33">7,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNC0zLTEtMS0zMDM1MQ_4657bf7d-5e90-47e8-a4a0-108b0f7bf3d7">2,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNi0xLTEtMS0zMDM1MQ_3f3d9598-88a2-433f-bfdd-57c5f260f350">20,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNi0zLTEtMS0zMDM1MQ_fc55a4e5-d299-498f-84c0-05aab262dfcb">15,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNy0xLTEtMS0zMDM1MQ_413dcb96-fbfc-490f-aeab-d103e03072bd">5,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNy0zLTEtMS0zMDM1MQ_b6f101c1-9cf4-4300-93ba-3285a0249a69">4,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOC0xLTEtMS0zMDM1MQ_185cf0d6-41ce-4056-8d4a-14ed25a91b26">25,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOC0zLTEtMS0zMDM1MQ_983dfd23-4fe3-4c4f-b9ef-d67edeece30d">20,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOS0xLTEtMS0zMDM1MQ_29199a91-ad38-4178-b708-c47354a6d32f">18,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOS0zLTEtMS0zMDM1MQ_c6c3a76c-71c6-4eee-b09c-9ad9b5cb14e2">18,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTEtMS0xLTEtMzAzNTE_859507f1-06a2-4230-88b5-4f1445a05e45">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTEtMy0xLTEtMzAzNTE_aa14abc4-9838-447c-b6b1-aa1c0fcf8bf6">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTItMS0xLTEtMzAzNTE_135d041c-9ae9-4bb9-ab63-7f69c0348411">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTItMy0xLTEtMzAzNTE_717c1d59-e7f5-4d17-b16f-adcd9ff24b4e">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMS0xLTEtMzAzNTE_51db5670-4bba-4313-b03a-ac51ae48c873"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMS0xLTEtMzAzNTE_54909531-7527-4e9c-b1cb-539b0ec1e5a2">18,281</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMy0xLTEtMzAzNTE_157277cf-f89d-4f37-828e-5f38b4a34b97"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMy0xLTEtMzAzNTE_bde72121-5ba7-47b4-8ceb-271961e2a5bf">18,292</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTYtMS0xLTEtMzAzNTE_0c2e77f7-f373-4472-8415-eb725a0612fd">18,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTYtMy0xLTEtMzAzNTE_2fbff7cc-1add-4c9a-8ff4-50dacc8e1d09">18,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMS0xLTEtMzAzNTE_0a7034a6-1bc6-4947-bd40-0910e8493e5c"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMS0xLTEtMzAzNTE_6340991b-2429-48e6-98fd-3f8a41c64d34">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMy0xLTEtMzAzNTE_187783a7-0f23-4aae-a139-55ef757802ab"><ix:nonFraction unitRef="usdPerShare" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMy0xLTEtMzAzNTE_508a1484-ade5-40a8-bd3f-7513e9d128de">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMS0xLTEtMzAzNTE_1addc553-431f-4df7-b127-ea43cf78adf5"><ix:nonFraction unitRef="shares" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMS0xLTEtMzAzNTE_dc32eb76-0761-4682-b33d-fe3c8c48115f">68,138,116</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMy0xLTEtMzAzNTE_b480c608-8bea-46f5-8461-59a2b1d15af4"><ix:nonFraction unitRef="shares" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMy0xLTEtMzAzNTE_f6714fc0-6ea7-465d-b3b6-de72099b8804">46,967,213</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMy0xLTEtMS0zMDM1MQ_f4da75b4-6268-401f-af2d-d23b4bc4608f">18,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMy0zLTEtMS0zMDM1MQ_956f127e-da52-4511-8523-c5658e8f307c">18,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNS0xLTEtMS0zMDM1MQ_614a6a77-881a-4c6d-b84c-726068ce42c4">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNS0zLTEtMS0zMDM1MQ_43a0dbd4-5488-48d5-bb78-27106d662202">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNi0xLTEtMS0zMDM1MQ_5d881fcc-52a4-4f6b-a5e0-86f3f5e62d7e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNi0zLTEtMS0zMDM1MQ_05ae4f35-77ca-4df3-ad20-d46c077999dd">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNy0xLTEtMS0zMDM1MQ_2d9db758-b38b-49c6-91d6-ff91ab2aaee4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNy0zLTEtMS0zMDM1MQ_ee214758-3f8e-4354-b4e3-f5d9f5aa41b9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOC0xLTEtMS0zMDM1MQ_3516d714-443a-4efa-8313-91a63e0e1683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOC0zLTEtMS0zMDM1MQ_1f510071-5800-472f-a87c-eb0d097bd40f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOS0xLTEtMS0zMDM1MQ_f07ba777-d9fa-46f0-a909-8eb5b0bb746c">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOS0zLTEtMS0zMDM1MQ_76fd1fe1-0ab9-40fb-8133-f455a70e2652">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTEtMS0xLTEtMzAzNTE_bf579bdc-192b-48f9-8d11-47c964cf08e1">3,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTEtMy0xLTEtMzAzNTE_58431fa1-e4a0-4ab2-8f33-ee4c30c3911b">11,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTItMS0xLTEtMzAzNTE_fef56929-b4f3-400b-95b4-8e61446775b5">1,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTItMy0xLTEtMzAzNTE_e8564112-627c-4632-9afd-9036e5e897fd">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTMtMS0xLTEtMzAzNTE_c412ddd5-7fd6-435e-94fe-d5360a4939d0">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTMtMy0xLTEtMzAzNTE_8ed7e0a2-a88d-4b55-9cac-38f534b8b3b4">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTQtMS0xLTEtMzAzNTE_dbf9102c-8f56-4e08-9908-19c9c52afbc9">1,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTQtMy0xLTEtMzAzNTE_3bfed273-ce34-4ea3-a9a6-4a7426385038">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTUtMS0xLTEtMzAzNTE_447724dd-07be-4064-b336-0275059063cb">844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTUtMy0xLTEtMzAzNTE_c8b88573-8a4d-4464-adb7-29f4a1d597ad">2,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMS0xLTEtMzY5MzE_a1930488-a88d-45ae-836f-66075646c0de">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMy0xLTEtMzY5Mzk_3b55bfba-356d-426f-bf69-30143f58c2f2">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMS0xLTEtMzAzNTE_c629d86f-00fa-487d-8a2d-5acc5e6d2ef8">23,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMy0xLTEtMzAzNTE_3f4ebe65-8b23-4179-94f9-c5dfb37ecda1">1,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTktMS0xLTEtMzAzNTE_adfc583b-23a3-4be3-9ea1-7e4d7980917e">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTktMy0xLTEtMzAzNTE_0566bf82-5bb2-425b-b8ec-69ba5759b117">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjAtMS0xLTEtMzAzNTE_ec6ec63c-52c3-4acb-b2b3-a52376aafa18">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjAtMy0xLTEtMzAzNTE_ead83b2f-e8e0-4ee1-b04f-63aa447f1986">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjQtMS0xLTEtMzAzNTE_fc5f0b4e-7a14-49d3-b7ab-de4108fd7a86">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjQtMy0xLTEtMzAzNTE_c916b134-da60-46b5-9026-0b365f6a92cc">8,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjUtMS0xLTEtMzAzNTE_93a904da-cf93-4f06-8689-19852c4d4742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjUtMy0xLTEtMzAzNTE_9d6ab3b1-91c8-4177-bfe4-34a676ada022">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjYtMS0xLTEtMzAzNTE_2a4d08c8-c23d-4259-807e-f031245772c6">1,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjYtMy0xLTEtMzAzNTE_03e39a9d-b59e-41bc-8d7c-d85fb09eee1e">1,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjctMS0xLTEtMzAzNTE_4efacc6a-a5b7-4e2b-8ffd-a7a26f37e33b">611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjctMy0xLTEtMzAzNTE_7a11bbeb-a8b1-460c-b9d4-d38a16ccc667">7,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjgtMS0xLTEtMzAzNTE_9d14d3fe-eb1a-4faa-abc7-9816b42e7b65">24,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjgtMy0xLTEtMzAzNTE_741206ea-66aa-4f21-b687-6b5fd9980189">5,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjktMS0xLTEtMzAzNTE_66dce5e6-f92f-4b70-b74d-4addb1f5372e">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed4d780fa7c4657ace1ca39915c5db9_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjktMy0xLTEtMzAzNTE_95b7ba49-1e70-49e1-aa51-b2a3793a988a">42,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzAtMS0xLTEtMzAzNTE_0cf8295b-3bdc-4781-bb85-1f7c4e63b73c">37,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594ac01243ff48a294a5691f8bb16ec7_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzAtMy0xLTEtMzAzNTE_5de310a3-923a-4f1f-b091-dc4db7b243b2">48,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzMtMS0xLTEtMzAzNTE_18bf7b8c-b1b9-4bab-9430-8f619da9adb4">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzMtMy0xLTEtMzAzNTE_3388f4b8-b1d2-4f2e-b1af-74c8ba95c5f8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzUtMS0xLTEtMzAzNTE_57a62f04-94ad-41f5-9184-596d7374aac6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzUtMy0xLTEtMzAzNTE_4fc2d7fe-8fb3-43a0-a404-fa15e4c73e28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ae401fe1ec94508a4c3bc1de6b123a7_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0yLTEtMS0zMDM1MQ_03c3238e-9b50-42e8-a63e-99662b19bf4f">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae401fe1ec94508a4c3bc1de6b123a7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy00LTEtMS0zMDM1MQ_d40e7920-5288-40dc-809d-35600867ce22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id29d0679e5a849fd8f0b328b0047051f_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy02LTEtMS0zMDM1MQ_b54666b0-6535-4b45-8056-2540ba2567d8">67,863,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29d0679e5a849fd8f0b328b0047051f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy04LTEtMS0zMDM1MQ_6650019d-016f-43ba-829d-9ae25c076a87">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e075b04cda432ea3e0bb290da8aa76_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0xMC0xLTEtMzAzNTE_4b95bf4c-bdfc-410e-ae36-5ae1118d3ed9">398,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb5be7deff5c45d58b2dabd268641ffa_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0xMi0xLTEtMzAzNTE_f3c63198-6897-4a19-9277-30265d9bbc0a">377,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0xNi0xLTEtMzAzNTE_a47eaf69-27ef-4cdc-946f-8cd3017f6d69">21,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie249caef64f94171b3f97f31b1702323_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfNi02LTEtMS0zMDM1MQ_07205ff7-732a-4f78-b677-dd3f0001c942">644,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffef7cfce9f74e188e663bb9b9e5a2b6_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfNi0xMC0xLTEtMzAzNTE_9b6cc98f-b1e3-42c2-a85c-3a9977dd3f10">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfNi0xNi0xLTEtMzAzNTE_08995a6d-b4b8-4d63-8ca7-584581812ab6">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie249caef64f94171b3f97f31b1702323_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfOC02LTEtMS0zMDM1MQ_d087f106-244a-4f6c-8424-d9d111a29127">541,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffef7cfce9f74e188e663bb9b9e5a2b6_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfOS0xMC0xLTEtMzAzNTE_db523a2a-aba5-486c-95c9-2c7236083c04">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfOS0xNi0xLTEtMzAzNTE_60f2f8b0-3e6e-4017-a31c-ce2e158b587e">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie90d7c5734cb4948aae78ef94bf77084_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTAtMTItMS0xLTMwMzUx_eef10547-07b8-4065-9c13-3d62effbc746">18,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTAtMTYtMS0xLTMwMzUx_f37735c6-a4eb-44a4-a2f3-762a49d6d065">18,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i078bfa49848346d5a1e3ebef80a9bf83_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMi0xLTEtMzAzNTE_69bbd421-afa5-4175-bf91-71d2fc72ca6b">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078bfa49848346d5a1e3ebef80a9bf83_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtNC0xLTEtMzAzNTE_72246a7c-d38a-4f16-9b2c-e988d0e2e430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic98e2da648634bd2abb09e30b07febad_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtNi0xLTEtMzAzNTE_17e74f8a-94c3-46e7-9fc1-f52bbeb69091">69,049,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98e2da648634bd2abb09e30b07febad_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtOC0xLTEtMzAzNTE_ebc6bd74-bf65-4b91-a662-bb702cfaaad9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfbfbe505a42456b8b907a1ce48ce8f8_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMTAtMS0xLTMwMzUx_11874c97-f915-47ab-b2f4-c92ce2b2280c">400,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a2d9cef5eea4c869286d364c1fc6da0_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMTItMS0xLTMwMzUx_0a091087-001f-44fb-acb3-8fea1c2c7990">395,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMTYtMS0xLTMwMzUx_a7a0cc15-57de-4e97-b592-4ae143ee1375">4,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75db0cf998d34c4f90645b2615a44ae4_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0yLTEtMS0zMDM1MQ_b6f04a7c-3763-4de7-a64b-50e48c009455">1,044,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75db0cf998d34c4f90645b2615a44ae4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy00LTEtMS0zMDM1MQ_86591ffe-01e1-4107-82c9-753fcc9b35d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy02LTEtMS0zMDM1MQ_35ecec31-bfc5-44d4-a5f6-e0e1fefc10e6">44,876,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy04LTEtMS0zMDM1MQ_6727d183-dcfa-4e8f-958d-f196c959c271">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20007356f9d4ba5be34c0e5c7493ff3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0xMC0xLTEtMzAzNTE_f0783746-c939-41d6-a115-07db97f12c60">345,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f61e4e8ab114e4e8fa4705c380ffc10_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0xMi0xLTEtMzAzNTE_9b21c427-8f68-46e7-b750-7d300dd6e8eb">334,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed4d780fa7c4657ace1ca39915c5db9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0xNi0xLTEtMzAzNTE_c271efc0-dafe-4e47-9412-2d89746ee8eb">10,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi02LTEtMS0zMDM1MQ_3dcd6481-89ae-4f96-8243-63219f6065a0">3,327,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi04LTEtMS0zNzgyNQ_6c550e9f-4993-4aa7-967e-e1e772866477">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi0xMC0xLTEtMzAzNTE_e4cea129-7d57-4888-93d6-5b97e381034a">8,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi0xNi0xLTEtMzAzNTE_3d9e4aad-a879-488f-b59b-63d934892013">8,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNy02LTEtMS0zMDM1MQ_b5aff5b6-39fa-405f-b95a-39ee19146dd8">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNy0xMC0xLTEtMzAzNTE_1e425a64-d00e-43f8-8105-6446edeeacf4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNy0xNi0xLTEtMzAzNTE_1e20f11c-09f5-4188-bfbc-2311b2e1a2ed">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfOC02LTEtMS0zMDM1MQ_789b9347-1e77-4617-8d12-63b4ab9cb33b">84,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfOS0xMC0xLTEtMzAzNTE_e0718acb-d991-490a-9847-d7800479e7df">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfOS0xNi0xLTEtMzAzNTE_50f41ff0-6c34-49da-a221-814db82bec7e">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic51fadbb95d64d119839876c70af802f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTAtMTItMS0xLTMwMzUx_7711c982-0c52-42c6-807a-b14d54ba0ad8">18,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTAtMTYtMS0xLTMwMzUx_7e98223c-9a0f-47bf-a73d-971ee8216180">18,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf01e9ab4d5447ae8695372ee5c96045_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMi0xLTEtMzAzNTE_11e775cf-dedd-447e-b1cf-dc4b7deec952">1,044,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf01e9ab4d5447ae8695372ee5c96045_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtNC0xLTEtMzAzNTE_b3bc3530-b42e-4d6a-88d9-7ce1485241e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie313ed150dbb4af980047e1f2ca2e27c_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtNi0xLTEtMzAzNTE_6d9442eb-d59a-4119-86e9-ff325f0ff1ac">48,288,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie313ed150dbb4af980047e1f2ca2e27c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtOC0xLTEtMzAzNTE_3cde04c4-6c1d-4b3c-bf89-5e62d5f0518d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3325f5645b9b4b7f988048d9368cbd44_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMTAtMS0xLTMwMzUx_6140e809-8f6e-4832-823c-b974e03de178">354,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570e663b09344feb9ff09e6ddb45fead_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMTItMS0xLTMwMzUx_7a59fb2b-0eec-42d5-9604-7efaf29ad8ed">352,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594ac01243ff48a294a5691f8bb16ec7_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMTYtMS0xLTMwMzUx_ebeb4718-5bc1-462d-bfab-03b9614d9535">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i12928d5708484b01a3ce462a99216eeb_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzcyNg_432cb031-2b07-45cb-8594-693849d50e7d" continuedAt="i65972a7c0d3c489fbbcb8cc477ea612f" escape="true">THE COMPANY AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i65972a7c0d3c489fbbcb8cc477ea612f" continuedAt="i4720dbf6ae664b7a8aca5662d6d96b1e"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. The Company is focused on infectious diseases and oncology. The Company&#8217;s lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections. In addition, the Company is using its Cloudbreak&#174; platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. The Company's initial development programs target influenza and other viral infections, including respiratory syncytial virus, or RSV, the SARS-CoV-2 strains causing COVID-19, and human immunodeficiency virus, or HIV. In addition, the Company has expanded the Cloudbreak platform to discover and develop DFCs to treat cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzc0MQ_3b548f3e-98c7-4480-a67b-716629383253" continuedAt="ibcc161edc9a84275bf71863f5dbe465f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfMTgxNQ_84c9364c-bd1c-4e33-a989-fb6f5784c0b7">395.4</ix:nonFraction> million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company had cash, cash equivalents and restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfMjEyNQ_008ada1f-ae13-4450-8765-0630b0ba02fb">38.0</ix:nonFraction> million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i4720dbf6ae664b7a8aca5662d6d96b1e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="ibcc161edc9a84275bf71863f5dbe465f">including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.</ix:continuation></span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="cdtx:UnauditedInterimFinancialDataPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzczNw_85694dd8-d0e4-48d7-b29c-28c617e0768c" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzc0OA_3d7244ec-2a5f-4ef7-b53c-ac633cdc3640" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzczNA_0fbe53c8-1722-4029-a4eb-6dc76fad3633" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options, estimated collaboration expenses and incurred expenses related to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement (each as defined below), certain accruals, including those related to nonclinical and clinical activities, and the Standalone Selling Price of performance obligations associated with license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzczNQ_456bb799-ace6-4720-b584-b44f7be4fb0b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzcwMQ_da2de6b8-6507-4f4f-888b-c1aabbb40571">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric></ix:continuation><div id="i12928d5708484b01a3ce462a99216eeb_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzQ_44e94ea9-bfd6-439c-9841-06977ae0dd60" continuedAt="i1ac10f217b8640748644f7e795d1614e" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i1ac10f217b8640748644f7e795d1614e" continuedAt="i99ff56155b844ff0b9490d4274c1af67"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzE_e4afda8d-4ebd-49fd-80e0-93bfec6e905a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash represents cash that the Company is required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 4 for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NjY_390aa4da-59a2-4df7-b8fa-c23f6f6b3648" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at March&#160;31, 2022 or December&#160;31, 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NTQ_b6540413-248e-48d3-b6f2-d0db957700a5" continuedAt="i7083bb4795a148c28ac050bded516b7e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i99ff56155b844ff0b9490d4274c1af67" continuedAt="ibb9381f26ea94848af509e9979bc9d2f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="i7083bb4795a148c28ac050bded516b7e">using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTIzNw_5527d6f8-bbd7-4b20-ac44-ff096fb03762">three</span> to <ix:nonNumeric contextRef="i21169da961a642269defd386e1909c8e_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTI0Mw_76115f46-ef89-4fb8-828b-684e2c002539">seven years</ix:nonNumeric>).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</ix:continuation></span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NDM_6416d935-2fad-46e2-904c-987b5a3202f7" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the FASB ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzY_d7237cdc-7535-4295-9af9-e809fba2059e" continuedAt="i7ca8c640a12f40b58e13cda72693277f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ibb9381f26ea94848af509e9979bc9d2f" continuedAt="i21992d09c9004bdc875f5d23c9d0ad3e"><ix:continuation id="i7ca8c640a12f40b58e13cda72693277f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three significant performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were three significant performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments and estimated reimbursable research and development and clinical supply costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 for additional information.</span></div></ix:continuation><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5Nzc_432e1f43-82c4-455d-8a39-740739ed2e21" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5Nzg_4203836a-244e-4108-ada0-d420cd3f6c41" continuedAt="ia747eee2691b4799a00ece2d9da98630" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i21992d09c9004bdc875f5d23c9d0ad3e" continuedAt="i491733c92762438e93650a3c4ab40f2c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="ia747eee2691b4799a00ece2d9da98630">periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</ix:continuation></span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NTU_af808914-513a-4f96-aa63-51e5f638fbcf" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTQ3Nzc_575ed202-d37d-49f5-b211-c4a8e9d8c972">zero</ix:nonFraction> reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NDQ_f7da15af-83ad-4bf5-9d05-997da0b73a24" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzM_5c6ee533-3cbf-4025-8db2-c782cd7b6dd2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95f5fe2a729b4d4b88d79c8b9f71926b_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMi0xLTEtMS0zMDM1MQ_baad4d6b-59d7-40d1-af92-01c34e046c97">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31a37a66cd6249378b32ab50166895a0_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMi0zLTEtMS0zMDM1MQ_69cc27de-5007-4339-9618-db9f109ad0ac">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4aa023587c32497cbf47ee68d3cbfb01_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMy0xLTEtMS0zMDM1MQ_dc73394b-1ab2-4a0f-a859-f1c5f015d641">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900152b8dae048ce8a4acda17d7bcb77_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMy0zLTEtMS0zMDM1MQ_5ea4b966-403b-4b64-a879-9b61bb424aa7">10,442,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1c94bb11270499696b1406f63c1b83d_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNC0xLTEtMS0zMDM1MQ_db580017-48f8-434d-9dfe-617306369b2e">10,847,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b5153e1e8ab48e49acff0d1756e5388_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNC0zLTEtMS0zMDM1MQ_53a72c2b-4577-4829-8d33-649f776bc931">8,648,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNS0xLTEtMS0zMDM1MQ_7bca099f-2708-4c4c-abef-f3248970a8d3">41,550,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNS0zLTEtMS0zMDM1MQ_a3298095-5f4c-4c78-90a9-a54ce754a1eb">31,608,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NDU_732687aa-55e6-435c-8153-49376320831f" continuedAt="i29bb3fc91d054efb97f9ee4038f65e29" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i491733c92762438e93650a3c4ab40f2c"><ix:continuation id="i29bb3fc91d054efb97f9ee4038f65e29"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described in Note 3, the Company believes that the fair value of the term loan approximates its carrying value.</span></div></ix:continuation><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NjA_f7260a32-9de4-4ca5-bff4-f1444bb3fee0" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i12928d5708484b01a3ce462a99216eeb_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RleHRyZWdpb246NWVmYmMzOTU0MzhkNDM3Mjk2MjU5OGVjOWY5YjU4MzZfMjE0OQ_885c6245-dbf2-4361-9d92-8f698d9e81e5" continuedAt="id513d69e8601409b8abd12d038c7d5a8" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="id513d69e8601409b8abd12d038c7d5a8" continuedAt="i72e42d21bbf3438b82fbdfbf472bb630"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i72e42d21bbf3438b82fbdfbf472bb630"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RleHRyZWdpb246NWVmYmMzOTU0MzhkNDM3Mjk2MjU5OGVjOWY5YjU4MzZfMjE1Nw_2ffc2870-631f-44c9-b435-8a297c7fc77d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy0xLTEtMS0zMDM1MQ_5fd18848-7a6e-4f20-81f2-b35a80d2bab8">36,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c6cdf33b80446aa3a77138caa526a0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy0zLTEtMS0zMDM1MQ_32d8783c-f9e4-4ad9-b9b3-c09c91b5267c">36,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041a511ce516484886b5ffe0acef8f8e_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy01LTEtMS0zMDM1MQ_bca230da-6877-4c75-9e48-d01bc5801e8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38f920be7245f686abc0a371da8a87_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy03LTEtMS0zMDM1MQ_bffda14b-9702-49ec-a343-39d3ee9611d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC0xLTEtMS0zMDM1MQ_5f598415-b468-4251-8142-3701419b9360">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c6cdf33b80446aa3a77138caa526a0_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC0zLTEtMS0zMDM1MQ_853295b1-9ae2-4bff-9c4a-62432a818d1f">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041a511ce516484886b5ffe0acef8f8e_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC01LTEtMS0zMDM1MQ_51eb015e-0d50-49d6-a4f1-4d8dae9f12a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38f920be7245f686abc0a371da8a87_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC03LTEtMS0zMDM1MQ_39650a03-71ca-4e45-b292-d1485aedd97d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS0xLTEtMS0zMDM1MQ_2ce801fa-ce03-44dd-be7a-bdb2b3121293">37,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c6cdf33b80446aa3a77138caa526a0_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS0zLTEtMS0zMDM1MQ_58a6d082-668a-4ff1-87e3-00171f329f94">37,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041a511ce516484886b5ffe0acef8f8e_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS01LTEtMS0zMDM1MQ_a87491c4-a7c4-439b-aa39-c8d427570f45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38f920be7245f686abc0a371da8a87_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS03LTEtMS0zMDM1MQ_71f578b4-c941-4682-921a-7c05472d7807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtMS0xLTEtMzAzNTE_e38d3470-143f-4461-8f70-1b3f1db89710">59,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b73da715794f18af42e513a2842fb7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtMy0xLTEtMzAzNTE_9dc9508d-1041-4223-897e-b0d28b5bcc86">59,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtNS0xLTEtMzAzNTE_5cd45946-9353-483f-ac21-6a4e1bddb04a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic713e533dda046afa29b8024f40c66d7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtNy0xLTEtMzAzNTE_5549cdf5-2655-481b-93f2-bb31d1e56da7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtMS0xLTEtMzAzNTE_a7b1f529-c9d0-4b40-a18d-b904d8af7bb0">2,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b73da715794f18af42e513a2842fb7_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtMy0xLTEtMzAzNTE_0e6be76f-8033-4694-9624-d8f0d5448dc7">2,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtNS0xLTEtMzAzNTE_ae1fa413-e455-4937-b8c6-041a164c1254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic713e533dda046afa29b8024f40c66d7_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtNy0xLTEtMzAzNTE_9e3dee3e-8f9c-47aa-99bf-c69de4be6519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtMS0xLTEtMzAzNTE_a5fa4b2f-1358-43b9-8f30-48d521f609a8">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b73da715794f18af42e513a2842fb7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtMy0xLTEtMzAzNTE_f894975c-d4ad-44f6-b6e7-e2a0f870d636">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtNS0xLTEtMzAzNTE_1164dd84-bfa1-418c-b9c5-f8e841d42dcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic713e533dda046afa29b8024f40c66d7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtNy0xLTEtMzAzNTE_13e435f6-d081-44d6-902e-38989566245f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i12928d5708484b01a3ce462a99216eeb_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMTUyNg_80b81c5a-dbdd-410b-88b8-113e985fd15b" continuedAt="i83f88f8be889467b97fb4e3eaf0e7453" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="i83f88f8be889467b97fb4e3eaf0e7453"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $<ix:nonFraction unitRef="usd" contextRef="i795c9fa22a224d2bbd52d8f2fe81648b_I20161003" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMjQ3_3df28e5e-86e1-47fe-86da-4e3241636ac4">10.0</ix:nonFraction>&#160;million&#160;from the Lender, or the Term A Loan. At March&#160;31, 2022, the Term A Loan bears interest at <ix:nonFraction unitRef="number" contextRef="i46940802d05a44c78644bacf035f8ab4_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMzI4_4389dfc8-2876-4fa5-9b66-8615b8bf2180">4.5</ix:nonFraction>% and matures on July 3, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 4, 2022, the Company and the Lender entered into a Fifth Amendment to the Loan Agreement, which modified certain debt covenants under the original agreement but had no impact on current or future cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the occurrence of certain events, including but not limited to the Company&#8217;s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement or the occurrence of a material adverse change, the Lender has the right, among other remedies, to declare all principal and interest and other amounts due to the Lender under the Loan Agreement immediately due and payable. The principal payments due under the Loan Agreement have been classified as a current liability at March&#160;31, 2022 and December&#160;31, 2021 due to the considerations discussed in Note 1 and the assessment that the material adverse change clause under the Loan Agreement is not within the Company's control. The Company has not been notified of an event of default by the Lenders as of the date of the filing of this Form 10-Q.</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMTUyOQ_434a95d5-7498-4ea1-8499-34a288ae99b6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future principal payments due under the Loan Agreement, as amended, are as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year ended:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46940802d05a44c78644bacf035f8ab4_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RhYmxlOmU2ZDBlYmFiYTcwNDQ5ZjI5NDlhMzgyYWYyNWYyNjg3L3RhYmxlcmFuZ2U6ZTZkMGViYWJhNzA0NDlmMjk0OWEzODJhZjI1ZjI2ODdfMS0xLTEtMS0zMDM1MQ_cb7a6a78-ba07-453c-b96f-95c0952471dc">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total future principal payments due under the Loan Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46940802d05a44c78644bacf035f8ab4_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RhYmxlOmU2ZDBlYmFiYTcwNDQ5ZjI5NDlhMzgyYWYyNWYyNjg3L3RhYmxlcmFuZ2U6ZTZkMGViYWJhNzA0NDlmMjk0OWEzODJhZjI1ZjI2ODdfMy0xLTEtMS0zMDM1MQ_a9fe83b0-352e-4ee5-a355-fa9ca318c3aa">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i12928d5708484b01a3ce462a99216eeb_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjkyNQ_b201d015-1138-4ddc-97bb-3f0a5d6f3f8a" continuedAt="i715beea89c044b688575611fc364daf3" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i715beea89c044b688575611fc364daf3" continuedAt="i85390ea9c4ad48bbbf4b702e584bd0f4"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp; Co, or the Sales Agreement. During the three months ended March&#160;31, 2022 and 2021, the company sold <ix:nonFraction unitRef="shares" contextRef="i6621b987d56742bdb57725ac1faabdbb_D20220101-20220331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTY2Nw_ecb2c339-7ce5-417d-ad13-f65abc4eec01">644,265</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i35c8f58bd982422a986ef78bf58fc3ed_D20210101-20210331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTY3NA_a58a1b96-29f8-490b-a200-accc1b1ebbb6">3,327,706</ix:nonFraction> shares of common stock, respectively, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i6621b987d56742bdb57725ac1faabdbb_D20220101-20220331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTc0OQ_7bf57142-4e17-4ebe-bcc8-9f95d2bb6051">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i35c8f58bd982422a986ef78bf58fc3ed_D20210101-20210331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTc1Ng_bbe8858d-c098-4343-97fd-ae82ac1af80c">8.6</ix:nonFraction>&#160;million, respectively, after deducting placement agent fees. As of March&#160;31, 2022, the aggregate offering price remaining under the Sales Agreement is $<ix:nonFraction unitRef="usd" contextRef="i0195058d79fa431882538deea9d40134_I20220331" decimals="-5" name="cdtx:SaleOfStockConsiderationRemainingOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODgxOA_e9667471-83a9-4ca7-b858-9782a171a4ee">48.0</ix:nonFraction> million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2021 Public Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 13, 2021, the Company completed concurrent but separate public offerings of <ix:nonFraction unitRef="shares" contextRef="ifbc4656677c945bea6a7f93277e0065d_D20211013-20211013" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODcwOQ_52136f82-53e3-469e-bd6d-5abcd13da86f">17,064,511</ix:nonFraction> shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ie51f2518f48844149c35fadeee45c717_D20211013-20211013" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODcyMQ_c088179b-a4bc-4485-b471-119676e71a88">2,225,805</ix:nonFraction> shares of common stock, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa0b0517b28c459d84c79bff7bdcb54e_I20211013" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODczMg_a4720fc9-c15e-4424-a1c7-d755325d7cc9">1.55</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="i0df47124083a4f99a0e151684e8f154c_I20211013" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODczOQ_c697f979-b9df-4acc-b360-72cba9b68a4e">774,194</ix:nonFraction> shares of its Series X Convertible Preferred </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i85390ea9c4ad48bbbf4b702e584bd0f4" continuedAt="i5f6bcb4643164322828a31bcb6a2102d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0df47124083a4f99a0e151684e8f154c_I20211013" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODc0OA_850fc90a-9229-4103-a6e6-5932653e9661">15.50</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib1eb42daf54d4b668a360dcc81934f30_D20211013-20211013" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODc1Ng_0455175c-ef23-4f8a-9058-696638f0588a">38.5</ix:nonFraction>&#160;million. The Company received total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i55bdd2d5589d4fe7b0309fed8211b8a8_D20211013-20211013" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODc3MQ_2434931f-7fa0-4b14-aefe-e8b270721f15">36.6</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to <ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjA4Mg_6b34ee58-b4fe-4455-aebf-d87c2a38ee7c">10,000,000</ix:nonFraction> shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had <ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjUyNg_187e4c7b-59e0-425a-a021-dbc7b03df472">10,000,000</ix:nonFraction> shares of preferred stock authorized at March&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated <ix:nonFraction unitRef="shares" contextRef="i69448e0c7d0b4165bc50aaf98eb14d71_I20180531" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODg2Mw_580a387c-e6e6-4695-982e-ea4534066b51">5,000,000</ix:nonFraction> shares of preferred stock as Series X Convertible Preferred Stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i69448e0c7d0b4165bc50aaf98eb14d71_I20180531" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjY5OA_30c39358-0923-4e47-8ae6-80dc478ac673">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On August 12, 2020, at the request of certain holders, <ix:nonFraction unitRef="shares" contextRef="i280b1d43fcd44cc3b820c5ccce18586b_D20200812-20200812" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjc2Nw_e9eecf55-4cc7-4867-a057-fdba4ba9d921">52,241</ix:nonFraction> shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of <ix:nonFraction unitRef="shares" contextRef="idc285ca9fc0947889305e6be663b5ce3_D20200812-20200812" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjg2NQ_e9862d56-7746-498a-8a77-5dc123324954">522,410</ix:nonFraction> shares of the Company&#8217;s common stock. As of March&#160;31, 2022 and December&#160;31, 2021, shares of preferred stock designated as Series X Convertible Preferred Stock totaled <ix:nonFraction unitRef="shares" contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODk4OA_909fa249-6047-486e-b101-415737f4c5a9"><ix:nonFraction unitRef="shares" contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODk4OA_d19122d3-7b00-4772-a86d-fde3b6f836c1">4,947,759</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into <ix:nonFraction unitRef="shares" contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMzA5Ng_7cb3cc20-6d03-4697-b4e6-84924dc6e3f2">10</ix:nonFraction> shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i2b1567b76bf14270856d0e77828b3edd_D20220101-20220331" decimals="4" name="cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMzQ2NQ_981e797f-a5bc-4f8b-8cec-01ffb123ab89">9.99</ix:nonFraction>% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company's common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNTYwMQ_bdf3c669-5675-4d31-92f8-a5bc4e5f638e">200,000,000</ix:nonFraction> shares of common stock authorized as of March&#160;31, 2022. Holders of outstanding shares of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="INF" name="cdtx:NumberOfVotesEntitlementForEachShareHeld" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjkyNg_024f318e-b746-458e-a91c-ea4e74f457ce">one</ix:nonFraction> vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i5f6bcb4643164322828a31bcb6a2102d"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i1202dce605be4c82a0a70d95af7a8593_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjY4Nw_9852fb81-694e-42f8-9760-b27f4a591ed4"><ix:nonFraction unitRef="shares" contextRef="i5971b45c3a7c412c88e46aa2b80a5a6e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjY4Nw_f7ea5052-39b5-4493-a3c2-b91ac1231949">12,517,328</ix:nonFraction></ix:nonFraction> shares of the Company's common stock were outstanding with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f8aa79b2a034ff484490a0f9ed5005a_I20220331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjc3MA_883c1077-2fbc-4ea5-99c6-f4a10c389aea"><ix:nonFraction unitRef="usdPerShare" contextRef="ic27040cee9f64227942f86974dfc7e07_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjc3MA_f2fcfd65-52e1-4aea-a1d8-711194c95190">6.82</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had <ix:nonFraction unitRef="usd" contextRef="i1202dce605be4c82a0a70d95af7a8593_I20220331" decimals="INF" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjU5NzA2OTc3ODcwOA_28f60326-1d62-490e-bf5e-f7a20d7d0cf4"><ix:nonFraction unitRef="usd" contextRef="i5971b45c3a7c412c88e46aa2b80a5a6e_I20211231" decimals="INF" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjU5NzA2OTc3ODcwOA_b9ac724e-1e07-4412-b7d3-29ac9c10b52f">no</ix:nonFraction></ix:nonFraction> intrinsic value at March&#160;31, 2022 and December&#160;31, 2021. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjkyNw_6a2d842d-305f-4cf8-a009-b8035804d164" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67507a3641814df4b10e074a32b49c2e_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMS0xLTEtMS0zMDM1MQ_6a25c959-9887-4446-8229-60577476423f">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bd0f0932ef8490bb6c1d6b126581749_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMS0zLTEtMS0zMDM1MQ_64add0c8-8cfb-4019-8434-a684654ed514">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a0d4f2214a74513a73c71607fd17646_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMi0xLTEtMS0zMDM1MQ_3be13d4f-f2c2-470f-a1cd-bfe0e635acc1">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id49a49faa40b4317b2251637999b3844_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMi0zLTEtMS0zMDM1MQ_0148870c-c15b-4d3f-8e32-11fa20947c15">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3394b2a276ce4f24a740ba07a69873e9_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMy0xLTEtMS0zMDM1MQ_42894f14-2858-4b9d-9ab1-287d6778a8e2">10,847,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieef9aeb2eaab46cf8f2dc459329f1dab_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMy0zLTEtMS0zMDM1MQ_74179735-6627-4681-bc5a-c424b8952349">9,470,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500728b40904350a970627b377ddbb0_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNC0xLTEtMS0zMDM1MQ_aac696d5-c7a0-47db-92cc-4f376afe9186">3,232,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieab45868d7b34980921f34867b165abc_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNC0zLTEtMS0zMDM1MQ_9edbf104-bda1-4c55-bfce-71a043d78cc8">2,436,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib71eefcf9d68457782ef30c211def3a7_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNS0xLTEtMS0zMDM1MQ_88209cf3-4cc7-4a3b-a7ad-fe6f3f892b3f">1,170,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i378b0ff196374173acefdb91629cc588_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNS0zLTEtMS0zMDM1MQ_db45ec69-dfd7-4924-931a-da4640f8c65e">680,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNi0xLTEtMS0zMDM1MQ_6be2c67d-eccf-4e05-8334-7411fac2821a">45,953,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNi0zLTEtMS0zMDM1MQ_4ef06de9-6022-46bd-b056-ea8654acebc4">43,289,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i12928d5708484b01a3ce462a99216eeb_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYwMg_7295d76c-b117-4a98-996d-7e0a70718b32" continuedAt="ie520b1890bcb48ff90697007c7b7b20e" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span></div><ix:continuation id="ie520b1890bcb48ff90697007c7b7b20e" continuedAt="i01609a38872e45b195d418008f0a7bbe"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company's board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by <ix:nonFraction unitRef="number" contextRef="i1a0dd60e595d4d90b99db4dfcc03e925_D20150301-20150331" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTA2MA_097ab02b-7006-454b-bf56-6309064cd054">4</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTQ2NQ_7675637d-1608-4a23-aa34-7b6bb8a8e302">three</span>- or <ix:nonNumeric contextRef="i2b6dd61a92f24717a10f0e25c4e1a31f_D20150301-20150331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYxMQ_b4e5395b-7f99-421e-b93e-d756eee87446">four-year</ix:nonNumeric> period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to <ix:nonNumeric contextRef="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTY1OA_b7a06134-e728-495f-9639-5e9ee46a5311">10</ix:nonNumeric> years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than <ix:nonFraction unitRef="number" contextRef="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTc5NA_c1b9fbba-7eff-49c1-b5af-1a1c7448fbcb">100</ix:nonFraction>% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than <ix:nonFraction unitRef="number" contextRef="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTk3Nw_fe63f4ee-9ea3-4700-8a2f-08f49126adc5">10</ix:nonFraction>% of the voting power of all classes of stock of the Company, the exercise price shall be no less than <ix:nonFraction unitRef="number" contextRef="i720b8558f3114a66b3afb7ddb6acfbda_D20150301-20150331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjA4MQ_0631f915-7917-4822-ba2c-650e7c43f996">110</ix:nonFraction>% of the value on the date of grant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i0b84d00a866d4c51b68551b7e95373d5_D20150301-20150331" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjQyNw_7d397e7d-de6b-47e4-aa36-24d0bf991376">1</ix:nonFraction>%&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii)&#160;<ix:nonFraction unitRef="shares" contextRef="i3fbce54647a341fba1a08f3e3d01f687_D20150301-20150331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjU0Mw_b0de8393-7bf1-4c96-8281-a44bb0ee9ddf">490,336</ix:nonFraction>&#160;shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to <ix:nonFraction unitRef="number" contextRef="i0b84d00a866d4c51b68551b7e95373d5_D20150301-20150331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjc2NA_2a199300-900e-4ed9-9d91-65104e80d5a4">85</ix:nonFraction>% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to <ix:nonFraction unitRef="number" contextRef="ib71eefcf9d68457782ef30c211def3a7_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjkzNw_ff259235-cc21-4bb6-840a-d3f9c7e2562d">15</ix:nonFraction>% of the employee&#8217;s eligible compensation. During the three months ended&#160;March&#160;31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i64417209e6a7431e9641d70ebaa9d805_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzAxOQ_67eabd9e-9462-44c7-9481-d54a3f4fffe3"><ix:nonFraction unitRef="shares" contextRef="i720f7ca4cb4d47c797738cd1efd27be0_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzAxOQ_a49c6f30-379d-40e0-8a25-b00263bd02b2">no</ix:nonFraction></ix:nonFraction> shares were issued pursuant to the ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, total unrecognized compensation expense related to the ESPP was approximately $<ix:nonFraction unitRef="usd" contextRef="ib71eefcf9d68457782ef30c211def3a7_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzE4MA_444669c5-fe56-40e1-aa7d-1a62d073bcac">0.4</ix:nonFraction>&#160;million. This unrecognized compensation cost is expected to be recognized over approximately <ix:nonNumeric contextRef="i64417209e6a7431e9641d70ebaa9d805_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzI2OA_66e2fb83-40c1-4b30-98aa-ab5fe90c6500">0.6</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i01609a38872e45b195d418008f0a7bbe"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYxNA_e13cc207-3d53-4801-b835-5da1a5cf7207" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7725d535d6df481ba4eb64e1f9497bb5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMS0xLTEtMS0zMDM1MQ_9c3dcc1b-98b4-4133-a054-5561e38b7a98">1,174,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7725d535d6df481ba4eb64e1f9497bb5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMS0zLTEtMS0zMDM1MQ_32a39488-60be-4989-8e59-0b9923927b27">2.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMi0xLTEtMS0zMDM1MQ_da6618d7-52f5-4347-b6c1-eb7463854dc5">1,466,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMi0zLTEtMS0zMDM1MQ_15dc7d7b-6fe0-4782-aed2-399d5c78431f">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMy0xLTEtMS0zMDM1MQ_3bd72751-e4e0-4eed-9406-1b4f44207a3c">749,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMy0zLTEtMS0zMDM1MQ_df7155e4-7bbc-4bed-ad53-75db0c733a9e">1.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNC0xLTEtMS0zMDM1MQ_60ed4d0a-e715-4de2-99e2-e480eea963c3">48,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNC0zLTEtMS0zMDM1MQ_53d1342b-8f49-4d2f-a60c-75fd711c9024">2.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36320806fa3c4b5f9432d569a7254fb3_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNS0xLTEtMS0zMDM1MQ_d3ad8c5d-25b9-4fa9-b90b-9cd3c67837aa">1,843,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36320806fa3c4b5f9432d569a7254fb3_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNS0zLTEtMS0zMDM1MQ_1f954461-b21d-4634-8c07-f605c2d087fa">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs and PRSUs granted during the three months ended March&#160;31, 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4d982e5d0cc6497c854d56be2b7a9838_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzQ5OA_8675d3cd-53d8-478f-86f8-10d92c40ebf3">2.56</ix:nonFraction> per share. The total fair value of RSUs and PRSUs vested during the three months ended March&#160;31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzYyNw_4dddd0e7-f823-4e04-89d7-462551675646">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4d982e5d0cc6497c854d56be2b7a9838_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzYzNA_b86b9f37-2096-4ac0-9330-b62607d6dc5d">0.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2022, estimated unrecognized compensation expense related to RSUs and PRSUs grants was approximately $<ix:nonFraction unitRef="usd" contextRef="i36320806fa3c4b5f9432d569a7254fb3_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzc1NA_87c39849-cd7d-4df9-9b0b-8e0d9637b9cb">2.7</ix:nonFraction> million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYxMg_26f6d826-e5b8-450a-bc04-c44092bda9d1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">in Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS0xLTEtMS0zMDM1MQ_3d8aead1-5004-4334-b17f-80e9555d128e">8,296,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS0zLTEtMS0zMDM1MQ_194cb8ce-543e-4fde-88a2-e34f2b1188bd">3.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if93aa19e1f944c0c881474a93809cb2c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS01LTEtMS0zMDM1MQ_405f7100-e1c6-4caa-8297-e56ee3cab2a1">6.31</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS03LTEtMS0zMDM1MQ_acbbea26-c778-40d8-962e-ad6dca31c754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMi0xLTEtMS0zMDM1MQ_c08fc83a-a3f5-4d1a-9020-257c68b2033d">1,804,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMi0zLTEtMS0zMDM1MQ_b3949582-524e-4d30-a793-67938015a848">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMy0xLTEtMS0zMDM1MQ_ff0a7bdb-dbb0-4b51-903b-29ad5853e246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMy0zLTEtMS0zMDM1MQ_84c41fbd-aaa6-417f-be2c-9643ec933242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNC0xLTEtMS0zMDM1MQ_b9429a8c-7d8c-46d2-9e0a-135c17c89ebf">1,096,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNC0zLTEtMS0zMDM1MQ_1f810185-44e2-4830-a0d5-31af12c565cd">3.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS0xLTEtMS0zMDM1MQ_b4bceee0-a57d-46c8-9de0-fc9d6e6fd12c">9,004,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS0zLTEtMS0zMDM1MQ_ebf3a1cb-a6bc-45bf-ae71-c04fa84458f9">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS01LTEtMS0zMDM1MQ_b4ef2d13-d445-4903-ab68-2c37e14359dd">7.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS03LTEtMS0zMDM1MQ_6a0f8551-9453-4f9b-868c-1c5d655d9796">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi0xLTEtMS0zMDM1MQ_f5451163-bf3e-4232-a408-848a2f3801ec">9,004,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi0zLTEtMS0zMDM1MQ_fbb5743c-b4e6-4086-b44a-8843dc5d8b33">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi01LTEtMS0zMDM1MQ_0e53bff5-c65b-4a5e-a00f-0dad84d005ac">7.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi03LTEtMS0zMDM1MQ_9d793cdd-d97a-42d8-a6aa-cda7a56ac41f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy0xLTEtMS0zMDM1MQ_a4d63223-2b5a-4e31-9722-55e163ed88b2">4,609,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy0zLTEtMS0zMDM1MQ_d096ac31-2df4-4665-8f76-e0b465b5ec21">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy01LTEtMS0zMDM1MQ_246f260b-c0a2-4235-9e09-2a6b335fc9a9">5.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy03LTEtMS0zMDM1MQ_9f27fafc-7428-432c-86a0-dc7cf6ee71b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDE0NQ_1441d193-d486-4a6e-9720-87c0b79d0d4c">0.53</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDE1Mg_70d14e77-fa34-4006-aa7c-778e4cc2393f">1.51</ix:nonFraction> per share, respectively.</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYwNw_f32779dd-3900-4efa-b624-de196ad864f8" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228ae513e4d048c1b3d1b4222fab3750_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMi0xLTEtMS0zMDM1MQ_2deb20f4-0b66-4236-9cac-5beae404aab3">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f64292f9a6949a8b73b0d21cbeefa6a_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMi0zLTEtMS0zMDM1MQ_f506ab67-c8a6-473f-88fc-521ddbdb6fc8">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0284b9283584c6a98c2cf36c7b67635_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMy0xLTEtMS0zMDM1MQ_6ac687ee-aaf2-4ac8-9943-c598825de86f">883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4d20a797ca4520be3b7156f337e50f_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMy0zLTEtMS0zMDM1MQ_d6f39eab-99a0-4ba3-9098-57b199324630">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfNC0xLTEtMS0zMDM1MQ_6fc806e3-54b1-4a85-9ab7-37a1c8f43163">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfNC0zLTEtMS0zMDM1MQ_9256432a-fb0d-43a0-8204-6f8e5b6490b7">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, total unrecognized share-based compensation expense related to unvested stock options was approximately $<ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDQ4MQ_40234606-3e7c-464d-aafa-cb46d0f88a36">4.1</ix:nonFraction> million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="i4b2950f3ff64498ea4482c1111550256_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDU5OA_f5b81b1f-2bed-4d2b-96a2-d621e487cb51">2.5</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjE2OTk_526699c2-62b7-4427-86c7-07ff75eca05b" continuedAt="ie1e826bd22cb4e2cb809e259b14b69a1" escape="true">SIGNIFICANT AGREEMENTS AND CONTRACTS</ix:nonNumeric></span></div><ix:continuation id="ie1e826bd22cb4e2cb809e259b14b69a1" continuedAt="i2b87a0f6e15548e58fae3422e10b311b"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Licensed Product for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#8217;s planned Phase&#160;3 pivotal clinical trial of the Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Licensed Product in the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#8209;bearing license to develop, register and commercialize the Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, subject to the Company&#8217;s retained right to lead a global development program for the Licensed Product in both the Mundipharma Territory and in the U.S. and Japan, or the Company Territory, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#8209;exclusive, worldwide license to manufacture the Licensed Product and rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until the seventh anniversary of the first commercial sale of the Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#8217;s territory. However, in the event of the acquisition of a party by a third party, this right of first negotiation will not apply to any such anti&#8209;fungal product of the acquiring third party prior to consummation of the acquisition of such party, acquired by such acquiring third party from another third party after consummation of the acquisition of such party, or developed internally by the acquiring third party, either before or after consummation of the acquisition of such party, without the use of, reliance upon or reference to any technology of the acquired party that is licensed to the other party under the Mundipharma Collaboration Agreement, any technology of the other party that is licensed to the acquired party under the Mundipharma Collaboration Agreement, or any technology jointly developed by the parties pursuant to the Mundipharma Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company retains the exclusive right to develop, register and commercialize the Licensed Product, Subcutaneous Product and Other Products in the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#8217;s Global Development Cost share of $<ix:nonFraction unitRef="usd" contextRef="i8d1f47cfaf864b5b8449cf27f8903001_D20190903-20190903" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNDMzOQ_0948c7c4-f45e-4214-bcf1-882439988b70">31.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The total potential transaction value is $<ix:nonFraction unitRef="usd" contextRef="i8d1f47cfaf864b5b8449cf27f8903001_D20190903-20190903" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNTE0MA_d5000e16-447c-4722-a029-2dcdad675e9e">568.4</ix:nonFraction>&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible for double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSPECT Trial and the ReSTORE Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company's patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i2b87a0f6e15548e58fae3422e10b311b" continuedAt="ieedd22e51e24484382d3d8b493ee5ed6"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$<ix:nonFraction unitRef="usd" contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNjQ1NQ_a034a72c-29e9-4427-a9ff-7105d9db30aa">30.0</ix:nonFraction>&#160;million plus the research and development funding of $<ix:nonFraction unitRef="usd" contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNjUwMw_e0abfbfa-b969-424d-a1b5-18ae9491e48b">31.2</ix:nonFraction>&#160;million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="i7a1b832c3bcc45ec9f16fa3306e87d89_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY2MDQyMA_a661fbc2-3c6e-4957-83f6-655ca1b03336">2.8</ix:nonFraction>&#160;million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that require judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="i59db54d089334f80bfc2bf1d019c720c_D20190901-20190930" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNzk0Mg_5440f401-da26-4ebd-895e-1e676231ad8a">17.9</ix:nonFraction>&#160;million&#160;in September 2019 as collaboration revenue in its condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Licensed Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company's initial obligation to supply rezafungin for ongoing clinical development in the Licensed Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company determined that as of&#160;March&#160;31, 2022, all the potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In November 2020, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i68f5f47ae533474f9d58f357b7560076_I20220331" decimals="-5" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfOTczOQ_531b73be-6c9c-414e-90e5-3b8ed3bf387b">11.1</ix:nonFraction>&#160;million milestone under the Mundipharma Collaboration Agreement, which is recorded as long-term deferred revenue as of March&#160;31, 2022 because the rights to consideration is not expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. In December 2021, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i7a1b832c3bcc45ec9f16fa3306e87d89_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY1MzcwMA_a661fbc2-3c6e-4957-83f6-655ca1b03336">2.8</ix:nonFraction>&#160;million milestone under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in January 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;<ix:nonFraction unitRef="usd" contextRef="i5b2c214fd2d34166a98231e78e89cb57_D20210101-20210331" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA4NjA_193484ea-0d46-4c0c-9278-587fcdb6f629"><ix:nonFraction unitRef="usd" contextRef="ie4961bcc2a42459fbdcff0f5d4ffbff3_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA4NjA_c8e9319b-7cd6-4267-9009-91084d6263df">No</ix:nonFraction></ix:nonFraction>&#160;royalty revenue was recognized during the three months ended March&#160;31, 2022 or 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ieedd22e51e24484382d3d8b493ee5ed6" continuedAt="i0a331f4ef8744a6babb079e6f916bece"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs (previously called Antiviral Drug Conjugates, or AVCs) based on the Company's Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or the Phase 2 Study. Unless otherwise agreed by the parties, the Company will be responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company will be the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget. In addition, upon the effectiveness of the Janssen Collaboration Agreement, Janssen will also reimburse the Company for certain costs incurred by the Company in independently performing certain research and development activities from the execution of the Janssen Collaboration Agreement until its effectiveness.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Within <ix:nonNumeric contextRef="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331" name="cdtx:CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTMxNzc_0fcd154a-ee6c-43bc-bb15-4c7c0788f378">90</ix:nonNumeric> days after delivery by the Company to Janssen of results of the Phase 2 Study and all then-available data from other clinical trials of the Development Candidate conducted under the Research Plan, or the Election Period, Janssen will be obligated to notify the Company of Janssen&#8217;s election to proceed with further clinical development of Products, such notice, an Election to Proceed Notice. If Janssen fails to deliver an Election to Proceed Notice prior to expiration of the Election Period, the Company will have the right to terminate the Janssen Collaboration Agreement upon written notice to Janssen. If Janssen provides an Election to Proceed Notice prior to expiration of the Election Period, then the parties will continue any then-ongoing Research Plan activities to completion, and Janssen will otherwise be solely responsible for the development, manufacture and commercialization of Products, at Janssen&#8217;s sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#8217;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#8217;s DFC technology more broadly. The Company&#8217;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i857d96ec633a44e1b0ea653816686201_D20210331-20210331" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTU5NjE_66db1af3-d4ad-47f7-9be6-036663fabd90">27.0</ix:nonFraction>&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company is entitled to reimbursement by Janssen of up to $<ix:nonFraction unitRef="usd" contextRef="i1be4c76c948d42acabc01f60c0e15d14_D20210331-20210331" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTYwODY_c3de1781-ef59-4ff4-b3e5-05045df4694a">58.2</ix:nonFraction>&#160;million in research and development costs incurred in conducting Research Plan activities. The Company will also be entitled to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="if8dadaa504524767be44ca25b519478f_D20210331-20210331" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTYyMzc_968b5ffc-9862-478d-b4cd-2e1fdc91d41b">695.0</ix:nonFraction>&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales of Products at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In addition to the Company&#8217;s right to terminate the Janssen Collaboration Agreement for Janssen&#8217;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, upon <ix:nonNumeric contextRef="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331" name="cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTY5OTU_1af3596f-9916-488d-81e4-66ba7d37d881">90</ix:nonNumeric> days&#8217; written notice to the Company, provided that if any clinical trial under the Research </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i0a331f4ef8744a6babb079e6f916bece" continuedAt="ic5fba775071f4ff0ad0ce675df0dd2fa"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after completion of the Phase 2 Study and before expiration of the Election Period, immediately upon written notice to the Company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after delivery of the Election to Proceed Notice, upon <ix:nonNumeric contextRef="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331" name="cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTc0MzE_1af3596f-9916-488d-81e4-66ba7d37d881">90</ix:nonNumeric> days&#8217; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company determined the transaction price is equal to the up-front fee of $<ix:nonFraction unitRef="usd" contextRef="i41dc4db26c7d45a799666fc33080b4f5_D20220101-20220331" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTc2OTk_e3199a3d-f66d-4ef8-908b-30120ae11bd2">27.0</ix:nonFraction>&#160;million plus the research and development funding of $<ix:nonFraction unitRef="usd" contextRef="i41dc4db26c7d45a799666fc33080b4f5_D20220101-20220331" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTc3NDc_11d40495-bdde-4c03-8a6a-f6184071996c">59.9</ix:nonFraction>&#160;million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="ia37c7f2020504762b3c04bc8f40f0ede_D20220301-20220331" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY2MDQ1Mw_1ea45ade-60b8-405c-b7b7-bd7ba28261a3">3.0</ix:nonFraction>&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that require judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $<ix:nonFraction unitRef="usd" contextRef="ifbcdd3cc2a2e4827a4681f970f6d7389_D20210501-20210531" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTg4NTE_f0598002-7b7a-489d-adfc-826e43e33dd6">27.0</ix:nonFraction>&#160;million in May 2021 as collaboration revenue in its condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The research and development services to be performed represents a distinct performance obligation. The Company records payments due from Janssen as collaboration revenue. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company's initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company determined that as of the latest financial statement date all the potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In March 2022, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="ia37c7f2020504762b3c04bc8f40f0ede_D20220301-20220331" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY1NDY0Mw_1ea45ade-60b8-405c-b7b7-bd7ba28261a3">3.0</ix:nonFraction>&#160;million milestone under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in May 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. <ix:nonFraction unitRef="usd" contextRef="i58b63e51f2fb46699aee3fdf1e54a345_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjA0MTU_d381383d-5e84-4822-9e0d-abf5a601ea9b">No</ix:nonFraction> royalty revenue was recognized during the three months ended March&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ic5fba775071f4ff0ad0ce675df0dd2fa"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjE2OTE_de66183a-0106-49f2-b76d-13cc481ce132" continuedAt="i490849c8ce914ed18cd96619e746e933" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement during the three months ended&#160;March&#160;31, 2022&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dab98a8e3e4d89a66719d5a46c5f73_I20211231" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMC0xLTEtMS0zMDM1MQ_9a8c88e6-4ab0-4c7e-8260-5d2b2f129a72">32,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMS0xLTEtMS0zMDM1MQ_9d7c8fa5-4a8c-4a9f-b02d-6117bb856d24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMi0xLTEtMS0zNDkxMw_3c8b7755-eff7-40a5-b963-af5d8d6beb3a">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMi0xLTEtMS0zMDM1MQ_4abf076d-aa7a-430a-ac4a-edbbe18e05f4">2,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b09de693048bc9accc5d0a7f832d4_I20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMy0xLTEtMS0zMDM1MQ_8df23cf0-97ab-46f7-ba8e-d56841659ee5">31,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfNS0xLTEtMS0zMDM1MQ_21d25af4-ab06-4dbf-ba44-2f417f6e4a72">14,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfNi0xLTEtMS0zMDM1MQ_43275ab1-3198-4251-bf2a-9d13e3e8640a">17,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred revenue, March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfNy0xLTEtMS0zMDM1MQ_94898f13-a870-41c8-adf7-ff196b034e96">31,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, aggregate transaction price allocated to performance obligations that are unsatisfied is $<ix:nonFraction unitRef="usd" contextRef="ia4458c0ab6aa4e3aa31bee9f21e043b2_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjA4NDg_92965b85-d846-48e7-9029-c061b0bb43ef">15.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i443dc61676d64544abd994b78e8e6267_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY0OTUzMw_6aa3ec45-4f54-47d3-b4d6-e52943d40285">48.9</ix:nonFraction>&#160;million under the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively. These amounts are expected to be recognized over <ix:nonNumeric contextRef="ia4458c0ab6aa4e3aa31bee9f21e043b2_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY0OTY3Mg_ca4947a4-976e-4fbf-873c-1b6ca16c1923">1.75</ix:nonNumeric> years which represent the remaining research periods under the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ie02b09de693048bc9accc5d0a7f832d4_I20220331" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY1OTQ0Mg_16db4746-aebb-4582-9ca7-309291871b8e">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i78a1639fe6204e6f9c15a4b4242bfe9e_I20220331" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjExNDg_62efef2a-bb19-42dd-87a7-50a3b93031a7">8.6</ix:nonFraction>&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.</span></div><ix:continuation id="i490849c8ce914ed18cd96619e746e933"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our contract revenues disaggregated by timing of revenue recognition and excludes royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Point in Time</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Mundipharma Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c53ce77870a41f5beea59ecd239000c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNC0xLTEtMS0zMDM1MQ_ad1738fb-f5cb-40c6-a99d-5e82015fab41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dad60c0f2e040f5b0673a6393394e63_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNC0zLTEtMS0zMDM1MQ_cf32723d-6059-47fa-bc29-1c0387872f81">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87caf4dd1d234587aa8a86b0e5f01f6c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNS0xLTEtMS0zMDM1MQ_f3ae2959-10d4-4af1-b931-d138d064bc79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837f36bd31f84edca1439985d38c4717_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNS0zLTEtMS0zMDM1MQ_39942dc3-4b6c-4892-9f69-68dccd5c0aa0">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Mundipharma Collaboration Agreement</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c225bd22cb4a8094a6e4710a63e69c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNi0xLTEtMS0zMDM1MQ_3b35d8c3-dfb4-479b-af63-433ae0ed5851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba15d9175213445a9632cc6854819319_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNi0zLTEtMS0zMDM1MQ_ed4c5c02-2de7-46cc-a7cc-47813b8319ce">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Janssen Collaboration Agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce9e60ff6584997b9bbb0384ed6d8f2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfOS0xLTEtMS0zMDM1MQ_20bb0ca7-b307-4e7d-ba58-eb79a35ddc8b">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2edbac57ce84f7b9906d418d840a9f0_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfOS0zLTEtMS0zMDM1MQ_b34e2897-215c-464b-bf2d-b905438b7495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57264f734480431092220a6ede4796c9_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTAtMS0xLTEtMzAzNTE_40e6e75e-dfb6-4c46-b321-cc218a37b443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615ceceeaed5466fb85286d706d29b85_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTAtMy0xLTEtMzAzNTE_74ebdd82-916d-49dc-8df6-11e9ab276241">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716d135486924cee81e022c6ac2e5d44_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTEtMS0xLTEtMzAzNTE_3184b778-085e-403c-be0d-cbf6b2a43ea7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5e6adc3fef490dbca284a3b1c6289d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTEtMy0xLTEtMzAzNTE_29df149d-ee85-49ff-9704-997b2c1518a8">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Janssen Collaboration Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ba2d8537d1401aa4d567fbd40f5201_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTItMS0xLTEtMzAzNTE_b83cef52-9043-4f89-8c30-90a74ffeb544">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie796a038ce0e48ce994e533569bf1dff_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTItMy0xLTEtMzAzNTE_3b245769-cdbe-48b8-8bfe-c9f3588fabc5">3,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Point in Time</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Mundipharma Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1fea76ca9d480da5ec1b4279d7de92_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNC0xLTEtMS0zMDM1MQ_be993971-a249-4ddc-8157-df4bf61b350e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic368059479da424f931465560c9ec6ae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNC0zLTEtMS0zMDM1MQ_6d39c3c8-0024-47c7-a294-e1133bc2f9cf">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8326f1cfdd2e45bda044cbe96cfa6825_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNS0xLTEtMS0zMDM1MQ_8b6842d3-ba0c-4192-b915-6114820ac999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7f4f7d381047d6b390662bf856366c_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNS0zLTEtMS0zMDM1MQ_76f5fec7-d714-4803-a0ce-86487b771eae">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Mundipharma Collaboration Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c0da6f182649489b0466ee3d5e1e90_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNi0xLTEtMS0zMDM1MQ_f9f3668a-4ca9-48b1-973a-1da8578ffd56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e055b607f746a7bb4d400492c18aae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNi0zLTEtMS0zMDM1MQ_0c14fdcb-ea8b-4875-b5fd-6bd05b1486c0">2,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYxMQ_b9c4ce2a-011c-4630-acf5-01f196790d04" continuedAt="i45c3ab756764416ebda6b39f9b63b712" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i45c3ab756764416ebda6b39f9b63b712"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 14, 2021, the Company entered into a sixth amendment to its lease with Nancy Ridge Technology Center, L.P. which extended the term of the lease by an additional <ix:nonNumeric contextRef="ida2575eac8b54cbd9b8d91895a8f0d63_I20210714" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMjI1_c17dcef2-d8e0-4aaa-af90-bbba41e924d6">24</ix:nonNumeric> months and increases the base rent to $<ix:nonFraction unitRef="usd" contextRef="i4d38d95a623e4c7db64c6031f9fbdbde_D20210714-20210714" decimals="0" name="cdtx:LesseeOperatingLeaseMonthlyRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMjU5_bd30beca-db7c-4b5b-81e4-6665c97073f1">103,733</ix:nonFraction> per month effective January 1, 2022, subject to <ix:nonFraction unitRef="number" contextRef="i4d38d95a623e4c7db64c6031f9fbdbde_D20210714-20210714" decimals="2" name="cdtx:LesseeOperatingLeaseAnnualRateIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMzEw_59f1f2e7-6532-4f4a-88ac-0d9f1c1bca02">3</ix:nonFraction>% increases every January. The lease expires on December 31, 2023 with options for <ix:nonFraction unitRef="option" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="INF" name="cdtx:NumberOfOperatingLeaseOptionsForExtension" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMzk0_65706300-ed17-401d-8681-ff258819d07b">two</ix:nonFraction> individual <ix:nonNumeric contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYwNg_bf86aeae-bb7d-4578-b2f2-fe73bc0c4f09">two-year</ix:nonNumeric> extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of March&#160;31, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. The incremental borrowing rate used in measuring the Company's lease liability was <ix:nonFraction unitRef="number" contextRef="ida2575eac8b54cbd9b8d91895a8f0d63_I20210714" decimals="3" name="cdtx:LesseeOperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfNjM5_63f6522f-ded7-4b00-b016-f133efff628e">10.8</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYwOA_88d5d57e-8c54-4617-84d6-bfc3a6e0add1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfMS0xLTEtMS0zMDM1MQ_d2487ffc-85a0-4511-97bb-e2778db125e5">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfMi0xLTEtMS0zMDM1MQ_f0182190-6490-4dbf-a41c-35b05525fc32">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfMy0xLTEtMS0zMDM1MQ_03728353-d822-4458-b3f3-8f87f7079bcb">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfNC0xLTEtMS0zMDM1MQ_593b8c6e-6c16-4d3d-8ce3-d8a8645d30b5">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfNS0xLTEtMS0zMDM1MQ_3b09184d-394b-4a7f-a15a-286617d9b79c">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="cdtx:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYxMg_23a4065e-c350-4f67-927f-7b4cdf432715" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company's operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfMS0xLTEtMS0zMDM1MQ_0430da2c-d7c6-4066-957a-28b8e7b71517">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfMy0xLTEtMS0zMDM1MQ_8cb80639-c3e2-474e-9cbe-cb38847fd5a0">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfNC0xLTEtMS0zMDM1MQ_06e03780-8709-4740-b711-1cd163a274dd">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfNS0xLTEtMS0zMDM1MQ_becc5def-94b5-4ad1-be7d-34eb6ebc364f">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the weighted average remaining lease term was <ix:nonNumeric contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfOTYz_e3dd4e90-ef86-4d48-b4fb-38a195a8217b">1.8</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTA1NA_6cba11a0-9788-4eea-805d-76a460f06905">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTA5OTUxMTYyOTkwOA_bac33516-b48f-4d61-a8fc-8bb7b8b7b8be">0.2</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTExMg_dcbfcf57-f092-4954-b335-d02bd08b2311">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTA5OTUxMTYyOTk2MQ_0ad4717d-c244-4b95-afa0-ff1a8a4e9131">0.2</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2022 and 2021 respectively. These costs are primarily related to the Company's long-term operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTMyMw_efbdc555-c3e4-4edc-824b-9774fb6cc882">30</ix:nonNumeric> days.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div></ix:continuation><div id="i12928d5708484b01a3ce462a99216eeb_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81OC9mcmFnOjFhYjZlMGMyNDRlMzQzZDlhOTQwMGRiMTdiYWJiNWI1L3RleHRyZWdpb246MWFiNmUwYzI0NGUzNDNkOWE5NDAwZGIxN2JhYmI1YjVfNTYx_72ab6694-be89-4dcf-8db9-fd2bea30e534" continuedAt="i22f972e4d7b744b3b562c6b92150b14d" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="i22f972e4d7b744b3b562c6b92150b14d">On April 20, 2022, the Company entered into a Letter Agreement with Mundipharma, which amended the Mundipharma Collaboration Agreement, under which the Company is eligible to receive prepayment of one milestone payable pursuant to Section 5.4 of the Mundipharma Collaboration Agreement as reimbursement for the cost of the Company continuing or conducting certain rezafungin development activities, up to a total of $<ix:nonFraction unitRef="usd" contextRef="i7ab61c4680194901bbce5f08a8fd1c4c_I20220420" decimals="-5" name="cdtx:CollaborativeArrangementPotentialPrepaymentMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81OC9mcmFnOjFhYjZlMGMyNDRlMzQzZDlhOTQwMGRiMTdiYWJiNWI1L3RleHRyZWdpb246MWFiNmUwYzI0NGUzNDNkOWE5NDAwZGIxN2JhYmI1YjVfMTA5OTUxMTYzMDYzOA_78b84767-c92d-491f-9b12-bec1f4492de4">11.1</ix:nonFraction> million. Any such amounts prepaid by Mundipharma will be deducted from the milestone anticipated to be payable in 2022 to the Company by Mundipharma pursuant to the Mundipharma Collaboration Agreement. If not prepaid, the remaining portion of such milestone will be due upon achievement of the applicable triggering event as set forth in the Mundipharma Collaboration Agreement.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report, and our Annual Report on Form 10-K, or our Annual Report, for the year ended December&#160;31, 2021, filed with the Securities and Exchange Commission, or the SEC, on March 7, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, clinical and nonclinical data, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management and the impact of the COVID-19 pandemic on the foregoing. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. We are focused on infectious diseases and oncology. Our lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we are using our Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. Our initial development programs target influenza and other viral infections, including RSV, the SARS-CoV-2 strains causing COVID-19, and HIV. In addition, we have recently expanded the Cloudbreak platform to discover and develop DFCs to treat cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our business is subject to various trends, events or uncertainties that are reasonably likely to cause our reported financial information not to be necessarily indicative of future operating results or of future financial condition. As discussed below, the COVID-19 pandemic has delayed our conduct of clinical trials and other key activities and there is uncertainty regarding the emergence of potential new COVID-19 strains. We may also be impacted by broader macroeconomic conditions, high inflation, and supply chain disruptions. The stock market, and in particular the market for pharmaceutical and biotechnology company stocks, has recently experienced significant decreases in value. This volatility and valuation decline have affected the market prices of securities issued by many companies, often for reasons unrelated to their operating performance. These and other uncertainties are discussed in greater detail below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We continue to monitor the potential impact of the COVID-19 global pandemic on our business and maintain our previously implemented measures designed to protect the health and safety of our workforce, including a work-from-home policy in line with state and local requirements for employees who can perform their jobs offsite. We are continuing our essential research and laboratory activities at our facilities and are taking precautionary measures to protect our employees working in our facilities in such capacities, including establishing a written worksite-specific COVID-19 prevention plan and implementing a vaccine mandate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are reliant on our information technology systems, infrastructure and data to conduct our business. Adopting a work-from-home policy during this pandemic has increased the complexity of our computer systems, making them inherently more vulnerable to service interruption or destruction, malicious intrusion and random attack.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While we have not experienced significant disruptions to our manufacturing supply chain or distribution to date, we are unable to fully assess the potential impact that an extended duration of this pandemic may have on our manufacturing or distribution processes in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As we continue to actively advance our rezafungin Phase 3 clinical development program, we remain in close contact with our principal investigators and clinical sites and continue to monitor the impact of COVID-19 on our trials, expected timelines and costs on an ongoing basis. While the ReSPECT Phase 3 clinical trial for prophylaxis remains open for enrollment, we continue to monitor the near- and long-term impact of COVID-19 on the ability of our clinical investigators to recruit patients at each of our global clinical trial sites. In addition, many clinical trial operational activities typically require travel, such as site activation, monitoring, investigators&#8217; meetings and quality audits. These activities are still impacted by travel restrictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to affect areas in which we operate, and we believe the outbreak continues to have a negative impact on our operating results and financial condition. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. Given these uncertainties and new information that may continue to emerge about COVID-19 strains, the full extent of the impact of the COVID-19 pandemic cannot be accurately predicted at this time, and we remain unable to reasonably estimate the related impact to our business, operating results and financial condition, if any. We will continue to evaluate and actively monitor the impact of the COVID-19 pandemic on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Rezafungin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin is a novel molecule in the echinocandin class of antifungals. We are developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSTORE Phase 3 clinical trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2021, we reported positive topline results from ReSTORE, our Phase 3 pivotal clinical trial in patients with candidemia and/or invasive candidiasis (NCT03667690). ReSTORE was a global, randomized, double-blind, controlled trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. ReSTORE enrolled 187 patients and evaluated one 400 milligram, or mg, dose of rezafungin for the first week followed by 200 mg of rezafungin dosed once-weekly for up to four weeks in total. The treatment arm was compared to approved daily dosing of caspofungin in a 1:1 randomization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Results from the ReSTORE trial showed:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Rezafungin met the primary endpoint for the U.S. Food and Drug Administration, or FDA, New Drug Application, or NDA, submission of all-cause mortality at Day 30 of 23.7% for rezafungin compared to 21.3% for caspofungin (difference, 2.4; 95% CI for risk difference -9.7 to 14.4); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Rezafungin also met the primary endpoint for the European Medicines Agency, or EMA, Marketing Authorization Application, or MAA, submission of global cure at Day 14 of 59.1% for rezafungin compared to 60.6% for caspofungin (difference, -1.1; 95% CI for risk difference -14.9 to 12.7).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To meet the pre-specified limit of non-inferiority, the upper (for all-cause mortality) and lower (for global cure) 95% confidence limits for the difference between arms must be within 20%. Both endpoints met the pre-specified 20% limit, establishing non-inferiority.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Patients receiving rezafungin were discharged from the intensive care unit, or ICU, a median 9.5 days earlier than patients receiving caspofungin (5.0 vs 14.5 days, respectively). Further data from the ReSTORE trial demonstrated high rates of early mycological efficacy with rezafungin:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Negative blood culture at 24 hours was 53.7% for rezafungin versus 46.2% for caspofungin and 74.2% versus 64.1% at 48 hours; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Median time to negative blood culture was 23.9 hours for rezafungin versus 27.0 hours for caspofungin (p=0.175).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin was generally well tolerated. Overall rates of adverse events and serious adverse events were comparable in patients receiving rezafungin and caspofungin. Rates of adverse events leading to study drug discontinuation were also similar for rezafungin and caspofungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have completed the ReSTORE trial and conducted the primary analyses required for potential approval in the U.S. and Europe. Enrollment of patients in China continues to support Chinese regulatory filings.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">STRIVE Phase 2 clinical trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2018 and July 2019, we reported positive topline results from Parts A and B, respectively, of STRIVE, our global, randomized Phase 2 clinical trial of rezafungin (NCT02734862). STRIVE was an international, multicenter, double-blind clinical trial evaluating the safety, tolerability and efficacy of once-weekly dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis. In the STRIVE clinical trial, rezafungin met all of its objectives for efficacy, safety and tolerability in the treatment of patients with candidemia and/or invasive candidiasis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Integrated ReSTORE Phase 3 and STRIVE Phase 2 results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Integrated results from both our Phase 3 ReSTORE trial and our Phase 2 STRIVE trial across all patients who received the 400 mg/200 mg dosing regimen demonstrate that rezafungin is non-inferior to caspofungin for treatment of candidemia and invasive candidiasis. The data showed numerically improved outcomes as compared to caspofungin across several key measures:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">All-cause mortality at Day 30, the primary endpoint for the FDA, was 18.7% for rezafungin and 19.4% for caspofungin (weighted mortality difference, -1.5%; 95% CI: -10.7 to 7.7, stratified analysis by study).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Mycological eradication at Day 5 and Day 14 was 73.4% and 71.9%, respectively, for rezafungin and 64.5% and 68.4%, respectively, for caspofungin.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Mycological eradication at Day 5 for patients with candidemia only was 80.0% for rezafungin and 67.8% for caspofungin.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">The percentage of subjects with negative blood culture at 24 hours was 60.0% for rezafungin versus 49.1% for caspofungin and 77.7% versus 63.5% at 48 hours.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Patients receiving rezafungin had faster median time to negative blood culture (22.3 hours) compared to caspofungin (26.3 hours) (p=0.0051).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Both the STRIVE and ReSTORE trials demonstrated similar tolerability outcomes for rezafungin and caspofungin and did not reveal any concerning trends in treatment emergent adverse events or serious adverse events.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Pre-NDA meetings with the FDA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following recent positive pre-NDA interactions with the FDA , we remain on track to submit our NDA for rezafungin for the treatment of candidemia and/or candidiasis, based on Phase 2 STRIVE and Phase 3 ReSTORE clinical studies, in mid-2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSPECT Phase 3 clinical trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are currently conducting the ReSPECT, single, global, randomized, double-blind, controlled Phase 3 pivotal clinical trial (NCT04368559) in patients undergoing allogeneic blood and marrow transplant to assess rezafungin in a 90-day prophylaxis regimen to prevent infections due to Candida, Aspergillus and Pneumocystis. Rezafungin, dosed at 400 mg for the first week followed by 200 mg once weekly doses out to 90 days, is being compared to a regimen containing two drugs (an azole and Bactrim) dosed once daily for 90 days. The primary efficacy outcome for the FDA and EMA is fungal-free survival at day 90. We expect this trial to enroll approximately 462 patients. While the ReSPECT trial remains open for enrollment, we continue to monitor the near- and long-term impact of COVID-19 on the ability of our clinical investigators to recruit patients at each of our global clinical trial sites.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we announced a strategic partnership with Mundipharma to develop and commercialize rezafungin in an intravenous formulation for the treatment and prevention of invasive fungal infections. Under the terms of the Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma, we granted Mundipharma an exclusive, royalty-bearing license to develop, register and commercialize rezafungin outside the U.S. and Japan. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we have received $9.0&#160;million from the sale of our equity to Mundipharma, a $30.0&#160;million up-front payment and $42.3&#160;million in global development funding, which includes an $11.1&#160;million milestone payment we received in January 2021 which is creditable against future royalties payable to us. In addition, we received $2.8&#160;million in January 2022 pursuant to a milestone achieved in December 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe our Cloudbreak platform has the potential to offer a fundamentally new approach to prevent and treat serious diseases, by developing product candidates designed to provide potent disease targeting activity and immune system engagement in a single long-acting molecule. Because serious disease often results when a pathogen or cancer cell evades or overcomes the host immune system, our Cloudbreak DFC candidates are designed to counter diseases in two ways: prevention of disease proliferation or immune evasion by directly targeting and, where applicable, by focusing the immune system on a pathogen or infected cell. We believe this is a potentially transformative approach, distinct from current therapies, monoclonal antibodies and vaccines. In addition, DFCs are designed to have several advantages, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Multivalent binding which has the potential to increase potency;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Ability to engage different targets on the same pathogen to decrease resistance or, in the case of a cancerous cell, to serve as a &#8220;drug cocktail&#8221; in a single molecule, which may improve response to treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential to target multiple viral pathogens or oncological targets with a single DFC; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential for universal coverage against all viral variants and all people irrespective of immune status.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In contrast to monoclonal antibodies, our DFCs are smaller, have the potential for better tissue penetration and are designed to target multiple sites. Unlike small molecules, we believe DFC optimization can be focused primarily on potency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lead Cloudbreak candidates are DFCs for the prevention and treatment of influenza, or influenza DFCs. In September 2020, we nominated CD388, our influenza DFC, as a development candidate. CD388 is similar to our previous development candidate, CD377, but provides the potential for longer-lasting protection from influenza. We submitted an IND for CD388 in December 2021. In March 2022, we initiated a Phase 1 trial for CD388 under an IND. The Phase 1 trial (NCT05285137), which dosed its first healthy volunteer in mid-March 2022, is a randomized, double-blind, dose-escalation study to determine the safety, tolerability and pharmacokinetics of intramuscular and subcutaneous administration of CD388 in healthy subjects. To date, dosing of the first three cohorts have been completed and the fourth dosing cohort is advancing as planned. This trial is fully funded by Janssen as part of the Janssen Collaboration Agreement (as defined below).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Cloudbreak platform has also enabled us to expand the development of DFCs to target other life-threatening viruses, including RSV and HIV. In response to the global pandemic, we are also leveraging our Cloudbreak platform to identify new DFCs against Coronavirus including the strains causing COVID-19. In addition, we have expanded the Cloudbreak platform beyond infectious diseases to discover and develop highly potent DFCs that can target multiple pathways with a single DFC for oncologic diseases.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we entered into the exclusive, worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize one or more DFCs based on our Cloudbreak platform for the prevention and treatment of influenza.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the Janssen Collaboration Agreement, we will collaborate in the research, preclinical and early clinical development of CD388, under a mutually-agreed research plan with the objective of advancing development through Phase 1 clinical trials and the first Phase 2a clinical trial. We will be responsible for performing all IND-enabling nonclinical studies and early-stage clinical trials under the research plan. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the research plan. Janssen will be solely responsible, and reimburse us for internal personnel and out-of-pocket costs incurred in performing the research plan activities in accordance with an agreed budget. After completion of the research plan and upon its election to proceed with development, Janssen will be solely responsible for late-stage development, manufacturing, licensure and commercialization. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid us an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, we are entitled to reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting research plan activities. As of March&#160;31, 2022, we have received the $27.0&#160;million up-front payment and $10.2&#160;million in research and development reimbursements. In addition, we received $3.0&#160;million in May 2022 pursuant to a milestone achieved in March 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to an additional $237.0&#160;million in development and regulatory milestone payments from Janssen for successful completion of certain activities over the next several years, including but not limited to Janssen's decision to proceed with clinical development and initiation of a pivotal trial. In addition, we may be eligible to receive approximately $455.0&#160;million in commercial milestones as well as royalties on tiers of annual net sales of products at rates from the mid-single digits to the high-single digits.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our financial resources and efforts to research and development and have incurred significant operating losses. As of March&#160;31, 2022, we had an accumulated deficit of $395.4 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the preparation of our financial statements for the three month period ended March&#160;31, 2022, we performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents may not be sufficient to fund our obligations for twelve months from the issuance of these financial statements. Our ability to execute our current business plan depends on our ability to obtain additional funding through equity offerings, debt and other non-dilutive financing alternatives, or potential licensing and collaboration arrangements. We may not be able to raise additional funding on terms acceptable to us, or at all, and any failure to raise funds as and when needed will compromise our ability to execute on our business plan.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, we have generated all of our revenues from our strategic partnerships with Mundipharma and Janssen. In the future, we may generate revenue from a combination of license fees and other upfront payments, other funded research and development agreements, milestone payments, product sales, government and other third-party funding and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of nonclinical, clinical, regulatory and commercialization milestones, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized. If we are unable to fund our development costs or we are unable to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues and our results of operations and financial position would be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to nonclinical development of our rezafungin acetate and our Cloudbreak platform, as well as clinical development of rezafungin acetate. Research and development expenses consist of wages, benefits and stock-based compensation for research and development employees, as well as the cost of scientific consultants, facilities and overhead expenses, laboratory supplies, manufacturing expenses and nonclinical and clinical trial costs. We accrue clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies or other activities within studies and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of the study or project and the invoices received from our external service providers. We adjust our accruals as actual costs become known.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may receive potential research and development funding through a partnership from the National Institute of Allergy and Infectious Diseases. We have evaluated the terms of the grants to assess our obligations and the classification of funding received. Amounts received for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet our obligations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several years as we continue to conduct nonclinical and clinical studies, expand our research and development pipeline and progress our product candidates through clinical trials. However, it is difficult to determine with certainty the duration, costs and timing to complete our current or future nonclinical programs and clinical trials of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact of the COVID-19 pandemic and other similar health crises;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients that participate in the trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">potential additional safety monitoring or other studies requested by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the duration of patient follow-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the phase of development of the product candidate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and safety profile of the product candidates.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses by major program or category were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rezafungin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cloudbreak platform</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We typically deploy our employees, consultants and infrastructure resources across our programs. Thus, some of our research and development expenses are not attributable to an individual program but are included in other research and development expenses as shown above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning, and support functions. Other general and administrative expenses include facility and overhead costs not otherwise included in research and development expenses, consultant expenses, travel expenses and professional fees for auditing, tax, legal, and other services. We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with operating as a publicly traded company. These increases will likely include legal fees, accounting fees, directors&#8217; and officers&#8217; liability insurance premiums and costs associated with investor relations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other expense consists primarily of interest income and expense, and various income or expense items of a non-recurring nature.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We earn interest income from interest-bearing accounts and money market funds for cash and cash equivalents. Interest expense represents interest payable related to term loans and the amortization of debt issuance costs.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based upon unaudited financial statements that we have prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these unaudited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities as of the date of the financial statements, and the revenues and expenses incurred during the reporting periods. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">judgments and assumptions are made. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. Historically, revisions to our estimates have not resulted in a material change to our financial statements. While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements contained in our Annual Report on Form 10-K, the significant accounting estimates that we believe are important to aid in fully understanding and evaluating our reported financial results include the following:</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We recognize revenue in accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or service we transfer to a customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and identify those that are performance obligations, and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, we recognize revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. We evaluate the measure of progress at each reporting period and, if necessary, adjust the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of milestones that are within our or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to our estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, we have not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the we entered into the Mundipharma Collaboration Agreement with Mundipharma. We concluded that there were three significant performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, we entered into the Janssen Collaboration Agreement with Janssen. We concluded that there were three significant performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. We periodically review and update the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to our estimates have no impact on our reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments and estimated reimbursable research and development and clinical supply costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 to the financial statements for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;We accrue nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events. We periodically confirm the accuracy of these estimates with our service providers and make adjustments if necessary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. Our accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We account for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance RSUs, or PRSUs, and employee stock purchase plan, or ESPP, rights by estimating the fair value on the date of grant. We estimate the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of our common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of our stock, (c) the expected term of the award, and (d) the expected dividend yield. We computed the historical volatility data using the daily close prices for our common stock during the equivalent period of the calculated expected term of our stock-based awards. We estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">securities. The expected dividend yield of zero reflects that we have not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We recognize forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended March&#160;31, 2022 and 2021 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Collaboration revenue was $7.1 million for the three months ended March&#160;31, 2022 and $2.4 million for the three months ended March&#160;31, 2021. Revenue for the three months ended March&#160;31, 2022 relates to ongoing research and development and clinical supply services provided to Mundipharma and Janssen of $2.5 million and $3.1&#160;million, respectively, as well as $1.5&#160;million of revenue recognized upon the achievement of a milestone under the Janssen Collaboration Agreement. Revenue for the three months ended March&#160;31, 2021 relates to ongoing research and development and clinical supply services provided to Mundipharma.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses were $20.2 million for the three months ended March&#160;31, 2022 and $15.8&#160;million for the three months ended March&#160;31, 2021.&#160;The increase in research and development expenses is primarily due to higher clinical expenses associated with the drug manufacturing costs for rezafungin, higher clinical expenses associated with the Janssen Collaboration Agreement, and higher consulting and personnel costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative expenses were $5.2 million for the three months ended March&#160;31, 2022 and $4.8 million for the three months ended March&#160;31, 2021. The increase in general and administrative expenses is primarily due to higher consulting and legal costs, offset by a decrease in personnel costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other expense, net during the three months ended&#160;March&#160;31, 2022&#160;and March&#160;31, 2021 related primarily to interest expense in connection with our loan from Pacific Western Bank, offset by interest income generated from cash held in interest-bearing investments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, as well as the cash flows generated from our partnerships with Mundipharma and Janssen, equity and debt financings. We have devoted our resources to funding research and development programs, including research, preclinical and clinical development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to fund future operating needs will depend on a combination of equity, debt or other financing structures, receipt of payments under the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement, as well as potentially entering into other collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts. Our ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the ongoing COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to $237.0&#160;million in development and regulatory milestone payments from Janssen for successful completion of certain activities over the next several years, including but not limited to Janssen's decision to proceed with clinical development and initiation of a pivotal trial. In addition, we may be eligible to receive approximately $455.0&#160;million in commercial milestones as well as royalties on tiers of annual net sales of products at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 8, 2018, we entered into the controlled equity offering sales agreement with Cantor Fitzgerald &amp; Co, or the Sales Agreement, pursuant to which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0&#160;million. As of March&#160;31, 2022, the aggregate offering price remaining under the Sales Agreement was $48.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The maturity date of our loan with Pacific Western Bank is July 3, 2022, at which time all obligations under the Loan Agreement will be due and payable. As of March&#160;31, 2022, future principal payments due under the loan agreement were $1.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lease with Nancy Ridge Technology Center, L.P. expires on December 31, 2023 with options for two individual two-year extensions, which have not been exercised, and remain in effect and available to the Company. As of March&#160;31, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. Total undiscounted operating lease payments are $2.4 million as of March&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed further below, we believe that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months. There are many factors that could impact our operating cash flow, most notably achievement of milestones under our Mundipharma and Janssen Collaboration Agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. We operate and conduct clinical trials in countries that face economic volatility and weakness. Sustained weakness or further deterioration of the local economies and currencies and adverse effects of the impact of the ongoing COVID-19 pandemic may pose operational challenges in those countries. We will continue to monitor these conditions and will attempt to adjust our business plans, as appropriate, to mitigate macroeconomic risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services that generally provide for termination either on notice or after a notice period. Our material cash requirements include costs to complete agreed-upon activities under our Mundipharma and Janssen Collaboration agreements, as well as personnel and general and administrative support costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had $38.0 million in cash, cash equivalents and restricted cash. The following table shows a summary of our cash flows for the three months ended March&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(23,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(24,303)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in operating activities was $23.6 million for the three months ended March&#160;31, 2022, compared to net cash used in operating activities of $1.8&#160;million for the three months ended March&#160;31, 2021. Cash used in operating activities for the three months ended March&#160;31, 2022 was primarily attributable to a net loss of $18.3 million and included $2.8&#160;million for a milestone achieved in December 2021 under the Mundipharma Collaboration Agreement, which was received in January 2022. Cash used in operating activities for the three months ended March&#160;31, 2021 was primarily attributable to a net loss of $18.3 million and included $11.1&#160;million for a milestone achieved in November 2020 under the Mundipharma Collaboration Agreement, which was received in January 2021. For all periods presented, the primary use of cash was to fund research and development activities for our product candidates, which activities and uses of cash we expect to continue to increase for the foreseeable future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our investing activities during the three months ended March&#160;31, 2022 and 2021 consisted of purchases of property and equipment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in financing activities during the three months ended March&#160;31, 2022 primarily consisted of net proceeds of $0.5&#160;million from the sale of 644,265 shares of common stock under the Sales Agreement, after deducting placement agent fees, offset by principal payments of $1.1 million made in connection with our loan from Pacific Western Bank. Net cash provided by financing activities during the three months ended March&#160;31, 2021 primarily consisted of net proceeds of $8.8&#160;million from the sale of 3,412,787 shares of common stock under the Sales Agreement, after deducting placement agent fees, offset by principal payments of $1.1&#160;million made in connection with our loan from Pacific Western Bank.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months. Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. We plan to continue to fund our losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide information typically disclosed under this item.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of March&#160;31, 2022 due to a material weakness in internal control over financial reporting described below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Material Weakness in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We determined that our review control over the evaluation of applicable accounting standards and assessment of completeness and accuracy of valuation assumptions, related to non-routine transactions that include collaboration revenue, was not appropriately designed or operating effectively. While this improper design and operation did not result in a material error in the annual or interim financial statements, there is a reasonable possibility that a material misstatement in the annual or interim financial statements would not have been detected. Based on these factors, we concluded that the control deficiency noted above represents a material weakness.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Remediation of Material Weakness</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are committed to maintaining a strong internal control environment and implementing measures to ensure that the control deficiency identified above is remediated as soon as possible. Management is in the process of implementing a remediation plan, which includes adding additional layers of review by members of our management team regarding the evaluation of applicable accounting standards and completeness and accuracy of valuation assumptions related to non-routine transactions that include collaboration revenue. The remediation actions are being monitored by the Audit Committee of our Board of Directors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i12928d5708484b01a3ce462a99216eeb_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div id="i12928d5708484b01a3ce462a99216eeb_97"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Our operations, business and financial results have been and could continue to be adversely impacted by the current public health pandemic related to COVID-19.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We depend heavily on the success of rezafungin, currently in Phase 3 clinical development, and CD388, currently in Phase 1 clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we experience delays or difficulties in enrolling patients in our clinical trials, including the ReSPECT trial, our ability to complete the rezafungin clinical development program, and therefore our receipt of necessary regulatory approvals, could be delayed or prevented.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If clinical trials for rezafungin, CD388 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We may not be successful in our efforts to identify, discover, and develop potential product candidates through our Cloudbreak platform or otherwise.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We need substantial additional funding to complete the development of rezafungin and to advance CD388 and our Cloudbreak program.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We are dependent on our collaboration partners to provide funding to continue the development of rezafungin and CD388; for the commercialization of rezafungin outside of the U.S. and Japan; and for the late-stage development, manufacturing, registration and commercialization of CD388. If the collaborations are not successful, we may not be able to complete the development of rezafungin and CD388, or capitalize on the full market potential for rezafungin and CD388.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be forced to suspend or terminate one or more of our preclinical Cloudbreak programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_1182"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, as well as the other information in this Quarterly Report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. When evaluating our business, you should consider all of the factors described as well as the other information in our Annual Report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_100"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our operations, business and financial results have been and could continue to be adversely impacted by the current public health pandemic related to COVID-19.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In January 2020, the World Health Organization, or WHO, announced a global health emergency because of a new strain of novel coronavirus known as COVID-19 and, in March 2020, the WHO declared the COVID-19 outbreak a pandemic, or the COVID-19 pandemic. The COVID-19 pandemic has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business interruptions and shutdowns. These precautions have disrupted our business operations and prospects. For example, we have experienced, and expect to continue to experience, trial site activation and enrollment delays for the ReSPECT clinical trial due to facility restrictions, quarantines, travel restrictions, focus on COVID-specific trials and other obstacles. The COVID-19 outbreak and mitigation measures also have had and may continue to have an adverse impact on global economic conditions which could impair our ability to raise capital when needed. While the disruption from COVID-19 has had and we expect it to continue to have an adverse effect on our business, financial condition and results of operations, we are unable to predict the extent or nature of these impacts at this time. In addition, to the extent the ongoing COVID-19 outbreak continues to adversely affect our business, financial condition, results of operations and growth prospects, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this "Risk Factors" section.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_103"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Drug Discovery, Development and Commercialization</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of rezafungin, currently in Phase 3 clinical development, and CD388, currently in Phase 1 clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are currently conducting two Phase 3 clinical trials of rezafungin. We have completed the ReSTORE trial and conducted the primary analyses required for potential approval in U.S. and Europe but are continuing to enroll and treat patients in China to support Chinese regulatory filings. The ReSPECT trial is currently enrolling globally. We have received IND clearance from the FDA allowing us to begin enrolling subjects in March 2022 in our first Phase 1 clinical trial of CD388, our DFC for prevention and treatment of influenza. We are also conducting in vitro and in vivo preclinical studies of other product candidates from our Cloudbreak program for viral infections and oncology indications. Our assumptions about why rezafungin and CD388 are worthy of continued development, as well as our assumptions about the markets for rezafungin, CD388 or any other potential products from our Cloudbreak program, are based on data primarily collected by other companies. The timing and costs of our preclinical and clinical development programs, the likelihood of marketing approval for rezafungin and CD388, and the regulatory paths for marketing approval for additional products from our Cloudbreak program remain uncertain. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of rezafungin, CD388 and any other product candidates we may develop will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact of the COVID-19 pandemic on our operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to secure adequate additional funding;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">agreement with regulatory authorities on study designs and other requirements for study initiation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful completion of preclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful enrollment and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">demonstration of safety and efficacy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">negotiation of favorable indications and other key elements of the product labeling;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">launching commercial sales of the product candidates if and when approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">effectively competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a continued acceptable safety profile of the products following approval; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enforcing and defending intellectual property rights and claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we do not timely enroll the ReSPECT Phase 3 clinical trial, or if we are unable to secure significant additional funding, we will not be able to complete the clinical development plans for the prophylaxis indication for rezafungin. If we do not accomplish one or more of any of the other goals in a timely manner, or at all, we could experience significant delays or an inability to successfully complete the development of and commercialize our product candidates, which would harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in enrolling patients in our clinical trials, including the ReSPECT trial, our ability to complete the rezafungin clinical development program, and therefore our receipt of necessary regulatory approvals, could be delayed or prevented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may not be able to complete the ReSPECT clinical trial or the ongoing portion of the ReSTORE trial in China if we are unable to identify and enroll a sufficient number of eligible patients, as required by the FDA or similar regulatory authorities outside the U.S., or if we do not believe that the number of patients required by such regulatory authorities can be enrolled in a reasonable timeframe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our rezafungin Phase 3 clinical development program is a global program and, as such, our ability to timely enroll the clinical trials may be affected by many different factors specific to those global localities, such as, delays in our receipt of approval to commence trials in a particular country from applicable regulatory authorities and ethics committees, timely completion of clinical trial site initiation within each country, delays in local importation and receipt of necessary clinical trial supplies, and our ongoing compliance with local regulations, which may change during the course of the clinical trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the rezafungin clinical trials are heavily reliant on third-party contractors, including contractors that import clinical trial materials, and CROs that conduct and monitor our clinical trials, and interact with regional or local regulators and ethics committees on our behalf. If we experience significant difficulties with any of our key contractors such that we determine it is in the best interests of the clinical trials to replace a key contractor, this could result in a significant delay in enrollment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, timely enrollment in the ReSPECT trial is reliant on global clinical trial sites, most of which have been adversely affected by the COVID-19 global pandemic. For example, the COVID-19 global pandemic has significantly impacted our ability to activate sites and enroll patients in the ReSPECT trial in Europe and the U.S., resulting in substantial delays and increases in the cost of completing the trial. Our enrollment of patients in ReSTORE in China was also delayed in part due to the pandemic. Some factors from the COVID-19 coronavirus outbreak that have adversely affected enrollment in our Phase 3 trials include:</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the diversion of healthcare resources away from the conduct of clinical trial matters to focus on pandemic concerns, including the attention of infectious disease physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the decision of some clinical trial sites to focus on the conduct of COVID-19 clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">limitations imposed by hospitals serving as our clinical trial sites that prohibit entry on hospital premises by persons other than those supporting the hospital's COVID-19 efforts;</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">limitations on travel that interrupt key trial activities, such as clinical trial site initiations and monitoring;</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">interruption in global shipping affecting the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our trials; and</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">employee quarantine or isolation days that delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These and other factors arising from the COVID-19 coronavirus could worsen in countries that are already afflicted with the virus or could continue to spread to additional countries, each of which may further adversely impact our Phase 3 trials. The global outbreak of the COVID-19 coronavirus continues to evolve and the conduct of our Phase 3 trials may continue to be adversely affected, despite efforts to mitigate this impact.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, some of our competitors may have ongoing or new clinical trials for product candidates that would treat the same indications as rezafungin, or be used in the same patients and, therefore, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment may also be affected by other factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">eligibility criteria, including regional or local practices that place additional limitations on patient eligibility;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">availability, safety and efficacy of approved medications or other investigational medications being studied clinically for the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">perceived risks and benefits of rezafungin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reluctance of physicians to encourage patient participation in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">delays or failures in maintaining an adequate supply of quality drug product for use in clinical trials; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changing treatment patterns that may reduce the burden of disease which rezfungin addresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our inability to enroll and retain a sufficient number of patients in a reasonable timeframe may require us to abandon the entire rezafungin Phase 3 clinical development program or terminate the ReSPECT trial or the ReSTORE trial in China. Enrollment delays have and will continue to result in increased development costs, which could cause the value of our company to decline and could limit our ability to obtain necessary additional financing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for rezafungin, CD388 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A delay in starting or completing our clinical trials would materially impact our timelines and our ability to complete development of our product candidates in a timely manner or at all. For example, our entire rezafungin clinical development program has been severely impacted by the effects of the COVID-19 global pandemic. Additionally, our ability to complete our rezafungin Phase 3 development program is dependent on our ability to secure adequate additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A failure of one or more clinical trials could occur at any stage of testing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a particular clinical trial do not necessarily predict final results of that trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, preclinical and clinical data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. For example, the historically observed high rate of correlation for clinical efficacy for anti-infectives based on preclinical data may not apply for our current or future product candidates, and any of the potential benefits that we anticipate for human clinical use may not be realized.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not know whether either the ReSPECT trial or the Phase 1 trial of CD388 will be completed on schedule. We are currently experiencing significant delays in these trials arising from the COVID-19 global pandemic. We may experience numerous other unforeseen events that could delay or prevent our ability to commence or complete our clinical trials, which could then delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial on our expected timeline, or at all, or conduct a clinical trial at a prospective trial site or in a given country;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may disagree with our interpretation of preclinical data, which may impact our ability to commence our trials on our expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may require that trials or studies be conducted, or sized or otherwise designed in ways, that were unforeseen in order to begin planned studies or to obtain marketing authorization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, modify planned clinical trial designs or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enrollment in these clinical trials may be slower than we anticipate, clinical sites may drop out of our clinical trials or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators, institutional review boards or the data safety monitoring board assembled by us to oversee our rezafungin clinical trials may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks due to serious and unexpected side effects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the FDA or comparable foreign regulatory authorities could require that we perform more studies than, or evaluate clinical endpoints other than, those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the supply of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be delayed or insufficient, or the quality of such materials may be inadequate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may be required to delay or terminate studies due to financial constraints.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside the U.S. do not agree with the design and implementation of our planned or ongoing clinical trials, including the safety database to support an NDA submission, or if we are unable to secure additional funding, we may not be able to complete the overall Phase 3 clinical development program for rezafungin as currently envisioned. For example, in response to feedback from the FDA, we may supplement the ReSTORE safety database with safety data from patients enrolled to date from the ReSPECT study who share comorbidities and concomitant medications with patients in the ReSTORE study. If the FDA does not agree with the details of this approach, the timing of our NDA submission and the timing of completion of the ReSPECT study may be impacted. If we do not accomplish one or more of any of the other goals in a timely manner, or at all, we could experience significant delays or an inability to successfully complete the development of and commercialize our product candidates, which would harm our business. If we are required to conduct additional clinical trials, or other tests of our product candidates beyond those that we currently contemplate, if we are unable to complete clinical trials of our product candidates or other tests successfully or in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">not obtain marketing approval at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to additional post-marketing testing requirements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to significant restrictions on reimbursement from public and/or private payors; or</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Product development costs will also increase if we experience delays in testing or in receiving marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, could allow our competitors to bring products to market before we do, could increase competition from generics of the same class, and could impair our ability to successfully commercialize our product candidates, any of which may harm our business and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because it is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval, the risk of each of our programs is high. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. For example, the PK properties, such as a longer half-life or less frequent dosing regimen, that differentiate rezafungin from other echinocandins could have side effects that we have not anticipated and the consequences of such side effects could be more severe than have been seen with other echinocandins that have shorter half-lives or more frequent dosing regimens, or are dosed at lower concentrations than we expect for rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, the treatment advantages that we are predicting for rezafungin, such as lower healthcare costs resulting from an ability to administer rezafungin once-weekly, which could allow earlier hospital discharge, or the predicted ability of rezafungin to be effective against resistant strains of fungal pathogens, may not be realized. For our DFCs, the bispecific mechanism of action, including the use of the immune system, may lead to side effects that are not anticipated based on the preclinical work we have conducted to date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the biotechnology industry, many agents that initially show promise in early stage testing may later be found to cause side effects that prevent further development of the agents. In addition, infections can occur in patients with co-morbidities and weakened immune systems, and there may be adverse events and deaths in our clinical trials that are attributable to factors other than investigational use of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited financial resources. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential than opportunities we pursue. For example, we believe that a supplemental NDA, or sNDA, filing for rezafungin adding the prophylaxis indication can be supported by one Phase 3 trial in prophylaxis, together with the data from our Phase 3 clinical trial in the treatment of candidemia and invasive candidiasis and the remainder of our rezafungin treatment program, however, if financial constraints require us to choose between our planned rezafungin treatment and prophylaxis programs, we may be required to choose our treatment program and forego or delay our prophylaxis program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In support of the global effort to identify effective therapeutics to treat and prevent the COVID-19 coronavirus and stem the current global pandemic, we have expended financial resources to identify DFCs which may be effective in this area. In addition, we have recently expended financial resources on identification of DFCs targeting multiple potentially synergistic oncology targets. We have limited experience in identification and nonclinical and clinical testing of oncology therapeutics. Our resource allocation decisions may not result in us identifying valuable products or may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target markets for a particular product candidate or opportunity, we may relinquish valuable rights to that product candidate or opportunity through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or opportunity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by hospitals and hospital pharmacies, physicians, patients, third-party payors and others in the medical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">community for us to achieve commercial success. If our product candidates do not achieve an adequate level of acceptance, we may not generate sufficient product revenue to become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and potential advantages compared to alternative therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size of the markets in the countries in which approvals are obtained;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terms, limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to offer any approved products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of the target patient population to try new therapies or dosing regimens;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of physicians to prescribe these therapies and, in the case of rezafungin, transition to a once-weekly dosing regimen from traditional once-daily dosing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the success of competing products and the marketing efforts of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sufficient third-party payor coverage and adequate reimbursement; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the prevalence and severity of any side effects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure. To achieve commercial success for any approved product, we must license the rights to third parties with such capabilities, develop a sales and marketing organization or outsource these functions to third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot reposition our sales and marketing personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability of sales personnel to obtain access to physicians or to achieve adequate numbers of prescriptions for any future products; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenues to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties and any of them may fail to market and sell our products effectively, including by failing to devote the necessary resources and attention. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Regulatory incentives to develop drugs for treatment of infectious diseases have increased interest and activity in this area and will lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">pursuing the development of products for the treatment of the indications on which we are focusing our product development efforts. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that rezafungin will primarily compete with certain antifungal classes of drugs, which include polyenes, azoles and echinocandins. Approved branded echinocandin antifungal therapies include Cancidas (caspofungin, marketed by Merck&#160;&amp; Co.), Eraxis (anidulafungin, marketed by Pfizer, Inc.), and Mycamine (micafungin, marketed by Astellas Pharma US, Inc.). We expect that there will be generics of all of the current echinocandins available at the time of rezafungin market approval, which will create added competition.&#160;In addition, there are other generic products approved for candidemia, marketed by companies such as Baxter Healthcare Corporation, Mylan Inc. and Glenmark Generics Inc., among others. In addition to approved therapies, we expect that rezafungin will compete with product candidates that we are aware of in clinical development by third parties, such as SCY-078, being developed by Scynexis, Inc.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">We expect that if we are successful in developing influenza product candidates identified through our Cloudbreak program, such product candidates will compete against approved and investigational agents for the treatment or prevention of viral influenza infections, including influenza vaccines, neuraminidase inhibitors such as Tamiflu, Relenza and Peramivir, and endonuclease inhibitors such as Xofluza. We may develop other product candidates through our Cloudbreak platform for the treatment or prevention of other serious diseases, such as RSV, the SARS-CoV-2 strains causing COVID-19, HIV, and various cancers.&#160;We are aware of a large number of approved and investigational therapies in these areas also.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater name recognition, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These same competitors may invent technology that competes with our rezafungin program, CD388, or our Cloudbreak platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6.25pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analysis of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:6.25pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6.25pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:18pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, these products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-top:6.3pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the U.S., new and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product-licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial marketing approval is granted. As a result, we might obtain marketing approval for a drug in a particular country but then be subject to price regulations that delay its commercial launch, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to commercialize and generate revenue from one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside the U.S. Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our overall financial condition. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and we will face an even greater risk if we commercially sell any products that receive marketing approval. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">decreased demand for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of clinical trial participants;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant costs and distraction of management to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the initiation of investigations by regulatory bodies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability to commercialize any products we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we have product liability insurance for our clinical trials, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue or expand our clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees in our workplace, including those resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, chemical, hazardous or radioactive materials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify, discover, and develop potential product candidates through our Cloudbreak platform or otherwise.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Through our Cloudbreak platform, we are developing DFCs for the treatment and prevention of serious diseases, including influenza, RSV, the SARS-CoV-2 strains causing COVID-19, HIV, and various cancers. We have nominated the DFC CD388 as our lead development candidate for influenza.&#160;In applying our Cloudbreak platform, we may not be successful in identifying additional DFCs that could be developed as drug therapies. In addition, our Cloudbreak platform may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons. In particular, our research methodology used may not be successful in identifying compounds with sufficient potency, bioavailability or efficacy to be potential product candidates. In addition, our potential product candidates may, on further study, be shown to have harmful side effects or other negative characteristics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical expertise and human resources. For example, we have limited experience with the use of the Cloudbreak platform applied to viral pathogens and oncology targets. A failure to optimize our expertise using the Cloudbreak platform for the development of our Cloudbreak program may limit our ability to successfully advance this program and identify future product candidates. Research programs to identify new product candidates also require substantial financial resources. We may choose to expend our financial resources on potential product candidates that ultimately prove to be unsuccessful. For example, in response to the immediate global pandemic crisis, we have expended financial resources to identify therapeutics to treat or prevent the COVID-19 coronavirus, and we may be unsuccessful in identifying such a DFC. If we are unable to identify successful product candidates from our Cloudbreak platform for preclinical and clinical development, we will have spent financial resources on programs that did not yield viable products and therefore generate product revenue, which would harm our financial position and adversely impact our stock price.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We need substantial additional funding to complete the development of rezafungin and to advance CD388 and our Cloudbreak program.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the preparation of our financial statements for the period ended March&#160;31, 2022, we performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months. Our ability to continue to fund the development of rezafungin through completion of our planned Phase 3 trials depends on our ability to obtain additional funding. Our ability to advance CD388 and other product candidates from our Cloudbreak program is also dependent on our ability to obtain additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we entered into the Mundipharma Collaboration Agreement, pursuant to which we granted Mundipharma exclusive commercialization rights to rezafungin outside the U.S. and Japan in exchange for a $30.0&#160;million upfront payment, near-term funding to support the global Phase 3 ReSTORE and ReSPECT trials, and the potential to receive development, regulatory and commercial milestone payments and double-digit royalties on product net sales. The Mundipharma Collaboration Agreement requires, among other things, that we complete the rezafungin development program. On March 31, 2021, we entered into the Janssen Collaboration Agreement, to develop and commercialize our Cloudbreak DFCs for the prevention and treatment of seasonal and pandemic influenza. Under the collaboration, we will be responsible for the development and manufacturing of the first influenza DFC, CD388, into the clinic and through Phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. We received an upfront payment of $27.0&#160;million. Janssen will fund all future research, development, manufacturing and commercialization for CD388, of which Janssen has funded $10.2&#160;million as of March&#160;31, 2022. Our ability to meet our development obligations under the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement depends on our ability to obtain additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There can be no assurance that additional funds will be available from any source or, if available, will be available on terms that are acceptable to us. There can also be no assurance that additional funds will be available to us without first obtaining the approval of our stockholders, which can be a difficult and lengthy process with an uncertain outcome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Even if we raise additional capital, our expenses may increase in connection with our ongoing activities beyond what is currently expected. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the ongoing effect of the COVID-19 global pandemic and the resulting impact on our rezafungin phase 3 clinical development program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing to complete our Phase 3 ReSPECT trial, the remaining Chinese portion of the ReSTORE trial and the CD388 Phase 1 trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs, timing and outcome of any regulatory review of rezafungin, CD388 or future development candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to establish and maintain collaborations, when and if necessary, on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing of commercialization activities, including manufacturing, marketing, sales and distribution, for rezafungin or any future product candidates that receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the scope, progress, results and costs of drug discovery, preclinical development, manufacturing development, laboratory testing and clinical trials for our product candidates, for the Cloudbreak platform; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Identifying potential development candidates and conducting preclinical studies, manufacturing development and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for any of our current or future product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accordingly, we need substantial additional funding in connection with our continuing operations and to achieve our goals. As of March&#160;31, 2022, we had cash, cash equivalents, and restricted cash of $38.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">stability. If the equity and credit markets continue to deteriorate, it may make any additional debt or equity financing more difficult, more costly and more dilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional capital on attractive terms or at all, we may be forced to delay, reduce or eliminate our development programs, including CD388 or one or more of our other Cloudbreak DFC programs, be unable to continue the development of rezafungin, complete the ReSPECT Phase 3 clinical trial and meet our development obligations under the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement, or our other current and future license or collaboration agreements, and/or be forced to make reductions in spending, extend payment terms with suppliers, and/or liquidate or grant rights to assets where possible. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity, debt or other financing structures, receipt of payments under the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement, as well as potentially entering into other collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts. In November 2018, we entered into the Sales Agreement which currently has an aggregate offering price of up to $50.0&#160;million, and, other than the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement, it is our only current external source of potential financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, we issued $9.0&#160;million of our common stock to Mundipharma in connection with entering into the Mundipharma Collaboration Agreement. In February 2020, we issued $30.0&#160;million of our common stock and Series X Preferred Stock upon the closing of a rights offering. In October 2021, we issued $38.5&#160;million of our common stock and Series X Preferred Stock upon the closing of concurrent but separate public offerings. As of March&#160;31, 2022, we have issued 11,779,452 shares of common stock pursuant to the Sales Agreement with an aggregate offering price of approximately $30.2&#160;million. To the extent that we raise additional capital through the sale of equity or convertible debt securities, like the sale of our common stock to Mundipharma, the sale of our common stock and Series X Preferred Stock issued in our rights offering, the sale of our common stock and Series X Preferred Stock in our concurrent public offerings or the sale of common stock under the Sales Agreement, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds by entering into collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. On September 3, 2019, we licensed all rights to rezafungin outside of the U.S. and Japan to Mundipharma in exchange for certain payments and royalties on net sales. In March 2021, we granted exclusive worldwide rights to CD388 and other influenza DFCs to Janssen in exchange for certain payments and royalties on net sales. We may need to enter into similar agreements with other third parties for the development and commercialization of rezafungin outside of the Mundipharma territory, or for the development of DFCs identified from our Cloudbreak program outside the scope of the Janssen Collaboration Agreement, which may require we relinquish valuable rights to these products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds through government grants and contracts, we may be subject to restrictions on our operations or certain unfavorable terms. U.S. government grants and contracts, if available, typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. If we receive a U.S. government grant or contract, we would be required to comply with numerous laws and regulations relating to the formation, administration and performance of the grant or contract, which can make it more difficult for us to retain our rights under such grant or contract and result in increased costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity, debt or other financing structures, or through collaborations, strategic alliances or licensing arrangements with third parties, or through receiving government and/or charitable grants or contracts, we may be required to delay, reduce or terminate our rezafungin development program, including our ReSPECT Phase 3 clinical trial, be unable to meet our development obligations under the Mundipharma Collaboration Agreement, and be unable to continue advancing the Cloudbreak program for non-influenza DFCs, or be forced to grant rights in the Cloudbreak program for non-influenza DFCs that we would otherwise prefer to retain for ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The terms of our term loan facility place restrictions on our operating and financial flexibility, and failure to comply with covenants or to satisfy certain conditions of the agreement governing the debt facility may result in acceleration of our repayment obligations and foreclosure on our pledged assets, which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our common stock to decline.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In October 2016, we entered into a loan and security agreement with Pacific Western Bank, or the Loan Agreement, as amended in June 2018, July 2018, November 2019, March 2021 and April 2022 under which we borrowed $10.0&#160;million, subject to certain terms and conditions set forth therein.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The outstanding principal balance under the Loan Agreement is secured by a security interest in substantially all of our assets, other than intellectual property, which is subject to a double negative pledge. The Loan Agreement requires us to comply with a number of customary affirmative and restrictive covenants, including covenants that limit our ability to, among other things: transfer any part of our business or property; merge or consolidate with another entity or otherwise experience a change in control, incur additional indebtedness, encumber the collateral securing the loan, declare or pay any cash dividend or make distributions on our capital stock, repurchase or redeem any class of stock or other equity interest, acquire, own or make investments, and make certain capitalized expenditures over a specified threshold, in each case subject to exceptions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Loan Agreement also includes standard events of default, including a provision that Pacific Western Bank could declare an event of default upon the occurrence of any event that it interprets as having a material adverse effect on (i)&#160;our operations, business or financial condition and subsidiaries taken as a whole; (ii)&#160;our ability to perform or pay the secured obligations under the Loan Agreement and related agreements; or (iii)&#160;the collateral pledged to Pacific Western Bank under the Loan Agreement.&#160;Upon such determination, Pacific Western Bank could declare all obligations under the Loan Agreement immediately due and payable. In November 2019, we entered into an amendment to the Loan Agreement that requires we maintain the cash value of the amounts borrowed on hand in our bank account, and a failure to comply with this obligation will also constitute an event of default and allow Pacific Western Bank to declare all obligations immediately due and payable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the audit of our 2021 financial statements, we received an unqualified auditor opinion with a going concern explanatory paragraph. Pacific Western Bank may determine that the underlying circumstances resulting in the receipt of a going concern explanatory note in the auditor opinion for our 2021 financial statements either on their own, or together with contemporaneous events or circumstances, such as a failure to timely secure additional funding, constitute a material adverse effect upon our business, operations, properties, assets, or financial condition or upon our ability to perform or pay the secured obligations under the Loan Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, Pacific Western Bank may determine that the occurrence of adverse results or delays in any clinical study or the denial, delay or limitation of approval of or taking of any other regulatory action by the FDA or another governmental entity may also constitute a material adverse effect upon our business, operations, properties, assets, or financial condition or upon our ability to perform or pay the secured obligations under the Loan Agreement, either on its own or together with contemporaneous events or circumstances, such as our status regarding going concern or a failure to timely secure additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Loan Agreement also requires us to timely deliver certain financial statements, reports, and certificates including a requirement to provide audited annual financial statements together with an unqualified audit opinion or a qualified opinion only for going concern so long as our investors provide additional equity as needed or if Pacific Western Bank otherwise provides its consent in writing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we default under the facility, Pacific Western Bank may accelerate all of our repayment obligations. At such time, we may not have enough available cash or be able to raise additional funds on satisfactory terms, if at all, through equity or debt financings to repay our indebtedness at the time any such repayment is required. If we are unable to access funds to meet those obligations or to renegotiate the Loan Agreement, Pacific Western Bank could take control of and may sell our pledged assets. In such an event, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If our assets were liquidated, Pacific Western Bank&#8217;s right to repayment would be senior to the rights of our stockholders to receive any proceeds from the liquidation.&#160;Any declaration by Pacific Western Bank of an event of default could significantly harm our liquidity, financial condition, operating results, business, and prospects and cause the price of our common stock to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may incur additional indebtedness in the future. The debt instruments governing such indebtedness may contain provisions that are as, or more, restrictive than the provisions governing our existing indebtedness under the Loan Agreement. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral or force us into bankruptcy or liquidation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since our inception, and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. Our net losses were $18.3 million and $18.3 million for the three months ended March&#160;31, 2022 and 2021, respectively. As of March&#160;31, 2022, we had an accumulated deficit of $395.4 million. To date, we have financed our operations primarily through sale of our stock in public offerings and private placements, through borrowings under loan facilities, and through payments received in connection with the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement. We have devoted substantially all of our financial resources and efforts to research and development. We are currently conducting the ReSPECT and ReSTORE China Phase 3 clinical trials of rezafungin, Phase 1 study of CD388, and preclinical studies of our other DFCs. We expect that it will be many years, if ever, before we receive regulatory approval and have a product candidate available for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">submit INDs to the FDA and equivalent filings to other regulatory authorities, and seek approval of our clinical protocols by institutional review boards at clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">continue to advance rezafungin and CD388 through clinical development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">continue the preclinical development of our other DFCs from our Cloudbreak platform or otherwise, and advance one or more of such product candidates into clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">seek marketing approvals for rezafungin, CD388 and other product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establish or contract for a sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">maintain, expand and enforce our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">hire additional manufacturing, clinical, regulatory, quality assurance and scientific personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">add operational, financial and management systems and personnel, including personnel to support product development; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenue that is significant or large enough to achieve profitability.&#160;Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the recent global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate, it may make any additional debt or equity financing more difficult, more costly and more dilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The conflict between Russia and Ukraine could lead to disruption, instability and volatility in global markets and industries that could negatively impact our operations. The U.S. government and other governments in jurisdictions in which we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">operate have imposed severe sanctions and export controls against Russia and Russian interests and threatened additional sanctions and controls. The impact of these measures, as well as potential responses to them by Russia, is currently unknown and they could adversely affect our business, supply chain, partners or customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and assess our future viability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We were founded in December 2012 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential development and product candidates, undertaking preclinical studies and conducting clinical trials. We have not yet demonstrated an ability to successfully complete large-scale, pivotal clinical trials required for regulatory approval of our product candidates, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop one new product from the time it is discovered to when it is commercially available. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had product candidates in advanced clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. We will need to continue to transition from a company with a research focus to a company capable of supporting late-stage development activities and, if a product candidate is approved, a company with commercial activities. We may not be successful in any step of such a transition.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_109"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our collaboration partners to provide funding to continue the development of rezafungin and CD388; for the commercialization of rezafungin outside of the U.S. and Japan; and for the late-stage development, manufacturing, registration and commercialization of CD388. If the collaborations are not successful, we may not be able to complete the development of rezafungin and CD388, or capitalize on the full market potential for rezafungin and CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we licensed the rights to rezafungin outside of the U.S. and Japan to Mundipharma, a large international pharmaceutical company. Our ability to complete the development of rezafungin is dependent, in part, on funds provided by Mundipharma. Additionally, our ability to receive payments from this arrangement will depend on Mundipharma&#8217;s ability to successfully commercialize rezafungin in its territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Mundipharma Collaboration Agreement poses many risks to us, including that our collaborator, Mundipharma:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">has significant discretion in determining the efforts and resources it will apply to commercializing rezafungin in its territory, and may not commit sufficient resources to the marketing and distribution of rezafungin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may terminate the Mundipharma Collaboration Agreement at will; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may be subject to changes in key personnel or strategic focus, have limited available funding or be subject to other external factors diverting resources or creates competing priorities, all of which could negatively impact the commercialization of rezafungin in its territory;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may independently develop, or develop with third parties, products that compete directly or indirectly with rezafungin if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may use our intellectual property or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may not agree with certain development decisions resulting in the delay or termination of the program, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be involved in a business combination and the continued pursuit and emphasis on rezafungin could be delayed, diminished or terminated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be financially impacted by the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our ability to generate revenue under the Mundipharma Collaboration Agreement is adversely impacted by these or any other risks, our right to receive additional payments from the Mundipharma Collaboration Agreement, including our share of the revenues generated by net sales of rezafungin, if approved, could be insufficient to allow us to complete the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">rezafungin development program including the ReSPECT Phase 3 clinical trial, to achieve or maintain profitability or may result in rezafungin being less valuable to us than if we had not entered into the Mundipharma Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we licensed the exclusive worldwide rights to CD388 and other influenza DFCs to Janssen. Our ability to complete the development of CD388 is dependent, on funds provided by Janssen. Additionally, our ability to receive payments from this arrangement will depend in part on Janssen&#8217;s ability to successfully commercialize CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Janssen Collaboration Agreement poses many risks to us, including that our collaborator, Janssen:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">has significant discretion in determining the efforts and resources it will apply to developing, manufacturing, registering and commercializing CD388;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may terminate the collaboration agreement at will, subject to certain limitations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may be subject to changes in key personnel or strategic focus, have limited available funding or be subject to other external factors diverting resources or creates competing priorities, all of which could negatively impact the development, manufacturing, registration and commercialization of CD388;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may independently develop, or develop with third parties, products that compete directly or indirectly with CD388 if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may use our intellectual property or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may not agree with certain development decisions resulting in the delay or termination of the program, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be involved in a business combination and the continued pursuit and emphasis on CD388 could be delayed, diminished or terminated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be financially impacted by the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our ability to generate revenue under the Janssen Collaboration Agreement is adversely impacted by these or any other risks, our right to receive additional payments under the Janssen Collaboration Agreement, including milestone payments and royalties, could be insufficient to allow us to achieve or maintain profitability or may result in CD388 being less valuable to us than if we had not entered into the Janssen Collaboration Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may seek to selectively establish other collaborations and, if we are unable to establish them on commercially reasonable terms or at all, we may have to alter our research, clinical development and commercialization plans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may seek to collaborate with other pharmaceutical and biotechnology companies to advance the Cloudbreak program for DFCs outside the scope of the Janssen Collaboration Agreement, or for the completion of development and commercialization of rezafungin in the U.S. and Japan. We may also seek funding from government grants or contracts to advance the Cloudbreak program for DFCs outside of the Janssen Collaboration Agreement. We cannot be certain that we will be successful in completing any such collaboration or obtaining any such government grants or contracts, or completing any of them on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate pharmaceutical or biotech collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, on the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Those factors may include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the design or results of preclinical studies, CMC development activities or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the likelihood of approval by the FDA or similar regulatory authorities outside the U.S.;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential market for the product candidate in the territories that are the subject of the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and complexities of manufacturing and delivering such product candidate to patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential of competing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">industry and market conditions generally.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also face significant competition for government grants and contracts for the Cloudbreak program, and there can be no assurances that such funding would be available to us if and when needed, or at all. For instance, government funding may be available only at certain phases of research and development, such as only after Phase 1 clinical trials have been completed. In order to advance the Cloudbreak program for DFCs outside of the Janssen Collaboration Agreement, we will need to obtain significant funding to complete IND-enabling studies, manufacturing development and Phase 1 clinical trials. Government grants and contracts may not be available to fund our activities at this earlier phase of the research and development process.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We intend to continue to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and preclinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely and expect to continue to rely on third parties, such as CROs, contract manufacturers of clinical supplies, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and to conduct some aspects of our research and preclinical testing. Many of these third parties may terminate their engagements with us at any time. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other international regulatory authorities require us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, available at www.clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the ability of these third parties to conduct certain of their operations, including monitoring of clinical sites, may be limited by the COVID-19 pandemic, and to the extent that such third parties are unable to fulfil their contractual obligations as a result of the COVID-19 pandemic or government orders in response to the pandemic, we may have limited or no recourse under the terms of our contractual agreements with such third parties. Further, if any of the third parties with whom we engage were to experience shutdowns or other substantial disruptions due to the COVID-19 pandemic, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operation and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical studies and clinical trials and for commercial supply of any of these product candidates should we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may be unable to establish agreements with third-party manufacturers for preclinical, clinical or commercial supply on terms favorable to us, or at all. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible breach of the manufacturing agreement by the third party, including the inability to supply sufficient quantities or to meet quality standards or timelines; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with current U.S. Good Manufacturing Practice requirements, or cGMPs, or similar regulatory requirements outside the U.S. Our failure, or the failure of our third-party manufacturers, to comply with cGMPs or other applicable regulations, even if such failures do not relate specifically to our product candidates or approved products, could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product that we develop may compete with other product candidates and products for access to these manufacturing facilities. There are a limited number of manufacturers that operate under cGMPs and that might be capable of manufacturing for us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers, including a failure that may not relate specifically to our product candidate or approved product or a failure due to the COVID-19 pandemic, could delay clinical development or marketing approval or adversely impact our ability to generate commercial sales. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Some of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials are located in countries affected by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these tests and trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties to release, label, store and distribute drug supplies for our clinical trials. Any performance failure on the part of these third parties, including a failure that may not relate specifically to our product candidate or approved product, could delay or otherwise adversely impact clinical development or marketing approval of our product candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, our manufacturers and suppliers may experience difficulties related to their overall businesses and financial stability, which could result in delays or interruptions of supply of our product candidates or approved products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have alternate manufacturing plans in place at this time. If we need to change to other manufacturers, the FDA and comparable foreign regulators may have to approve these manufacturers&#8217; facilities and processes prior to our use, which would require new testing and compliance inspections. In addition, the new manufacturers would have to be educated in or independently develop the processes necessary for production. This would result in delays and costs, and in the case of approved products, the potential loss of revenue.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_112"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to take full advantage of regulatory programs designed to expedite drug development or provide other incentives, our development programs may be adversely impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are a number of incentive programs administered by the FDA and other regulatory bodies to facilitate development of drugs in areas of unmet medical need. In the U.S., rezafungin has been designated a Qualified Infectious Disease Product, or QIDP, a fast track product, and, with respect to the indication for treatment of candidemia and invasive candidiasis, rezafungin has also been designated as an orphan drug. Our product candidates may not qualify for, or maintain, designations under these or other similar incentive programs. For example, rezafungin may not receive orphan drug designation in the U.S. for the prophylaxis indication. Our inability to fully take advantage of these incentive programs may require us to run larger trials, incur delays, lose opportunities that may not otherwise be available to us, lose marketing exclusivity for which we would otherwise be eligible and incur greater expense in the development of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, release, safety, efficacy, regulatory filings, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">the U.S. and by comparable authorities in other countries. For example, in order to commence clinical trials of our product candidates in the U.S., we must file an IND and obtain FDA agreement to proceed. The FDA may place our development program on clinical hold and require further preclinical testing prior to allowing our clinical trials to proceed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must obtain marketing approval in each jurisdiction in which we market our products. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted a marketing application or received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. As a company we have not previously submitted an NDA, and we may not be able to prepare our contract manufacturers and clinical sites for inspection associated with NDA review, or appearing before an FDA advisory committee, if required. Failure to submit a substantially complete NDA for rezafungin may result in a Refusal to File decision from the FDA, and even if filed, our NDA may receive a Complete Response Letter rather than approval. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process, testing and release and inspection of manufacturing facilities and personnel by the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the U.S. and elsewhere, is expensive, may take many years and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot assure you that we will ever obtain any marketing approvals in any jurisdiction. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical or other studies, changes in the manufacturing process or facilities or clinical trials. Moreover, approval by the FDA or an equivalent foreign authority does not ensure approval by regulatory authorities in any other countries or jurisdictions, but a failure to obtain marketing approval in one jurisdiction may adversely impact the likelihood of approval in other jurisdictions. In addition, varying interpretations of the data obtained from preclinical testing, manufacturing and product testing and clinical trials could delay, limit or prevent marketing approval of a product candidate. Additionally, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The COVID-19 pandemic could also potentially affect the business of the FDA and comparable authorities in other countries, which could result in delays in meetings related to planned clinical trials and ultimately of reviews and approvals of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of promotional materials and safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements for product facilities, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and related recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not comply with these restrictions, we may be subject to enforcement actions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes and facilities or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on such products, manufacturers or manufacturing processes or facilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on the labeling, marketing, distribution or use of a product;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">requirements to conduct post-approval clinical trials, other studies or other post-approval commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of the products from the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product seizure; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Healthcare professionals and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal healthcare anti-kickback statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false claims laws, which impose criminal and civil penalties, including civil whistleblower or qui tam actions under the federal civil False Claims Act, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates and their covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which require, among other things, certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or the CMS, information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and information regarding physician ownership and investment interests; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business activities, including sales or marketing arrangements and claims involving healthcare items or services including, in some states, those reimbursed by non-governmental third-party payors, including private </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">insurers, some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments or other transfers of value provided to physicians and other health care providers and entities, marketing expenditures, or drug pricing, state and local laws that require the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.&#160;Interpretations of standards of compliance under these laws and regulations are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or sensitive information, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may collect, store, use, transmit, receive, generate, transfer, disclose, make accessible, protect, secure, dispose of, share and otherwise process sensitive, proprietary and confidential information, including, but not limited to, intellectual property, proprietary business information owned or controlled by ourselves or our customers, financial information and personal data (including protected health information) (collectively, sensitive information). We are dependent upon our own or third-party information technology systems, infrastructure and sensitive information, including mobile technologies, to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. The secure collection, storage, use, transmission and processing of such information is vital to our operations and business strategy. Any actual or perceived breach of our security measures or those of our third-party service providers, consultants, or contractors could adversely affect our business, operations, financial condition, and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase. These threats are becoming increasingly difficult to detect. The procedures and controls we use to monitor cybersecurity threats and mitigate our exposure to such threats may not be sufficient to prevent security incidents, and our internal information technology systems and those of our third-party service providers, consultants, and contractors are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, public health crises (such as the COVID-19 global pandemic), telecommunication and electrical failures, theft as well as security incidents from inadvertent or intentional actions. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation, nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyberattacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We and the third parties upon which we rely may be subject to additional threats, including, but not limited to, the deployment of harmful malware (including as a result of advanced persistent threat intrusions), ransomware, viruses, worms, denial-of-service attacks (such as credential stuffing), supply chain attacks, social engineering schemes (including through phishing attacks) and other means to affect service reliability and threaten the confidentiality, integrity and availability of sensitive information, which may compromise our, or our third-party service providers&#8217;, consultants&#8217;, or contractors&#8217; system infrastructure or lead to data leakage or misdirected payments to and from us. Ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, loss of data, loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our platform, systems and networks or the systems and networks of third parties that support us and our services. Despite the security controls we have in place, such attacks are very difficult to avoid. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of security incidents. Additionally, the COVID-19 pandemic and our remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. Future or past business transactions (such as acquisitions or integrations) could also expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of sensitive information, we could incur liability and reputational damage. In addition, these incidents could result in disrupted operations, lost opportunities, misstated financial data, increased costs arising from the implementation of additional security protective measures and litigation costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are also required to comply with laws, rules, industry standards and regulations, policies and contracts that may require us to maintain the security of sensitive information. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may have contractual and other legal obligations to notify relevant stakeholders of security incidents. Most jurisdictions have enacted laws requiring companies to notify individuals, regulatory authorities and others of security incidents involving certain types of data, such as personal data. In addition, our agreements with certain customers and partners may require us to notify them in the event of a security incident. Such disclosures are costly, could lead to negative publicity, may cause our customers to lose confidence in the effectiveness of our security measures and not use our services, and require us to expend significant capital and other resources to respond to and/or alleviate problems caused by the actual or perceived security breach. In addition, any costs or other liabilities related to responding to a security incident or to mitigate any identified security vulnerabilities could be significant, including costs for remediating the effects of such an event, paying a ransom, restoring data from backups, and conducting data analysis to determine what data may have been affected by the breach. In addition, our efforts to contain or remediate a security incident or any vulnerability exploited to cause a breach may be unsuccessful, and efforts and any related failures to contain or remediate them could result in interruptions, delays, loss in customer trust, harm to our reputation, and increases to our insurance coverage. For example, any such event that leads to unauthorized access, use, or disclosure of personal data, related to our patient samples or personnel, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal data, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may not have adequate insurance coverage for security incidents, including fines, judgments, settlements, penalties, costs, attorney fees and other impacts that arise out of incidents or breaches. We cannot assure you that any insurance coverage will adequately cover liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. Additionally, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. Our risks are likely to increase as we continue to expand, grow our customer base, and process, store, and transmit increasingly large amounts of confidential, proprietary and sensitive information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of business, we process sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. Our data processing activities subject us to numerous data privacy and security obligations, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">such as various foreign and domestic laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. For example, HIPAA, as amended by HITECH, and their respective implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information. Such laws may apply to us, our customers or our service providers. Most healthcare providers in the U.S., including institutions from which we may obtain customer data, are subject to privacy and security regulations promulgated under HIPAA, as amended by HITECH. A person may be prosecuted for alleged HIPAA violations either directly or indirectly, such as under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial civil and criminal penalties and liabilities if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, the California Consumer Privacy Act of 2018, or CCPA, which took effect on January 1, 2020, gives California residents expanded rights to access and delete their personal data, opt out of certain personal data sharing, and receive detailed information about how their personal data is used. The CCPA also provides for civil penalties for violations (up to $7,500 per violation) and contains a private right of action for certain data breaches that is expected to increase litigation. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase our compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, it is anticipated that the California Privacy Rights Act of 2020, or CPRA, which goes into effect on January 1, 2023 will expand the CCPA. Additionally, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of enforcement. Some observers have noted that the CCPA and CPRA could mark the beginning of a trend of states adopting more stringent privacy laws in the U.S., which could further increase our compliance costs, potential liability and adversely affect our business. For example, Virginia recently passed its Consumer Data Protection Act, and Colorado recently passed the Colorado Privacy Act, both of which differ from the CCPA and the CPRA and become effective in 2023. In addition, data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts. In addition, privacy advocates and industry groups have proposed, and may propose, standards with which we are legally or contractually bound to comply.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The global data protection landscape is also rapidly evolving, and we expect there will continue to be new and proposed laws, regulations, and industry standards concerning privacy, data protection, and information security. For example, the EU&#8217;s General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR, Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law, or PIPL, impose strict requirements for processing personal data. We cannot yet determine the impact that such future laws, regulations and standards may have on our business. The EU GDPR and UK GDPR impose stringent requirements and to date, have increased compliance burdens on us, including by mandating burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process their personal data. EU member states may allow enact additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of the EU GDPR (or UK GDPR) and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other foreign jurisdictions). For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the European Economic Area, or EEA, that the European Commission does not consider to provide an adequate level of data privacy and security, such as the U.S. These requirements apply not only to third-party transactions, but also to transfers of information within our company, including employee information. The European Commission recently adopted new Standard Contractual Clauses, or SCCs, under the EU GDPR for personal data transfers outside the EEA, which may require us to expend significant resources to update our contractual arrangements and conduct personal data transfer impact assessments. Currently, these SCCs are a valid mechanism to transfer personal data outside of the EEA, but there exists some uncertainty regarding whether the SCCs will remain a valid mechanism. Additionally, the SCCs impose additional compliance burdens, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. In addition, Switzerland and the UK similarly restrict personal data transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. Loss of our ability to transfer personal data from Europe may reduce demand for our services from companies subject to European data protection laws and also require us to increase our data processing capabilities in those jurisdictions at significant expense. Moreover, other countries outside of Europe </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(e.g. China, Brazil) have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may be contractually subject to data privacy and security obligations, including industry standards adopted by industry groups and may become subject to new data privacy and security obligations in the future. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal data. Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so, or may be perceived to have failed to do so. Despite our efforts, we may not be successful in achieving compliance if our personnel, customers, or service providers fail to comply with our policies and documentation. Such failures can subject us to potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Any failure or perceived failure by us, or third parties working on our behalf, to comply with applicable laws and regulations, any privacy and data security obligations pursuant to contract, our stated privacy or security policies, or obligations to customers or other third parties may result in governmental enforcement actions (including fines, penalties, judgments, settlements, imprisonment of company officials and public censure), civil claims, litigation, damage to our brand and reputation and loss of goodwill (both in relation to existing customers and prospective customers), any of which could have a material adverse effect on our business, operations and financial performance. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations.&#160;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&#160;We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.&#160;Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&#160;We may engage third parties for clinical trials outside of the U.S., to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&#160;We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations.&#160;We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Currently, we conduct the ReSTORE trial in China and have exclusively licensed the rights to commercialize rezafungin, our investigational drug studied in the ReSTORE trial, in China to our third-party collaborator, Mundipharma. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. For example, in order to conduct a clinical trial in China, sponsors must not only obtain the approval of the National Medical Product Administration of China, but also a separate approval from or filing with the Ministry of Science and Technology under the Administrative </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Regulations on Human Genetic Resources of the People's Republic of China, or HGR Regulation, for clinical trials involving HGR Materials or Information. Any failure to comply with these requirements could cause our ReSTORE trial to be suspended by governing authorities, may result in fines and also may constitute a breach under our agreements with third parties assisting us in the conduct of the trial in China, such as our CRO. In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Certain changes or amendments to policy or law may result in increased compliance costs on our business or cause delays in the timely completion of the ReSTORE trial in China, or prevent the approval of rezafungin in China. Chinese authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by us to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our clinical activities in China.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system, including cost-containment measures, that could reduce or limit coverage and reimbursement for newly approved drugs, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For example, in March 2010, President Obama signed into law the Affordable Care Act, a sweeping law intended to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable Care Act and subsequent regulations revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. However, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024. Further, the Affordable Care Act imposed a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance were also enacted under the Affordable Care Act, which may affect our business practices with healthcare practitioners. There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments will remain in effect through 2031 unless additional congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, in January 2013, the President signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule and guidance in September 2020, implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the Department of Health and Human Services finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of this rule has been delayed until January 1, 2026. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. We expect that additional healthcare reform measures will be adopted within and outside the U.S. in the future, any of which could add difficulty to the regulatory approval processes for our product candidates or limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. The continuing efforts of third-party payors to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability and the level of taxes that we are required to pay.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_115"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to rezafungin, CD388, our other Cloudbreak compounds or our other product candidates or compounds are not adequate, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to rezafungin and our other product candidates and compounds. Any involuntary disclosure to or misappropriation by third parties of our proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain and our commercial success will depend on our ability to obtain patents and maintain adequate protection for rezafungin, our DFCs and other compounds and product candidates in the U.S. and other countries. We currently hold issued U.S. utility and foreign patents and multiple pending U.S. utility patent applications, pending U.S. provisional patent applications and pending international, foreign national and regional counterpart patent applications covering various aspects of rezafungin and our DFCs. The patent applications may fail to result in issued patents in the U.S. or in foreign countries or jurisdictions. Even if the applications do successfully issue, third parties may challenge the patents.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, the existing and/or future patents, if any, may be too narrow to prevent third parties from developing or designing around these patents. If the sufficiency of the breadth or strength of protection provided by the patent and patent applications we own with respect to rezafungin or our DFCs or the patents we pursue related to any of our other product candidates or compounds is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize the product candidates or compounds. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced, although a patent term extension or supplementary protection certificate having varied scope may be available in certain jurisdictions to compensate for some of the lost patent term. In addition, we do not know whether:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to make the inventions covered by each of our pending patent applications or our issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">others will independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our pending patent applications will result in issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our patents, once issued, will be valid or enforceable or will issue with claims sufficient to protect our products, or will be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any patents issued to us will provide us with any competitive advantages;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we will develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the patents of others will have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office, or USPTO, developed new regulations and procedures to govern administration of the Leahy-Smith Act and many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the first to file provisions, only became effective in March 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable in one or more jurisdictions, inventions for which patents are difficult to enforce and any other elements of our drug discovery program that involve proprietary know-how, information and technology that is not covered by patents. Although we require all of our employees, consultants, advisers and third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or used in an unauthorized manner or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There also may be challenges or other disputes concerning the inventorship, ownership or right to use our intellectual property. For example, our consultants and advisors may have obligations to assign certain inventions and/or know-how that they develop to third-party entities in certain instances, and these third parties may challenge our ownership or other rights to our intellectual property, which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An inability to obtain, enforce and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S. We may encounter significant problems in protecting, enforcing and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of the intellectual property related to our technologies to third parties or are otherwise unable to protect, enforce or defend our intellectual property, we will not be able to establish or, if established, maintain a competitive advantage in our markets, which could materially adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various foreign or jurisdictional governmental patent agencies in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm to pay these fees due to foreign patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such noncompliance events are outside of our direct control for (1)&#160;non-U.S. patents and patent applications owned by us and, (2)&#160;if applicable in the future, patents and patent applications licensed to us by another entity. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents with claims to materials, methods of manufacture or methods of treatment related to the use or manufacture of rezafungin, our DFCs and/or our other product candidates or compounds. If any third-party patents were held by a court of competent jurisdiction to cover the rezafungin or DFC manufacturing process, any molecules formed during these processes or the final products or any use thereof, the holders of any such patents may be able to block our ability to commercialize the product unless we obtained a license under the applicable patent or patents or until such patents expire. These same issues and risks arise in connection with any other product candidates we develop as well. We cannot predict whether we would be able to obtain a license on commercially reasonable terms, or at all. Any inability to obtain such a license under the applicable patents on commercially reasonable terms, or at all, would have a material adverse effect on our ability to commercialize the affected product until such patents expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, third parties may obtain patents in the future and claim that our product candidates and/or the use of our technologies infringes upon these patents. Furthermore, parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case of willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products, which may be impossible and/or require substantial time and monetary expenditure. In addition, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of one or more of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would not be able to further develop and commercialize such product candidates, which could harm our business significantly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be required to file lawsuits or take other actions to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Competitors may infringe our current or future patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our asserted patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Pursuit of these claims would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Interference proceedings or derivative proceedings provoked by third parties or brought by the USPTO may be necessary to determine the entitlement to patent protection with respect to our patents or patent applications. An unfavorable outcome could result in a loss of our patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or patent office proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws or legal process may not protect those rights as fully as in the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates and technologies could be found invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technologies, the defendant could counterclaim that the patent covering our product candidate or our technology, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates or our technologies. The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art or that prior art that was cited during prosecution, but not relied on by the patent examiner, will not be revisited. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection directed to our product candidates or technologies. Such a loss of patent rights could have a material adverse impact on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and are therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has implemented wide-ranging patent reform legislation, including patent office administrative proceedings that offer broad opportunities to third parties to challenge issued patents. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO and foreign governmental bodies and tribunals, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> the U.S. Supreme Court held in 2013 that certain claims to DNA molecules are not patentable and lower courts have since been applying this case in the context of other types of biological subject matter. We cannot predict how future decisions by the courts, the U.S. Congress, the USPTO or foreign governmental bodies or tribunals may impact the value of our patent rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws and legal processes of some foreign countries do not protect intellectual property to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">substantial costs and divert our efforts and attention from other aspects of our business, could put any of our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of any of our current or future patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if any of our patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors, and academic or research institutions. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_118"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to U.S. Government Contracts and Grants</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be forced to suspend or terminate one or more of our preclinical Cloudbreak programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In order to continue our Cloudbreak programs for DFCs outside the scope of the Janssen Collaboration Agreement, we will need to seek funding from partnerships, the government or other sources of funding. There can be no assurances that we will be able to obtain funding from partnerships, or enter into new contracts with the U.S. government or obtain other sources of funding to support such programs. The process of completing a partnership or obtaining government contracts is lengthy and uncertain and we will have to compete with other companies and institutions in each instance. Further, with respect to government contracting, changes in government budgets and agendas may result in a decreased and de-prioritized emphasis on supporting the discovery and development of anti-infective products. If we cannot obtain or maintain government or other funding for our Cloudbreak programs for DFCs outside the scope of the Janssen Collaboration Agreement, we may be forced to discontinue those programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our use of government funding adds uncertainty to our research and commercialization efforts and may impose requirements that increase our costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Contracts funded by the U.S. government and its agencies include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terminate agreements, in whole or in part, for any reason or no reason;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">claim rights, including intellectual property rights, in products and data developed under such agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">audit contract-related costs and fees, including allocated indirect costs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend or debar the contractor from doing future business with the government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">control and potentially prohibit the export of products; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">pursue criminal or civil remedies under the Federal Civil Monetary Penalties Act and the federal civil False Claims Act and similar remedy provisions specific to government agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, government contracts contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">specialized accounting systems unique to government contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory socioeconomic compliance requirements, including labor standards, anti-human-trafficking, non-discrimination, and affirmative action programs and environmental compliance requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we fail to maintain compliance with these requirements, we may be subject to potential liability and to termination of our contracts.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the&#160;FDA, the Securities and Exchange Commission, or SEC,&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018 and ending on January 25, 2019, the U.S. government has shut down several times and certain regulatory authorities, such as the&#160;FDA and the SEC, have had to furlough critical&#160;FDA, SEC and other government&#160;employees and stop critical activities. If repeated or prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to audit by the U.S. government and a negative audit could adversely affect our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. government agencies routinely audit and investigate government contractors and recipients of Federal grants. These agencies review a contractor&#8217;s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Government agencies also review the adequacy of, and a contractor&#8217;s compliance with, its internal control systems and policies, including the contractor&#8217;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">termination of contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">forfeiture of profits;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension of payments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or prohibition from conducting business with the U.S. government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our government grant contracts. These laws and regulations affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Federal Acquisition Regulations, or FAR, and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other requirements such as the Anti-Kickback Statute and Foreign Corrupt Practices Act;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">export and import control laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any changes in applicable laws and regulations could restrict our ability to obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_121"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our ability to manage our business operations, to execute our strategic plan and to recruit talented employees may be adversely impacted by COVID-19.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since early March 2020, we have taken precautionary measures intended to help minimize the risk of COVID-19 to our employees and their families, including temporarily moving to working remotely for all personnel other than those supporting laboratory operations. We have suspended non-essential travel worldwide for our employees and convene company meetings virtually. Further measures may be taken as the COVID-19 outbreak continues. These measures could negatively affect our business. For instance, remote work may disrupt our operations, limit our ability to interact with and effectively manage our third-party manufacturers CROs or current and planned clinical trial sites. The measures taken now or in the future to contain the COVID-19 pandemic could negatively affect our ability to recruit and engage new employees and contractors necessary to the successful operation of our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our senior management team and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management team, as well as the other principal members of our research and development teams. All of our executive officers are employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory, quality assurance and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisers, including scientific, regulatory, quality assurance and clinical advisers, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisers may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our operations, and may encounter difficulties in managing our growth, which could disrupt our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect to expand the scope of our operations, particularly in the areas of drug development, manufacturing, clinical, regulatory affairs, quality assurance and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the future, we may enter into transactions to acquire other businesses, products or technologies and our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may fail to strengthen our competitive position and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_124"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the commencement, timing, enrollment or results of the current and planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter, "complete response" letter, or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse results, suspensions, terminations or delays in pre-clinical or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial or development program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact of the COVID-19 pandemic on our business and industry as well as the global economy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in laws or regulations applicable to our products, including but not limited to requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the structure of healthcare payment systems or limitations on the ability of hospitals and outpatient treatment centers to receive adequate reimbursement for the purchase and use of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse developments concerning our contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices or acceptable quality;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to establish collaborations, if needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to commercialize our product candidates successfully, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">announcements of significant acquisitions, strategic partnerships, joint ventures, government grants or contracts or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to effectively manage our growth;&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size and growth of our fungal infection, bacterial infection or other target markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to successfully enter new markets or develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our cash position and our ability to raise additional capital and the manner and terms on which we raise it, and the expectation of future fundraising activities by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">publication of research reports or other media coverage about us or our industry or our therapeutic approaches in particular or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sales of our common stock by us or our stockholders in the future or the expectation of such sales;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">disputes or other developments relating to proprietary rights, including patent rights, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">general political and economic conditions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Global Market, pharmaceutical companies and companies in the anti-infective sector in particular, have experienced extreme price and volume fluctuations that may or may not have been related or proportionate to the operating performance of these companies or their product potential. Broad market and industry factors, such as the COVID-19 pandemic and actions taken to slow its spread, may negatively affect the market price of our common stock, regardless of our actual operating performance. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders&#160;and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Securities Exchange Act of 1934, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the political environment and the level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to continue to result in substantial legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. These costs could decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations could make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired and our public reporting may be unreliable.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Based on our evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2022, we determined that we had a material weakness as of March 31, 2022 because our review control over the evaluation of applicable accounting standards and assessment of completeness and accuracy of valuation assumptions, related to non-routine transactions that include collaboration revenue, was not appropriately designed or operating effectively. While this improper design and operation did not result in a material error in the annual or interim financial statements, there is a reasonable possibility that a material misstatement in the annual or interim financial statements would not have been detected. A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are in the process of implementing a remediation plan, which includes adding additional layers of review by members of our management team regarding the evaluation of applicable accounting standards and completeness and accuracy of valuation assumptions related to non-routine transactions that include collaboration revenue. The remediation actions are being monitored by the Audit Committee of our Board of Directors. However, we cannot assure you that these efforts will remediate this material weakness in a timely manner, or at all, or that we will be able to maintain effective controls and procedures even if we remediate this material weakness. If we are unable to successfully remediate this material weakness, design or operate effective controls and procedures, or identify any future material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and we may experience a loss of public confidence, which could have an adverse effect on our business, financial condition and the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal control procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are a &#8220;non-accelerated filer,&#8221; our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur additional expenses of remediation. In addition, if we are unable to remediate this material weakness, or if we are otherwise unable to conclude that our internal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our securities could decline, and we could be subject to sanctions or investigations by The Nasdaq Global Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. We had 69,049,247 shares of common stock outstanding as of March&#160;31, 2022.&#160;We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate and may make it more difficult for you to sell shares of our common stock. In addition, shares of common stock that are either issuable upon the exercise of outstanding options or warrants or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act.&#160;If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the twelve months following the filing of this report. Significant additional capital will be needed to continue our operations as currently planned, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, new investors could gain rights, preferences and privileges senior to our existing stockholders and our existing stockholders may be materially diluted by such subsequent sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to our 2015 Equity Incentive Plan, or the 2015 EIP, our management is authorized to grant stock options to our employees, directors and consultants.&#160;The number of shares of our common stock reserved for issuance under the 2015 EIP will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by 4% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Additionally, the number of shares of our common stock reserved for issuance under our 2015 Employee Stock Purchase Plan, or the ESPP, will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by the lesser of 1% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or 490,336 shares. Unless our board of directors elects not to increase the number of shares available for future grant each year under the 2015 EIP and the ESPP, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of working capital and may not use it effectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our working capital. Because of the number and variability of factors that determine our use of our working capital, its ultimate use may vary substantially from its currently intended use. Our management might not apply our working capital in ways that ultimately increase the value of your investment. We expect to use our working capital to fund research and development activities and general operating expenses. The failure by our management to apply this working capital effectively could harm our business. Pending its use, we may invest our working capital in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our working capital in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer or by a majority of the total number of authorized directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While the Delaware courts have determined that exclusive choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under current law, unused U.S. federal net operating losses generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely, but the deductibility of such federal net operating losses in taxable years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of capital raising and other transactions that have occurred since our inception in 2012, we may or may not have experienced an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2021, we had U.S. federal net operating loss carryforwards of approximately $306.8&#160;million, portions of which will begin to expire in 2033, and which could be limited if we experience an &#8220;ownership change.&#8221; In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and we may incur substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and/or the further development of our product candidates could be delayed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity, public health crisis, pandemic diseases and other events beyond our control, the occurrence of which could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Businesses located in California have, in the past, been subject to electrical blackouts as a result of a shortage of available electrical power and any future blackouts could disrupt our operations. We are also vulnerable to a major earthquake, wildfire, inclement weather and other natural and man-made disasters and public health crisis and pandemic diseases, such as coronavirus, and we have not undertaken a systematic analysis of the potential consequences to our business as a result of any such natural disaster, public health crisis or pandemic diseases and do not have an applicable recovery plan in place. In addition, if any of our third-party contract manufacturers are affected by natural disasters, such as earthquakes, power shortages or outages, floods, wildfire, public health crises, such as pandemics and epidemics, terrorism or other events outside of our control, our business and operating results could suffer. For example, as a result of the COVID-19 pandemic, we have experienced significant disruptions in the conduct of our clinical trials and our general business operations as the result of various federal, state and local stay-at-home, shelter-in-place and quarantine measures. We carry only limited business interruption insurance that would compensate us for actual losses from interruption of our business that may occur and any losses or damages incurred by us in excess of insured amounts could cause our business to materially suffer.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i12928d5708484b01a3ce462a99216eeb_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.1(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.2(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex32.htm">Amended and Restated Bylaws of the Registrant, as currently in effect.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.3(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex312018-05x21.htm">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.1(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex41.htm">Form of Common Stock Certificate of the Registrant.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.2(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312516729294/d161044dex102.htm">Form of Warrant to Purchase Common Stock issued to Pacific Western Bank.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.3(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex412018-05x21.htm">Form of Common Stock Purchase Warrant for First Private Placement.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3112022-03.htm">Certification of Principal Executive Officer required by Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3122022-03.htm">Certification of Principal Financial Officer required by Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3212022-03.htm">Certification of Principal Executive Officer required by Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3222022-03.htm">Certification of Principal Financial Officer required by Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q has been formatted in Inline</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed with the SEC on March 13, 2015.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant's Current Report on Form 8-K, filed on October 3, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant's Current Report on Form 8-K, filed on May 21, 2018.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i12928d5708484b01a3ce462a99216eeb_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cidara Therapeutics, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: May 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: May 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Preetam Shah, Ph.D., MBA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D., MBA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">75</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit3112022-03.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia1c2e3527ea0410fb6f0ab1429ad58e9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">PURSUANT TO RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">I, Jeffrey Stein, Ph.D., certify that&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 11, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit3122022-03.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i881ca0e4ec2f4d18a81baea5971ee8d8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">PURSUANT TO RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">I, Preetam Shah, Ph.D., MBA, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 11, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit3212022-03.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6cfe5bb0ca2f4384b036e3dd63571ae9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the quarterly report of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">March&#160;31, 2022</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jeffrey Stein, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167; 1350)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 11, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The foregoing certification accompanies the Form 10-Q to which it relates, is being furnished solely pursuant to 18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit3222022-03.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8fa2d2904a854fe98d6e955b01ed1745_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the quarterly report of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">March&#160;31, 2022</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Preetam Shah, Ph.D., MBA, Chief Financial Officer and Chief Business Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167; 1350)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, that, to my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 11, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The foregoing certification accompanies the Form 10-Q to which it relates, is being furnished solely pursuant to 18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cdtx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8627cbaf-6f66-4b32-bb14-4a9dea57dc11,g:21d3a7c8-7ecf-40b1-a09c-92da8f218d01-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdtx="http://cidara.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cidara.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://cidara.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATION" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION">
        <link:definition>2101101 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails">
        <link:definition>2402401 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails">
        <link:definition>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2108103 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2309302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2410404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://cidara.com/role/DEBT">
        <link:definition>2111104 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://cidara.com/role/DEBTTables">
        <link:definition>2312303 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTAdditionalInformationDetails" roleURI="http://cidara.com/role/DEBTAdditionalInformationDetails">
        <link:definition>2413405 - Disclosure - DEBT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofFuturePrincipalPaymentsDetails" roleURI="http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails">
        <link:definition>2414406 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2115105 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2316304 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>2417407 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>2418408 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANS" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS">
        <link:definition>2119106 - Disclosure - EQUITY INCENTIVE PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSTables" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables">
        <link:definition>2320305 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSAdditionalInformationDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails">
        <link:definition>2421409 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails">
        <link:definition>2422410 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails">
        <link:definition>2423411 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>2424412 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTS" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS">
        <link:definition>2125107 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSTables" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables">
        <link:definition>2326306 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails">
        <link:definition>2427413 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1">
        <link:definition>2427413 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails">
        <link:definition>2428414 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
        <link:definition>2429415 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2130108 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>2331307 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails">
        <link:definition>2432416 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails">
        <link:definition>2433417 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1">
        <link:definition>2433417 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails">
        <link:definition>2434418 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://cidara.com/role/SUBSEQUENTEVENTS">
        <link:definition>2135109 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://cidara.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2436419 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" abstract="false" name="CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_MundipharmaMedicalCompanyMember" abstract="true" name="MundipharmaMedicalCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" abstract="false" name="IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTransactionPotentialValue" abstract="false" name="CollaborativeArrangementTransactionPotentialValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" abstract="false" name="PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_AuthorizedSharesForFutureStockAwardsMember" abstract="true" name="AuthorizedSharesForFutureStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_SaleOfStockConsiderationRemainingOnTransaction" abstract="false" name="SaleOfStockConsiderationRemainingOnTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_PaymentsRelatedToCollaborativeAgreements" abstract="false" name="PaymentsRelatedToCollaborativeAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_SeriesXConvertiblePreferredStockMember" abstract="true" name="SeriesXConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_JanssenPharmaceuticalsIncMember" abstract="true" name="JanssenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RDFundingMember" abstract="true" name="RDFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CommonStockWarrantMember" abstract="true" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" abstract="true" name="MoreThanTenPercentVotingRightsClassesOfStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" abstract="true" name="DevelopmentRegulatoryAndCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementCostSharingPercentage" abstract="false" name="CollaborativeArrangementCostSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" abstract="false" name="LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" abstract="false" name="ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" abstract="true" name="ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" abstract="false" name="CollaborativeArrangementMaximumThirdPartyShareOfCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LicensesOfIntellectualPropertyMember" abstract="true" name="LicensesOfIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseAnnualRateIncrease" abstract="false" name="LesseeOperatingLeaseAnnualRateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_NumberOfVotesEntitlementForEachShareHeld" abstract="false" name="NumberOfVotesEntitlementForEachShareHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseMonthlyRate" abstract="false" name="LesseeOperatingLeaseMonthlyRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" abstract="true" name="TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_NumberOfOperatingLeaseOptionsForExtension" abstract="false" name="NumberOfOperatingLeaseOptionsForExtension" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_ResearchAndDevelopmentServicesMember" abstract="true" name="ResearchAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" abstract="true" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" abstract="false" name="LesseeOperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_TwoThousandFifteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_ClinicalSupplyServicesMember" abstract="true" name="ClinicalSupplyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_WarrantsAggregateIntrinsicValueOutstanding" abstract="false" name="WarrantsAggregateIntrinsicValueOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" abstract="false" name="CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_UpfrontPaymentMember" abstract="true" name="UpfrontPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementPotentialPrepaymentMilestone" abstract="false" name="CollaborativeArrangementPotentialPrepaymentMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" abstract="false" name="ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_UnauditedInterimFinancialDataPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialDataPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cdtx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8627cbaf-6f66-4b32-bb14-4a9dea57dc11,g:21d3a7c8-7ecf-40b1-a09c-92da8f218d01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d1ce3a37-4e44-448e-a0e4-ec520aa4bd58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_82842a02-5e44-44fa-9376-d25f78b04c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d1ce3a37-4e44-448e-a0e4-ec520aa4bd58" xlink:to="loc_us-gaap_StockholdersEquity_82842a02-5e44-44fa-9376-d25f78b04c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1ce1a14f-4688-4988-a5f4-3c7b9467a794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d1ce3a37-4e44-448e-a0e4-ec520aa4bd58" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1ce1a14f-4688-4988-a5f4-3c7b9467a794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_47020421-137f-4670-a85f-100ea9738201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d1ce3a37-4e44-448e-a0e4-ec520aa4bd58" xlink:to="loc_us-gaap_Liabilities_47020421-137f-4670-a85f-100ea9738201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e763f52a-7556-45be-bd83-38bb59283a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e929c8f5-e985-40b5-aa82-3c0eec1d3acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e763f52a-7556-45be-bd83-38bb59283a19" xlink:to="loc_us-gaap_AssetsCurrent_e929c8f5-e985-40b5-aa82-3c0eec1d3acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ec3ac663-4cf8-4f1f-adfd-db32505dc94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e763f52a-7556-45be-bd83-38bb59283a19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ec3ac663-4cf8-4f1f-adfd-db32505dc94a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8475ba9b-7586-426d-9307-fae4a9c00a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e763f52a-7556-45be-bd83-38bb59283a19" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8475ba9b-7586-426d-9307-fae4a9c00a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2b91aafb-24a0-478c-8739-290c170094a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e763f52a-7556-45be-bd83-38bb59283a19" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2b91aafb-24a0-478c-8739-290c170094a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a4e6841d-eab7-4f7e-a78b-483f262683af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8d633085-9599-425d-b992-7c414fbdb9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e6841d-eab7-4f7e-a78b-483f262683af" xlink:to="loc_us-gaap_AccountsPayableCurrent_8d633085-9599-425d-b992-7c414fbdb9a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_98f3a638-0a16-49e2-8c20-2216dde334ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e6841d-eab7-4f7e-a78b-483f262683af" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_98f3a638-0a16-49e2-8c20-2216dde334ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1a19e529-79d8-4059-a40f-eb51c2f2ca98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e6841d-eab7-4f7e-a78b-483f262683af" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1a19e529-79d8-4059-a40f-eb51c2f2ca98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_927a5932-61ee-4b8b-acbe-217b3844c2bb" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e6841d-eab7-4f7e-a78b-483f262683af" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_927a5932-61ee-4b8b-acbe-217b3844c2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_a74e3244-1956-4f68-a8f0-332c922c3953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e6841d-eab7-4f7e-a78b-483f262683af" xlink:to="loc_us-gaap_LoansPayableCurrent_a74e3244-1956-4f68-a8f0-332c922c3953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f1135a0-c3d5-4eb8-9ab4-b2da44c1df85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e6841d-eab7-4f7e-a78b-483f262683af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f1135a0-c3d5-4eb8-9ab4-b2da44c1df85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b509fd81-326a-48fb-a4ce-876752e6a683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f12c496e-9024-406a-b711-f52556f1d89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b509fd81-326a-48fb-a4ce-876752e6a683" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f12c496e-9024-406a-b711-f52556f1d89a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_d7faf28d-b3d0-40f2-80b4-de7b39b422d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b509fd81-326a-48fb-a4ce-876752e6a683" xlink:to="loc_us-gaap_RestrictedCashCurrent_d7faf28d-b3d0-40f2-80b4-de7b39b422d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9651fc38-5a72-464e-b88b-e0912794a408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b509fd81-326a-48fb-a4ce-876752e6a683" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9651fc38-5a72-464e-b88b-e0912794a408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30eace54-4af2-4197-a113-de448c25ffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b509fd81-326a-48fb-a4ce-876752e6a683" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30eace54-4af2-4197-a113-de448c25ffc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d0340ce0-14ff-4852-86d9-cd7cbd95bb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b207157-93a3-4fb6-a0bb-e40222b073bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0340ce0-14ff-4852-86d9-cd7cbd95bb73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b207157-93a3-4fb6-a0bb-e40222b073bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_90e808f9-f3e1-47a8-8add-d097a002ed7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0340ce0-14ff-4852-86d9-cd7cbd95bb73" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_90e808f9-f3e1-47a8-8add-d097a002ed7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_066612c6-0ba4-40d3-9887-d1d635b1946f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0340ce0-14ff-4852-86d9-cd7cbd95bb73" xlink:to="loc_us-gaap_CommonStockValue_066612c6-0ba4-40d3-9887-d1d635b1946f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5198168f-b00d-459d-abe0-9bb511cb949f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0340ce0-14ff-4852-86d9-cd7cbd95bb73" xlink:to="loc_us-gaap_PreferredStockValue_5198168f-b00d-459d-abe0-9bb511cb949f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6a07dbd2-b16e-46e4-82fb-33070defb63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_40aef3be-c3b2-475a-9837-d9d458fc6877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6a07dbd2-b16e-46e4-82fb-33070defb63b" xlink:to="loc_us-gaap_LiabilitiesCurrent_40aef3be-c3b2-475a-9837-d9d458fc6877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_f0423350-f723-42d9-9082-018a199794d3" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6a07dbd2-b16e-46e4-82fb-33070defb63b" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_f0423350-f723-42d9-9082-018a199794d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02fd125c-dbe8-484a-ac7e-e8c2f3f0fe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6a07dbd2-b16e-46e4-82fb-33070defb63b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02fd125c-dbe8-484a-ac7e-e8c2f3f0fe5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_831b6533-f864-45d6-aad9-9f4bf700bcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3f2d1c9d-319e-44a5-9d60-6ff4bea6b361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_831b6533-f864-45d6-aad9-9f4bf700bcf9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3f2d1c9d-319e-44a5-9d60-6ff4bea6b361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4df6b3f8-59c6-46b1-a861-dff1eede9e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_831b6533-f864-45d6-aad9-9f4bf700bcf9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4df6b3f8-59c6-46b1-a861-dff1eede9e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c84d6e4-da33-43c6-9b3f-6f4ab864d05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_09cfa1df-5eb8-47d4-bf7a-d8f64c010ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c84d6e4-da33-43c6-9b3f-6f4ab864d05e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_09cfa1df-5eb8-47d4-bf7a-d8f64c010ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c3f18ff-461e-404e-a875-c281ff493810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c84d6e4-da33-43c6-9b3f-6f4ab864d05e" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c3f18ff-461e-404e-a875-c281ff493810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7c2f01af-072f-450e-9a08-b955ef8b53c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_b379d3e3-e760-44fa-9497-ccea6b1af90f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7c2f01af-072f-450e-9a08-b955ef8b53c9" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_b379d3e3-e760-44fa-9497-ccea6b1af90f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ae973776-c125-4b7a-a766-0b8cb5e6c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7c2f01af-072f-450e-9a08-b955ef8b53c9" xlink:to="loc_us-gaap_OperatingExpenses_ae973776-c125-4b7a-a766-0b8cb5e6c7c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d1ccb211-30cb-4c36-854e-0ce30820ddf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0eab50f-2fc5-4680-89d9-461d0471fa57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d1ccb211-30cb-4c36-854e-0ce30820ddf7" xlink:to="loc_us-gaap_NetIncomeLoss_d0eab50f-2fc5-4680-89d9-461d0471fa57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_27545c0e-b6cc-43dc-ab02-0adc7b6daa56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1a41aa85-a780-4c2e-a12b-3e7064b9c162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_27545c0e-b6cc-43dc-ab02-0adc7b6daa56" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1a41aa85-a780-4c2e-a12b-3e7064b9c162" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca9091c9-98a5-4651-b6ca-ac7dfd2b600b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_61b9cb64-c337-4966-92d5-59ab6d7ca0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca9091c9-98a5-4651-b6ca-ac7dfd2b600b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_61b9cb64-c337-4966-92d5-59ab6d7ca0be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6a1e461d-f037-4cc9-9e32-3dbb9d50ad70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6a1e461d-f037-4cc9-9e32-3dbb9d50ad70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_978e6db4-da0b-429d-a724-f56495876d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_978e6db4-da0b-429d-a724-f56495876d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_d9d69ef4-b41e-4501-ae56-f05c44ccb3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_PaidInKindInterest_d9d69ef4-b41e-4501-ae56-f05c44ccb3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a3d17d34-4b26-445f-a38d-645324986264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a3d17d34-4b26-445f-a38d-645324986264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_473487ff-c0e2-41c7-916c-504db2c5fbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_ShareBasedCompensation_473487ff-c0e2-41c7-916c-504db2c5fbc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6ac63a81-0dc6-43de-9eab-9f21a6e00102" xlink:href="cdtx-20220331.xsd#cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6ac63a81-0dc6-43de-9eab-9f21a6e00102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_fc496be6-b571-4cdb-a874-529a10b34ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_fc496be6-b571-4cdb-a874-529a10b34ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f5dcc10-3d59-4444-8729-edb53c407667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_NetIncomeLoss_8f5dcc10-3d59-4444-8729-edb53c407667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2c1e14d3-4a2a-4bf0-be82-64482e6d43c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2c1e14d3-4a2a-4bf0-be82-64482e6d43c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2028c3aa-22a2-4500-b25f-f3a45ff2f5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_DepreciationAndAmortization_2028c3aa-22a2-4500-b25f-f3a45ff2f5ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_6a7973fe-bdda-4501-86d0-888d845690b6" xlink:href="cdtx-20220331.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_6a7973fe-bdda-4501-86d0-888d845690b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fd66b06e-b934-41e0-bcc0-bec4a1f58581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8274c5c7-9050-47e2-bd4c-a99dbb51c2d8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fd66b06e-b934-41e0-bcc0-bec4a1f58581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfa1d9bd-35a4-4e45-915a-aecee815536f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51bf71cf-34e1-4046-aa3b-1417038054ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfa1d9bd-35a4-4e45-915a-aecee815536f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51bf71cf-34e1-4046-aa3b-1417038054ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d5849138-168d-428d-bcb0-bf5e90b0e0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfa1d9bd-35a4-4e45-915a-aecee815536f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d5849138-168d-428d-bcb0-bf5e90b0e0a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e16f7425-78c2-489f-a965-3780b7b09241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfa1d9bd-35a4-4e45-915a-aecee815536f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e16f7425-78c2-489f-a965-3780b7b09241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_308a4b71-02da-4333-9aae-c12610da1c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f96b10f-fbd3-4cf8-8df8-9113e10899c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_308a4b71-02da-4333-9aae-c12610da1c18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f96b10f-fbd3-4cf8-8df8-9113e10899c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41019179-01c8-41f4-b1ad-336a60978f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_308a4b71-02da-4333-9aae-c12610da1c18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41019179-01c8-41f4-b1ad-336a60978f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9dde830-5b52-463a-b372-41b07aae5fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_308a4b71-02da-4333-9aae-c12610da1c18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9dde830-5b52-463a-b372-41b07aae5fb2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4c2c038f-0b06-4eb2-bfd0-89bc5b46a812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2aefd69d-3889-4803-8cb6-5b5166b231bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4c2c038f-0b06-4eb2-bfd0-89bc5b46a812" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2aefd69d-3889-4803-8cb6-5b5166b231bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8b8cd466-700f-4449-93f1-d51ad7515093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4c2c038f-0b06-4eb2-bfd0-89bc5b46a812" xlink:to="loc_us-gaap_RestrictedCash_8b8cd466-700f-4449-93f1-d51ad7515093" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2fcf0dd4-95cf-42a3-8dfe-ee0d48f27eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_cea836d2-2289-4b44-aae2-cb5ca78c6ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2fcf0dd4-95cf-42a3-8dfe-ee0d48f27eba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_cea836d2-2289-4b44-aae2-cb5ca78c6ba0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_8d95eb4a-adfd-4dc4-9cdc-e96a5ebdc211" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_170d13c5-8fb9-43ae-a90d-9a35a5a6b4bf" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_8d95eb4a-adfd-4dc4-9cdc-e96a5ebdc211" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_170d13c5-8fb9-43ae-a90d-9a35a5a6b4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_d0847d7d-9ef2-4593-b3bd-2bdf231796a5" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_8d95eb4a-adfd-4dc4-9cdc-e96a5ebdc211" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_d0847d7d-9ef2-4593-b3bd-2bdf231796a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ea60317-b77c-4b13-bf41-c28b40b6a004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a819e8e1-adae-4ccd-a1b3-9709615fc7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ea60317-b77c-4b13-bf41-c28b40b6a004" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a819e8e1-adae-4ccd-a1b3-9709615fc7cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8a7aaedc-331e-44a9-b5a6-17b028674a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ea60317-b77c-4b13-bf41-c28b40b6a004" xlink:to="loc_us-gaap_OperatingLeaseLiability_8a7aaedc-331e-44a9-b5a6-17b028674a11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dfae062a-35f6-46a8-9996-20d332390312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_50f1bc74-1023-490a-a2fb-ed9704a1b0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dfae062a-35f6-46a8-9996-20d332390312" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_50f1bc74-1023-490a-a2fb-ed9704a1b0ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3225d4ed-df8a-450d-9578-02dc19e2acbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dfae062a-35f6-46a8-9996-20d332390312" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3225d4ed-df8a-450d-9578-02dc19e2acbe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a562b42f-6183-420c-b373-1877e01d3705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57a7bc2e-5280-4f5a-aba0-3fd3e204c7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a562b42f-6183-420c-b373-1877e01d3705" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57a7bc2e-5280-4f5a-aba0-3fd3e204c7cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_881ad90d-ccc6-459b-b15a-c00f0578223e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a562b42f-6183-420c-b373-1877e01d3705" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_881ad90d-ccc6-459b-b15a-c00f0578223e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cdtx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8627cbaf-6f66-4b32-bb14-4a9dea57dc11,g:21d3a7c8-7ecf-40b1-a09c-92da8f218d01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="icf05c53e15cd44a48bfd96ca64cc342d_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:to="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6576f362-3828-408e-aba9-0be57f73bbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6576f362-3828-408e-aba9-0be57f73bbaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ca9b35c9-e210-4e21-8f5b-700750231188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_RestrictedCashCurrent_ca9b35c9-e210-4e21-8f5b-700750231188" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_56d7dbbc-2f16-4c37-a0bd-3f0d3130157e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_56d7dbbc-2f16-4c37-a0bd-3f0d3130157e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cb85a43-18bc-4acf-9e05-b73a13e7f7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cb85a43-18bc-4acf-9e05-b73a13e7f7ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2432ba93-4753-4715-bf87-265a435631ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_AssetsCurrent_2432ba93-4753-4715-bf87-265a435631ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a781ba8a-72c1-4101-ba0f-3875a71c5a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a781ba8a-72c1-4101-ba0f-3875a71c5a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_51d0b7a5-eac2-44ce-8163-7573ecb2826c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_51d0b7a5-eac2-44ce-8163-7573ecb2826c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3015cf29-f300-4336-aab8-a6ae1b3f7873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3015cf29-f300-4336-aab8-a6ae1b3f7873" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7a74ee35-126a-41a0-aa35-1fdce71bd8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_Assets_7a74ee35-126a-41a0-aa35-1fdce71bd8b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_966b9470-a6ca-41ee-a904-68a7b75e24e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_AccountsPayableCurrent_966b9470-a6ca-41ee-a904-68a7b75e24e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ba68a548-2370-4abf-87a1-65213db2aba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ba68a548-2370-4abf-87a1-65213db2aba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_412b01e4-8999-4279-9e28-783d20b57f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_412b01e4-8999-4279-9e28-783d20b57f22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_e78f82df-0cf2-4907-bb45-8c0380c40449" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_e78f82df-0cf2-4907-bb45-8c0380c40449" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_bf7a334d-0518-4c84-9671-248f4283e34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_LoansPayableCurrent_bf7a334d-0518-4c84-9671-248f4283e34f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_669cc55d-86a4-44df-9d3c-df23e9bf2615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_669cc55d-86a4-44df-9d3c-df23e9bf2615" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_211c07c8-e147-4ec3-89b4-1390a61c7712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_LiabilitiesCurrent_211c07c8-e147-4ec3-89b4-1390a61c7712" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_3a595eb7-6e8f-4a4f-b24c-ada5941c976c" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_3a595eb7-6e8f-4a4f-b24c-ada5941c976c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_148d13aa-491c-42db-86b6-376b6dc86d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_148d13aa-491c-42db-86b6-376b6dc86d1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cafb94df-b886-41fe-bda5-953ba43b6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_Liabilities_cafb94df-b886-41fe-bda5-953ba43b6c9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2fa89369-a712-4b85-93ea-81fc4d57b748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2fa89369-a712-4b85-93ea-81fc4d57b748" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_46d3af7a-a8d9-44de-8e56-ecf532069b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_PreferredStockValue_46d3af7a-a8d9-44de-8e56-ecf532069b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_52395134-8d47-434a-a676-5cad37f0cb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_CommonStockValue_52395134-8d47-434a-a676-5cad37f0cb1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86cf365f-bee1-4a64-8267-372a15ed653d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86cf365f-bee1-4a64-8267-372a15ed653d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6f5135b-5fd3-40be-a1ca-1aa698f6a5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6f5135b-5fd3-40be-a1ca-1aa698f6a5de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fe75785c-a4bd-4a82-bcb3-9671e202e0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_StockholdersEquity_fe75785c-a4bd-4a82-bcb3-9671e202e0c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_afeaa8b8-3318-42e9-8147-1568b5d2c402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_afeaa8b8-3318-42e9-8147-1568b5d2c402" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2d80040d-f49a-4b71-b07f-df4e0a5092d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2d80040d-f49a-4b71-b07f-df4e0a5092d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:to="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f407b95-c5d6-4dab-b505-6440141bd61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f407b95-c5d6-4dab-b505-6440141bd61c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f407b95-c5d6-4dab-b505-6440141bd61c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f407b95-c5d6-4dab-b505-6440141bd61c" xlink:to="loc_us-gaap_ClassOfStockDomain_4f407b95-c5d6-4dab-b505-6440141bd61c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e3063f1-d2da-474c-9cfb-7d5e985fa9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f407b95-c5d6-4dab-b505-6440141bd61c" xlink:to="loc_us-gaap_ClassOfStockDomain_7e3063f1-d2da-474c-9cfb-7d5e985fa9f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_d6d94d52-7e39-4452-847f-0c5b273d333b" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7e3063f1-d2da-474c-9cfb-7d5e985fa9f1" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_d6d94d52-7e39-4452-847f-0c5b273d333b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7b7ffd18-557d-490e-ac17-71842fd08593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7b7ffd18-557d-490e-ac17-71842fd08593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7b7ffd18-557d-490e-ac17-71842fd08593_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b7ffd18-557d-490e-ac17-71842fd08593" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7b7ffd18-557d-490e-ac17-71842fd08593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_80bcc7e6-de51-42ba-ab5f-0814a6a705a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b7ffd18-557d-490e-ac17-71842fd08593" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_80bcc7e6-de51-42ba-ab5f-0814a6a705a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i6d38486a38bc4c028e9052ed856a57d3_CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_14e00b70-373b-422b-8877-35d72abc68a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_14e00b70-373b-422b-8877-35d72abc68a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7608efc4-25e0-41ee-a780-50ce603d1ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7608efc4-25e0-41ee-a780-50ce603d1ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_39245533-b2e0-4a33-bbc0-5ec10bebe361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockSharesIssued_39245533-b2e0-4a33-bbc0-5ec10bebe361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_56419856-db96-4a1a-ad26-bd149c12f700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_56419856-db96-4a1a-ad26-bd149c12f700" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1697e85e-a08a-4a1a-b877-2705642fc6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1697e85e-a08a-4a1a-b877-2705642fc6af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d64ef304-37db-4c6b-aaf1-d8608a542df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d64ef304-37db-4c6b-aaf1-d8608a542df1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d1eb0492-1603-448c-8826-a84bdd6beb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockSharesIssued_d1eb0492-1603-448c-8826-a84bdd6beb1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_99b41dd5-a82c-4b54-9b02-ea889f282fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_99b41dd5-a82c-4b54-9b02-ea889f282fb7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c834858-ff57-4f72-98cc-07b648d9d5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_StatementTable_5c834858-ff57-4f72-98cc-07b648d9d5e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_580813bb-5f08-4c9b-8065-3785089c37c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5c834858-ff57-4f72-98cc-07b648d9d5e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_580813bb-5f08-4c9b-8065-3785089c37c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_580813bb-5f08-4c9b-8065-3785089c37c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_580813bb-5f08-4c9b-8065-3785089c37c7" xlink:to="loc_us-gaap_ClassOfStockDomain_580813bb-5f08-4c9b-8065-3785089c37c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c22e323-d2d1-4afe-889e-40a13873602b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_580813bb-5f08-4c9b-8065-3785089c37c7" xlink:to="loc_us-gaap_ClassOfStockDomain_7c22e323-d2d1-4afe-889e-40a13873602b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_8bdaeb57-2acc-434f-aeb8-4082652473fc" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7c22e323-d2d1-4afe-889e-40a13873602b" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_8bdaeb57-2acc-434f-aeb8-4082652473fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited" xlink:type="extended" id="i64e102a79e8f4f4796c334e722f27bbf_CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fe36a69c-d923-4448-8b62-c77e4e74ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fe36a69c-d923-4448-8b62-c77e4e74ef8b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7759668e-c76e-41d3-9e14-683db829e822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_SharesOutstanding_7759668e-c76e-41d3-9e14-683db829e822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_549f7645-bcc5-4451-8ee3-4f7edcc34735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockholdersEquity_549f7645-bcc5-4451-8ee3-4f7edcc34735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4f28b018-ce39-4d12-a7dd-434198e41b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4f28b018-ce39-4d12-a7dd-434198e41b87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7723f60-1941-4b3e-a09b-ef7051f490e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7723f60-1941-4b3e-a09b-ef7051f490e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e70af8d-e57b-4f0b-9935-25b7894a88e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e70af8d-e57b-4f0b-9935-25b7894a88e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3691ef9f-c442-446a-a2f0-f4eab6050671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3691ef9f-c442-446a-a2f0-f4eab6050671" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_93535bfe-89be-4f42-9a04-cba2b6817ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_93535bfe-89be-4f42-9a04-cba2b6817ed4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_bf37f1ea-d479-4d95-8716-4cf486540b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_bf37f1ea-d479-4d95-8716-4cf486540b22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1addd23b-8a82-4ccb-917a-5ed312406ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_NetIncomeLoss_1addd23b-8a82-4ccb-917a-5ed312406ca8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_64150368-fb84-4565-a46a-5c94250cbd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5fc81334-a89a-47ed-8670-665e62bce7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fe36a69c-d923-4448-8b62-c77e4e74ef8b" xlink:to="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cbab2bd6-0272-468e-b6e7-40e681a44927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cbab2bd6-0272-468e-b6e7-40e681a44927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cbab2bd6-0272-468e-b6e7-40e681a44927_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cbab2bd6-0272-468e-b6e7-40e681a44927" xlink:to="loc_us-gaap_ClassOfStockDomain_cbab2bd6-0272-468e-b6e7-40e681a44927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6b53c07-a0c8-438d-aa94-f90aef3b066a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cbab2bd6-0272-468e-b6e7-40e681a44927" xlink:to="loc_us-gaap_ClassOfStockDomain_e6b53c07-a0c8-438d-aa94-f90aef3b066a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_7c00c303-6739-4723-887f-fb5421bfde21" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e6b53c07-a0c8-438d-aa94-f90aef3b066a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_7c00c303-6739-4723-887f-fb5421bfde21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0" xlink:to="loc_us-gaap_EquityComponentDomain_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0" xlink:to="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_2c083d04-6ead-42f3-bae2-a0efb11a84e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_PreferredStockMember_2c083d04-6ead-42f3-bae2-a0efb11a84e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_433bf25d-1a4d-4cc7-83bc-84cbe5fb3809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_CommonStockMember_433bf25d-1a4d-4cc7-83bc-84cbe5fb3809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7d355c30-32ae-4149-9e6f-ae95acde4f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7d355c30-32ae-4149-9e6f-ae95acde4f22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_518682d4-e953-4c6e-bbb7-7b9ddc6f57e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_RetainedEarningsMember_518682d4-e953-4c6e-bbb7-7b9ddc6f57e4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended" id="ie74da5b52d204f7bbe99be9ab65e5ee3_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39b1e995-ded1-4a62-b5f4-9bd9c4476aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39b1e995-ded1-4a62-b5f4-9bd9c4476aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efa54408-1297-45f5-9248-f0a1d8395f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efa54408-1297-45f5-9248-f0a1d8395f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19ef4660-b1d5-44f7-b73a-243760de4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19ef4660-b1d5-44f7-b73a-243760de4a29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5971cbc3-a4b7-4c03-abd7-610e78455718" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19ef4660-b1d5-44f7-b73a-243760de4a29" xlink:to="loc_srt_RangeAxis_5971cbc3-a4b7-4c03-abd7-610e78455718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5971cbc3-a4b7-4c03-abd7-610e78455718_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5971cbc3-a4b7-4c03-abd7-610e78455718" xlink:to="loc_srt_RangeMember_5971cbc3-a4b7-4c03-abd7-610e78455718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5971cbc3-a4b7-4c03-abd7-610e78455718" xlink:to="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d1339b7-eed0-4204-9c3e-157911936b6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:to="loc_srt_MinimumMember_1d1339b7-eed0-4204-9c3e-157911936b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4e19cc57-abb6-4bd8-a852-fc7c32cbf187" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:to="loc_srt_MaximumMember_4e19cc57-abb6-4bd8-a852-fc7c32cbf187" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="extended" id="icd157accb3e24969b0357a3c30105f4f_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea81547d-b106-4df3-86d8-f33315ca3bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_56d4143d-5fe6-41c9-b6a6-2b38479b99f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea81547d-b106-4df3-86d8-f33315ca3bc0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_56d4143d-5fe6-41c9-b6a6-2b38479b99f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18abfa04-d846-4192-b05a-9e762ce9a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea81547d-b106-4df3-86d8-f33315ca3bc0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18abfa04-d846-4192-b05a-9e762ce9a8fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ce47142-42f0-47bf-a718-d2bad6ada776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18abfa04-d846-4192-b05a-9e762ce9a8fa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ce47142-42f0-47bf-a718-d2bad6ada776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ce47142-42f0-47bf-a718-d2bad6ada776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ce47142-42f0-47bf-a718-d2bad6ada776" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ce47142-42f0-47bf-a718-d2bad6ada776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ce47142-42f0-47bf-a718-d2bad6ada776" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cd9f8ac3-17f9-44ee-becd-b6e7d1636c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:to="loc_us-gaap_WarrantMember_cd9f8ac3-17f9-44ee-becd-b6e7d1636c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b79e5c3b-0bd7-4fc5-859c-aa38fada0861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b79e5c3b-0bd7-4fc5-859c-aa38fada0861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_97fc8e11-bbed-4ad6-93a3-5df4be5973ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:to="loc_us-gaap_StockCompensationPlanMember_97fc8e11-bbed-4ad6-93a3-5df4be5973ff" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i56a21e3219cc46288f3588d5cf198f98_FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba34066-1804-478b-8f67-cd3fe15b9fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba34066-1804-478b-8f67-cd3fe15b9fc6" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_534c866f-b36a-42c0-9538-a20a601b4b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_534c866f-b36a-42c0-9538-a20a601b4b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c0f14e31-0f38-4c2a-b512-1e9b25d690d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:to="loc_us-gaap_RestrictedCash_c0f14e31-0f38-4c2a-b512-1e9b25d690d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_639842d9-a5ed-4a64-b88b-74370d9cfc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_639842d9-a5ed-4a64-b88b-74370d9cfc6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce10cf86-d899-4fd6-b7cf-33f7e5d879af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba34066-1804-478b-8f67-cd3fe15b9fc6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce10cf86-d899-4fd6-b7cf-33f7e5d879af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eef812e-6fcc-45b9-a281-c92f59b41bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce10cf86-d899-4fd6-b7cf-33f7e5d879af" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eef812e-6fcc-45b9-a281-c92f59b41bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5eef812e-6fcc-45b9-a281-c92f59b41bf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eef812e-6fcc-45b9-a281-c92f59b41bf6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5eef812e-6fcc-45b9-a281-c92f59b41bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eef812e-6fcc-45b9-a281-c92f59b41bf6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e41609c7-f5b0-4c9c-b63b-15eaea3b56ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e41609c7-f5b0-4c9c-b63b-15eaea3b56ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_38caa92d-8446-47e0-a72c-591d6168e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_38caa92d-8446-47e0-a72c-591d6168e1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2128193a-6aa9-46bd-9197-bb7fb9f8b5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2128193a-6aa9-46bd-9197-bb7fb9f8b5c8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#DEBTAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="extended" id="i3c458023713e4f2fbe74724d67554b73_DEBTAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e394bf53-b851-4b8a-abf5-b1c7f01832df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e394bf53-b851-4b8a-abf5-b1c7f01832df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_103720b8-407b-403d-90b0-dcc63176494d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_103720b8-407b-403d-90b0-dcc63176494d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:to="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_92974a5f-28d6-4d0f-93c0-2bfc726a71c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_92974a5f-28d6-4d0f-93c0-2bfc726a71c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_92974a5f-28d6-4d0f-93c0-2bfc726a71c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_92974a5f-28d6-4d0f-93c0-2bfc726a71c5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_92974a5f-28d6-4d0f-93c0-2bfc726a71c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c6eeb98d-422e-4985-8d30-3b0ac1ee6d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_92974a5f-28d6-4d0f-93c0-2bfc726a71c5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c6eeb98d-422e-4985-8d30-3b0ac1ee6d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_427e05a7-e3b1-42af-ac4d-87e1e5c9de5f" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c6eeb98d-422e-4985-8d30-3b0ac1ee6d6c" xlink:to="loc_cdtx_TermLoanMember_427e05a7-e3b1-42af-ac4d-87e1e5c9de5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c74f35f5-51be-4cbb-b6df-139b7c32ea16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:to="loc_us-gaap_DebtInstrumentAxis_c74f35f5-51be-4cbb-b6df-139b7c32ea16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c74f35f5-51be-4cbb-b6df-139b7c32ea16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c74f35f5-51be-4cbb-b6df-139b7c32ea16" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c74f35f5-51be-4cbb-b6df-139b7c32ea16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cdb2afcc-4c82-4c11-9219-6d7c6f213aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c74f35f5-51be-4cbb-b6df-139b7c32ea16" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cdb2afcc-4c82-4c11-9219-6d7c6f213aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_4489be12-d968-402c-bd54-129a68095749" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cdb2afcc-4c82-4c11-9219-6d7c6f213aba" xlink:to="loc_cdtx_TermLoanAMember_4489be12-d968-402c-bd54-129a68095749" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended" id="i7f5b9b98b9054f97a4b91138152e3593_DEBTScheduleofFuturePrincipalPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cf7bb5be-4497-4c25-88d6-d9f5a712dd06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf7bb5be-4497-4c25-88d6-d9f5a712dd06" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_51f07e73-2d5c-4a92-a8cc-01caff772311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_51f07e73-2d5c-4a92-a8cc-01caff772311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f546271e-334f-451f-ab6e-f62a97e66b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:to="loc_us-gaap_LongTermDebt_f546271e-334f-451f-ab6e-f62a97e66b35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf7bb5be-4497-4c25-88d6-d9f5a712dd06" xlink:to="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2a1941a4-b696-4337-ab22-4fc3f2fe7b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:to="loc_us-gaap_DebtInstrumentAxis_2a1941a4-b696-4337-ab22-4fc3f2fe7b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2a1941a4-b696-4337-ab22-4fc3f2fe7b40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a1941a4-b696-4337-ab22-4fc3f2fe7b40" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2a1941a4-b696-4337-ab22-4fc3f2fe7b40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ab5a229b-1eb0-443b-87d4-e84277cb2ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a1941a4-b696-4337-ab22-4fc3f2fe7b40" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ab5a229b-1eb0-443b-87d4-e84277cb2ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_9d5f0ef5-6ad5-41d3-a838-8e6d719029af" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ab5a229b-1eb0-443b-87d4-e84277cb2ccd" xlink:to="loc_cdtx_TermLoanAMember_9d5f0ef5-6ad5-41d3-a838-8e6d719029af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d05876ce-56fd-49ed-8891-d89c8a85f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d05876ce-56fd-49ed-8891-d89c8a85f25a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d05876ce-56fd-49ed-8891-d89c8a85f25a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d05876ce-56fd-49ed-8891-d89c8a85f25a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d05876ce-56fd-49ed-8891-d89c8a85f25a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_de6c2daf-e972-49b4-ba92-61a217bca764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d05876ce-56fd-49ed-8891-d89c8a85f25a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_de6c2daf-e972-49b4-ba92-61a217bca764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_86170882-2c71-4495-ac39-d325c9b0d959" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_de6c2daf-e972-49b4-ba92-61a217bca764" xlink:to="loc_cdtx_TermLoanMember_86170882-2c71-4495-ac39-d325c9b0d959" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended" id="ibcb177760a0349b89256d7dba514f79e_STOCKHOLDERSEQUITYNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_09112cbe-4556-426a-9635-3bb27f602eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_09112cbe-4556-426a-9635-3bb27f602eb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48eb3763-959e-4f04-9034-8119d19fcc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48eb3763-959e-4f04-9034-8119d19fcc2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_cc054e8d-db4c-42a2-a135-bf2be29850b1" xlink:href="cdtx-20220331.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_cc054e8d-db4c-42a2-a135-bf2be29850b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f44ec4cc-9ffc-43d6-b8ab-03f9fff06398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f44ec4cc-9ffc-43d6-b8ab-03f9fff06398" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b168543a-0728-4765-86ef-e1680cd53a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b168543a-0728-4765-86ef-e1680cd53a65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_6c3bd1eb-6320-468d-9ec6-8db930e1abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_6c3bd1eb-6320-468d-9ec6-8db930e1abbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_2d2e77f9-1547-4daa-821a-2294ed881d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_2d2e77f9-1547-4daa-821a-2294ed881d09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9f3b9773-a313-481f-a107-4bc1ddfe79d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9f3b9773-a313-481f-a107-4bc1ddfe79d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_30029260-52cc-4791-827c-fb8aa36fdcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_30029260-52cc-4791-827c-fb8aa36fdcd1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_11970393-8cb4-4fcb-b725-0674af1764b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_11970393-8cb4-4fcb-b725-0674af1764b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_98e1ebaf-85d6-4abc-8d9a-bc0918f3ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_98e1ebaf-85d6-4abc-8d9a-bc0918f3ff9a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_adf10359-4d78-4946-804a-a2e8e53dbfeb" xlink:href="cdtx-20220331.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_adf10359-4d78-4946-804a-a2e8e53dbfeb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7a8183b7-7137-4bd4-a434-6f35ad465666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7a8183b7-7137-4bd4-a434-6f35ad465666" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_20816423-b6b8-4832-8258-fbff8fe854ee" xlink:href="cdtx-20220331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_20816423-b6b8-4832-8258-fbff8fe854ee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d89fe076-18ab-48fa-b948-af6f9bfcece7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d89fe076-18ab-48fa-b948-af6f9bfcece7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6238a7e9-02c6-4f6e-8d46-07221f95a863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6238a7e9-02c6-4f6e-8d46-07221f95a863" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_fdde0556-1028-4702-adde-1295f6ecbd80" xlink:href="cdtx-20220331.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_fdde0556-1028-4702-adde-1295f6ecbd80" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d1ccf77e-5fa6-4c9f-874a-f52c227de4c0" xlink:href="cdtx-20220331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d1ccf77e-5fa6-4c9f-874a-f52c227de4c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicStockOfferingMember_681699ef-5726-4915-a620-6d566a1ea31c" xlink:href="cdtx-20220331.xsd#cdtx_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:to="loc_cdtx_PublicStockOfferingMember_681699ef-5726-4915-a620-6d566a1ea31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_ad44eb00-9ffc-4d44-87bf-9e0a7ac78993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:to="loc_us-gaap_OverAllotmentOptionMember_ad44eb00-9ffc-4d44-87bf-9e0a7ac78993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d6e6453-4c96-47aa-92e3-679a285b526f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_srt_RangeAxis_8d6e6453-4c96-47aa-92e3-679a285b526f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d6e6453-4c96-47aa-92e3-679a285b526f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d6e6453-4c96-47aa-92e3-679a285b526f" xlink:to="loc_srt_RangeMember_8d6e6453-4c96-47aa-92e3-679a285b526f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b8de3a0-ce6f-4ee3-9253-c83ce3bc28be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d6e6453-4c96-47aa-92e3-679a285b526f" xlink:to="loc_srt_RangeMember_0b8de3a0-ce6f-4ee3-9253-c83ce3bc28be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_5ed095b8-2b6c-42d7-a9fa-869807049900" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b8de3a0-ce6f-4ee3-9253-c83ce3bc28be" xlink:to="loc_srt_WeightedAverageMember_5ed095b8-2b6c-42d7-a9fa-869807049900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc8b273a-25fa-4b75-bc49-520630ae2470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc8b273a-25fa-4b75-bc49-520630ae2470" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fc8b273a-25fa-4b75-bc49-520630ae2470_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc8b273a-25fa-4b75-bc49-520630ae2470" xlink:to="loc_us-gaap_ClassOfStockDomain_fc8b273a-25fa-4b75-bc49-520630ae2470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5837103a-febd-4a4e-9b06-0865be110d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc8b273a-25fa-4b75-bc49-520630ae2470" xlink:to="loc_us-gaap_ClassOfStockDomain_5837103a-febd-4a4e-9b06-0865be110d30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_47412370-c3a3-44af-b3d3-054b25a7a1e0" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5837103a-febd-4a4e-9b06-0865be110d30" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_47412370-c3a3-44af-b3d3-054b25a7a1e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a64bb16-0e32-4047-9314-4bf83345b0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a64bb16-0e32-4047-9314-4bf83345b0eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a64bb16-0e32-4047-9314-4bf83345b0eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a64bb16-0e32-4047-9314-4bf83345b0eb" xlink:to="loc_us-gaap_EquityComponentDomain_1a64bb16-0e32-4047-9314-4bf83345b0eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1725e16e-639b-4434-be3e-7e6a9f195b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a64bb16-0e32-4047-9314-4bf83345b0eb" xlink:to="loc_us-gaap_EquityComponentDomain_1725e16e-639b-4434-be3e-7e6a9f195b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3e911107-f991-4136-95b3-daeb36540b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1725e16e-639b-4434-be3e-7e6a9f195b2d" xlink:to="loc_us-gaap_CommonStockMember_3e911107-f991-4136-95b3-daeb36540b5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1e960507-e393-40bf-a9e1-0d52ea9f8342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1e960507-e393-40bf-a9e1-0d52ea9f8342" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1e960507-e393-40bf-a9e1-0d52ea9f8342_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1e960507-e393-40bf-a9e1-0d52ea9f8342" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1e960507-e393-40bf-a9e1-0d52ea9f8342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_74cca0e5-3503-4a99-8487-3ef2a0b7b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1e960507-e393-40bf-a9e1-0d52ea9f8342" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_74cca0e5-3503-4a99-8487-3ef2a0b7b3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_f28435ea-a28b-4ba6-9843-8047debd9675" xlink:href="cdtx-20220331.xsd#cdtx_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74cca0e5-3503-4a99-8487-3ef2a0b7b3dd" xlink:to="loc_cdtx_CommonStockWarrantMember_f28435ea-a28b-4ba6-9843-8047debd9675" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="i4a1b6fe8e72649d49b811c0f3f1fca08_STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c168c541-d9d4-4f3c-9756-93714e1f4797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7493fc5d-24b9-4fdf-87d6-361c1dafad17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c168c541-d9d4-4f3c-9756-93714e1f4797" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7493fc5d-24b9-4fdf-87d6-361c1dafad17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1cdbb14d-b116-4a10-9c57-7a23a89ef86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c168c541-d9d4-4f3c-9756-93714e1f4797" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1cdbb14d-b116-4a10-9c57-7a23a89ef86a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3873ee2f-593d-4f0a-8198-dd25738f6c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1cdbb14d-b116-4a10-9c57-7a23a89ef86a" xlink:to="loc_us-gaap_AwardTypeAxis_3873ee2f-593d-4f0a-8198-dd25738f6c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3873ee2f-593d-4f0a-8198-dd25738f6c85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3873ee2f-593d-4f0a-8198-dd25738f6c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3873ee2f-593d-4f0a-8198-dd25738f6c85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3873ee2f-593d-4f0a-8198-dd25738f6c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c9ebe24c-c673-4176-93e7-c47602ada2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_us-gaap_WarrantMember_c9ebe24c-c673-4176-93e7-c47602ada2a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_2fa7a9c1-ff8e-42cb-9544-3f7328c7f8ee" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_2fa7a9c1-ff8e-42cb-9544-3f7328c7f8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_4fe94ce8-fb8b-460f-a00b-07a8a1ab889d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_us-gaap_StockCompensationPlanMember_4fe94ce8-fb8b-460f-a00b-07a8a1ab889d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_3bb0e88b-b0a7-43d0-9f09-717f10358908" xlink:href="cdtx-20220331.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_3bb0e88b-b0a7-43d0-9f09-717f10358908" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a2b4680d-ce36-4e2d-8eaf-1aafb8c830cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_us-gaap_EmployeeStockMember_a2b4680d-ce36-4e2d-8eaf-1aafb8c830cd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended" id="i7b4cf8d2f766463aa004f0b3add36eb0_EQUITYINCENTIVEPLANSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_4d7748c9-fe75-454a-8476-4d9aaea4525e" xlink:href="cdtx-20220331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_4d7748c9-fe75-454a-8476-4d9aaea4525e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5b90c7b8-2cb8-4e25-ad41-6bda4da1f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5b90c7b8-2cb8-4e25-ad41-6bda4da1f2f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2d925b9e-134e-4858-8891-e6834bab5126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2d925b9e-134e-4858-8891-e6834bab5126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_37cae47c-385a-466a-808e-2fc71360d000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_37cae47c-385a-466a-808e-2fc71360d000" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_6267a92e-5329-4aa5-9072-a8643c605d2b" xlink:href="cdtx-20220331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_6267a92e-5329-4aa5-9072-a8643c605d2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c268213b-b046-4f04-8377-0b0ab9e00532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c268213b-b046-4f04-8377-0b0ab9e00532" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cdc1f928-6369-437f-9c9b-0dd6992f7f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cdc1f928-6369-437f-9c9b-0dd6992f7f4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1584ed73-e458-4045-9cdc-610e6d303717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1584ed73-e458-4045-9cdc-610e6d303717" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26aebc3a-4e60-4be9-8dee-033c7f4f53ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26aebc3a-4e60-4be9-8dee-033c7f4f53ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_05dffcc3-52eb-477e-be6d-5ec51f8496e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_05dffcc3-52eb-477e-be6d-5ec51f8496e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bd74c00b-0727-4992-950b-c4341489a247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bd74c00b-0727-4992-950b-c4341489a247" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_86b4f223-d891-45be-b1f2-30a107f7ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_86b4f223-d891-45be-b1f2-30a107f7ef3a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b28099af-f692-42f6-9a37-b904894c81f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b28099af-f692-42f6-9a37-b904894c81f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16a59658-5d08-4bb8-baab-1ed58db86c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16a59658-5d08-4bb8-baab-1ed58db86c0d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_us-gaap_PlanNameAxis_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957" xlink:to="loc_us-gaap_PlanNameDomain_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d1f27cae-d24e-4d09-ab88-e65d3025f568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957" xlink:to="loc_us-gaap_PlanNameDomain_d1f27cae-d24e-4d09-ab88-e65d3025f568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_ec50ee85-f2e3-4a8d-b30c-4a76c3a5c07a" xlink:href="cdtx-20220331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d1f27cae-d24e-4d09-ab88-e65d3025f568" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_ec50ee85-f2e3-4a8d-b30c-4a76c3a5c07a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_srt_RangeAxis_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14" xlink:to="loc_srt_RangeMember_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14" xlink:to="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_268a070c-f73d-4c6c-982d-9511381d5d54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:to="loc_srt_MinimumMember_268a070c-f73d-4c6c-982d-9511381d5d54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46098a70-102e-49ad-896a-8957b6e1f6ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:to="loc_srt_MaximumMember_46098a70-102e-49ad-896a-8957b6e1f6ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_64da565e-9994-41dd-a42e-5b7f2ad722c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_64da565e-9994-41dd-a42e-5b7f2ad722c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_64da565e-9994-41dd-a42e-5b7f2ad722c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_64da565e-9994-41dd-a42e-5b7f2ad722c4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_64da565e-9994-41dd-a42e-5b7f2ad722c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_6db08075-424c-4f42-85f2-ccc908f6f616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_64da565e-9994-41dd-a42e-5b7f2ad722c4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_6db08075-424c-4f42-85f2-ccc908f6f616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_a55fecd7-716c-48c3-a21a-94068fd0a039" xlink:href="cdtx-20220331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_6db08075-424c-4f42-85f2-ccc908f6f616" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_a55fecd7-716c-48c3-a21a-94068fd0a039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e220c9b1-f704-48df-b785-27c30a9130ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_us-gaap_AwardTypeAxis_e220c9b1-f704-48df-b785-27c30a9130ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e220c9b1-f704-48df-b785-27c30a9130ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e220c9b1-f704-48df-b785-27c30a9130ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e220c9b1-f704-48df-b785-27c30a9130ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e220c9b1-f704-48df-b785-27c30a9130ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ccf14cf7-708b-4805-bf69-94ecc3114950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:to="loc_us-gaap_EmployeeStockMember_ccf14cf7-708b-4805-bf69-94ecc3114950" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_824d3799-0904-4f7a-9100-1093f3832d6b" xlink:href="cdtx-20220331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_824d3799-0904-4f7a-9100-1093f3832d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c20c2312-3416-4d06-8bb1-f42bd451195c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c20c2312-3416-4d06-8bb1-f42bd451195c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i4787e642b08340de98b41ed88dc4cead_EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf90747b-a8f6-4b53-8415-b47cc05e9ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf90747b-a8f6-4b53-8415-b47cc05e9ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7adb308-5205-4d0a-9fac-bf93de8d8dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7adb308-5205-4d0a-9fac-bf93de8d8dbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d9f5a074-2850-43b6-bfc7-dc6663a4439e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d9f5a074-2850-43b6-bfc7-dc6663a4439e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_42d48a38-2788-4652-b401-bc885093bd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_42d48a38-2788-4652-b401-bc885093bd3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_df05a0b8-3488-4145-8b2f-dcc9ef2322f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c9f9889-a303-40d2-a5f0-2335f271470d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c9f9889-a303-40d2-a5f0-2335f271470d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8782635-e2f2-4f62-a2a9-8f712b29575c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8782635-e2f2-4f62-a2a9-8f712b29575c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8191fa9d-655a-4fc0-aa4f-1936ca8eadd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8191fa9d-655a-4fc0-aa4f-1936ca8eadd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_aba4eb09-1493-4b3a-a7ac-af734db8537c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_aba4eb09-1493-4b3a-a7ac-af734db8537c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bee294d2-fe19-47b5-96c6-4d63fa889e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65d2258b-ea04-4bf2-b5a0-e8724e88a5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65d2258b-ea04-4bf2-b5a0-e8724e88a5f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_464d2f45-7215-4cdf-b61d-6c9b3e845e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65d2258b-ea04-4bf2-b5a0-e8724e88a5f0" xlink:to="loc_us-gaap_AwardTypeAxis_464d2f45-7215-4cdf-b61d-6c9b3e845e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_464d2f45-7215-4cdf-b61d-6c9b3e845e7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_464d2f45-7215-4cdf-b61d-6c9b3e845e7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_464d2f45-7215-4cdf-b61d-6c9b3e845e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc7af86-9621-4c58-ac70-beb34566a4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_464d2f45-7215-4cdf-b61d-6c9b3e845e7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc7af86-9621-4c58-ac70-beb34566a4cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_c40cc7d1-800b-491d-bd48-b0b4a0ba4006" xlink:href="cdtx-20220331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc7af86-9621-4c58-ac70-beb34566a4cf" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_c40cc7d1-800b-491d-bd48-b0b4a0ba4006" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i396723089d3b4267883678d3f2ad65cc_EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fd6983e7-179d-474b-befd-a86acb1217f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ed3ca4-f49e-4e31-a431-264dd7ea74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fd6983e7-179d-474b-befd-a86acb1217f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ed3ca4-f49e-4e31-a431-264dd7ea74fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_42eb9e60-67f6-44e9-a669-7e088b905349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fd6983e7-179d-474b-befd-a86acb1217f2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_42eb9e60-67f6-44e9-a669-7e088b905349" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a3287274-95fd-49a7-8c1a-778de40f67f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_42eb9e60-67f6-44e9-a669-7e088b905349" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a3287274-95fd-49a7-8c1a-778de40f67f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a3287274-95fd-49a7-8c1a-778de40f67f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a3287274-95fd-49a7-8c1a-778de40f67f8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a3287274-95fd-49a7-8c1a-778de40f67f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a3287274-95fd-49a7-8c1a-778de40f67f8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_027ddd05-afbf-49f3-9ddb-5ea52bd5fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_027ddd05-afbf-49f3-9ddb-5ea52bd5fc33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bb0b93c-e130-4f94-8273-a87bd8800e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bb0b93c-e130-4f94-8273-a87bd8800e7e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="extended" id="i5549584a6aef45aabc6e38eafdf80ca3_SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_59ff4bef-9ec7-401c-9acc-3dd8eb84845c" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_59ff4bef-9ec7-401c-9acc-3dd8eb84845c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_54a77fd8-afa6-411c-9871-4db2c20272e0" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_54a77fd8-afa6-411c-9871-4db2c20272e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_91f9b645-81fd-4db6-a4f5-0f274edde62c" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_91f9b645-81fd-4db6-a4f5-0f274edde62c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_1a766f73-e40e-4da8-9d2e-556048cf65bb" xlink:href="cdtx-20220331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_1a766f73-e40e-4da8-9d2e-556048cf65bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2235722a-e3a6-498b-800b-9b90faad00ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2235722a-e3a6-498b-800b-9b90faad00ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_61bf1264-61dc-4162-aa2d-e2950ab1a2d0" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_61bf1264-61dc-4162-aa2d-e2950ab1a2d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_27161765-6212-44c3-b63e-c549c09980a2" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_27161765-6212-44c3-b63e-c549c09980a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_96da9f0b-dff7-469c-aece-6acc617d37a7" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_96da9f0b-dff7-469c-aece-6acc617d37a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_047e31d5-c965-458c-a448-bff3ad2c018f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_047e31d5-c965-458c-a448-bff3ad2c018f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_498ad2c4-89b3-4e83-a248-37a6d1b88fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_498ad2c4-89b3-4e83-a248-37a6d1b88fc1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_3892d793-3901-48a5-8a1a-8ad98fc92df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_3892d793-3901-48a5-8a1a-8ad98fc92df9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1df34e49-e251-43d6-adc4-399acf70b356_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1df34e49-e251-43d6-adc4-399acf70b356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_2d21a709-0cc7-43ff-bc44-f75a170a136d" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_2d21a709-0cc7-43ff-bc44-f75a170a136d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_58ce307f-afc9-4c22-811c-73c689d4cfca" xlink:href="cdtx-20220331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_58ce307f-afc9-4c22-811c-73c689d4cfca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_537342d6-56fb-45c5-bf66-5621fd5cfea9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:to="loc_us-gaap_RelatedPartyDomain_537342d6-56fb-45c5-bf66-5621fd5cfea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:to="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_632b7fac-a2fd-45fd-91fe-b944d0626132" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:to="loc_srt_AffiliatedEntityMember_632b7fac-a2fd-45fd-91fe-b944d0626132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5d1f8ac1-d610-44a1-a517-8fbe987eac89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5d1f8ac1-d610-44a1-a517-8fbe987eac89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_31810314-0826-4cd7-8d50-a9ed1976994d" xlink:href="cdtx-20220331.xsd#cdtx_UpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_UpfrontPaymentMember_31810314-0826-4cd7-8d50-a9ed1976994d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_52d93b8f-afba-45a3-b417-b42bb14a3364" xlink:href="cdtx-20220331.xsd#cdtx_RDFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_RDFundingMember_52d93b8f-afba-45a3-b417-b42bb14a3364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_c059ea44-9030-4358-8098-5eb8234abcc2" xlink:href="cdtx-20220331.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_c059ea44-9030-4358-8098-5eb8234abcc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38d9421c-a5a8-4186-a5e0-dd7e905839d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:to="loc_srt_ProductsAndServicesDomain_38d9421c-a5a8-4186-a5e0-dd7e905839d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:to="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_31ee9aa1-9edf-44a1-9472-1b8ee3411b42" xlink:href="cdtx-20220331.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_31ee9aa1-9edf-44a1-9472-1b8ee3411b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_ce22cbf0-6956-4e85-af72-9d2d7df448a0" xlink:href="cdtx-20220331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_cdtx_MilestoneAchievementMember_ce22cbf0-6956-4e85-af72-9d2d7df448a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_73a30a90-af19-4013-a60a-e5c11138561c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_us-gaap_RoyaltyMember_73a30a90-af19-4013-a60a-e5c11138561c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fbba86fb-9bee-4b4b-9274-7e1f0f520e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fbba86fb-9bee-4b4b-9274-7e1f0f520e01" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="extended" id="i2bd34055958142be8b0907f0d4a1c3c6_SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_59ff4bef-9ec7-401c-9acc-3dd8eb84845c" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_59ff4bef-9ec7-401c-9acc-3dd8eb84845c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_54a77fd8-afa6-411c-9871-4db2c20272e0" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_54a77fd8-afa6-411c-9871-4db2c20272e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_91f9b645-81fd-4db6-a4f5-0f274edde62c" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_91f9b645-81fd-4db6-a4f5-0f274edde62c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_1a766f73-e40e-4da8-9d2e-556048cf65bb" xlink:href="cdtx-20220331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_1a766f73-e40e-4da8-9d2e-556048cf65bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2235722a-e3a6-498b-800b-9b90faad00ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2235722a-e3a6-498b-800b-9b90faad00ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_61bf1264-61dc-4162-aa2d-e2950ab1a2d0" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_61bf1264-61dc-4162-aa2d-e2950ab1a2d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_27161765-6212-44c3-b63e-c549c09980a2" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_27161765-6212-44c3-b63e-c549c09980a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_96da9f0b-dff7-469c-aece-6acc617d37a7" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_96da9f0b-dff7-469c-aece-6acc617d37a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_047e31d5-c965-458c-a448-bff3ad2c018f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_047e31d5-c965-458c-a448-bff3ad2c018f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_498ad2c4-89b3-4e83-a248-37a6d1b88fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_498ad2c4-89b3-4e83-a248-37a6d1b88fc1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_3892d793-3901-48a5-8a1a-8ad98fc92df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_3892d793-3901-48a5-8a1a-8ad98fc92df9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1df34e49-e251-43d6-adc4-399acf70b356_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1df34e49-e251-43d6-adc4-399acf70b356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_2d21a709-0cc7-43ff-bc44-f75a170a136d" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_2d21a709-0cc7-43ff-bc44-f75a170a136d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_58ce307f-afc9-4c22-811c-73c689d4cfca" xlink:href="cdtx-20220331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_58ce307f-afc9-4c22-811c-73c689d4cfca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_537342d6-56fb-45c5-bf66-5621fd5cfea9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:to="loc_us-gaap_RelatedPartyDomain_537342d6-56fb-45c5-bf66-5621fd5cfea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:to="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_632b7fac-a2fd-45fd-91fe-b944d0626132" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:to="loc_srt_AffiliatedEntityMember_632b7fac-a2fd-45fd-91fe-b944d0626132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5d1f8ac1-d610-44a1-a517-8fbe987eac89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5d1f8ac1-d610-44a1-a517-8fbe987eac89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_31810314-0826-4cd7-8d50-a9ed1976994d" xlink:href="cdtx-20220331.xsd#cdtx_UpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_UpfrontPaymentMember_31810314-0826-4cd7-8d50-a9ed1976994d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_52d93b8f-afba-45a3-b417-b42bb14a3364" xlink:href="cdtx-20220331.xsd#cdtx_RDFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_RDFundingMember_52d93b8f-afba-45a3-b417-b42bb14a3364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_c059ea44-9030-4358-8098-5eb8234abcc2" xlink:href="cdtx-20220331.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_c059ea44-9030-4358-8098-5eb8234abcc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38d9421c-a5a8-4186-a5e0-dd7e905839d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:to="loc_srt_ProductsAndServicesDomain_38d9421c-a5a8-4186-a5e0-dd7e905839d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:to="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_31ee9aa1-9edf-44a1-9472-1b8ee3411b42" xlink:href="cdtx-20220331.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_31ee9aa1-9edf-44a1-9472-1b8ee3411b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_ce22cbf0-6956-4e85-af72-9d2d7df448a0" xlink:href="cdtx-20220331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_cdtx_MilestoneAchievementMember_ce22cbf0-6956-4e85-af72-9d2d7df448a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_73a30a90-af19-4013-a60a-e5c11138561c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_us-gaap_RoyaltyMember_73a30a90-af19-4013-a60a-e5c11138561c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended" id="i441381d570e84222ab09be77ce5fc108_SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_1cb3540d-58a8-46f0-b11d-3d7160a2a48b" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_1cb3540d-58a8-46f0-b11d-3d7160a2a48b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_35e3c204-0b3c-465b-addf-80691e891351" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_35e3c204-0b3c-465b-addf-80691e891351" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_644ae068-e766-46af-9ec9-f4872b1582c7" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_644ae068-e766-46af-9ec9-f4872b1582c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_deb0d0da-6e81-46dd-a598-7e6a61af879a" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_deb0d0da-6e81-46dd-a598-7e6a61af879a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_85c5d8f8-dae2-4556-a3c5-4bad100bc698" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_856a2513-bfb1-46db-a898-8d3b54325e30" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_73cf2cbc-dd2e-4aa9-a177-201a524e2337" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_73cf2cbc-dd2e-4aa9-a177-201a524e2337" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_44e48f31-e902-43be-849a-d6edbfb4c992" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_44e48f31-e902-43be-849a-d6edbfb4c992" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_546e8b65-7026-433b-a45e-c1cd673c7cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_546e8b65-7026-433b-a45e-c1cd673c7cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_546e8b65-7026-433b-a45e-c1cd673c7cd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_546e8b65-7026-433b-a45e-c1cd673c7cd9" xlink:to="loc_us-gaap_RelatedPartyDomain_546e8b65-7026-433b-a45e-c1cd673c7cd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_db2e043e-49a4-407d-a74b-4e390f99d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_546e8b65-7026-433b-a45e-c1cd673c7cd9" xlink:to="loc_us-gaap_RelatedPartyDomain_db2e043e-49a4-407d-a74b-4e390f99d7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_6db7f4af-f9c3-494a-a957-5ca2712b4682" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_db2e043e-49a4-407d-a74b-4e390f99d7b3" xlink:to="loc_srt_AffiliatedEntityMember_6db7f4af-f9c3-494a-a957-5ca2712b4682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:to="loc_srt_CounterpartyNameAxis_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42e2793b-29a7-42b1-a70c-b28c8e4128f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42e2793b-29a7-42b1-a70c-b28c8e4128f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_2422ffac-6b60-4852-8ca1-d018aaeba82a" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42e2793b-29a7-42b1-a70c-b28c8e4128f0" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_2422ffac-6b60-4852-8ca1-d018aaeba82a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended" id="ia6b9bd5d42f6443f958dafeac4963a5a_SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e939166-cbe1-49e8-87f1-b274e1a62866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8ed3115a-66bb-4db3-83d5-ec77a580718b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e939166-cbe1-49e8-87f1-b274e1a62866" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8ed3115a-66bb-4db3-83d5-ec77a580718b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e939166-cbe1-49e8-87f1-b274e1a62866" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad1669fe-1b47-4274-9679-3f5e95c8c404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad1669fe-1b47-4274-9679-3f5e95c8c404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ad1669fe-1b47-4274-9679-3f5e95c8c404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad1669fe-1b47-4274-9679-3f5e95c8c404" xlink:to="loc_us-gaap_RelatedPartyDomain_ad1669fe-1b47-4274-9679-3f5e95c8c404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ed838b8e-b43d-4f68-afc8-f871d79e4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad1669fe-1b47-4274-9679-3f5e95c8c404" xlink:to="loc_us-gaap_RelatedPartyDomain_ed838b8e-b43d-4f68-afc8-f871d79e4d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_56cb0773-a179-4cf6-a60b-0d8a4127fc1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ed838b8e-b43d-4f68-afc8-f871d79e4d7e" xlink:to="loc_srt_AffiliatedEntityMember_56cb0773-a179-4cf6-a60b-0d8a4127fc1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_srt_CounterpartyNameAxis_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_5e174a3b-c091-4d6c-a05e-cf503ee9e1a8" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_5e174a3b-c091-4d6c-a05e-cf503ee9e1a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_17ef0bff-60ed-4abc-8c7f-8cf60b89328a" xlink:href="cdtx-20220331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_17ef0bff-60ed-4abc-8c7f-8cf60b89328a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_367d4cae-4a3f-414d-9ca9-67f29ddb5111" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_srt_ProductOrServiceAxis_367d4cae-4a3f-414d-9ca9-67f29ddb5111" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_367d4cae-4a3f-414d-9ca9-67f29ddb5111_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_367d4cae-4a3f-414d-9ca9-67f29ddb5111" xlink:to="loc_srt_ProductsAndServicesDomain_367d4cae-4a3f-414d-9ca9-67f29ddb5111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_367d4cae-4a3f-414d-9ca9-67f29ddb5111" xlink:to="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_f4fab729-7860-4191-af4f-ee8665bad7ac" xlink:href="cdtx-20220331.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_f4fab729-7860-4191-af4f-ee8665bad7ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_c0688021-7909-48b7-bb34-98e815ba535d" xlink:href="cdtx-20220331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_c0688021-7909-48b7-bb34-98e815ba535d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_87eb9c45-0a3e-46d1-8fdd-d112f1b19584" xlink:href="cdtx-20220331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_87eb9c45-0a3e-46d1-8fdd-d112f1b19584" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5017a9c2-b389-4008-b5ad-334b570b3964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5017a9c2-b389-4008-b5ad-334b570b3964" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_5017a9c2-b389-4008-b5ad-334b570b3964_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5017a9c2-b389-4008-b5ad-334b570b3964" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_5017a9c2-b389-4008-b5ad-334b570b3964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5017a9c2-b389-4008-b5ad-334b570b3964" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_2722eb84-2cb7-47da-ba10-ba531ec5067e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_2722eb84-2cb7-47da-ba10-ba531ec5067e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_c387c997-209c-4344-b6f6-20eb177c6dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:to="loc_us-gaap_TransferredOverTimeMember_c387c997-209c-4344-b6f6-20eb177c6dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_94d7d69a-7129-4f4e-92db-e02ca145ff45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_94d7d69a-7129-4f4e-92db-e02ca145ff45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94d7d69a-7129-4f4e-92db-e02ca145ff45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_94d7d69a-7129-4f4e-92db-e02ca145ff45" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94d7d69a-7129-4f4e-92db-e02ca145ff45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f7801d1-a371-4c94-a2f3-62f2ad64f13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_94d7d69a-7129-4f4e-92db-e02ca145ff45" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f7801d1-a371-4c94-a2f3-62f2ad64f13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e3bfc86b-d2ba-45e3-8295-958ee0017aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f7801d1-a371-4c94-a2f3-62f2ad64f13c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e3bfc86b-d2ba-45e3-8295-958ee0017aaa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="ic858a311806a4bbab79b7966307b645f_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a9b85a03-5b34-4d80-b3e0-eef3c8b7572a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone_a0343382-8f27-4b8f-bead-706ce78bc932" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementPotentialPrepaymentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9b85a03-5b34-4d80-b3e0-eef3c8b7572a" xlink:to="loc_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone_a0343382-8f27-4b8f-bead-706ce78bc932" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9b85a03-5b34-4d80-b3e0-eef3c8b7572a" xlink:to="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_382c3ca4-ad75-4c2d-b9d0-50862d07ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_382c3ca4-ad75-4c2d-b9d0-50862d07ef34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_382c3ca4-ad75-4c2d-b9d0-50862d07ef34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_382c3ca4-ad75-4c2d-b9d0-50862d07ef34" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_382c3ca4-ad75-4c2d-b9d0-50862d07ef34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_18d95e7c-de4a-4fac-8714-5065108b8cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_382c3ca4-ad75-4c2d-b9d0-50862d07ef34" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_18d95e7c-de4a-4fac-8714-5065108b8cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_966e2fca-7fae-46a3-b42f-7e215ddf75b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_18d95e7c-de4a-4fac-8714-5065108b8cff" xlink:to="loc_us-gaap_SubsequentEventMember_966e2fca-7fae-46a3-b42f-7e215ddf75b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_92d33a16-1bfa-4587-a572-3cf6da3ccc77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_srt_CounterpartyNameAxis_92d33a16-1bfa-4587-a572-3cf6da3ccc77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92d33a16-1bfa-4587-a572-3cf6da3ccc77_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_92d33a16-1bfa-4587-a572-3cf6da3ccc77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92d33a16-1bfa-4587-a572-3cf6da3ccc77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d1132da-f4ee-4697-b5c3-057c3ef2ece1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_92d33a16-1bfa-4587-a572-3cf6da3ccc77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d1132da-f4ee-4697-b5c3-057c3ef2ece1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_20a8889e-c44e-47e5-b916-793ace049301" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d1132da-f4ee-4697-b5c3-057c3ef2ece1" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_20a8889e-c44e-47e5-b916-793ace049301" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ffdd2273-2385-456f-a7d0-f734258b5790" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_srt_ProductOrServiceAxis_ffdd2273-2385-456f-a7d0-f734258b5790" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffdd2273-2385-456f-a7d0-f734258b5790_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ffdd2273-2385-456f-a7d0-f734258b5790" xlink:to="loc_srt_ProductsAndServicesDomain_ffdd2273-2385-456f-a7d0-f734258b5790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_719243f8-7a15-4f20-bd77-521eb5f6c7a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ffdd2273-2385-456f-a7d0-f734258b5790" xlink:to="loc_srt_ProductsAndServicesDomain_719243f8-7a15-4f20-bd77-521eb5f6c7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_c07d5b3c-64ef-4168-a650-743f8a031ef0" xlink:href="cdtx-20220331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_719243f8-7a15-4f20-bd77-521eb5f6c7a3" xlink:to="loc_cdtx_MilestoneAchievementMember_c07d5b3c-64ef-4168-a650-743f8a031ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0023cf37-8aa9-494b-9a89-188a08750fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0023cf37-8aa9-494b-9a89-188a08750fde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0023cf37-8aa9-494b-9a89-188a08750fde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0023cf37-8aa9-494b-9a89-188a08750fde" xlink:to="loc_us-gaap_RelatedPartyDomain_0023cf37-8aa9-494b-9a89-188a08750fde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0c268ab7-4c84-4ee4-bc3d-186dfd84e3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0023cf37-8aa9-494b-9a89-188a08750fde" xlink:to="loc_us-gaap_RelatedPartyDomain_0c268ab7-4c84-4ee4-bc3d-186dfd84e3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5252d11a-3966-4be2-8f2e-5a7c920da538" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0c268ab7-4c84-4ee4-bc3d-186dfd84e3bc" xlink:to="loc_srt_AffiliatedEntityMember_5252d11a-3966-4be2-8f2e-5a7c920da538" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationRevenueMember_ede406a8-d450-4d94-8721-49366537d7bc" xlink:href="cdtx-20220331.xsd#cdtx_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="loc_cdtx_CollaborationRevenueMember_ede406a8-d450-4d94-8721-49366537d7bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cdtx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8627cbaf-6f66-4b32-bb14-4a9dea57dc11,g:21d3a7c8-7ecf-40b1-a09c-92da8f218d01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f83938ab-48f4-4f94-ab91-d897dc727519_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CommonStockWarrantMember_73731c61-6ed7-48dc-afee-c8b03023c6e9_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_label_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_documentation_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember" xlink:href="cdtx-20220331.xsd#cdtx_CommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockWarrantMember" xlink:to="lab_cdtx_CommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_77313060-1483-445f-9231-d9860120af8a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cff12539-9d9b-42b2-857d-732aa61b4dbb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b2f5d3c8-ed26-4d3c-8d3b-083768a49d11_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7fb24e4e-c288-4bd2-8e05-0190276ec11a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_140fdb4c-3099-4674-b549-46132e89549d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowed from the lender</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e5ef3c6-f98f-44c7-ae31-2cb438921633_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0ab96b28-f670-47b0-b7d0-d91ce3137883_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_47a18509-eeed-4585-8a07-8b362f1f07a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c7969157-6142-445b-bb3b-e000132e5ad1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4cf235f5-c750-40bd-b8cf-a601ec7c2f0a_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b537db7e-894f-4c12-9239-9c270f573223_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9b17ce90-cbfd-4ef9-9642-6983c77729f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c8dbb615-711a-416a-8d25-ae3f6e00228c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_dc9f9e0f-3cb9-4ab9-a4fc-08d65debc990_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_8fcdb5fa-ad88-473b-8849-2a5b7a15c349_terseLabel_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, and Commercial Milestones</link:label>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_label_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, And Commercial Milestones [Member]</link:label>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_documentation_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, And Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:href="cdtx-20220331.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c5eee240-a33d-4f72-8a20-3c4c461c71c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_76e0163d-e554-40bb-8c41-f6576ea50b34_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_85b4fa6f-41fb-4083-b09f-d3d10f940b06_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_b8ee4966-7816-4a23-9fed-5890dda6312c_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options, RSUs and PRSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_a0ff5ae9-ef83-4248-89ef-c8d9984c8de2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, RSUs and PRSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e1dfb03e-76e7-43c5-859a-5a1c0b651b4f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for stock options to be granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d561eeba-cb67-4038-a722-550063116864_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Principal Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2c76af83-0e8a-4637-b3a0-dc6898ff75ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3ab62fc9-2d6b-45da-8be7-a98590a3c018_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b3193ba7-2b1f-436e-84b0-c93732cdcfc0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5b205f0e-c90f-476c-8b89-9fce8639b46a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d0b152d5-c8d6-4c0a-8283-98d9a7f890af_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a76c30d5-11b3-4d31-a21d-d1ff8c77063f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d1d5cd6e-1aba-4bbd-aaeb-e9fe416069e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ae03da07-050f-4c6d-9b31-bbbb66a53a9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7a905f10-1e63-41f4-b3d4-39da7ba8e49b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7497e4c1-f3ab-45bb-bcb4-8b42d4fab2fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_46a74c9a-ba0e-4938-93e7-9acb6d118b87_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ad1d436f-d260-42df-840e-fe01d9518a01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_36d20fef-542f-4739-b316-0dfa1e52edcf_negatedTerseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from performance obligations satisfied during reporting period</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_fbb0f1c7-1f46-4b0c-9fa8-941bb454e4fe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aea9b045-2fac-415f-9e3b-ad91fe63e702_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_8d39cd3d-0ee3-4aab-afe8-02443cf946c3_verboseLabel_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 EIP</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fifteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:href="cdtx-20220331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_513ee9b1-db95-4daf-8cc3-d8163a714d31_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d0c05d3-8918-4556-b6dd-f2bdf0101227_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b3ab09e4-cd90-45e0-9708-e29bb990afff_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_bbb3bbbc-1416-4410-8c4b-c72134a9ff52_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_26575013-9f32-48e8-aaeb-6d37ef15f07e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e6e08e5a-0829-4b23-a820-ef0ca76cb636_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_be7a9889-bdd1-42b3-9357-0a8675126fbc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a60d743f-fec9-462e-ba77-b4c28e509915_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0b3ab003-5f22-4067-9657-aa1891af7efc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e3d82765-206f-455b-9634-c38df986ea1a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1fdbb7e6-3d44-43a6-8207-14491098d826_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_368f5054-b006-4367-be01-916b29f43a7e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_721e9393-1315-40dd-8fb3-47662159ab50_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e0320e24-b3c9-4398-8fd3-f1c7a21bde4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e9e35bd7-9c1e-49de-89e6-bc1a4f779f6d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7c5e1ddb-2729-4e7f-840c-27a912b499b9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_96dbb8aa-aafd-4090-94da-ce46e53ae6ce_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b03070a2-f031-45a5-95a4-56a7d00f5de1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_7571db85-a259-4510-bd55-f093f655ce59_terseLabel_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than 10% of voting power</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_label_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More Than Ten Percent Voting Rights Classes Of Stock [Member]</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_documentation_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than ten percent voting rights classes of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:href="cdtx-20220331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:to="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4844c790-3a54-4b5e-8c78-c417e84ce1f0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_93f70367-e2a4-4289-ab02-3aef45a28478_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_63c6fc61-0a54-48b7-8a26-7dc4c91f65f7_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_744adc80-a0c4-4185-810f-1ffe1944c8d2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cdb8788e-7ed1-46e9-838e-cf80b6b19c86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eeb72f0-9dcc-422b-b2e2-c4696027031a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_aa5f1755-fd77-4d7c-b832-2da75c50c3f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_18b53d6c-14c9-45ea-9d14-8344b40c0bb9_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent per month</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:href="cdtx-20220331.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:to="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_db064e04-8c99-4fca-a76e-e0d622ca6296_terseLabel_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Services</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_label_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_documentation_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember" xlink:href="cdtx-20220331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClinicalSupplyServicesMember" xlink:to="lab_cdtx_ClinicalSupplyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PublicStockOfferingMember_fc12d832-d9b1-467f-9e87-fbfc86d2395d_terseLabel_en-US" xlink:label="lab_cdtx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_cdtx_PublicStockOfferingMember_label_en-US" xlink:label="lab_cdtx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_cdtx_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_cdtx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicStockOfferingMember" xlink:href="cdtx-20220331.xsd#cdtx_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PublicStockOfferingMember" xlink:to="lab_cdtx_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1df3517b-6c53-4be6-981b-b75ce2592ea5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from right offerings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aa4c6260-27b2-4027-bb1b-7f4312783c9d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_eb277f75-3679-441a-9333-01d2863be68f_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic annual increase in shares authorized for issuance in equity incentive plan</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Number Of Shares Authorized For Issuance Percentage</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:href="cdtx-20220331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1772cb22-1e8a-484b-880a-1797c541b678_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ed173889-2ea3-4a05-98c4-031975ece2bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a873242d-9dd4-404a-b3a3-c4026985866e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_8aa7e352-08e4-47e6-b4e1-b546b40f2bae_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a689c512-1d48-4722-a016-df621ca0c361_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f03b07a3-16fd-4720-9be3-d867d26dc881_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_869f17be-2bb2-4bea-9b71-b53428eb1151_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f1a32956-823d-417c-90c1-a0c768570829_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_72d92918-f152-4fd5-8267-8c06d8de2e53_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated unrecognized share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ae27c354-5e51-4005-b43e-e61b6649ca77_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_ad97b473-bea2-440c-814f-e1b7aea8b5ec_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:to="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_17c6eddf-0fe5-4eb7-b532-8befb241d5da_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e7e848ab-a088-4255-bab3-d7e215d6c7cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65d371da-74ff-4467-aad0-70208cbeec3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4720c41f-652d-4956-9716-0af507dfcd49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f5a02b4a-d37d-4615-aced-c3b5f27f78ec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_acb1cc07-01dc-4690-8a0e-24607374f151_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccb119b0-ab1e-4205-85d9-91c1580ff9dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_cafeadb5-06cb-465b-b81d-c4e1677906bd_terseLabel_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Data</link:label>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Data [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited interim financial data.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:href="cdtx-20220331.xsd#cdtx_UnauditedInterimFinancialDataPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:to="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e495533b-d531-4863-b101-013019ba989e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c759b7b2-e1f6-4a20-90ac-cd77b2026456_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39156fcc-7798-47e3-a919-d4a931edd8d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f9f0c3bf-3f63-4c38-a4e4-ceab80eea610_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a631be46-4fbd-47dc-b7bb-58eaf332b43d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_af4f867e-e243-42d5-a22c-d27ebf537bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c29c2306-3b23-4ca3-9dfa-164af3546408_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_398ce833-2b01-4abc-835e-e92764954ebf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_d8ddf221-6c60-430b-8c5a-4086966b49d6_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of term loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_bf67afa4-8568-4a89-8031-ffaa5dbbd28d_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d220de9f-876a-4661-9208-bb93ded9133e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3a5a4cab-c6b8-4b83-9324-d50f7a14103d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_2c9dbe6c-e387-40d2-9aa9-d02c09012c5e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aaf9aa34-22dc-495d-9875-b1219c52fffe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a7ee7f7a-50fa-4cbc-a15f-e8809bd2e85d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c6c136e6-021e-4a95-9f2d-993b0af35aeb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_29131671-b5b3-4945-9e30-a3cd3618f19a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_21d3e868-a58f-43cd-8478-7e8864e218df_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_78ec8263-d347-414c-ba27-7949d70e855d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4e602669-3df1-4575-ac19-bf2b2c2171e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7c8a1330-668e-4264-a1f5-e0620abb71ed_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_1997dd80-47ef-4e03-b137-fbf7afc06d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_94f1d1e6-84ba-4e35-ad3f-4c15659cf8f0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_642cf508-c7f9-4835-b1ff-f53068092fbb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2c999e34-74c0-4f7a-8116-6bcab30f2504_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, other current assets, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_bf2eb351-8e69-456c-9cf7-45cf4e150cfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_e3fe4fb7-1eea-41f0-927a-d689b4735279_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0679c306-9593-4504-9e91-06c63f66cb8a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7aadb4da-d604-4c7f-a950-111723239b28_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of stock option as percentage of estimated fair value of shares on date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a8e823b7-d964-478d-b650-7c0c18b290b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abdd6298-3946-49d2-8054-03f136b8b30f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_f4fe9023-e67a-4992-be49-6d25025faeca_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_bbaf96cf-a278-44e9-ae59-331c7d4f18e1_verboseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41b8576f-51ea-468a-a694-3e2c5c808540_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_db76a51c-dfbe-492d-81fc-ce9f34d80e4e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_075c5bd4-c67e-434b-8776-ef274da88f78_terseLabel_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical and Clinical Trial Accruals</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:href="cdtx-20220331.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:to="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4684758a-3f41-4c4e-a368-a217982ebee3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_233107ac-f144-4c4b-9a8b-9a0abb030f64_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_10d7d54b-74cc-4f4c-8d46-10bb8317108c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95808e32-f490-418a-8d4f-8e39541bdede_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_5ede1944-94d3-4aeb-9032-ed6860719e3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b6b1302d-a2b7-4de7-bad5-5c54703f3c54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limit on employee's payroll deductions as a percentage of eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f51b1377-fbb8-4952-a272-4c206db8af96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14d62bd4-aa4c-4bf7-ba7b-2dc835e280ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_15595eb2-2bf7-4662-863b-e218d1438258_terseLabel_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Services</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_label_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:href="cdtx-20220331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:to="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_54496fd5-095e-4e74-aa54-e4215a8174a9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_97d4b23f-c5ac-4be6-abf8-86869a85be28_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0a5992b7-3347-4472-8acf-280be668495f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a1d494f4-51bb-428c-89e1-b680218be432_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e943d787-7ebe-4d96-a717-3a6ab592225f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ee78b769-0a8a-4c00-a15a-f3e7b5cb3824_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_d78f363c-bccf-4d2c-9bf6-3b8f740f2984_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in base rent annual</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:href="cdtx-20220331.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:to="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c5b6a80e-0abc-4b2c-90a4-a122aa6feccb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a010778a-ad3e-401d-9f69-13d39aea3261_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e9d25bc9-f673-4079-8614-14d081a6d859_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_61da43ca-cf68-49d1-83b0-5e08ebf23a57_terseLabel_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized for future stock awards</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_label_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Shares For Future Stock Awards [Member]</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_documentation_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Shares For Future Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:href="cdtx-20220331.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:to="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7ad860bf-8619-426f-84e4-4c119ac6b4f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_938a87f1-f4a7-4a3b-ab3a-6a446efb57e2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_50cd1741-8244-4ede-9823-cb0bb209b4d3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0fc06d50-034b-49b2-afd5-a00025317328_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_9bab7e4c-0e8f-4add-90d9-dbafcb2bf79f_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost sharing percentage</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cost Sharing Percentage</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cost Sharing Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:to="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8ad06203-a2c6-4c2f-9bb1-6ca12af5fab9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8ccf990b-38f4-414c-aa03-b273238b7fbd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_4a6e1e1b-1923-4eef-b788-d9e5e8879362_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9abc079-5d44-41a6-b1be-cacad7898a20_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable annual rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_7ba07ea4-4c09-46ae-bebc-6d97523734ea_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting power threshold</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:href="cdtx-20220331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9967d276-91ed-4187-b304-4db0b4815c1c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_894f65c7-7f69-4ee4-847f-7cd35c96759e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_42c48875-3a95-4491-b723-2389b1f498f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c8a544b7-7be7-4b07-8498-8bff39aca229_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d4fd0bd1-e0ad-4578-a3cf-013a8b7fdf5f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4c33156b-a74b-45cb-904a-d847f2de4cde_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6f56b8e3-43d1-4665-bf17-2ea6ae503b26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_2c4c4e13-797e-439e-b0b5-f1e2a8aa8348_terseLabel_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:href="cdtx-20220331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_61950829-2b6c-441f-b7ac-740381a672ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9031d74e-2be0-4a33-bc82-329f62d74df2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_27ad85b4-cbc1-4f1d-abad-7461b728e530_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_ac0e2a7a-62c2-4bc9-8fa4-ba721ac9d298_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_46ba95aa-7f4d-4221-9404-0faa92043650_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5259fa64-dc25-4f49-8bd2-e096c25a5896_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute basic net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_041ecb3d-37ae-4dbd-a16c-b76863ac1fd7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_4c3a8810-663e-4c7e-bf80-3a0821fe34d4_terseLabel_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cdtx-20220331.xsd#cdtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_09868711-a18c-4553-b19e-0105a3d68a65_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RDFundingMember_16963f97-17f6-4d03-bd3d-4a4a246babe5_terseLabel_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Funding</link:label>
    <link:label id="lab_cdtx_RDFundingMember_label_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Funding [Member]</link:label>
    <link:label id="lab_cdtx_RDFundingMember_documentation_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember" xlink:href="cdtx-20220331.xsd#cdtx_RDFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RDFundingMember" xlink:to="lab_cdtx_RDFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9563b46f-d9d9-4631-8295-820f269cc569_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8479ef7c-778e-45bf-8b42-deb8afc900d3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ef0eb329-80fe-493a-b327-62e48ecc8477_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ae46923d-efb4-4aff-9744-134ade519359_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_0413b49f-9515-4f9c-9e41-604b5acf4967_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future principal payments due under the Loan Agreement</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1b2ed94c-93f9-4805-9c38-0b34fa673459_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0b19008d-0314-490f-89f0-5daa105814cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1055dde-d254-459e-9aef-671bad312e30_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_ff0a8c7f-fb7f-4e10-90db-ce6222d75d71_verboseLabel_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_bda15824-2cc8-4046-ab7a-28b608a7d5c9_terseLabel_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_label_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:to="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_43e9fcc4-a398-4ac0-950e-985b85a0bd71_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LicensesOfIntellectualPropertyMember_3d38ed1f-a0cf-41a8-87c3-f0c8b5422e43_terseLabel_en-US" xlink:label="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License of Intellectual Property</link:label>
    <link:label id="lab_cdtx_LicensesOfIntellectualPropertyMember_label_en-US" xlink:label="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses Of Intellectual Property [Member]</link:label>
    <link:label id="lab_cdtx_LicensesOfIntellectualPropertyMember_documentation_en-US" xlink:label="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses Of Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember" xlink:href="cdtx-20220331.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LicensesOfIntellectualPropertyMember" xlink:to="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_55ac026e-4f6d-47c3-b380-ea48b96a3be0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0498ba11-ebad-4011-9bb7-e16e6ef0081a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cf3b12b6-c168-448e-a050-0e24b966faaf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_40591f58-2f4e-4d05-9048-b15e31f5cd9b_terseLabel_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership following conversion</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_label_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_documentation_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:href="cdtx-20220331.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:to="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_184fd0fe-2223-45c3-bf74-5b268c84af49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_fbbb4cfc-e12a-442b-9b49-3279775948a5_totalLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_cb7939e1-e3b4-4e50-ab78-49fe38510268_terseLabel_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_documentation_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="cdtx-20220331.xsd#cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4eced9bf-67ce-4345-b6ff-f7af978c0402_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_636e3af5-398b-4607-8d81-38ec64d5ddb1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c1d27d38-f0e6-4269-b7b5-5d2ac9a4a390_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_ee56cee2-8696-4389-841f-7f9364f11af6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and money market accounts</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637e5448-67e4-4213-b9f1-9a11cf06dfea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Instruments Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f84c79-4abe-497d-b55b-a9e1f157f08b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7d328aa7-5071-4968-ba43-efe795d00a12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">THE COMPANY AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_f10e1000-d0aa-412a-b20b-c20c38265979_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_81dc3ab8-d750-415a-869f-5a7c86de0b1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_df55d6ec-8232-4ac8-a929-24be302e19a1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_9b035da0-f36b-41ed-aa6d-dac15aa097c6_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b586df0c-ed67-46df-abfe-7e58284079aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8c5b8cd7-afbf-498d-a9a4-6e1dae6c7a0b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_76e3a4f9-f523-43f8-834f-2d0a8cc96e68_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UpfrontPaymentMember_3667c25f-a4a8-4990-9b28-b7ed8fc9ff66_terseLabel_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_label_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_documentation_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember" xlink:href="cdtx-20220331.xsd#cdtx_UpfrontPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UpfrontPaymentMember" xlink:to="lab_cdtx_UpfrontPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d58b4056-6498-4f16-9593-1d2e0d57737c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ead6c71b-1e03-47ea-b042-3d2781985a15_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_25925e44-888c-499a-97b2-06eecb9001db_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_869c148d-4355-44a1-9be4-f149fc1f7121_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for restricted share units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_a27742ea-a6a2-437b-bba0-b6f212c2ce75_terseLabel_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_documentation_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:href="cdtx-20220331.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:to="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bc78ac4f-ae45-497d-8463-aaf3b8181e97_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f72ff819-05ef-424c-b5de-bd0cf2328563_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_94846f13-eb3d-4c66-897f-eada3a5fa133_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_8272dd6d-18ae-428f-b571-117db6e8a922_terseLabel_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_label_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_documentation_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:href="cdtx-20220331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:to="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TermLoanMember_9612ebe5-0921-42f0-843c-a2e865cd38b4_terseLabel_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_cdtx_TermLoanMember_label_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanMember_documentation_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanMember" xlink:to="lab_cdtx_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_48f7cc47-a773-405f-83c5-42b0769c3a69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d1f0bfbf-91bd-4e39-b84c-da76606752b5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_d191a9d1-67d0-4029-be1c-2f813097c7f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7e392c7c-cf5a-4c62-bb35-3f22c7ebd0ee_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c21d4d6c-b293-4d91-a750-128c6cf87cb8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_3d357f93-2f8f-4fa9-bab2-7b4e1255c0a9_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Election to proceed notice, period post delivery of results</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:to="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_10e1ae98-d457-467d-863c-0a938c6565d7_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, maximum cost share</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:to="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ec1b0a67-2186-45d6-bf59-2dd5b15639fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_194e8665-d9ae-458c-b473-c1522882d8a5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e87e718b-3949-43e7-bc83-0b981efd8bba_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_69b4d93e-8d11-466e-aaf8-19637d880f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic increase in number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_786dfc5f-54a7-4e05-834d-85528f67cb8d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_467a07b0-89ee-4466-aeef-333423d9fcec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_deeaf462-2eb6-41c8-a092-0b027ceaf68d_terseLabel_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease and short-term lease term included within operating lease cost (greater than)</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_label_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_documentation_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:href="cdtx-20220331.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:to="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f5e7bb5b-e500-4493-ae96-39949270f871_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bf69ab4e-1054-4fc0-91e6-88fcfeef45d8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a1277640-12eb-4519-91d9-63e31034276f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2689902b-a81c-4372-8d32-207f86f3ccb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_867b1bb4-542a-4dc0-824b-40e902a58139_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd8a94fc-7b72-485b-975f-a524d9afbb1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_545ff5eb-b4d6-4119-af5d-cb68cec5316a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a346ed5d-3bca-4b9f-bc70-cc528d40793e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_f8c5dedf-80fe-4ed4-98d2-165ef64b9f2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayments of Term Loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8c1afdd1-ead2-412a-b4af-f6bfffe833aa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_20db294b-2010-4554-aa62-3b186d17c761_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8d0e2258-9827-4f1e-b46b-00fb0591db89_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_afe64f6a-6682-44f1-ae8f-82a0b32b1c1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0c26c15c-6399-4e01-9b52-6828087cd3da_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY INCENTIVE PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1e7a6610-96a3-4b3f-b04c-8ef6d14d5860_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_59c97caf-6bb4-494d-837b-a8007acfca9d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e6c25933-f3e4-44ab-a259-42dfc92b0d14_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d6ae05bf-512a-4cfb-b2af-98809a3da0e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_3db979e4-e072-4a02-b8e5-a139da0ee4e7_terseLabel_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:href="cdtx-20220331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:to="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97afa7b2-4ee5-4d22-acbf-48a66113a472_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fee6c923-c88d-4370-955d-0fe64570465c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_87a9397a-3023-4bca-b87b-55e1f8947360_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_6401bdf1-7ebd-4b89-9643-595ceabf17de_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_af56b901-8f2d-4013-a004-24e22af0b01f_periodStartLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance, December&#160;31, 2021</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_f813cb17-2a24-43fc-b2c3-5643cecf4c6e_periodEndLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing balance, March&#160;31, 2022</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_ee06c7e5-899e-4a16-9539-684f76123535_netLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4b991912-4c2e-4d97-abf5-596362fd0817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_662b4d58-0843-430c-8625-1e5f0ce1a789_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3e160fb9-0adf-456b-8532-557c5d1090fa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f2a6ba96-10e0-4bd4-989a-11ffafe3b81d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8ce977f-188f-4d25-af12-f0880db20d2f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_621a8fb3-bb45-432e-9d0e-a13b489dc00a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_535c579a-c7e9-4e8d-921a-d4dff98d2b78_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_11fe2f09-9991-4b69-b401-f2b3f3c26960_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">#REF!</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7eb0391a-9a9c-43f8-a1b4-fc4d39ad5b5b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3fd74222-7623-4b82-8bc0-3da7cccc265d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f2f6d4f-4e91-44d5-835c-f8a05457ec6b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bf1f35fa-a5e8-4200-ad66-11651b0f96c8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c718c6c4-b179-4de2-8573-47757e572f92_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_2bee722d-035e-4201-aa95-cd6229bd5b8c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ended:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_b3095e7a-0e3e-4c7d-abd1-d080f3f02b7e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ae204f4b-4e88-49d0-b9d5-29003e143c19_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8191342f-51c1-40bf-b175-72eecd7800c6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1ff9c2c5-1dc4-401b-b4eb-cdad10c7253c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_70f21540-a270-4f69-84c8-451f6f00cc7e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7a056a59-3154-4d64-83ff-f0c2a7ec4105_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5ca07cc4-5b52-4c22-affd-fd1456590971_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_e9d44837-340f-4723-a475-d416d2e71cdc_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for each preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_5b566b82-9a2b-4004-8df7-7f4f2db2c440_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_e3bcaaef-191b-4dd4-92ef-830b7af38ed8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8ccf4d85-ff29-4c80-bec4-add52a33ad8d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ad1f028e-1829-42f2-bb49-adbb87ba9a54_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7c5c35c5-917b-4780-804d-77e3749051bb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1b47272-3c5e-4012-8b83-131a58e89ecd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_336e23cc-53f5-488c-ad60-c47eaddfe54d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc22b0da-e767-41a0-8300-701a888916e9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_da9cc2b6-6fdc-4607-85be-499c1c56c7f4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_f22a4ca4-4360-4914-b92f-32920a37fd45_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination provisions, required period of written notice</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:to="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e8497d0-3295-4818-8c71-0dac54894123_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5352480e-fe26-4bad-a77a-0dce8ce7b8d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_06b90f2b-5305-436a-97ab-788fd7dc55d7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MilestoneAchievementMember_159b9bbf-e55c-4d67-be8f-7f115cdd0513_terseLabel_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_label_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember" xlink:href="cdtx-20220331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MilestoneAchievementMember" xlink:to="lab_cdtx_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_fb444df2-5e63-47e6-812a-f553e01ef984_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d3f882c7-3db2-4b4f-bda4-c20433a0643b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_177f9226-d321-4638-b70a-0007985e4a2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dfa91e56-1392-4f3e-830f-43a1d92b6922_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_fc5f02bf-3dee-4932-ab82-755fb9c615e0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_74db11cf-973f-41e4-a112-4c1458e8decd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_56ce4390-e204-405a-8475-00b3e113c08e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_4398e067-7471-4d7d-a048-5fd08ead4504_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_label_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_documentation_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:href="cdtx-20220331.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:to="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone_91f341f4-9eae-495c-96a5-25aced3a000c_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, potential prepayment receivable</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Prepayment Milestone</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Prepayment Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementPotentialPrepaymentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone" xlink:to="lab_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5de5a614-2e75-47fa-ad39-a6bc4c67e12c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7c791e42-07d7-4f77-a48b-0c3385ff2c54_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_574493bf-866b-4b03-8ca4-acfeef919245_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3e97741-bbf0-46cf-89db-d09d62f5ab6d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_41461421-28ed-40bf-85ca-0ac0b2b5c777_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e215d6c5-25e3-44bf-b61e-a248ebf696a4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_471a2fa8-b5e6-4374-a498-429b2907f973_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f6f843e0-2d76-422b-9b2a-f4931083f399_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_b6bb17ef-67d7-4efb-ba22-4a06a4259ba2_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ff31bec6-da3d-4246-a7f1-d44803e2285f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8ce83fea-dff1-4ca9-8c87-1791baf8f6bb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5cb84590-8f3c-461d-877e-692011d34028_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_299930fb-7fb2-47dc-a1ea-b6ebcd208cba_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred at Point in Time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f5f66eac-e8ef-49ab-8f26-707f66822420_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_ed2e17ff-ba73-454e-941c-d232f6f02be4_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Incremental Borrowing Rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:href="cdtx-20220331.xsd#cdtx_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:to="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6c3f9f9a-89fa-4d37-921e-f88df643ade1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_16bbc05b-2c55-43f0-af4e-7ed8e240b241_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_277e2574-d658-4fbb-9356-4c9be5140f4b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_710a6815-6ccb-41f7-9d40-bb10980e70fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5ae81126-7646-40f0-b295-33fca23a21c6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_18c96bd5-36eb-4ab5-832c-184b56772099_terseLabel_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration remaining on transaction</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_label_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Remaining on Transaction</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_documentation_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Remaining on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:href="cdtx-20220331.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:to="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_230e0833-8dbf-4865-a1b5-c9b388c9c209_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_a2a21439-bfe5-4884-81ac-489f542bcbdd_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_756b5b2f-272f-48c0-b7dc-8ecf7fa59d2a_terseLabel_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to collaborative agreement</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_label_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_documentation_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:href="cdtx-20220331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:to="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_77b34279-57e5-42f6-80f2-665f6eb14cc4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_7bc8b944-bf1e-4d13-a899-a0b6325f6f36_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_df9e4e91-acde-4f85-aba5-956d5c065713_terseLabel_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_label_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_documentation_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:href="cdtx-20220331.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:to="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2854ce83-bcdf-4e74-9f37-be44c53fc995_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a22cf88f-6a0d-44b6-bf24-700f0ad4e376_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_09df5470-3b3a-4177-b421-7c3a6e3f502d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_298cb9c0-d99d-404f-b3cd-199663035448_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b705310b-efdb-40ac-90f1-d9a9cfb14b3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d86e86d8-2ab3-48f1-a223-973675d145c3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_2cde5aef-983f-47e1-8ee1-ae9466d3b5c8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d5b5b4dc-c5ae-46a8-b00e-a5258f3a7ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_7550b746-4d0c-4cec-a06b-c93d67822553_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_32b8a020-9da8-4b7a-98cb-11fd2c06169b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_594421d3-36b9-4369-a254-08bd7ad5b766_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_17f2f8c4-6839-47e2-9efe-46b7d786f6f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0748fa33-bbdb-4965-8596-f34ac3bfc001_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_53cc9f6d-d917-42e7-8e32-e1717b2d6489_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT AGREEMENTS AND CONTRACTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6451cf07-324b-4d6f-85a4-934255c6b2c3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_2dd76eb7-1652-416d-8361-7ecc9a8ae4a2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available under the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_0fd08157-4e82-40a2-b9ca-1ca1aaae04fe_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c51a4fe7-f817-4124-a025-d502db686bc8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_44f69ddd-fd2c-47a7-bcdd-4bcd991c51ae_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b49a21f3-f8e1-4473-9064-7a8bdb7c2e35_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6951c762-7f51-452f-9616-119be0fec87b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_f9812766-8692-466f-a6c5-3361e97f5e78_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_74dd1ff0-3795-4b36-b9e5-13526d48f8b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_524c6640-a002-4458-bf86-2c81c9e6a4e3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_dd532477-8964-46d1-a9a3-e100f9da66b8_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes for each share held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_label_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Entitlement For Each Share Held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_documentation_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitlement for each share held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:href="cdtx-20220331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:to="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5653dc36-d02f-4366-b661-b9a111790f3b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_1011a25e-90e8-483e-bfbd-e310b747f5ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dc439186-9a05-4581-ae5f-6770ad2c215c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1234b2fb-5b03-40b8-b785-431a8a9872e7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d86de15-0d8d-4e91-8549-b80286ee85ec_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e69c6146-4660-4137-b168-7330da3884d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4aef3562-6b0d-49c5-b640-be76ae96ec7f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5a7cdc71-d8dd-4856-9942-9269c8dab19e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a293bbf-285f-4db1-aafc-fe1aae3afcc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_09b2dcd6-337b-4228-83e0-439a587330d4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8d9cd2c9-2a50-4dac-bc79-78b19396d4fb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_44bc7306-7ec8-45d2-982d-97ce27feb724_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments receivable</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_77a729a2-ee64-4a50-9120-232f22cd3f55_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12c5b6ec-ea86-448d-960b-b3ea45b263dd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9ce5f069-240a-4709-8981-c77d2f13e734_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_563baace-8053-48d2-a2cf-5ef6504d5e4d_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_db41ccca-8388-4751-ac3a-3f66005da09d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f1564622-2167-4659-a7fa-258f6c26090c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3204a86f-1b33-436c-a65d-85901f113169_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_afdde95d-87b4-45b0-b2a9-2d1fbaa9b7c2_terseLabel_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mundipharma Medical Company</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_label_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_documentation_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:to="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9bbfcd09-bd1b-4387-b5fc-f71c8acfe21a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_247512e9-22f6-40e2-ac94-d2c99a8829cd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c1046f79-d490-4520-b5f0-c6eac5515932_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b0b26a48-5452-4fce-857f-035f302e208f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_12c782fc-165c-4250-b168-2e9fc660b1df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_37c323d3-b384-4abb-b328-6c9ec062553d_terseLabel_en-US" xlink:label="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_label_en-US" xlink:label="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock In Underwritten Public Offering</link:label>
    <link:label id="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_documentation_en-US" xlink:label="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock In Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:href="cdtx-20220331.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:to="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7195e1cc-d53f-4f38-8083-9a62de7a676e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8808c002-bc75-4f9f-b45f-26abc69332b7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ed27cf19-4e2c-424a-bd2e-3f6256287f94_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a3d4f002-2775-4912-a18d-d69ca8909e07_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1450c332-34bd-4619-9091-2bc39a9e6852_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_87210502-b235-4dea-b973-75b0c0618b16_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0baec457-d03c-4049-b2da-502a2e338db7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TermLoanAMember_a1224ddd-7b9d-4fff-8dc6-69ef02045a84_verboseLabel_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loan</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_label_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_documentation_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanAMember" xlink:to="lab_cdtx_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_68b3803f-2654-42ed-bea9-00ca7139d376_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb6aab23-a5fc-4dc4-932e-aed767f57fa3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7a7de2c8-e1f2-4c45-ab41-1fea381e4cf7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_93ac1f3b-b014-4a7f-a387-e1c6bef1eabc_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, potential transaction value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction, Potential Value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction, Potential Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:to="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a0d811ba-8e7c-464e-8e47-e2ba12a5d913_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2b955cfb-820a-463a-a064-77524a9f9910_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c1f108e1-6f79-4113-92b6-44c1f975cefa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3900b76a-6357-4f81-ab67-8a3bedfab318_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_86c80673-3b66-4c4b-b226-d5566cd7180f_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received in advance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_62821008-f4a7-4b8d-aae9-5e3811cb0c22_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3b70b517-b721-466a-b112-8f51509b6f8c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborationRevenueMember_label_en-US" xlink:label="lab_cdtx_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_cdtx_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_cdtx_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationRevenueMember" xlink:href="cdtx-20220331.xsd#cdtx_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborationRevenueMember" xlink:to="lab_cdtx_CollaborationRevenueMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cdtx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8627cbaf-6f66-4b32-bb14-4a9dea57dc11,g:21d3a7c8-7ecf-40b1-a09c-92da8f218d01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/CoverPage" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b009a17c-0a86-4e71-a187-7cfdcac9f577" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_DocumentType_b009a17c-0a86-4e71-a187-7cfdcac9f577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4b284b5d-2fc1-4c27-a17c-60ff7c181434" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_DocumentQuarterlyReport_4b284b5d-2fc1-4c27-a17c-60ff7c181434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_25611b1f-4439-4798-95bc-1a7e95d8dff3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_DocumentPeriodEndDate_25611b1f-4439-4798-95bc-1a7e95d8dff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ed8ea9b2-de22-4d87-adc6-2f1558016e93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_DocumentTransitionReport_ed8ea9b2-de22-4d87-adc6-2f1558016e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_848c91ab-f521-4e41-8975-87769e40ab7f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityFileNumber_848c91ab-f521-4e41-8975-87769e40ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_22516c1e-088d-4d77-b92d-628363a40900" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityRegistrantName_22516c1e-088d-4d77-b92d-628363a40900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7f7af5b0-23b6-427d-93c8-048cf87c27a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7f7af5b0-23b6-427d-93c8-048cf87c27a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5868b3de-23ef-4e0c-8ebd-59140046cc5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityTaxIdentificationNumber_5868b3de-23ef-4e0c-8ebd-59140046cc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_58a01427-fcdb-4630-be54-10e86f26e593" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityAddressAddressLine1_58a01427-fcdb-4630-be54-10e86f26e593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_85a7fa98-ede6-4ecc-9071-ffc3c7714898" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityAddressAddressLine2_85a7fa98-ede6-4ecc-9071-ffc3c7714898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e1c1cad2-1013-424d-bd25-839d5618d7aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityAddressCityOrTown_e1c1cad2-1013-424d-bd25-839d5618d7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1141afc4-a862-4264-a3f5-67212dedbf04" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityAddressStateOrProvince_1141afc4-a862-4264-a3f5-67212dedbf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1f00936c-e4de-4d0f-b64f-1592d8ef6bed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityAddressPostalZipCode_1f00936c-e4de-4d0f-b64f-1592d8ef6bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6c4b6781-5fd6-4b32-a8b4-689c517138c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_CityAreaCode_6c4b6781-5fd6-4b32-a8b4-689c517138c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a1b34a67-fbf9-45a4-899d-3d49c94bfb81" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_LocalPhoneNumber_a1b34a67-fbf9-45a4-899d-3d49c94bfb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_411be3cb-b438-48a5-9b64-03550187fd64" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_Security12bTitle_411be3cb-b438-48a5-9b64-03550187fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c35f205f-256d-4f11-9b51-6a36a2e67791" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_TradingSymbol_c35f205f-256d-4f11-9b51-6a36a2e67791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_82927297-f491-4dcd-a4d8-41fa7cc042ba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_SecurityExchangeName_82927297-f491-4dcd-a4d8-41fa7cc042ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_934884db-f149-4417-8087-f908c39be074" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityCurrentReportingStatus_934884db-f149-4417-8087-f908c39be074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bb6e208e-02bb-4d47-a7d4-66a7631dbac6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityInteractiveDataCurrent_bb6e208e-02bb-4d47-a7d4-66a7631dbac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f1a040fb-3a6b-4983-88df-9fb1a063b03c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityFilerCategory_f1a040fb-3a6b-4983-88df-9fb1a063b03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_01020dac-9b72-451c-b43e-5ce6bfc28686" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntitySmallBusiness_01020dac-9b72-451c-b43e-5ce6bfc28686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_58533d7c-2cd0-4444-b490-939282311e18" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityEmergingGrowthCompany_58533d7c-2cd0-4444-b490-939282311e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c9a673ff-367e-457e-979b-0b59e846a2dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityShellCompany_c9a673ff-367e-457e-979b-0b59e846a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_56017716-7116-470c-873a-6b958bf436a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_56017716-7116-470c-873a-6b958bf436a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ae7126a5-48cf-498a-b5e4-3a2bc0ad4ebe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_AmendmentFlag_ae7126a5-48cf-498a-b5e4-3a2bc0ad4ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6e1a5baa-80fb-40d4-8787-fbc7308cc381" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_DocumentFiscalYearFocus_6e1a5baa-80fb-40d4-8787-fbc7308cc381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f4612335-ce64-48cd-8326-2ddc3ca0f7e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f4612335-ce64-48cd-8326-2ddc3ca0f7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7918e04f-f0c4-4005-9ea7-729faa1ab7ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_EntityCentralIndexKey_7918e04f-f0c4-4005-9ea7-729faa1ab7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e223e084-511b-45fc-9c92-2d10a6fd363f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d5134058-f5bf-45dd-bb8a-b11fe42e8db8" xlink:to="loc_dei_CurrentFiscalYearEndDate_e223e084-511b-45fc-9c92-2d10a6fd363f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_eb1585f0-9082-4e0c-872b-2350e186ce12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb1585f0-9082-4e0c-872b-2350e186ce12" xlink:to="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f407b95-c5d6-4dab-b505-6440141bd61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f407b95-c5d6-4dab-b505-6440141bd61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e3063f1-d2da-474c-9cfb-7d5e985fa9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f407b95-c5d6-4dab-b505-6440141bd61c" xlink:to="loc_us-gaap_ClassOfStockDomain_7e3063f1-d2da-474c-9cfb-7d5e985fa9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_d6d94d52-7e39-4452-847f-0c5b273d333b" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7e3063f1-d2da-474c-9cfb-7d5e985fa9f1" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_d6d94d52-7e39-4452-847f-0c5b273d333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7b7ffd18-557d-490e-ac17-71842fd08593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7b7ffd18-557d-490e-ac17-71842fd08593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_80bcc7e6-de51-42ba-ab5f-0814a6a705a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b7ffd18-557d-490e-ac17-71842fd08593" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_80bcc7e6-de51-42ba-ab5f-0814a6a705a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ddd8a78-4b4b-4a2e-b6d2-46c4bd445fb0" xlink:to="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:to="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6576f362-3828-408e-aba9-0be57f73bbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6576f362-3828-408e-aba9-0be57f73bbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ca9b35c9-e210-4e21-8f5b-700750231188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_RestrictedCashCurrent_ca9b35c9-e210-4e21-8f5b-700750231188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_56d7dbbc-2f16-4c37-a0bd-3f0d3130157e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_56d7dbbc-2f16-4c37-a0bd-3f0d3130157e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cb85a43-18bc-4acf-9e05-b73a13e7f7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cb85a43-18bc-4acf-9e05-b73a13e7f7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2432ba93-4753-4715-bf87-265a435631ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c1704e1-9d5a-4a4c-b29c-ec8e3cdaff88" xlink:to="loc_us-gaap_AssetsCurrent_2432ba93-4753-4715-bf87-265a435631ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a781ba8a-72c1-4101-ba0f-3875a71c5a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a781ba8a-72c1-4101-ba0f-3875a71c5a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_51d0b7a5-eac2-44ce-8163-7573ecb2826c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_51d0b7a5-eac2-44ce-8163-7573ecb2826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3015cf29-f300-4336-aab8-a6ae1b3f7873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3015cf29-f300-4336-aab8-a6ae1b3f7873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7a74ee35-126a-41a0-aa35-1fdce71bd8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3225a5d2-9214-4c0f-822e-afd4ee35f3b1" xlink:to="loc_us-gaap_Assets_7a74ee35-126a-41a0-aa35-1fdce71bd8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_966b9470-a6ca-41ee-a904-68a7b75e24e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_AccountsPayableCurrent_966b9470-a6ca-41ee-a904-68a7b75e24e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ba68a548-2370-4abf-87a1-65213db2aba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ba68a548-2370-4abf-87a1-65213db2aba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_412b01e4-8999-4279-9e28-783d20b57f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_412b01e4-8999-4279-9e28-783d20b57f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_e78f82df-0cf2-4907-bb45-8c0380c40449" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_e78f82df-0cf2-4907-bb45-8c0380c40449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_bf7a334d-0518-4c84-9671-248f4283e34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_LoansPayableCurrent_bf7a334d-0518-4c84-9671-248f4283e34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_669cc55d-86a4-44df-9d3c-df23e9bf2615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_669cc55d-86a4-44df-9d3c-df23e9bf2615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_211c07c8-e147-4ec3-89b4-1390a61c7712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a39ee6de-222d-498b-80b8-795e7b51e55f" xlink:to="loc_us-gaap_LiabilitiesCurrent_211c07c8-e147-4ec3-89b4-1390a61c7712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_3a595eb7-6e8f-4a4f-b24c-ada5941c976c" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_3a595eb7-6e8f-4a4f-b24c-ada5941c976c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_148d13aa-491c-42db-86b6-376b6dc86d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_148d13aa-491c-42db-86b6-376b6dc86d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cafb94df-b886-41fe-bda5-953ba43b6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_Liabilities_cafb94df-b886-41fe-bda5-953ba43b6c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2fa89369-a712-4b85-93ea-81fc4d57b748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2fa89369-a712-4b85-93ea-81fc4d57b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_46d3af7a-a8d9-44de-8e56-ecf532069b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_PreferredStockValue_46d3af7a-a8d9-44de-8e56-ecf532069b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_52395134-8d47-434a-a676-5cad37f0cb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_CommonStockValue_52395134-8d47-434a-a676-5cad37f0cb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86cf365f-bee1-4a64-8267-372a15ed653d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86cf365f-bee1-4a64-8267-372a15ed653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6f5135b-5fd3-40be-a1ca-1aa698f6a5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6f5135b-5fd3-40be-a1ca-1aa698f6a5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fe75785c-a4bd-4a82-bcb3-9671e202e0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a1c2f5a-7cb3-452f-ae60-4bf30c4bfeeb" xlink:to="loc_us-gaap_StockholdersEquity_fe75785c-a4bd-4a82-bcb3-9671e202e0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_afeaa8b8-3318-42e9-8147-1568b5d2c402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6014fabf-6a78-421f-8fba-0e61065782af" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_afeaa8b8-3318-42e9-8147-1568b5d2c402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2d80040d-f49a-4b71-b07f-df4e0a5092d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8252a7cb-4be1-4aec-a196-b4be3949dba9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2d80040d-f49a-4b71-b07f-df4e0a5092d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a11d966-7d5b-4cc4-af2a-75d7f2278624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c834858-ff57-4f72-98cc-07b648d9d5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a11d966-7d5b-4cc4-af2a-75d7f2278624" xlink:to="loc_us-gaap_StatementTable_5c834858-ff57-4f72-98cc-07b648d9d5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_580813bb-5f08-4c9b-8065-3785089c37c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c834858-ff57-4f72-98cc-07b648d9d5e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_580813bb-5f08-4c9b-8065-3785089c37c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c22e323-d2d1-4afe-889e-40a13873602b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_580813bb-5f08-4c9b-8065-3785089c37c7" xlink:to="loc_us-gaap_ClassOfStockDomain_7c22e323-d2d1-4afe-889e-40a13873602b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_8bdaeb57-2acc-434f-aeb8-4082652473fc" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7c22e323-d2d1-4afe-889e-40a13873602b" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_8bdaeb57-2acc-434f-aeb8-4082652473fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c834858-ff57-4f72-98cc-07b648d9d5e2" xlink:to="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_14e00b70-373b-422b-8877-35d72abc68a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_14e00b70-373b-422b-8877-35d72abc68a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7608efc4-25e0-41ee-a780-50ce603d1ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7608efc4-25e0-41ee-a780-50ce603d1ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_39245533-b2e0-4a33-bbc0-5ec10bebe361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockSharesIssued_39245533-b2e0-4a33-bbc0-5ec10bebe361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_56419856-db96-4a1a-ad26-bd149c12f700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_56419856-db96-4a1a-ad26-bd149c12f700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1697e85e-a08a-4a1a-b877-2705642fc6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1697e85e-a08a-4a1a-b877-2705642fc6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d64ef304-37db-4c6b-aaf1-d8608a542df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d64ef304-37db-4c6b-aaf1-d8608a542df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d1eb0492-1603-448c-8826-a84bdd6beb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockSharesIssued_d1eb0492-1603-448c-8826-a84bdd6beb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_99b41dd5-a82c-4b54-9b02-ea889f282fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83457d64-f2c5-40e0-82cd-eef805a329ce" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_99b41dd5-a82c-4b54-9b02-ea889f282fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList_baf9ccc7-2bb2-4a07-b95d-d081ad507543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_TypeOfRevenueExtensibleList_baf9ccc7-2bb2-4a07-b95d-d081ad507543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fdd8f5ef-47a0-4735-ba41-4e318f263194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fdd8f5ef-47a0-4735-ba41-4e318f263194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d2b556d4-010e-45ae-965a-0075e2102914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d2b556d4-010e-45ae-965a-0075e2102914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10670f90-64dc-41f2-9956-51ae009320fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d2b556d4-010e-45ae-965a-0075e2102914" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10670f90-64dc-41f2-9956-51ae009320fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cbb17556-0cde-4b30-a424-84f20a8816f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d2b556d4-010e-45ae-965a-0075e2102914" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cbb17556-0cde-4b30-a424-84f20a8816f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0868c68b-ee60-44ff-8fc5-d754f956dc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d2b556d4-010e-45ae-965a-0075e2102914" xlink:to="loc_us-gaap_OperatingExpenses_0868c68b-ee60-44ff-8fc5-d754f956dc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cd87dbe8-f050-44c6-9d05-429fb1665288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_OperatingIncomeLoss_cd87dbe8-f050-44c6-9d05-429fb1665288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d0c01cdf-df32-4fd9-9401-96ee1cf76830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d0c01cdf-df32-4fd9-9401-96ee1cf76830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0a180a20-526b-4ce4-9efe-43a546b3ff91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d0c01cdf-df32-4fd9-9401-96ee1cf76830" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0a180a20-526b-4ce4-9efe-43a546b3ff91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_521bcc72-c355-4c7b-abdb-c98a2c4a5d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d0c01cdf-df32-4fd9-9401-96ee1cf76830" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_521bcc72-c355-4c7b-abdb-c98a2c4a5d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_32e273e8-f17b-4f48-a8cf-534dd030a1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d0c01cdf-df32-4fd9-9401-96ee1cf76830" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_32e273e8-f17b-4f48-a8cf-534dd030a1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9765f8fe-ac98-42b7-bf66-69df5ef2d7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d0c01cdf-df32-4fd9-9401-96ee1cf76830" xlink:to="loc_us-gaap_NetIncomeLoss_9765f8fe-ac98-42b7-bf66-69df5ef2d7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_29618f56-3dc4-4601-ae82-647164e3c8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_29618f56-3dc4-4601-ae82-647164e3c8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cca43ee0-e9f9-4f7c-abaa-38f3f1713e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_EarningsPerShareBasic_cca43ee0-e9f9-4f7c-abaa-38f3f1713e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d218d053-56d0-4853-992f-992747659801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d218d053-56d0-4853-992f-992747659801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95718b46-4e9d-4e6c-b225-b6fb74182cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95718b46-4e9d-4e6c-b225-b6fb74182cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4a2f678-c3b5-4cd0-a122-3a8d37d121fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_897f29b1-0dea-47cf-9569-71519561e4a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4a2f678-c3b5-4cd0-a122-3a8d37d121fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2dbeca29-19ce-42e0-a527-32ebd84ecc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2dbeca29-19ce-42e0-a527-32ebd84ecc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0eedfb7a-d18c-44bd-b627-9d260c6d6492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2dbeca29-19ce-42e0-a527-32ebd84ecc99" xlink:to="loc_us-gaap_NetIncomeLoss_0eedfb7a-d18c-44bd-b627-9d260c6d6492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2dbeca29-19ce-42e0-a527-32ebd84ecc99" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b9fde043-d0db-46a3-be81-2708114ef963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:to="loc_us-gaap_ShareBasedCompensation_b9fde043-d0db-46a3-be81-2708114ef963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_7e7ab335-452f-484d-81d0-6f56ac434535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:to="loc_us-gaap_DepreciationAndAmortization_7e7ab335-452f-484d-81d0-6f56ac434535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_3eb8e908-3b8a-464f-a2b1-916567f1f57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:to="loc_us-gaap_PaidInKindInterest_3eb8e908-3b8a-464f-a2b1-916567f1f57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c75f2b74-4119-499f-a7ec-419fd80f7ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c75f2b74-4119-499f-a7ec-419fd80f7ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_415200a1-b247-4be5-abb7-873f11880d84" xlink:href="cdtx-20220331.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:to="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_415200a1-b247-4be5-abb7-873f11880d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60c3d860-d65f-47be-8390-2d598b211332" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe56d632-2243-484a-8175-70d2d55152b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe56d632-2243-484a-8175-70d2d55152b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f8430aa9-3e3e-4efc-bbcb-40cf5f403022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f8430aa9-3e3e-4efc-bbcb-40cf5f403022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6684d8ce-54c8-4741-930b-daea86a1bc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6684d8ce-54c8-4741-930b-daea86a1bc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_47a5ed62-3e42-4b2a-84f9-437d7dcdc89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_47a5ed62-3e42-4b2a-84f9-437d7dcdc89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8448c2ce-a60e-4127-ba42-a67f7b4716f0" xlink:href="cdtx-20220331.xsd#cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:to="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8448c2ce-a60e-4127-ba42-a67f7b4716f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5c9c9dbb-4c72-443d-b6db-a1e012d6cccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab453dd4-93be-46de-8c10-5fbed867d236" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5c9c9dbb-4c72-443d-b6db-a1e012d6cccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2dbe24dd-a213-47a8-b0a7-5f4bbb32db23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2dbeca29-19ce-42e0-a527-32ebd84ecc99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2dbe24dd-a213-47a8-b0a7-5f4bbb32db23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b989571a-d165-483c-bdcc-f575462cfb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b989571a-d165-483c-bdcc-f575462cfb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_935d2be3-a5f9-4bab-ad89-896e1cb50bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b989571a-d165-483c-bdcc-f575462cfb74" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_935d2be3-a5f9-4bab-ad89-896e1cb50bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81292686-f559-49a4-a966-73970481ba27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b989571a-d165-483c-bdcc-f575462cfb74" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81292686-f559-49a4-a966-73970481ba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d514b1f6-0f9c-44fa-981f-22109d3a790b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d514b1f6-0f9c-44fa-981f-22109d3a790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3e5e0acf-baf7-4feb-8c10-a6c923f055bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d514b1f6-0f9c-44fa-981f-22109d3a790b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3e5e0acf-baf7-4feb-8c10-a6c923f055bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_df1fcdc8-bc98-48d6-b34f-75eb2351a76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d514b1f6-0f9c-44fa-981f-22109d3a790b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_df1fcdc8-bc98-48d6-b34f-75eb2351a76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ab5e93be-06ca-4dfe-b84f-f9a815e45daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d514b1f6-0f9c-44fa-981f-22109d3a790b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ab5e93be-06ca-4dfe-b84f-f9a815e45daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b130758d-0d95-49e8-8cad-a8fed0532842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d514b1f6-0f9c-44fa-981f-22109d3a790b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b130758d-0d95-49e8-8cad-a8fed0532842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6208288d-fc39-4013-b9e3-2f0e9cdc854b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6208288d-fc39-4013-b9e3-2f0e9cdc854b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6eb7c8cd-708b-4fd1-ab2f-27e3e9bc5b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6eb7c8cd-708b-4fd1-ab2f-27e3e9bc5b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32833efd-d452-411d-be98-2a3edc99212f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32833efd-d452-411d-be98-2a3edc99212f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f73fce5-cb2d-4f1f-b146-d62578a5bade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f73fce5-cb2d-4f1f-b146-d62578a5bade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_35cfcaf0-2eb5-4dd8-a147-403abb5e28c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f73fce5-cb2d-4f1f-b146-d62578a5bade" xlink:to="loc_us-gaap_InterestPaidNet_35cfcaf0-2eb5-4dd8-a147-403abb5e28c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_74b05a6f-2023-49d4-97b5-321594aaba46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fde2163-7eac-4174-aea4-475ce3b111ab" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_74b05a6f-2023-49d4-97b5-321594aaba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_61f0183e-d8f7-4935-a3d3-4ed05731695e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_74b05a6f-2023-49d4-97b5-321594aaba46" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_61f0183e-d8f7-4935-a3d3-4ed05731695e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited" xlink:type="simple" xlink:href="cdtx-20220331.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_839ade1d-3c08-4258-aa07-2a0c94a7d797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_839ade1d-3c08-4258-aa07-2a0c94a7d797" xlink:to="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cbab2bd6-0272-468e-b6e7-40e681a44927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cbab2bd6-0272-468e-b6e7-40e681a44927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6b53c07-a0c8-438d-aa94-f90aef3b066a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cbab2bd6-0272-468e-b6e7-40e681a44927" xlink:to="loc_us-gaap_ClassOfStockDomain_e6b53c07-a0c8-438d-aa94-f90aef3b066a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_7c00c303-6739-4723-887f-fb5421bfde21" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e6b53c07-a0c8-438d-aa94-f90aef3b066a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_7c00c303-6739-4723-887f-fb5421bfde21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eab6c1f7-70eb-4b3d-bd58-7fb16a378dc0" xlink:to="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_2c083d04-6ead-42f3-bae2-a0efb11a84e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_PreferredStockMember_2c083d04-6ead-42f3-bae2-a0efb11a84e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_433bf25d-1a4d-4cc7-83bc-84cbe5fb3809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_CommonStockMember_433bf25d-1a4d-4cc7-83bc-84cbe5fb3809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7d355c30-32ae-4149-9e6f-ae95acde4f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7d355c30-32ae-4149-9e6f-ae95acde4f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_518682d4-e953-4c6e-bbb7-7b9ddc6f57e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44eccaeb-5144-4fb3-9169-798747699d1d" xlink:to="loc_us-gaap_RetainedEarningsMember_518682d4-e953-4c6e-bbb7-7b9ddc6f57e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fe36a69c-d923-4448-8b62-c77e4e74ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dbbb0ec0-d1a6-4662-8597-1e3d1a956e06" xlink:to="loc_us-gaap_StatementLineItems_fe36a69c-d923-4448-8b62-c77e4e74ef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fe36a69c-d923-4448-8b62-c77e4e74ef8b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7759668e-c76e-41d3-9e14-683db829e822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_SharesOutstanding_7759668e-c76e-41d3-9e14-683db829e822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_549f7645-bcc5-4451-8ee3-4f7edcc34735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockholdersEquity_549f7645-bcc5-4451-8ee3-4f7edcc34735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4f28b018-ce39-4d12-a7dd-434198e41b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4f28b018-ce39-4d12-a7dd-434198e41b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7723f60-1941-4b3e-a09b-ef7051f490e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7723f60-1941-4b3e-a09b-ef7051f490e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e70af8d-e57b-4f0b-9935-25b7894a88e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e70af8d-e57b-4f0b-9935-25b7894a88e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3691ef9f-c442-446a-a2f0-f4eab6050671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3691ef9f-c442-446a-a2f0-f4eab6050671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_93535bfe-89be-4f42-9a04-cba2b6817ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_93535bfe-89be-4f42-9a04-cba2b6817ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_bf37f1ea-d479-4d95-8716-4cf486540b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_bf37f1ea-d479-4d95-8716-4cf486540b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1addd23b-8a82-4ccb-917a-5ed312406ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_NetIncomeLoss_1addd23b-8a82-4ccb-917a-5ed312406ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_64150368-fb84-4565-a46a-5c94250cbd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_SharesOutstanding_64150368-fb84-4565-a46a-5c94250cbd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5fc81334-a89a-47ed-8670-665e62bce7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a1da4629-5f26-4b89-8680-50f5182fe082" xlink:to="loc_us-gaap_StockholdersEquity_5fc81334-a89a-47ed-8670-665e62bce7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="cdtx-20220331.xsd#THECOMPANYANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f26db4d-65a8-4806-906b-acc95c9466a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_5fec2045-6cf1-4095-988d-35dc32d13007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f26db4d-65a8-4806-906b-acc95c9466a9" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_5fec2045-6cf1-4095-988d-35dc32d13007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#THECOMPANYANDBASISOFPRESENTATIONDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e981ffd8-3c78-46ad-aa54-39bc581d79df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0dddfd99-2082-4cc0-a206-189ddb62285b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e981ffd8-3c78-46ad-aa54-39bc581d79df" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0dddfd99-2082-4cc0-a206-189ddb62285b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b187f69-0198-4bec-8dce-c3ad4c573db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e981ffd8-3c78-46ad-aa54-39bc581d79df" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b187f69-0198-4bec-8dce-c3ad4c573db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a21abd3a-1ae5-4bae-96d1-c2193dde6108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e981ffd8-3c78-46ad-aa54-39bc581d79df" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a21abd3a-1ae5-4bae-96d1-c2193dde6108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6550a703-d3e1-425f-823c-025bced7696b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3e61d13b-c6a8-4fc8-9023-683a8c3b5b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6550a703-d3e1-425f-823c-025bced7696b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3e61d13b-c6a8-4fc8-9023-683a8c3b5b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2222e1e8-5e23-4403-a263-973526f2d829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2222e1e8-5e23-4403-a263-973526f2d829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_eafe8517-b04e-4798-a56d-3633a4f022da" xlink:href="cdtx-20220331.xsd#cdtx_UnauditedInterimFinancialDataPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_eafe8517-b04e-4798-a56d-3633a4f022da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9775ddd2-c105-4acb-a29c-1f5facbf4334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9775ddd2-c105-4acb-a29c-1f5facbf4334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0c3be523-660a-4d52-85d6-a7af9ff52b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_UseOfEstimates_0c3be523-660a-4d52-85d6-a7af9ff52b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c3b03a3e-7bef-4753-ba35-3c50ef6ead10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c3b03a3e-7bef-4753-ba35-3c50ef6ead10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a17bfe1c-b648-410a-bcf6-feeedd791aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a17bfe1c-b648-410a-bcf6-feeedd791aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_b119f409-71ab-4f0c-9d74-151af527c262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_b119f409-71ab-4f0c-9d74-151af527c262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e1626941-f8f8-4258-8384-130f0666dd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e1626941-f8f8-4258-8384-130f0666dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1e34801d-6b79-4dc9-804e-79b7ad0f9dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1e34801d-6b79-4dc9-804e-79b7ad0f9dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8507a909-43e9-4599-a66a-caa2657a20f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8507a909-43e9-4599-a66a-caa2657a20f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ddeb0558-00d3-48a6-951d-4d9509e8495f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ddeb0558-00d3-48a6-951d-4d9509e8495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_ed94a2d4-84c3-490a-848c-c4eb741ad8d0" xlink:href="cdtx-20220331.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_ed94a2d4-84c3-490a-848c-c4eb741ad8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a925a1e7-8398-48cd-a909-f8d336265335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a925a1e7-8398-48cd-a909-f8d336265335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b436ad15-10e3-493b-9e2f-b116cec1a903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b436ad15-10e3-493b-9e2f-b116cec1a903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_fa27d6dd-721c-466d-8fc0-e92fea35d721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_fa27d6dd-721c-466d-8fc0-e92fea35d721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac04c806-85b8-4a24-bdcd-b08d661da812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11dac76e-2b74-42da-acee-97a0a49ddf79" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac04c806-85b8-4a24-bdcd-b08d661da812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0940cf2d-ac47-4355-adcd-0e1ee9c7fcae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3f3c3abf-586c-42a1-81fc-b1c1bf5f0b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0940cf2d-ac47-4355-adcd-0e1ee9c7fcae" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3f3c3abf-586c-42a1-81fc-b1c1bf5f0b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5e434998-3b01-47c0-abc4-7fcc5713edcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19ef4660-b1d5-44f7-b73a-243760de4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e434998-3b01-47c0-abc4-7fcc5713edcb" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19ef4660-b1d5-44f7-b73a-243760de4a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5971cbc3-a4b7-4c03-abd7-610e78455718" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19ef4660-b1d5-44f7-b73a-243760de4a29" xlink:to="loc_srt_RangeAxis_5971cbc3-a4b7-4c03-abd7-610e78455718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5971cbc3-a4b7-4c03-abd7-610e78455718" xlink:to="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d1339b7-eed0-4204-9c3e-157911936b6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:to="loc_srt_MinimumMember_1d1339b7-eed0-4204-9c3e-157911936b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4e19cc57-abb6-4bd8-a852-fc7c32cbf187" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9a1dc8b-c95f-45cc-987b-0c44f8993d5d" xlink:to="loc_srt_MaximumMember_4e19cc57-abb6-4bd8-a852-fc7c32cbf187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19ef4660-b1d5-44f7-b73a-243760de4a29" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39b1e995-ded1-4a62-b5f4-9bd9c4476aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39b1e995-ded1-4a62-b5f4-9bd9c4476aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efa54408-1297-45f5-9248-f0a1d8395f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c0a47be4-5a0f-4c67-9134-f94116bc3dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efa54408-1297-45f5-9248-f0a1d8395f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_36db5587-d26d-4781-94dc-f46688e315c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18abfa04-d846-4192-b05a-9e762ce9a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_36db5587-d26d-4781-94dc-f46688e315c3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18abfa04-d846-4192-b05a-9e762ce9a8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ce47142-42f0-47bf-a718-d2bad6ada776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18abfa04-d846-4192-b05a-9e762ce9a8fa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ce47142-42f0-47bf-a718-d2bad6ada776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ce47142-42f0-47bf-a718-d2bad6ada776" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cd9f8ac3-17f9-44ee-becd-b6e7d1636c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:to="loc_us-gaap_WarrantMember_cd9f8ac3-17f9-44ee-becd-b6e7d1636c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b79e5c3b-0bd7-4fc5-859c-aa38fada0861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b79e5c3b-0bd7-4fc5-859c-aa38fada0861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_97fc8e11-bbed-4ad6-93a3-5df4be5973ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_792a464c-bcde-4acb-9280-55b00887ccc9" xlink:to="loc_us-gaap_StockCompensationPlanMember_97fc8e11-bbed-4ad6-93a3-5df4be5973ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea81547d-b106-4df3-86d8-f33315ca3bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18abfa04-d846-4192-b05a-9e762ce9a8fa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea81547d-b106-4df3-86d8-f33315ca3bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_56d4143d-5fe6-41c9-b6a6-2b38479b99f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea81547d-b106-4df3-86d8-f33315ca3bc0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_56d4143d-5fe6-41c9-b6a6-2b38479b99f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cdtx-20220331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_21df78d7-efc7-43ff-8e33-0df605e5f49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9182d60d-c288-4fa9-b4d1-1a9d72363f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_21df78d7-efc7-43ff-8e33-0df605e5f49b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9182d60d-c288-4fa9-b4d1-1a9d72363f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="cdtx-20220331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_51110893-ca18-4659-a80d-b7b35664866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d049975c-c5cc-4945-8327-ee4f8efaf812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_51110893-ca18-4659-a80d-b7b35664866e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d049975c-c5cc-4945-8327-ee4f8efaf812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0454a170-8362-418d-bfd1-6b3a9ba8ca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce10cf86-d899-4fd6-b7cf-33f7e5d879af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0454a170-8362-418d-bfd1-6b3a9ba8ca8d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce10cf86-d899-4fd6-b7cf-33f7e5d879af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eef812e-6fcc-45b9-a281-c92f59b41bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce10cf86-d899-4fd6-b7cf-33f7e5d879af" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eef812e-6fcc-45b9-a281-c92f59b41bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eef812e-6fcc-45b9-a281-c92f59b41bf6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e41609c7-f5b0-4c9c-b63b-15eaea3b56ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e41609c7-f5b0-4c9c-b63b-15eaea3b56ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_38caa92d-8446-47e0-a72c-591d6168e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_38caa92d-8446-47e0-a72c-591d6168e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2128193a-6aa9-46bd-9197-bb7fb9f8b5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b4216d-8fe4-4e9e-a02e-32ffb21bb6c3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2128193a-6aa9-46bd-9197-bb7fb9f8b5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba34066-1804-478b-8f67-cd3fe15b9fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce10cf86-d899-4fd6-b7cf-33f7e5d879af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba34066-1804-478b-8f67-cd3fe15b9fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba34066-1804-478b-8f67-cd3fe15b9fc6" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_534c866f-b36a-42c0-9538-a20a601b4b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_534c866f-b36a-42c0-9538-a20a601b4b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c0f14e31-0f38-4c2a-b512-1e9b25d690d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:to="loc_us-gaap_RestrictedCash_c0f14e31-0f38-4c2a-b512-1e9b25d690d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_639842d9-a5ed-4a64-b88b-74370d9cfc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e1910e5-25de-4f97-b778-f9cec0c1e45c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_639842d9-a5ed-4a64-b88b-74370d9cfc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBT" xlink:type="simple" xlink:href="cdtx-20220331.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eda83c88-c6c1-47b4-9583-8c3c99ff7367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0148c082-b4e2-4740-bf56-0334fbf1d8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eda83c88-c6c1-47b4-9583-8c3c99ff7367" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_0148c082-b4e2-4740-bf56-0334fbf1d8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTTables" xlink:type="simple" xlink:href="cdtx-20220331.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f245dcd5-a6b4-4c4a-a350-51dc4aa5fde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_14fa17b6-4c5b-4807-bb4c-5ff5c68806c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f245dcd5-a6b4-4c4a-a350-51dc4aa5fde3" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_14fa17b6-4c5b-4807-bb4c-5ff5c68806c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#DEBTAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f3e9a9d2-337b-4706-ae99-0e13d61e005d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f3e9a9d2-337b-4706-ae99-0e13d61e005d" xlink:to="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_92974a5f-28d6-4d0f-93c0-2bfc726a71c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_92974a5f-28d6-4d0f-93c0-2bfc726a71c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c6eeb98d-422e-4985-8d30-3b0ac1ee6d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_92974a5f-28d6-4d0f-93c0-2bfc726a71c5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c6eeb98d-422e-4985-8d30-3b0ac1ee6d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_427e05a7-e3b1-42af-ac4d-87e1e5c9de5f" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c6eeb98d-422e-4985-8d30-3b0ac1ee6d6c" xlink:to="loc_cdtx_TermLoanMember_427e05a7-e3b1-42af-ac4d-87e1e5c9de5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c74f35f5-51be-4cbb-b6df-139b7c32ea16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:to="loc_us-gaap_DebtInstrumentAxis_c74f35f5-51be-4cbb-b6df-139b7c32ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cdb2afcc-4c82-4c11-9219-6d7c6f213aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c74f35f5-51be-4cbb-b6df-139b7c32ea16" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cdb2afcc-4c82-4c11-9219-6d7c6f213aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_4489be12-d968-402c-bd54-129a68095749" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cdb2afcc-4c82-4c11-9219-6d7c6f213aba" xlink:to="loc_cdtx_TermLoanAMember_4489be12-d968-402c-bd54-129a68095749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c8232db0-e4f5-4e34-a46b-d6975bb80357" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e394bf53-b851-4b8a-abf5-b1c7f01832df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e394bf53-b851-4b8a-abf5-b1c7f01832df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_103720b8-407b-403d-90b0-dcc63176494d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5beeb7f6-6a75-4260-b094-cea3289b99d0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_103720b8-407b-403d-90b0-dcc63176494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bd23658c-613f-4e02-801f-770a7738c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bd23658c-613f-4e02-801f-770a7738c88f" xlink:to="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2a1941a4-b696-4337-ab22-4fc3f2fe7b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:to="loc_us-gaap_DebtInstrumentAxis_2a1941a4-b696-4337-ab22-4fc3f2fe7b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ab5a229b-1eb0-443b-87d4-e84277cb2ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a1941a4-b696-4337-ab22-4fc3f2fe7b40" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ab5a229b-1eb0-443b-87d4-e84277cb2ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_9d5f0ef5-6ad5-41d3-a838-8e6d719029af" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ab5a229b-1eb0-443b-87d4-e84277cb2ccd" xlink:to="loc_cdtx_TermLoanAMember_9d5f0ef5-6ad5-41d3-a838-8e6d719029af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d05876ce-56fd-49ed-8891-d89c8a85f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d05876ce-56fd-49ed-8891-d89c8a85f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_de6c2daf-e972-49b4-ba92-61a217bca764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d05876ce-56fd-49ed-8891-d89c8a85f25a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_de6c2daf-e972-49b4-ba92-61a217bca764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_86170882-2c71-4495-ac39-d325c9b0d959" xlink:href="cdtx-20220331.xsd#cdtx_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_de6c2daf-e972-49b4-ba92-61a217bca764" xlink:to="loc_cdtx_TermLoanMember_86170882-2c71-4495-ac39-d325c9b0d959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cf7bb5be-4497-4c25-88d6-d9f5a712dd06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc6451e9-9807-4163-95ba-b4695b60fcc7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cf7bb5be-4497-4c25-88d6-d9f5a712dd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf7bb5be-4497-4c25-88d6-d9f5a712dd06" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_51f07e73-2d5c-4a92-a8cc-01caff772311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_51f07e73-2d5c-4a92-a8cc-01caff772311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f546271e-334f-451f-ab6e-f62a97e66b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3128e826-d661-444c-9ff9-a8043b2a77ba" xlink:to="loc_us-gaap_LongTermDebt_f546271e-334f-451f-ab6e-f62a97e66b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cdtx-20220331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_30a83a66-a377-4106-8cd8-63704c93367c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0ae9ce75-6a34-47f0-b8bb-5c21c6cad5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a83a66-a377-4106-8cd8-63704c93367c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0ae9ce75-6a34-47f0-b8bb-5c21c6cad5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="cdtx-20220331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b14a0284-cb48-46ce-a592-3efe13fe8f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_bc56d1c8-73a1-48b8-a479-d5c7c58683c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b14a0284-cb48-46ce-a592-3efe13fe8f08" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_bc56d1c8-73a1-48b8-a479-d5c7c58683c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5e6d8b7f-22ca-46b6-898f-834bff9fe82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5e6d8b7f-22ca-46b6-898f-834bff9fe82d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc53bdf1-ec56-4f88-8e74-f4b006c3a6e6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d1ccf77e-5fa6-4c9f-874a-f52c227de4c0" xlink:href="cdtx-20220331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d1ccf77e-5fa6-4c9f-874a-f52c227de4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicStockOfferingMember_681699ef-5726-4915-a620-6d566a1ea31c" xlink:href="cdtx-20220331.xsd#cdtx_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:to="loc_cdtx_PublicStockOfferingMember_681699ef-5726-4915-a620-6d566a1ea31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_ad44eb00-9ffc-4d44-87bf-9e0a7ac78993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68ad11ab-fc0e-4bd6-9810-45a35d1c37d7" xlink:to="loc_us-gaap_OverAllotmentOptionMember_ad44eb00-9ffc-4d44-87bf-9e0a7ac78993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d6e6453-4c96-47aa-92e3-679a285b526f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_srt_RangeAxis_8d6e6453-4c96-47aa-92e3-679a285b526f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b8de3a0-ce6f-4ee3-9253-c83ce3bc28be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d6e6453-4c96-47aa-92e3-679a285b526f" xlink:to="loc_srt_RangeMember_0b8de3a0-ce6f-4ee3-9253-c83ce3bc28be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_5ed095b8-2b6c-42d7-a9fa-869807049900" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b8de3a0-ce6f-4ee3-9253-c83ce3bc28be" xlink:to="loc_srt_WeightedAverageMember_5ed095b8-2b6c-42d7-a9fa-869807049900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc8b273a-25fa-4b75-bc49-520630ae2470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc8b273a-25fa-4b75-bc49-520630ae2470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5837103a-febd-4a4e-9b06-0865be110d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc8b273a-25fa-4b75-bc49-520630ae2470" xlink:to="loc_us-gaap_ClassOfStockDomain_5837103a-febd-4a4e-9b06-0865be110d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_47412370-c3a3-44af-b3d3-054b25a7a1e0" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5837103a-febd-4a4e-9b06-0865be110d30" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_47412370-c3a3-44af-b3d3-054b25a7a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a64bb16-0e32-4047-9314-4bf83345b0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a64bb16-0e32-4047-9314-4bf83345b0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1725e16e-639b-4434-be3e-7e6a9f195b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a64bb16-0e32-4047-9314-4bf83345b0eb" xlink:to="loc_us-gaap_EquityComponentDomain_1725e16e-639b-4434-be3e-7e6a9f195b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3e911107-f991-4136-95b3-daeb36540b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1725e16e-639b-4434-be3e-7e6a9f195b2d" xlink:to="loc_us-gaap_CommonStockMember_3e911107-f991-4136-95b3-daeb36540b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1e960507-e393-40bf-a9e1-0d52ea9f8342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1e960507-e393-40bf-a9e1-0d52ea9f8342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_74cca0e5-3503-4a99-8487-3ef2a0b7b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1e960507-e393-40bf-a9e1-0d52ea9f8342" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_74cca0e5-3503-4a99-8487-3ef2a0b7b3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_f28435ea-a28b-4ba6-9843-8047debd9675" xlink:href="cdtx-20220331.xsd#cdtx_CommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74cca0e5-3503-4a99-8487-3ef2a0b7b3dd" xlink:to="loc_cdtx_CommonStockWarrantMember_f28435ea-a28b-4ba6-9843-8047debd9675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6e28fd76-7dc2-4397-ada2-f8520f23302d" xlink:to="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_09112cbe-4556-426a-9635-3bb27f602eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_09112cbe-4556-426a-9635-3bb27f602eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48eb3763-959e-4f04-9034-8119d19fcc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48eb3763-959e-4f04-9034-8119d19fcc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_cc054e8d-db4c-42a2-a135-bf2be29850b1" xlink:href="cdtx-20220331.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_cc054e8d-db4c-42a2-a135-bf2be29850b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f44ec4cc-9ffc-43d6-b8ab-03f9fff06398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f44ec4cc-9ffc-43d6-b8ab-03f9fff06398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b168543a-0728-4765-86ef-e1680cd53a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b168543a-0728-4765-86ef-e1680cd53a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_6c3bd1eb-6320-468d-9ec6-8db930e1abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_6c3bd1eb-6320-468d-9ec6-8db930e1abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_2d2e77f9-1547-4daa-821a-2294ed881d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_2d2e77f9-1547-4daa-821a-2294ed881d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9f3b9773-a313-481f-a107-4bc1ddfe79d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9f3b9773-a313-481f-a107-4bc1ddfe79d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_30029260-52cc-4791-827c-fb8aa36fdcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_30029260-52cc-4791-827c-fb8aa36fdcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_11970393-8cb4-4fcb-b725-0674af1764b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_11970393-8cb4-4fcb-b725-0674af1764b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_98e1ebaf-85d6-4abc-8d9a-bc0918f3ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_98e1ebaf-85d6-4abc-8d9a-bc0918f3ff9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_adf10359-4d78-4946-804a-a2e8e53dbfeb" xlink:href="cdtx-20220331.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_adf10359-4d78-4946-804a-a2e8e53dbfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7a8183b7-7137-4bd4-a434-6f35ad465666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7a8183b7-7137-4bd4-a434-6f35ad465666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_20816423-b6b8-4832-8258-fbff8fe854ee" xlink:href="cdtx-20220331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_20816423-b6b8-4832-8258-fbff8fe854ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d89fe076-18ab-48fa-b948-af6f9bfcece7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d89fe076-18ab-48fa-b948-af6f9bfcece7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6238a7e9-02c6-4f6e-8d46-07221f95a863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6238a7e9-02c6-4f6e-8d46-07221f95a863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_fdde0556-1028-4702-adde-1295f6ecbd80" xlink:href="cdtx-20220331.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e8b2bed-4dd1-4e70-b1c7-3425ded0a81f" xlink:to="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_fdde0556-1028-4702-adde-1295f6ecbd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0bbedd87-87aa-48cd-862a-051147b3fe64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1cdbb14d-b116-4a10-9c57-7a23a89ef86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bbedd87-87aa-48cd-862a-051147b3fe64" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1cdbb14d-b116-4a10-9c57-7a23a89ef86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3873ee2f-593d-4f0a-8198-dd25738f6c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1cdbb14d-b116-4a10-9c57-7a23a89ef86a" xlink:to="loc_us-gaap_AwardTypeAxis_3873ee2f-593d-4f0a-8198-dd25738f6c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3873ee2f-593d-4f0a-8198-dd25738f6c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c9ebe24c-c673-4176-93e7-c47602ada2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_us-gaap_WarrantMember_c9ebe24c-c673-4176-93e7-c47602ada2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_2fa7a9c1-ff8e-42cb-9544-3f7328c7f8ee" xlink:href="cdtx-20220331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_2fa7a9c1-ff8e-42cb-9544-3f7328c7f8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_4fe94ce8-fb8b-460f-a00b-07a8a1ab889d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_us-gaap_StockCompensationPlanMember_4fe94ce8-fb8b-460f-a00b-07a8a1ab889d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_3bb0e88b-b0a7-43d0-9f09-717f10358908" xlink:href="cdtx-20220331.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_3bb0e88b-b0a7-43d0-9f09-717f10358908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a2b4680d-ce36-4e2d-8eaf-1aafb8c830cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72586eb8-643b-4c42-962e-3e95dce8aaf1" xlink:to="loc_us-gaap_EmployeeStockMember_a2b4680d-ce36-4e2d-8eaf-1aafb8c830cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c168c541-d9d4-4f3c-9756-93714e1f4797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1cdbb14d-b116-4a10-9c57-7a23a89ef86a" xlink:to="loc_us-gaap_ClassOfStockLineItems_c168c541-d9d4-4f3c-9756-93714e1f4797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7493fc5d-24b9-4fdf-87d6-361c1dafad17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c168c541-d9d4-4f3c-9756-93714e1f4797" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7493fc5d-24b9-4fdf-87d6-361c1dafad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c5bcb27-52ab-48a8-965e-1821fea810d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_77a9fa8b-e859-4c1e-b9b0-9e5cb9eaea7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c5bcb27-52ab-48a8-965e-1821fea810d6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_77a9fa8b-e859-4c1e-b9b0-9e5cb9eaea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49c93782-1fee-4d2b-af94-d8fb899d028a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_56593ca9-6266-4ac2-9ae7-246cc0ebb038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49c93782-1fee-4d2b-af94-d8fb899d028a" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_56593ca9-6266-4ac2-9ae7-246cc0ebb038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ea8ef98e-d0ab-4bab-bb74-53c4ec901481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49c93782-1fee-4d2b-af94-d8fb899d028a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ea8ef98e-d0ab-4bab-bb74-53c4ec901481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e43fce24-7ab6-4e61-9902-4fa556b31fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49c93782-1fee-4d2b-af94-d8fb899d028a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e43fce24-7ab6-4e61-9902-4fa556b31fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f31d22de-05f7-4189-b4b6-976293587c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f31d22de-05f7-4189-b4b6-976293587c4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_us-gaap_PlanNameAxis_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d1f27cae-d24e-4d09-ab88-e65d3025f568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f2c29b1d-f4b5-4ad9-acd7-bd9f524c9957" xlink:to="loc_us-gaap_PlanNameDomain_d1f27cae-d24e-4d09-ab88-e65d3025f568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_ec50ee85-f2e3-4a8d-b30c-4a76c3a5c07a" xlink:href="cdtx-20220331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d1f27cae-d24e-4d09-ab88-e65d3025f568" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_ec50ee85-f2e3-4a8d-b30c-4a76c3a5c07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_srt_RangeAxis_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d9c49dbd-f386-4bdc-aa06-95d7e50a2a14" xlink:to="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_268a070c-f73d-4c6c-982d-9511381d5d54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:to="loc_srt_MinimumMember_268a070c-f73d-4c6c-982d-9511381d5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46098a70-102e-49ad-896a-8957b6e1f6ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53c2b367-b98f-48fa-b279-07ef818b893a" xlink:to="loc_srt_MaximumMember_46098a70-102e-49ad-896a-8957b6e1f6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_64da565e-9994-41dd-a42e-5b7f2ad722c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_64da565e-9994-41dd-a42e-5b7f2ad722c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_6db08075-424c-4f42-85f2-ccc908f6f616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_64da565e-9994-41dd-a42e-5b7f2ad722c4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_6db08075-424c-4f42-85f2-ccc908f6f616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_a55fecd7-716c-48c3-a21a-94068fd0a039" xlink:href="cdtx-20220331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_6db08075-424c-4f42-85f2-ccc908f6f616" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_a55fecd7-716c-48c3-a21a-94068fd0a039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e220c9b1-f704-48df-b785-27c30a9130ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_us-gaap_AwardTypeAxis_e220c9b1-f704-48df-b785-27c30a9130ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e220c9b1-f704-48df-b785-27c30a9130ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ccf14cf7-708b-4805-bf69-94ecc3114950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:to="loc_us-gaap_EmployeeStockMember_ccf14cf7-708b-4805-bf69-94ecc3114950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_824d3799-0904-4f7a-9100-1093f3832d6b" xlink:href="cdtx-20220331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_824d3799-0904-4f7a-9100-1093f3832d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c20c2312-3416-4d06-8bb1-f42bd451195c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0076f45-5ce0-43f2-93e7-6098d222e9b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c20c2312-3416-4d06-8bb1-f42bd451195c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_803edf23-be8a-4175-9f9f-7dbb65a39292" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_4d7748c9-fe75-454a-8476-4d9aaea4525e" xlink:href="cdtx-20220331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_4d7748c9-fe75-454a-8476-4d9aaea4525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5b90c7b8-2cb8-4e25-ad41-6bda4da1f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5b90c7b8-2cb8-4e25-ad41-6bda4da1f2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2d925b9e-134e-4858-8891-e6834bab5126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2d925b9e-134e-4858-8891-e6834bab5126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_37cae47c-385a-466a-808e-2fc71360d000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_37cae47c-385a-466a-808e-2fc71360d000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_6267a92e-5329-4aa5-9072-a8643c605d2b" xlink:href="cdtx-20220331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_6267a92e-5329-4aa5-9072-a8643c605d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c268213b-b046-4f04-8377-0b0ab9e00532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c268213b-b046-4f04-8377-0b0ab9e00532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cdc1f928-6369-437f-9c9b-0dd6992f7f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cdc1f928-6369-437f-9c9b-0dd6992f7f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1584ed73-e458-4045-9cdc-610e6d303717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1584ed73-e458-4045-9cdc-610e6d303717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26aebc3a-4e60-4be9-8dee-033c7f4f53ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26aebc3a-4e60-4be9-8dee-033c7f4f53ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_05dffcc3-52eb-477e-be6d-5ec51f8496e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_05dffcc3-52eb-477e-be6d-5ec51f8496e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bd74c00b-0727-4992-950b-c4341489a247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bd74c00b-0727-4992-950b-c4341489a247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_86b4f223-d891-45be-b1f2-30a107f7ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_86b4f223-d891-45be-b1f2-30a107f7ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b28099af-f692-42f6-9a37-b904894c81f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b28099af-f692-42f6-9a37-b904894c81f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16a59658-5d08-4bb8-baab-1ed58db86c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3af9ce08-920f-4a31-aec7-3fd3b6a262ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16a59658-5d08-4bb8-baab-1ed58db86c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c40ea161-4906-4a5e-a3f9-7e28a97bf84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65d2258b-ea04-4bf2-b5a0-e8724e88a5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c40ea161-4906-4a5e-a3f9-7e28a97bf84b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65d2258b-ea04-4bf2-b5a0-e8724e88a5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_464d2f45-7215-4cdf-b61d-6c9b3e845e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65d2258b-ea04-4bf2-b5a0-e8724e88a5f0" xlink:to="loc_us-gaap_AwardTypeAxis_464d2f45-7215-4cdf-b61d-6c9b3e845e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc7af86-9621-4c58-ac70-beb34566a4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_464d2f45-7215-4cdf-b61d-6c9b3e845e7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc7af86-9621-4c58-ac70-beb34566a4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_c40cc7d1-800b-491d-bd48-b0b4a0ba4006" xlink:href="cdtx-20220331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc7af86-9621-4c58-ac70-beb34566a4cf" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_c40cc7d1-800b-491d-bd48-b0b4a0ba4006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65d2258b-ea04-4bf2-b5a0-e8724e88a5f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf90747b-a8f6-4b53-8415-b47cc05e9ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf90747b-a8f6-4b53-8415-b47cc05e9ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7adb308-5205-4d0a-9fac-bf93de8d8dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7adb308-5205-4d0a-9fac-bf93de8d8dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d9f5a074-2850-43b6-bfc7-dc6663a4439e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d9f5a074-2850-43b6-bfc7-dc6663a4439e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_42d48a38-2788-4652-b401-bc885093bd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_42d48a38-2788-4652-b401-bc885093bd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_df05a0b8-3488-4145-8b2f-dcc9ef2322f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f817a2f9-dc93-413a-ae05-c4472c4d3271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_df05a0b8-3488-4145-8b2f-dcc9ef2322f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08e49ad5-0073-49c3-94e8-63f353b1beb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c9f9889-a303-40d2-a5f0-2335f271470d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c9f9889-a303-40d2-a5f0-2335f271470d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8782635-e2f2-4f62-a2a9-8f712b29575c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f8782635-e2f2-4f62-a2a9-8f712b29575c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8191fa9d-655a-4fc0-aa4f-1936ca8eadd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8191fa9d-655a-4fc0-aa4f-1936ca8eadd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_aba4eb09-1493-4b3a-a7ac-af734db8537c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_aba4eb09-1493-4b3a-a7ac-af734db8537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bee294d2-fe19-47b5-96c6-4d63fa889e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e1d60097-fcc9-4d6d-ae22-4695b8cdb80c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bee294d2-fe19-47b5-96c6-4d63fa889e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0bd0b1-8a1e-4e33-bc6b-b8a57bb8c362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0bd0b1-8a1e-4e33-bc6b-b8a57bb8c362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ee157d4-dc64-4b24-86ff-d84c7bd48c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0bd0b1-8a1e-4e33-bc6b-b8a57bb8c362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ee157d4-dc64-4b24-86ff-d84c7bd48c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f41512f3-881c-4b89-b901-10186f18373c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0bd0b1-8a1e-4e33-bc6b-b8a57bb8c362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f41512f3-881c-4b89-b901-10186f18373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d8625eda-3d61-4ea4-b769-ed0a9a1b53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0bd0b1-8a1e-4e33-bc6b-b8a57bb8c362" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d8625eda-3d61-4ea4-b769-ed0a9a1b53a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1140a521-e05c-4807-8af5-ffa37c2cb449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0bd0b1-8a1e-4e33-bc6b-b8a57bb8c362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1140a521-e05c-4807-8af5-ffa37c2cb449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be4fdfd9-f334-4b5e-9919-c33d957b4b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0bd0b1-8a1e-4e33-bc6b-b8a57bb8c362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be4fdfd9-f334-4b5e-9919-c33d957b4b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2fa6a58f-790f-42b2-91aa-0e71aca582bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2fa6a58f-790f-42b2-91aa-0e71aca582bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9df14c4b-066f-4958-9ffb-571ae47847d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9df14c4b-066f-4958-9ffb-571ae47847d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3d9ff07-38b3-4a2e-89ce-5769f8399370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3d9ff07-38b3-4a2e-89ce-5769f8399370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50459562-8219-4d1f-ba88-08f964a8b339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3d9ff07-38b3-4a2e-89ce-5769f8399370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50459562-8219-4d1f-ba88-08f964a8b339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5acf8120-6bdc-4ab9-a1e7-09141a0f7064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3d9ff07-38b3-4a2e-89ce-5769f8399370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5acf8120-6bdc-4ab9-a1e7-09141a0f7064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_84024666-2c9a-4d30-92f5-c737546234f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3d9ff07-38b3-4a2e-89ce-5769f8399370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_84024666-2c9a-4d30-92f5-c737546234f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7620483c-7345-4e5b-934f-1bfcef1ff042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3d9ff07-38b3-4a2e-89ce-5769f8399370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7620483c-7345-4e5b-934f-1bfcef1ff042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f97be8de-fcc0-4dc6-a712-53dc1cbf14f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3d9ff07-38b3-4a2e-89ce-5769f8399370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f97be8de-fcc0-4dc6-a712-53dc1cbf14f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a204d748-231c-4991-ae4a-09e348d6cabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a204d748-231c-4991-ae4a-09e348d6cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4b96e1e6-d093-463f-9462-bcb55534e107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4b96e1e6-d093-463f-9462-bcb55534e107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_984f68ea-c6c5-42c0-a199-2deb8e3a42b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_984f68ea-c6c5-42c0-a199-2deb8e3a42b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9c9be391-5918-467e-af74-ffbbead99da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_984f68ea-c6c5-42c0-a199-2deb8e3a42b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9c9be391-5918-467e-af74-ffbbead99da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0321ac00-d14c-4c97-94fd-cd9f9f325b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_984f68ea-c6c5-42c0-a199-2deb8e3a42b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0321ac00-d14c-4c97-94fd-cd9f9f325b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4301a724-4b30-4f16-b70e-30a9d8b75f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_984f68ea-c6c5-42c0-a199-2deb8e3a42b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4301a724-4b30-4f16-b70e-30a9d8b75f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_2fd59baf-7d20-4099-98fa-70e7c02a410b" xlink:href="cdtx-20220331.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9ec2aba-884a-4609-9def-045815c9e6df" xlink:to="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_2fd59baf-7d20-4099-98fa-70e7c02a410b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_43575009-6a0a-48d0-ad2d-87e9aa334512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_2fd59baf-7d20-4099-98fa-70e7c02a410b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_43575009-6a0a-48d0-ad2d-87e9aa334512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9ca28a29-854d-4ec1-89ed-7ad9677d54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_2fd59baf-7d20-4099-98fa-70e7c02a410b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9ca28a29-854d-4ec1-89ed-7ad9677d54b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2e142283-fe67-4f02-833b-f40bb9e1307c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_2fd59baf-7d20-4099-98fa-70e7c02a410b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2e142283-fe67-4f02-833b-f40bb9e1307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fed9c55-75d4-4c26-9fd0-2f1b02d270e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_42eb9e60-67f6-44e9-a669-7e088b905349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fed9c55-75d4-4c26-9fd0-2f1b02d270e5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_42eb9e60-67f6-44e9-a669-7e088b905349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a3287274-95fd-49a7-8c1a-778de40f67f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_42eb9e60-67f6-44e9-a669-7e088b905349" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a3287274-95fd-49a7-8c1a-778de40f67f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a3287274-95fd-49a7-8c1a-778de40f67f8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_027ddd05-afbf-49f3-9ddb-5ea52bd5fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_027ddd05-afbf-49f3-9ddb-5ea52bd5fc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bb0b93c-e130-4f94-8273-a87bd8800e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53fd55c2-4b4d-4fb2-aa09-b4f9da6bfd86" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bb0b93c-e130-4f94-8273-a87bd8800e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fd6983e7-179d-474b-befd-a86acb1217f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_42eb9e60-67f6-44e9-a669-7e088b905349" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fd6983e7-179d-474b-befd-a86acb1217f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ed3ca4-f49e-4e31-a431-264dd7ea74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fd6983e7-179d-474b-befd-a86acb1217f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9ed3ca4-f49e-4e31-a431-264dd7ea74fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be89fca3-62a1-4ec2-a296-d6b08622b3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_577b84dc-09d4-40a4-bd5f-6aa81ea72e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be89fca3-62a1-4ec2-a296-d6b08622b3c9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_577b84dc-09d4-40a4-bd5f-6aa81ea72e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4fde724-77e1-425b-999c-7770f5653eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_f1f99c24-ec1b-46de-9097-8e29b058c457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4fde724-77e1-425b-999c-7770f5653eaf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_f1f99c24-ec1b-46de-9097-8e29b058c457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6251e8aa-fad9-4e74-9f50-17a57fe847d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6251e8aa-fad9-4e74-9f50-17a57fe847d5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1df34e49-e251-43d6-adc4-399acf70b356" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_2d21a709-0cc7-43ff-bc44-f75a170a136d" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_2d21a709-0cc7-43ff-bc44-f75a170a136d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_58ce307f-afc9-4c22-811c-73c689d4cfca" xlink:href="cdtx-20220331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f9d44dd-9ee9-48c3-b1af-8397b7eab4c0" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_58ce307f-afc9-4c22-811c-73c689d4cfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_537342d6-56fb-45c5-bf66-5621fd5cfea9" xlink:to="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_632b7fac-a2fd-45fd-91fe-b944d0626132" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f4fdfb1e-a148-49e3-a122-18edbd0dacba" xlink:to="loc_srt_AffiliatedEntityMember_632b7fac-a2fd-45fd-91fe-b944d0626132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d1f8ac1-d610-44a1-a517-8fbe987eac89" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_31810314-0826-4cd7-8d50-a9ed1976994d" xlink:href="cdtx-20220331.xsd#cdtx_UpfrontPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_UpfrontPaymentMember_31810314-0826-4cd7-8d50-a9ed1976994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_52d93b8f-afba-45a3-b417-b42bb14a3364" xlink:href="cdtx-20220331.xsd#cdtx_RDFundingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_RDFundingMember_52d93b8f-afba-45a3-b417-b42bb14a3364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_c059ea44-9030-4358-8098-5eb8234abcc2" xlink:href="cdtx-20220331.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f8db4a5b-edf1-4b61-839b-406b1e89c647" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_c059ea44-9030-4358-8098-5eb8234abcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_38d9421c-a5a8-4186-a5e0-dd7e905839d7" xlink:to="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_31ee9aa1-9edf-44a1-9472-1b8ee3411b42" xlink:href="cdtx-20220331.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_31ee9aa1-9edf-44a1-9472-1b8ee3411b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_ce22cbf0-6956-4e85-af72-9d2d7df448a0" xlink:href="cdtx-20220331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_cdtx_MilestoneAchievementMember_ce22cbf0-6956-4e85-af72-9d2d7df448a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_73a30a90-af19-4013-a60a-e5c11138561c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0aeed8c5-3cfd-40bc-85d4-3c42d0f28b83" xlink:to="loc_us-gaap_RoyaltyMember_73a30a90-af19-4013-a60a-e5c11138561c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fbba86fb-9bee-4b4b-9274-7e1f0f520e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fbba86fb-9bee-4b4b-9274-7e1f0f520e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f30ac0a-810d-4880-a9d2-272bc8dcd150" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_59ff4bef-9ec7-401c-9acc-3dd8eb84845c" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_59ff4bef-9ec7-401c-9acc-3dd8eb84845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_54a77fd8-afa6-411c-9871-4db2c20272e0" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_54a77fd8-afa6-411c-9871-4db2c20272e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_91f9b645-81fd-4db6-a4f5-0f274edde62c" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_91f9b645-81fd-4db6-a4f5-0f274edde62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_1a766f73-e40e-4da8-9d2e-556048cf65bb" xlink:href="cdtx-20220331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_1a766f73-e40e-4da8-9d2e-556048cf65bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2235722a-e3a6-498b-800b-9b90faad00ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2235722a-e3a6-498b-800b-9b90faad00ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_61bf1264-61dc-4162-aa2d-e2950ab1a2d0" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_61bf1264-61dc-4162-aa2d-e2950ab1a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_27161765-6212-44c3-b63e-c549c09980a2" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_27161765-6212-44c3-b63e-c549c09980a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_96da9f0b-dff7-469c-aece-6acc617d37a7" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_96da9f0b-dff7-469c-aece-6acc617d37a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_047e31d5-c965-458c-a448-bff3ad2c018f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_047e31d5-c965-458c-a448-bff3ad2c018f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_498ad2c4-89b3-4e83-a248-37a6d1b88fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_498ad2c4-89b3-4e83-a248-37a6d1b88fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_3892d793-3901-48a5-8a1a-8ad98fc92df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8a965e-f47a-4e1a-9f34-3e6dc3a5345f" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_3892d793-3901-48a5-8a1a-8ad98fc92df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb4fd95c-21e2-48bf-831d-7330dadabbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb4fd95c-21e2-48bf-831d-7330dadabbf8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_546e8b65-7026-433b-a45e-c1cd673c7cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_546e8b65-7026-433b-a45e-c1cd673c7cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_db2e043e-49a4-407d-a74b-4e390f99d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_546e8b65-7026-433b-a45e-c1cd673c7cd9" xlink:to="loc_us-gaap_RelatedPartyDomain_db2e043e-49a4-407d-a74b-4e390f99d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_6db7f4af-f9c3-494a-a957-5ca2712b4682" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_db2e043e-49a4-407d-a74b-4e390f99d7b3" xlink:to="loc_srt_AffiliatedEntityMember_6db7f4af-f9c3-494a-a957-5ca2712b4682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:to="loc_srt_CounterpartyNameAxis_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42e2793b-29a7-42b1-a70c-b28c8e4128f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0489914b-eaf4-40e0-9eee-4a2e36dd7c9d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42e2793b-29a7-42b1-a70c-b28c8e4128f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_2422ffac-6b60-4852-8ca1-d018aaeba82a" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42e2793b-29a7-42b1-a70c-b28c8e4128f0" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_2422ffac-6b60-4852-8ca1-d018aaeba82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cd134795-910b-4dcf-be7a-a13f9e8e5ce7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_1cb3540d-58a8-46f0-b11d-3d7160a2a48b" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_1cb3540d-58a8-46f0-b11d-3d7160a2a48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_35e3c204-0b3c-465b-addf-80691e891351" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_35e3c204-0b3c-465b-addf-80691e891351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_644ae068-e766-46af-9ec9-f4872b1582c7" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_644ae068-e766-46af-9ec9-f4872b1582c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_deb0d0da-6e81-46dd-a598-7e6a61af879a" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_deb0d0da-6e81-46dd-a598-7e6a61af879a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_85c5d8f8-dae2-4556-a3c5-4bad100bc698" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_402be5e7-93a3-4e99-ab98-8a5ca3fddd61" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_85c5d8f8-dae2-4556-a3c5-4bad100bc698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_856a2513-bfb1-46db-a898-8d3b54325e30" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_856a2513-bfb1-46db-a898-8d3b54325e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_73cf2cbc-dd2e-4aa9-a177-201a524e2337" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_73cf2cbc-dd2e-4aa9-a177-201a524e2337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_44e48f31-e902-43be-849a-d6edbfb4c992" xlink:href="cdtx-20220331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f02e238-fdfc-4ea7-9d0d-48f26cc33451" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_44e48f31-e902-43be-849a-d6edbfb4c992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d2f73df-a2be-4e48-9eff-f0ab85f47219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d2f73df-a2be-4e48-9eff-f0ab85f47219" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad1669fe-1b47-4274-9679-3f5e95c8c404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad1669fe-1b47-4274-9679-3f5e95c8c404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ed838b8e-b43d-4f68-afc8-f871d79e4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad1669fe-1b47-4274-9679-3f5e95c8c404" xlink:to="loc_us-gaap_RelatedPartyDomain_ed838b8e-b43d-4f68-afc8-f871d79e4d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_56cb0773-a179-4cf6-a60b-0d8a4127fc1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ed838b8e-b43d-4f68-afc8-f871d79e4d7e" xlink:to="loc_srt_AffiliatedEntityMember_56cb0773-a179-4cf6-a60b-0d8a4127fc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_srt_CounterpartyNameAxis_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bf66d7ff-d0c6-4e4b-a934-4d8403ad7ddd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_5e174a3b-c091-4d6c-a05e-cf503ee9e1a8" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_5e174a3b-c091-4d6c-a05e-cf503ee9e1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_17ef0bff-60ed-4abc-8c7f-8cf60b89328a" xlink:href="cdtx-20220331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1119c574-e1f7-4581-aa24-8aa3d2383091" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_17ef0bff-60ed-4abc-8c7f-8cf60b89328a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_367d4cae-4a3f-414d-9ca9-67f29ddb5111" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_srt_ProductOrServiceAxis_367d4cae-4a3f-414d-9ca9-67f29ddb5111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_367d4cae-4a3f-414d-9ca9-67f29ddb5111" xlink:to="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_f4fab729-7860-4191-af4f-ee8665bad7ac" xlink:href="cdtx-20220331.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_f4fab729-7860-4191-af4f-ee8665bad7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_c0688021-7909-48b7-bb34-98e815ba535d" xlink:href="cdtx-20220331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_c0688021-7909-48b7-bb34-98e815ba535d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_87eb9c45-0a3e-46d1-8fdd-d112f1b19584" xlink:href="cdtx-20220331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8fe82f9-4b78-4388-bd16-d83164defec1" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_87eb9c45-0a3e-46d1-8fdd-d112f1b19584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5017a9c2-b389-4008-b5ad-334b570b3964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5017a9c2-b389-4008-b5ad-334b570b3964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5017a9c2-b389-4008-b5ad-334b570b3964" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_2722eb84-2cb7-47da-ba10-ba531ec5067e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_2722eb84-2cb7-47da-ba10-ba531ec5067e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_c387c997-209c-4344-b6f6-20eb177c6dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_edb34b10-d0e5-4374-9a41-46ba786ed093" xlink:to="loc_us-gaap_TransferredOverTimeMember_c387c997-209c-4344-b6f6-20eb177c6dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_94d7d69a-7129-4f4e-92db-e02ca145ff45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_94d7d69a-7129-4f4e-92db-e02ca145ff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f7801d1-a371-4c94-a2f3-62f2ad64f13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_94d7d69a-7129-4f4e-92db-e02ca145ff45" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f7801d1-a371-4c94-a2f3-62f2ad64f13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e3bfc86b-d2ba-45e3-8295-958ee0017aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f7801d1-a371-4c94-a2f3-62f2ad64f13c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e3bfc86b-d2ba-45e3-8295-958ee0017aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e939166-cbe1-49e8-87f1-b274e1a62866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f6951f8-44c2-4b11-8f4a-8e902ed3867a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e939166-cbe1-49e8-87f1-b274e1a62866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8ed3115a-66bb-4db3-83d5-ec77a580718b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e939166-cbe1-49e8-87f1-b274e1a62866" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8ed3115a-66bb-4db3-83d5-ec77a580718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_96f40d1e-96b6-4188-8268-29f84416c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e8b63b78-1fd6-4d97-bddb-b1eb9c862aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_96f40d1e-96b6-4188-8268-29f84416c3d3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e8b63b78-1fd6-4d97-bddb-b1eb9c862aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9949c8e-32d0-4c12-a563-b4292a5b9801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2884ee61-7e81-4054-8df9-15481f9a9694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9949c8e-32d0-4c12-a563-b4292a5b9801" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2884ee61-7e81-4054-8df9-15481f9a9694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_e128220b-cdaa-4467-bf35-e8abc2f996bf" xlink:href="cdtx-20220331.xsd#cdtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9949c8e-32d0-4c12-a563-b4292a5b9801" xlink:to="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_e128220b-cdaa-4467-bf35-e8abc2f996bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c9b33155-18d1-4d53-90d2-2d988107ea12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c9b33155-18d1-4d53-90d2-2d988107ea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate_8f8c60a3-665c-4fff-abb8-df1b81a2d3c8" xlink:href="cdtx-20220331.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_cdtx_LesseeOperatingLeaseMonthlyRate_8f8c60a3-665c-4fff-abb8-df1b81a2d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_a85ef2cb-091e-4f38-8ac6-1784b6c25429" xlink:href="cdtx-20220331.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_a85ef2cb-091e-4f38-8ac6-1784b6c25429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_daba6180-6176-447e-90d2-90f3b284c9e0" xlink:href="cdtx-20220331.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_daba6180-6176-447e-90d2-90f3b284c9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_0b957b53-53f0-474a-a7c2-82ef2068cfb1" xlink:href="cdtx-20220331.xsd#cdtx_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_0b957b53-53f0-474a-a7c2-82ef2068cfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_56357c6c-5315-470f-baeb-e3504401fad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_56357c6c-5315-470f-baeb-e3504401fad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a6a6c4f9-7502-46b1-8117-b95e2c0aad23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_us-gaap_OperatingLeasePayments_a6a6c4f9-7502-46b1-8117-b95e2c0aad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_75da1584-c726-4f98-a246-1893d8b174d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_us-gaap_OperatingLeaseCost_75da1584-c726-4f98-a246-1893d8b174d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_64bccc5e-c1ee-43ec-87e1-1f80d5b75180" xlink:href="cdtx-20220331.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_396091ec-a96a-49b4-8d96-9f26927dd8fa" xlink:to="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_64bccc5e-c1ee-43ec-87e1-1f80d5b75180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa2f9d00-426e-4a19-a26f-715cee308f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a0be310b-3c20-4ef9-ab97-b2e666696380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa2f9d00-426e-4a19-a26f-715cee308f79" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a0be310b-3c20-4ef9-ab97-b2e666696380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0b176956-2cee-41c3-913e-13185f10ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa2f9d00-426e-4a19-a26f-715cee308f79" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0b176956-2cee-41c3-913e-13185f10ba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62ace741-29a0-46a5-bbe5-08330a0164e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa2f9d00-426e-4a19-a26f-715cee308f79" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62ace741-29a0-46a5-bbe5-08330a0164e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_597aaac1-49bc-46ea-b965-4a7975390a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa2f9d00-426e-4a19-a26f-715cee308f79" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_597aaac1-49bc-46ea-b965-4a7975390a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d70e9e5f-a13d-4ff9-9b63-85b7742b7395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa2f9d00-426e-4a19-a26f-715cee308f79" xlink:to="loc_us-gaap_OperatingLeaseLiability_d70e9e5f-a13d-4ff9-9b63-85b7742b7395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bb3bf11-2832-4bad-9897-0558bc42c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c6a200d2-0c0a-47f8-b1b5-25c26c9b826f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bb3bf11-2832-4bad-9897-0558bc42c0de" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c6a200d2-0c0a-47f8-b1b5-25c26c9b826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_04e1fc8e-017d-4a49-9fb1-9a92defdc89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bb3bf11-2832-4bad-9897-0558bc42c0de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_04e1fc8e-017d-4a49-9fb1-9a92defdc89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ff2fc3b-c192-4a34-b9e9-f0719190d5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bb3bf11-2832-4bad-9897-0558bc42c0de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ff2fc3b-c192-4a34-b9e9-f0719190d5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_72ae5998-8e32-4f0d-b1ab-7d6b3503f3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bb3bf11-2832-4bad-9897-0558bc42c0de" xlink:to="loc_us-gaap_OperatingLeaseLiability_72ae5998-8e32-4f0d-b1ab-7d6b3503f3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_51492e99-aedc-4d71-9916-a7372721e54a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_96497824-aed1-4f63-943f-fe4b4ede33bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_51492e99-aedc-4d71-9916-a7372721e54a" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_96497824-aed1-4f63-943f-fe4b4ede33bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cdtx-20220331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1b54e3f6-77b1-4051-923b-29d28957499e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1b54e3f6-77b1-4051-923b-29d28957499e" xlink:to="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_382c3ca4-ad75-4c2d-b9d0-50862d07ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_382c3ca4-ad75-4c2d-b9d0-50862d07ef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_18d95e7c-de4a-4fac-8714-5065108b8cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_382c3ca4-ad75-4c2d-b9d0-50862d07ef34" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_18d95e7c-de4a-4fac-8714-5065108b8cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_966e2fca-7fae-46a3-b42f-7e215ddf75b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_18d95e7c-de4a-4fac-8714-5065108b8cff" xlink:to="loc_us-gaap_SubsequentEventMember_966e2fca-7fae-46a3-b42f-7e215ddf75b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_92d33a16-1bfa-4587-a572-3cf6da3ccc77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_srt_CounterpartyNameAxis_92d33a16-1bfa-4587-a572-3cf6da3ccc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d1132da-f4ee-4697-b5c3-057c3ef2ece1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_92d33a16-1bfa-4587-a572-3cf6da3ccc77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d1132da-f4ee-4697-b5c3-057c3ef2ece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_20a8889e-c44e-47e5-b916-793ace049301" xlink:href="cdtx-20220331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d1132da-f4ee-4697-b5c3-057c3ef2ece1" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_20a8889e-c44e-47e5-b916-793ace049301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ffdd2273-2385-456f-a7d0-f734258b5790" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_srt_ProductOrServiceAxis_ffdd2273-2385-456f-a7d0-f734258b5790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_719243f8-7a15-4f20-bd77-521eb5f6c7a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ffdd2273-2385-456f-a7d0-f734258b5790" xlink:to="loc_srt_ProductsAndServicesDomain_719243f8-7a15-4f20-bd77-521eb5f6c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_c07d5b3c-64ef-4168-a650-743f8a031ef0" xlink:href="cdtx-20220331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_719243f8-7a15-4f20-bd77-521eb5f6c7a3" xlink:to="loc_cdtx_MilestoneAchievementMember_c07d5b3c-64ef-4168-a650-743f8a031ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0023cf37-8aa9-494b-9a89-188a08750fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0023cf37-8aa9-494b-9a89-188a08750fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0c268ab7-4c84-4ee4-bc3d-186dfd84e3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0023cf37-8aa9-494b-9a89-188a08750fde" xlink:to="loc_us-gaap_RelatedPartyDomain_0c268ab7-4c84-4ee4-bc3d-186dfd84e3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5252d11a-3966-4be2-8f2e-5a7c920da538" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0c268ab7-4c84-4ee4-bc3d-186dfd84e3bc" xlink:to="loc_srt_AffiliatedEntityMember_5252d11a-3966-4be2-8f2e-5a7c920da538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a9b85a03-5b34-4d80-b3e0-eef3c8b7572a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9dc4a621-be3f-476a-9747-ff3c71743edf" xlink:to="loc_us-gaap_SubsequentEventLineItems_a9b85a03-5b34-4d80-b3e0-eef3c8b7572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone_a0343382-8f27-4b8f-bead-706ce78bc932" xlink:href="cdtx-20220331.xsd#cdtx_CollaborativeArrangementPotentialPrepaymentMilestone"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9b85a03-5b34-4d80-b3e0-eef3c8b7572a" xlink:to="loc_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone_a0343382-8f27-4b8f-bead-706ce78bc932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469805896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CIDARA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1537286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6310 Nancy Ridge Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">752-6170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469621304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,488<span></span>
</td>
<td class="nump">$ 59,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">8,783<span></span>
</td>
<td class="nump">5,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,254<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">52,007<span></span>
</td>
<td class="nump">71,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,030<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">55,295<span></span>
</td>
<td class="nump">75,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,861<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">9,234<span></span>
</td>
<td class="nump">10,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">4,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">14,260<span></span>
</td>
<td class="nump">13,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,105<span></span>
</td>
<td class="nump">34,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">17,229<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,338<span></span>
</td>
<td class="nump">53,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">#REF!</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">400,398<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(395,448)<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 55,295<span></span>
</td>
<td class="nump">$ 75,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469681432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">69,049,247<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">69,049,247<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469925784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="nump">$ 7,109<span></span>
</td>
<td class="nump">$ 2,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,166<span></span>
</td>
<td class="nump">15,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,204<span></span>
</td>
<td class="nump">4,781<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,370<span></span>
</td>
<td class="nump">20,630<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,261)<span></span>
</td>
<td class="num">(18,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">(18,292)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">(18,292)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (18,281)<span></span>
</td>
<td class="num">$ (18,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net loss per common share (in shares)</a></td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">46,967,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">46,967,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472340168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,281)<span></span>
</td>
<td class="num">$ (18,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,427)<span></span>
</td>
<td class="nump">11,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="num">(1,120)<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">657<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(1,953)<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Deferred revenue</a></td>
<td class="num">(844)<span></span>
</td>
<td class="nump">2,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(276)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,608)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">8,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of Term Loan</a></td>
<td class="num">(1,111)<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(611)<span></span>
</td>
<td class="nump">7,645<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(24,303)<span></span>
</td>
<td class="nump">5,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">42,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">37,970<span></span>
</td>
<td class="nump">48,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock In Underwritten Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706470203784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Series X Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,876,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 10,715<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 345,411<span></span>
</td>
<td class="num">$ (334,700)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,327,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, net of issuance costs</a></td>
<td class="nump">8,589<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(18,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,288,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2021</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">354,879<span></span>
</td>
<td class="num">(352,992)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">21,573<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, net of issuance costs</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(18,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2022</a></td>
<td class="nump">$ 4,957<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 400,398<span></span>
</td>
<td class="num">$ (395,448)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472169752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">THE COMPANY AND BASIS OF PRESENTATION</a></td>
<td class="text">THE COMPANY AND BASIS OF PRESENTATION<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. The Company is focused on infectious diseases and oncology. The Company&#8217;s lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections. In addition, the Company is using its Cloudbreak&#174; platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. The Company's initial development programs target influenza and other viral infections, including respiratory syncytial virus, or RSV, the SARS-CoV-2 strains causing COVID-19, and human immunodeficiency virus, or HIV. In addition, the Company has expanded the Cloudbreak platform to discover and develop DFCs to treat cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2022, the Company had an accumulated deficit of $395.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company had cash, cash equivalents and restricted cash of $38.0 million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options, estimated collaboration expenses and incurred expenses related to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement (each as defined below), certain accruals, including those related to nonclinical and clinical activities, and the Standalone Selling Price of performance obligations associated with license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706476750312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash represents cash that the Company is required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 4 for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTIzNw_5527d6f8-bbd7-4b20-ac44-ff096fb03762">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the FASB ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three significant performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were three significant performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments and estimated reimbursable research and development and clinical supply costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,442,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,847,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,648,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,550,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,608,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described in Note 3, the Company believes that the fair value of the term loan approximates its carrying value.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472285880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706476794296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $10.0&#160;million&#160;from the Lender, or the Term A Loan. At March&#160;31, 2022, the Term A Loan bears interest at 4.5% and matures on July 3, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 4, 2022, the Company and the Lender entered into a Fifth Amendment to the Loan Agreement, which modified certain debt covenants under the original agreement but had no impact on current or future cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the occurrence of certain events, including but not limited to the Company&#8217;s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement or the occurrence of a material adverse change, the Lender has the right, among other remedies, to declare all principal and interest and other amounts due to the Lender under the Loan Agreement immediately due and payable. The principal payments due under the Loan Agreement have been classified as a current liability at March&#160;31, 2022 and December&#160;31, 2021 due to the considerations discussed in Note 1 and the assessment that the material adverse change clause under the Loan Agreement is not within the Company's control. The Company has not been notified of an event of default by the Lenders as of the date of the filing of this Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future principal payments due under the Loan Agreement, as amended, are as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year ended:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total future principal payments due under the Loan Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472274104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp; Co, or the Sales Agreement. During the three months ended March&#160;31, 2022 and 2021, the company sold 644,265 and 3,327,706 shares of common stock, respectively, for net proceeds of approximately $0.5&#160;million and $8.6&#160;million, respectively, after deducting placement agent fees. As of March&#160;31, 2022, the aggregate offering price remaining under the Sales Agreement is $48.0 million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2021 Public Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 13, 2021, the Company completed concurrent but separate public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common stock, at a price to the public of $1.55 per share, and 774,194 shares of its Series X Convertible Preferred </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock at a price to the public of $15.50 per share, for aggregate gross proceeds of $38.5&#160;million. The Company received total net proceeds of $36.6&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at March&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On August 12, 2020, at the request of certain holders, 52,241 shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of 522,410 shares of the Company&#8217;s common stock. As of March&#160;31, 2022 and December&#160;31, 2021, shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 10 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company's common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had 200,000,000 shares of common stock authorized as of March&#160;31, 2022. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, warrants to purchase 12,517,328 shares of the Company's common stock were outstanding with a weighted average exercise price of $6.82 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had no intrinsic value at March&#160;31, 2022 and December&#160;31, 2021. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,847,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,470,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,232,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,436,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,170,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">680,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,953,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43,289,438&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706476770328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY INCENTIVE PLANS</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company's board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by 4% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTQ2NQ_7675637d-1608-4a23-aa34-7b6bb8a8e302">three</span>- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;1%&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii)&#160;490,336&#160;shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to 15% of the employee&#8217;s eligible compensation. During the three months ended&#160;March&#160;31, 2022 and 2021, no shares were issued pursuant to the ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, total unrecognized compensation expense related to the ESPP was approximately $0.4&#160;million. This unrecognized compensation cost is expected to be recognized over approximately 0.6 years.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,174,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,466,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(749,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(48,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,843,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs and PRSUs granted during the three months ended March&#160;31, 2021 was $2.56 per share. The total fair value of RSUs and PRSUs vested during the three months ended March&#160;31, 2022 and 2021 was approximately $1.0 million and $0.3 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2022, estimated unrecognized compensation expense related to RSUs and PRSUs grants was approximately $2.7 million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">in Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,296,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,804,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,096,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,004,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,004,368&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,609,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the three months ended March&#160;31, 2022 and 2021 was $0.53 and $1.51 per share, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, total unrecognized share-based compensation expense related to unvested stock options was approximately $4.1 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.5 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472159176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS AND CONTRACTS</a></td>
<td class="text">SIGNIFICANT AGREEMENTS AND CONTRACTS<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Licensed Product for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#8217;s planned Phase&#160;3 pivotal clinical trial of the Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Licensed Product in the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#8209;bearing license to develop, register and commercialize the Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, subject to the Company&#8217;s retained right to lead a global development program for the Licensed Product in both the Mundipharma Territory and in the U.S. and Japan, or the Company Territory, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#8209;exclusive, worldwide license to manufacture the Licensed Product and rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until the seventh anniversary of the first commercial sale of the Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#8217;s territory. However, in the event of the acquisition of a party by a third party, this right of first negotiation will not apply to any such anti&#8209;fungal product of the acquiring third party prior to consummation of the acquisition of such party, acquired by such acquiring third party from another third party after consummation of the acquisition of such party, or developed internally by the acquiring third party, either before or after consummation of the acquisition of such party, without the use of, reliance upon or reference to any technology of the acquired party that is licensed to the other party under the Mundipharma Collaboration Agreement, any technology of the other party that is licensed to the acquired party under the Mundipharma Collaboration Agreement, or any technology jointly developed by the parties pursuant to the Mundipharma Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company retains the exclusive right to develop, register and commercialize the Licensed Product, Subcutaneous Product and Other Products in the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#8217;s Global Development Cost share of $31.2&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible for double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSPECT Trial and the ReSTORE Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company's patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million plus the research and development funding of $31.2&#160;million, plus milestones achieved of $2.8&#160;million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that require judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$17.9&#160;million&#160;in September 2019 as collaboration revenue in its condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Licensed Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company's initial obligation to supply rezafungin for ongoing clinical development in the Licensed Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company determined that as of&#160;March&#160;31, 2022, all the potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In November 2020, the Company achieved a $11.1&#160;million milestone under the Mundipharma Collaboration Agreement, which is recorded as long-term deferred revenue as of March&#160;31, 2022 because the rights to consideration is not expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. In December 2021, the Company achieved a $2.8&#160;million milestone under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in January 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;No&#160;royalty revenue was recognized during the three months ended March&#160;31, 2022 or 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs (previously called Antiviral Drug Conjugates, or AVCs) based on the Company's Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or the Phase 2 Study. Unless otherwise agreed by the parties, the Company will be responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company will be the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget. In addition, upon the effectiveness of the Janssen Collaboration Agreement, Janssen will also reimburse the Company for certain costs incurred by the Company in independently performing certain research and development activities from the execution of the Janssen Collaboration Agreement until its effectiveness.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Within 90 days after delivery by the Company to Janssen of results of the Phase 2 Study and all then-available data from other clinical trials of the Development Candidate conducted under the Research Plan, or the Election Period, Janssen will be obligated to notify the Company of Janssen&#8217;s election to proceed with further clinical development of Products, such notice, an Election to Proceed Notice. If Janssen fails to deliver an Election to Proceed Notice prior to expiration of the Election Period, the Company will have the right to terminate the Janssen Collaboration Agreement upon written notice to Janssen. If Janssen provides an Election to Proceed Notice prior to expiration of the Election Period, then the parties will continue any then-ongoing Research Plan activities to completion, and Janssen will otherwise be solely responsible for the development, manufacture and commercialization of Products, at Janssen&#8217;s sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#8217;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#8217;s DFC technology more broadly. The Company&#8217;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company is entitled to reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting Research Plan activities. The Company will also be entitled to receive up to an additional $695.0&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales of Products at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In addition to the Company&#8217;s right to terminate the Janssen Collaboration Agreement for Janssen&#8217;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, upon 90 days&#8217; written notice to the Company, provided that if any clinical trial under the Research </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after completion of the Phase 2 Study and before expiration of the Election Period, immediately upon written notice to the Company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after delivery of the Election to Proceed Notice, upon 90 days&#8217; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million plus the research and development funding of $59.9&#160;million, plus milestones achieved of $3.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that require judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $27.0&#160;million in May 2021 as collaboration revenue in its condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The research and development services to be performed represents a distinct performance obligation. The Company records payments due from Janssen as collaboration revenue. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company's initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company determined that as of the latest financial statement date all the potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In March 2022, the Company achieved a $3.0&#160;million milestone under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in May 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the three months ended March&#160;31, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement during the three months ended&#160;March&#160;31, 2022&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred revenue, March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, aggregate transaction price allocated to performance obligations that are unsatisfied is $15.5&#160;million and $48.9&#160;million under the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively. These amounts are expected to be recognized over 1.75 years which represent the remaining research periods under the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company recorded $0.1&#160;million and $8.6&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our contract revenues disaggregated by timing of revenue recognition and excludes royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Point in Time</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Mundipharma Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Mundipharma Collaboration Agreement</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,526&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Janssen Collaboration Agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Janssen Collaboration Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Point in Time</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Mundipharma Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Mundipharma Collaboration Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472159176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 14, 2021, the Company entered into a sixth amendment to its lease with Nancy Ridge Technology Center, L.P. which extended the term of the lease by an additional 24 months and increases the base rent to $103,733 per month effective January 1, 2022, subject to 3% increases every January. The lease expires on December 31, 2023 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of March&#160;31, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. The incremental borrowing rate used in measuring the Company's lease liability was 10.8%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company's operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the weighted average remaining lease term was 1.8 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $0.3 million and $0.2&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $0.3 million and $0.2&#160;million for the three months ended March&#160;31, 2022 and 2021 respectively. These costs are primarily related to the Company's long-term operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472159176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTSOn April 20, 2022, the Company entered into a Letter Agreement with Mundipharma, which amended the Mundipharma Collaboration Agreement, under which the Company is eligible to receive prepayment of one milestone payable pursuant to Section 5.4 of the Mundipharma Collaboration Agreement as reimbursement for the cost of the Company continuing or conducting certain rezafungin development activities, up to a total of $11.1 million. Any such amounts prepaid by Mundipharma will be deducted from the milestone anticipated to be payable in 2022 to the Company by Mundipharma pursuant to the Mundipharma Collaboration Agreement. If not prepaid, the remaining portion of such milestone will be due upon achievement of the applicable triggering event as set forth in the Mundipharma Collaboration Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469795160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2022, the Company had an accumulated deficit of $395.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company had cash, cash equivalents and restricted cash of $38.0 million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, </span></div>including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_UnauditedInterimFinancialDataPolicyTextBlock', window );">Unaudited Interim Financial Data</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options, estimated collaboration expenses and incurred expenses related to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement (each as defined below), certain accruals, including those related to nonclinical and clinical activities, and the Standalone Selling Price of performance obligations associated with license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash represents cash that the Company is required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 4 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at March&#160;31, 2022 or December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated </span></div>using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTIzNw_5527d6f8-bbd7-4b20-ac44-ff096fb03762">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the FASB ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three significant performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were three significant performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments and estimated reimbursable research and development and clinical supply costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock', window );">Preclinical and Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future </span></div>periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described in Note 3, the Company believes that the fair value of the term loan approximates its carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_UnauditedInterimFinancialDataPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_UnauditedInterimFinancialDataPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706476770328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,442,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,847,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,648,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,550,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,608,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706476764280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Instruments Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706476745880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future principal payments due under the Loan Agreement, as amended, are as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year ended:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total future principal payments due under the Loan Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706476764280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,847,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,470,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,232,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,436,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,170,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">680,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,953,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43,289,438&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706475723432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,174,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,466,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(749,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(48,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,843,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">in Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,296,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,804,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,096,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,004,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,004,368&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,609,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472159176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement during the three months ended&#160;March&#160;31, 2022&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred revenue, March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our contract revenues disaggregated by timing of revenue recognition and excludes royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Point in Time</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Mundipharma Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Mundipharma Collaboration Agreement</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,526&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Janssen Collaboration Agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Janssen Collaboration Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Point in Time</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Mundipharma Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Mundipharma Collaboration Agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706477669864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company's operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472508104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (395,448)<span></span>
</td>
<td class="num">$ (377,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">$ 37,970<span></span>
</td>
<td class="nump">$ 62,273<span></span>
</td>
<td class="nump">$ 48,789<span></span>
</td>
<td class="nump">$ 42,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706470203944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706471317640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">41,550,044<span></span>
</td>
<td class="nump">31,608,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">12,517,328<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series X Convertible Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">18,184,720<span></span>
</td>
<td class="nump">10,442,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options, RSUs and PRSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">10,847,996<span></span>
</td>
<td class="nump">8,648,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472466024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market funds</a></td>
<td class="nump">$ 36,488<span></span>
</td>
<td class="nump">$ 59,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">37,970<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">LEVEL 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market funds</a></td>
<td class="nump">36,488<span></span>
</td>
<td class="nump">59,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">37,970<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">LEVEL 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">LEVEL 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472760360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Additional Information (Details) - Term Loan - Term A Loan - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Oct. 03, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowed from the lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Variable annual rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706475711288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Future Principal Payments (Details) - Term A Loan - Term Loan<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Year ended:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of fiscal year</a></td>
<td class="nump">$ 1,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total future principal payments due under the Loan Agreement</a></td>
<td class="nump">$ 1,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706466605080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 13, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock, proceeds | $</a></td>
<td class="nump">$ 36,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_NumberOfVotesEntitlementForEachShareHeld', window );">Number of votes for each share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember', window );">Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_WarrantsAggregateIntrinsicValueOutstanding', window );">Warrants, aggregate intrinsic value, outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">774,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from right offerings | $</a></td>
<td class="nump">$ 38,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued for each preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion', window );">Maximum ownership following conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember', window );">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,265<span></span>
</td>
<td class="nump">3,327,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_SaleOfStockConsiderationRemainingOnTransaction', window );">Consideration remaining on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicStockOfferingMember', window );">Public Stock Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">17,064,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">2,225,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfVotesEntitlementForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitlement for each share held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfVotesEntitlementForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_SaleOfStockConsiderationRemainingOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Remaining on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_SaleOfStockConsiderationRemainingOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_WarrantsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Aggregate Intrinsic Value, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_WarrantsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706471073096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">45,953,012<span></span>
</td>
<td class="nump">43,289,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">12,517,328<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">18,184,720<span></span>
</td>
<td class="nump">18,184,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock options, RSUs and PRSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">10,847,996<span></span>
</td>
<td class="nump">9,470,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember', window );">Authorized for future stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">3,232,404<span></span>
</td>
<td class="nump">2,436,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Awards available under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">1,170,564<span></span>
</td>
<td class="nump">680,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706470688344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term for stock options to be granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold', window );">Voting power threshold</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic annual increase in shares authorized for issuance in equity incentive plan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Limit on employee's payroll deductions as a percentage of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember', window );">Restricted Stock Units and Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs and PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember', window );">More than 10% of voting power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Automatic increase in number of shares available for issuance (in shares)</a></td>
<td class="nump">490,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic annual increase in shares authorized for issuance in equity incentive plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472471560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details) - Restricted Stock Units and Performance-based Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs and PRSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,174,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs and PRSUs granted (in shares)</a></td>
<td class="nump">1,466,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs and PRSUs vested (in shares)</a></td>
<td class="num">(749,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs and PRSUs canceled (in shares)</a></td>
<td class="num">(48,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,843,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs granted (in dollars per share)</a></td>
<td class="nump">0.83<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs vested (in dollars per share)</a></td>
<td class="nump">1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs canceled (in dollars per share)</a></td>
<td class="nump">2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706466565896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">8,296,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,804,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares)</a></td>
<td class="num">(1,096,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">9,004,368<span></span>
</td>
<td class="nump">8,296,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">9,004,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">4,609,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share)</a></td>
<td class="nump">3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">2.74<span></span>
</td>
<td class="nump">$ 3.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract', window );"><strong>Total Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706471049432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="nump">$ 879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">455<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706465853720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 03, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,109,000<span></span>
</td>
<td class="nump">$ 2,408,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementCostSharingPercentage', window );">Cost sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults', window );">Election to proceed notice, period post delivery of results</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice', window );">Termination provisions, required period of written notice</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | R&amp;D Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="nump">58,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Development, Regulatory, and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="nump">$ 695,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementCostSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cost Sharing Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementCostSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Third Party Share Of Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTransactionPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Transaction, Potential Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTransactionPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PaymentsRelatedToCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Related To Collaborative Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PaymentsRelatedToCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706472472104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward', window );"><strong>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Opening balance, December&#160;31, 2021</a></td>
<td class="nump">$ 13,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Closing balance, March&#160;31, 2022</a></td>
<td class="nump">14,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">14,260<span></span>
</td>
<td class="nump">$ 13,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">17,229<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="nump">31,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward', window );"><strong>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Opening balance, December&#160;31, 2021</a></td>
<td class="nump">32,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance', window );">Payments received in advance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable', window );">Payments receivable</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized', window );">Revenue from performance obligations satisfied during reporting period</a></td>
<td class="num">(2,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Closing balance, March&#160;31, 2022</a></td>
<td class="nump">31,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">$ 31,489<span></span>
</td>
<td class="nump">$ 32,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706466905160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,109<span></span>
</td>
<td class="nump">$ 2,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">2,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company | Research and Development Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company | Clinical Supply Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma Medical Company | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | License of Intellectual Property | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | License of Intellectual Property | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | Research and Development Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | Clinical Supply Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen Pharmaceuticals, Inc. | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469553336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseMonthlyRate', window );">Base rent per month</a></td>
<td class="nump">$ 103,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease', window );">Percentage increase in base rent annual</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_NumberOfOperatingLeaseOptionsForExtension', window );">Number of options to extend | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost', window );">Variable lease and short-term lease term included within operating lease cost (greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rate Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseAnnualRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseMonthlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseMonthlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfOperatingLeaseOptionsForExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Lease Options For Extension</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfOperatingLeaseOptionsForExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469713128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 1,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 2,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706477609400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 2,030<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">$ 1,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139706469778824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 20, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Mundipharma Medical Company | Milestone Achievement | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone', window );">Collaborative arrangement, potential prepayment receivable</a></td>
<td class="nump">$ 11.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementPotentialPrepaymentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Prepayment Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementPotentialPrepaymentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>cdtx-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cdtx="http://cidara.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cdtx-20220331.xsd" xlink:type="simple"/>
    <context id="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c51335a81484dfb9629cbe37cd15f71_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="ic36326a3df014b8d992c03bd0101de68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2191d31021fb49a59ba0e5e2e38662fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b6a39ac194e4bdfbf136edfa309899a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ca662309536454c8fc2ec20aa598bfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifed4d780fa7c4657ace1ca39915c5db9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i594ac01243ff48a294a5691f8bb16ec7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7ae401fe1ec94508a4c3bc1de6b123a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id29d0679e5a849fd8f0b328b0047051f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01e075b04cda432ea3e0bb290da8aa76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb5be7deff5c45d58b2dabd268641ffa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie249caef64f94171b3f97f31b1702323_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iffef7cfce9f74e188e663bb9b9e5a2b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie90d7c5734cb4948aae78ef94bf77084_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i078bfa49848346d5a1e3ebef80a9bf83_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic98e2da648634bd2abb09e30b07febad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idfbfbe505a42456b8b907a1ce48ce8f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8a2d9cef5eea4c869286d364c1fc6da0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75db0cf998d34c4f90645b2615a44ae4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib20007356f9d4ba5be34c0e5c7493ff3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f61e4e8ab114e4e8fa4705c380ffc10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52015336fa754888b0567c048a6a08cd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic51fadbb95d64d119839876c70af802f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf01e9ab4d5447ae8695372ee5c96045_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie313ed150dbb4af980047e1f2ca2e27c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3325f5645b9b4b7f988048d9368cbd44_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i570e663b09344feb9ff09e6ddb45fead_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iae0fb3f8928942308d937ccfcd35d926_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21169da961a642269defd386e1909c8e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95f5fe2a729b4d4b88d79c8b9f71926b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31a37a66cd6249378b32ab50166895a0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4aa023587c32497cbf47ee68d3cbfb01_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i900152b8dae048ce8a4acda17d7bcb77_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia1c94bb11270499696b1406f63c1b83d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b5153e1e8ab48e49acff0d1756e5388_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i16c6cdf33b80446aa3a77138caa526a0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i041a511ce516484886b5ffe0acef8f8e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa38f920be7245f686abc0a371da8a87_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i28b73da715794f18af42e513a2842fb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic713e533dda046afa29b8024f40c66d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i795c9fa22a224d2bbd52d8f2fe81648b_I20161003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-03</instant>
        </period>
    </context>
    <context id="i46940802d05a44c78644bacf035f8ab4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6621b987d56742bdb57725ac1faabdbb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i35c8f58bd982422a986ef78bf58fc3ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0195058d79fa431882538deea9d40134_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifbc4656677c945bea6a7f93277e0065d_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="ie51f2518f48844149c35fadeee45c717_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="ifa0b0517b28c459d84c79bff7bdcb54e_I20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="i0df47124083a4f99a0e151684e8f154c_I20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="ib1eb42daf54d4b668a360dcc81934f30_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="i55bdd2d5589d4fe7b0309fed8211b8a8_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="i69448e0c7d0b4165bc50aaf98eb14d71_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i280b1d43fcd44cc3b820c5ccce18586b_D20200812-20200812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-12</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="idc285ca9fc0947889305e6be663b5ce3_D20200812-20200812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-12</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="i2b1567b76bf14270856d0e77828b3edd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1202dce605be4c82a0a70d95af7a8593_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5971b45c3a7c412c88e46aa2b80a5a6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f8aa79b2a034ff484490a0f9ed5005a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic27040cee9f64227942f86974dfc7e07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67507a3641814df4b10e074a32b49c2e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8bd0f0932ef8490bb6c1d6b126581749_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a0d4f2214a74513a73c71607fd17646_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id49a49faa40b4317b2251637999b3844_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3394b2a276ce4f24a740ba07a69873e9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieef9aeb2eaab46cf8f2dc459329f1dab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6500728b40904350a970627b377ddbb0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieab45868d7b34980921f34867b165abc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib71eefcf9d68457782ef30c211def3a7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i378b0ff196374173acefdb91629cc588_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a0dd60e595d4d90b99db4dfcc03e925_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="iebf1af9bc014431a9d173becef761d0e_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i2b6dd61a92f24717a10f0e25c4e1a31f_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i720b8558f3114a66b3afb7ddb6acfbda_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i0b84d00a866d4c51b68551b7e95373d5_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i3fbce54647a341fba1a08f3e3d01f687_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i64417209e6a7431e9641d70ebaa9d805_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i720f7ca4cb4d47c797738cd1efd27be0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7725d535d6df481ba4eb64e1f9497bb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36320806fa3c4b5f9432d569a7254fb3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4d982e5d0cc6497c854d56be2b7a9838_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if93aa19e1f944c0c881474a93809cb2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i228ae513e4d048c1b3d1b4222fab3750_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f64292f9a6949a8b73b0d21cbeefa6a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia0284b9283584c6a98c2cf36c7b67635_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a4d20a797ca4520be3b7156f337e50f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b2950f3ff64498ea4482c1111550256_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8d1f47cfaf864b5b8449cf27f8903001_D20190903-20190903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-03</startDate>
            <endDate>2019-09-03</endDate>
        </period>
    </context>
    <context id="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a1b832c3bcc45ec9f16fa3306e87d89_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59db54d089334f80bfc2bf1d019c720c_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i68f5f47ae533474f9d58f357b7560076_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5b2c214fd2d34166a98231e78e89cb57_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie4961bcc2a42459fbdcff0f5d4ffbff3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i857d96ec633a44e1b0ea653816686201_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1be4c76c948d42acabc01f60c0e15d14_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:RDFundingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8dadaa504524767be44ca25b519478f_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i41dc4db26c7d45a799666fc33080b4f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia37c7f2020504762b3c04bc8f40f0ede_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifbcdd3cc2a2e4827a4681f970f6d7389_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i58b63e51f2fb46699aee3fdf1e54a345_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i79dab98a8e3e4d89a66719d5a46c5f73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie02b09de693048bc9accc5d0a7f832d4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia4458c0ab6aa4e3aa31bee9f21e043b2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i443dc61676d64544abd994b78e8e6267_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i78a1639fe6204e6f9c15a4b4242bfe9e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c53ce77870a41f5beea59ecd239000c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3dad60c0f2e040f5b0673a6393394e63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87caf4dd1d234587aa8a86b0e5f01f6c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i837f36bd31f84edca1439985d38c4717_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i10c225bd22cb4a8094a6e4710a63e69c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iba15d9175213445a9632cc6854819319_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ce9e60ff6584997b9bbb0384ed6d8f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id2edbac57ce84f7b9906d418d840a9f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57264f734480431092220a6ede4796c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i615ceceeaed5466fb85286d706d29b85_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i716d135486924cee81e022c6ac2e5d44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc5e6adc3fef490dbca284a3b1c6289d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2ba2d8537d1401aa4d567fbd40f5201_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie796a038ce0e48ce994e533569bf1dff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc1fea76ca9d480da5ec1b4279d7de92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic368059479da424f931465560c9ec6ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8326f1cfdd2e45bda044cbe96cfa6825_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a7f4f7d381047d6b390662bf856366c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i38c0da6f182649489b0466ee3d5e1e90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i80e055b607f746a7bb4d400492c18aae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i051d9f3eac064cabb12542bb0d83033e_D20190903-20190903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-03</startDate>
            <endDate>2019-09-03</endDate>
        </period>
    </context>
    <context id="ida2575eac8b54cbd9b8d91895a8f0d63_I20210714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="i4d38d95a623e4c7db64c6031f9fbdbde_D20210714-20210714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="i7ab61c4680194901bbce5f08a8fd1c4c_I20220420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="segment">
        <measure>cdtx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>cdtx:vote</measure>
    </unit>
    <unit id="option">
        <measure>cdtx:option</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF8zLTEtMS0xLTMwMzUx_4a6b0b4e-8a05-4003-bba1-fc48bb5209f6">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF80LTEtMS0xLTMwMzUx_1c7ff4c0-19a8-4cee-bcbd-954ec3704db2">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF81LTEtMS0xLTMwMzUx_2fb96d12-edbe-41dc-ab84-746e20e87c74">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF82LTEtMS0xLTMwMzUx_8e10f395-0e29-412a-84f6-86f77eea7d93">0001610618</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80L2ZyYWc6ODVlNTU2MzJmNWRiNDlmODhjM2Y0NTEyYzA2YjM3ZTYvdGFibGU6NThjZjZkOWU4MmJmNGFkNjgwZTc0MWIzYWM3YTliYTQvdGFibGVyYW5nZTo1OGNmNmQ5ZTgyYmY0YWQ2ODBlNzQxYjNhYzdhOWJhNF83LTEtMS0xLTMwMzUx_1d4cdba9-d15f-4ec2-9640-9319f81b9fa8">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_86037227-b16d-461a-8143-948ba4f1025f">http://cidara.com/20220331#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_8a3b3de7-da47-4d52-a743-ea2ee0014004">http://cidara.com/20220331#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_9cd6c1ef-ede4-4be7-85be-696217c96ca5">http://cidara.com/20220331#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0wLTEtMS0zMDM1MQ_ae2b0c7e-d3fd-4c73-b2ea-1dbaad18b7f6">http://cidara.com/20220331#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iae0fb3f8928942308d937ccfcd35d926_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTIzNw_5527d6f8-bbd7-4b20-ac44-ff096fb03762">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iebf1af9bc014431a9d173becef761d0e_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTQ2NQ_7675637d-1608-4a23-aa34-7b6bb8a8e302">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cdtx:CollaborativeArrangementCostSharingPercentage
      contextRef="i051d9f3eac064cabb12542bb0d83033e_D20190903-20190903"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81Mi9mcmFnOmM0OTY0MmFlOGVlOTQzOWU5NTdjNzAwM2UxZjdhNjZlL3RleHRyZWdpb246YzQ5NjQyYWU4ZWU5NDM5ZTk1N2M3MDAzZTFmN2E2NmVfNTM_2a567704-bb7c-44ac-a6c2-12446c599271"
      unitRef="number">0.50</cdtx:CollaborativeArrangementCostSharingPercentage>
    <dei:DocumentType
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODgx_e79ea0a7-212c-482a-bd44-f994abd3f5aa">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6ZWY4ZmE5M2M4MjE0NGY2M2EyZjgxOGFjNmFkNjNkYjMvdGFibGVyYW5nZTplZjhmYTkzYzgyMTQ0ZjYzYTJmODE4YWM2YWQ2M2RiM18wLTAtMS0xLTMwMzUx_706a7d44-1a98-4654-9c09-90a1d26591e1">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xMzU_f9180fe2-5d31-4c61-8b6d-691f153954b7">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6MGIwYTg3OTEwYmE4NDk1Y2JlOThiNWNjNTUwMjIwODAvdGFibGVyYW5nZTowYjBhODc5MTBiYTg0OTVjYmU5OGI1Y2M1NTAyMjA4MF8wLTAtMS0xLTMwMzUx_5b9a3081-35c7-4303-87ec-744009650dbb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODc3_31d8eee7-dac4-4e96-b54a-1a6b0a9a7efe">001-36912</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODgz_64b2ca14-058c-4a78-9959-7197099a81d9">CIDARA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8wLTAtMS0xLTMwMzUx_43c1ae04-c697-4b81-b6c6-79fc824a5d5f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8wLTUtMS0xLTMwMzUx_04b541c2-13df-445a-a5ab-26a100090735">46-1537286</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8zLTAtMS0xLTMwMzUx_9dcc38e8-d7d5-4182-b585-f7e2fbd4769e">6310 Nancy Ridge Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl8zLTMtMS0xLTMwMzUx_2ca57ff4-138d-4da0-95c0-1f9647bca35c">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTAtMS0xLTMwMzUx_cb579e33-3c40-470a-bf46-0ed1a5abcaa9">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTEtMS0xLTMwMzUx_82512724-3e6e-42f7-8a21-3fbcbf59a3ab">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTItMS0xLTMwMzUx_bad7e71d-9619-4be7-8566-b06772a62bd1">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTUtMS0xLTMwMzUx_6133b653-da89-48c1-a693-ee218812462b">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6YmNjMDEzY2NkMmJjNGM2Nzg5ZDQzMjBjYzg1Y2YzMWYvdGFibGVyYW5nZTpiY2MwMTNjY2QyYmM0YzY3ODlkNDMyMGNjODVjZjMxZl80LTYtMS0xLTMwMzUx_1ad196c2-3089-432b-81e3-f547cc80f3f6">752-6170</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6M2FhMDAwZDNhYzY2NDU2MzgyZWUxNWMxYjc4YjhjZjUvdGFibGVyYW5nZTozYWEwMDBkM2FjNjY0NTYzODJlZTE1YzFiNzhiOGNmNV8xLTAtMS0xLTMwMzUx_5561ba2c-ae8c-425e-b682-197a03ca3c8b">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6M2FhMDAwZDNhYzY2NDU2MzgyZWUxNWMxYjc4YjhjZjUvdGFibGVyYW5nZTozYWEwMDBkM2FjNjY0NTYzODJlZTE1YzFiNzhiOGNmNV8xLTItMS0xLTMwMzUx_f6bf048d-754f-4fef-957d-d38ae8e4eeb4">CDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6M2FhMDAwZDNhYzY2NDU2MzgyZWUxNWMxYjc4YjhjZjUvdGFibGVyYW5nZTozYWEwMDBkM2FjNjY0NTYzODJlZTE1YzFiNzhiOGNmNV8xLTQtMS0xLTMwMzUx_03694a31-3e53-4ffa-9dd5-62690ee1aafc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODg0_863d9a22-ae5a-43a6-907b-3b2dc113e5da">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODc4_2d747890-e4bd-4432-aac2-35cc0a66e3df">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6OWVkNzZiYWI1MDY4NGNlZmI2ZDVhZjUzYTE4ZTdlN2YvdGFibGVyYW5nZTo5ZWQ3NmJhYjUwNjg0Y2VmYjZkNWFmNTNhMThlN2U3Zl8yLTAtMS0xLTMwMzUx_df6f5289-e7b6-4b50-abe5-68230e1a0943">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6OWVkNzZiYWI1MDY4NGNlZmI2ZDVhZjUzYTE4ZTdlN2YvdGFibGVyYW5nZTo5ZWQ3NmJhYjUwNjg0Y2VmYjZkNWFmNTNhMThlN2U3Zl8yLTQtMS0xLTMwMzUx_193c67c4-1bf0-413a-8c41-66c0b024ce46">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGFibGU6OWVkNzZiYWI1MDY4NGNlZmI2ZDVhZjUzYTE4ZTdlN2YvdGFibGVyYW5nZTo5ZWQ3NmJhYjUwNjg0Y2VmYjZkNWFmNTNhMThlN2U3Zl80LTQtMS0xLTMwMzUx_ca67f5a8-dcce-42e7-b71f-4b24354d742a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODgw_57fcccde-25a4-44c0-9b3b-a0609b775cd0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3c51335a81484dfb9629cbe37cd15f71_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODIy_2d37c7f5-1b98-49f1-83ad-66b43e503bf8"
      unitRef="shares">69049497</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODUw_8b478aae-549a-4e2d-a19f-5136389dba24"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xL2ZyYWc6NDIxN2NhNzE1OGVlNDI2MDhjYmIyZDA2NjAxYzYxZWIvdGV4dHJlZ2lvbjo0MjE3Y2E3MTU4ZWU0MjYwOGNiYjJkMDY2MDFjNjFlYl8xODUw_d12bf858-1794-49fb-9a77-0ab91deae01e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNC0xLTEtMS0zMDM1MQ_cb194f26-c0cf-41cf-bc0c-dc9aee4faf12"
      unitRef="usd">36488000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNC0zLTEtMS0zMDM1MQ_81e8889b-01a5-437d-9bfe-c29379b7b3be"
      unitRef="usd">59680000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNS0xLTEtMS0zMDM1MQ_16fe966c-9de2-4a55-bfc4-7b68f4baf91b"
      unitRef="usd">1482000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNS0zLTEtMS0zMDM1MQ_ff1199f9-7bba-4a93-82a0-f39e6a44db0a"
      unitRef="usd">2593000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNi0xLTEtMS0zMDM1MQ_63a8f60d-134e-4ffb-953a-e44aafebdf8b"
      unitRef="usd">8783000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNi0zLTEtMS0zMDM1MQ_e9c9dabb-c211-411d-bf63-94bdd8d5d894"
      unitRef="usd">5356000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNy0xLTEtMS0zMDM1MQ_22b96ac9-ebc2-40a7-8143-d7c2024eff14"
      unitRef="usd">5254000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfNy0zLTEtMS0zMDM1MQ_9df4bd79-47e2-4279-ad8b-ebcb0f28ff02"
      unitRef="usd">4069000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOC0xLTEtMS0zMDM1MQ_afa18d15-b5f6-415b-955e-4220450047cb"
      unitRef="usd">52007000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOC0zLTEtMS0zMDM1MQ_02c165a9-5070-4ef7-9f1f-c5a81349d0a1"
      unitRef="usd">71698000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOS0xLTEtMS0zMDM1MQ_b4c52575-8021-4f12-922a-37ebf886db41"
      unitRef="usd">239000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfOS0zLTEtMS0zMDM1MQ_9c196d4a-c020-4e46-aa42-f0fbb53489ff"
      unitRef="usd">256000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTAtMS0xLTEtMzAzNTE_aecc2adf-5fcf-464e-b460-b0339e4adb0e"
      unitRef="usd">2030000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTAtMy0xLTEtMzAzNTE_74461d08-5b5f-41c2-9e8d-68053b37ed0b"
      unitRef="usd">2287000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTEtMS0xLTEtMzAzNTE_8ce4bd22-d0e3-4dc2-b71f-acb835ef0db9"
      unitRef="usd">1019000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTEtMy0xLTEtMzAzNTE_4f3fe3e7-0b51-4243-96ab-cadeef995807"
      unitRef="usd">1084000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTItMS0xLTEtMzAzNTE_c00a4ebc-4695-4a3f-93bf-c1ffb9f2ed27"
      unitRef="usd">55295000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTItMy0xLTEtMzAzNTE_e01e2a77-8261-4614-93a4-786d8e954764"
      unitRef="usd">75325000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTYtMS0xLTEtMzAzNTE_2e0f5c95-8ec5-4559-8489-82b80fe897d3"
      unitRef="usd">2861000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTYtMy0xLTEtMzAzNTE_fc418efc-e148-489c-8293-68328c3273d5"
      unitRef="usd">1301000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTctMS0xLTEtMzAzNTE_2da19e45-185c-4ed1-9652-a6c76bfda4e0"
      unitRef="usd">9234000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTctMy0xLTEtMzAzNTE_b0fbc6ec-33fc-4572-8f1f-4191b574c934"
      unitRef="usd">10198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTgtMS0xLTEtMzAzNTE_f57af066-6177-42a1-b64f-bb6019015587"
      unitRef="usd">3079000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTgtMy0xLTEtMzAzNTE_7d8a96e0-0995-4702-8e73-254e817d71f9"
      unitRef="usd">4859000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTktMS0xLTEtMzAzNTE_0c3c6009-d83d-4853-9936-3be8232de0c1"
      unitRef="usd">14260000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMTktMy0xLTEtMzAzNTE_cebe6857-1604-495f-851b-7028d3f177d9"
      unitRef="usd">13920000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjAtMS0xLTEtMzAzNTE_0e7acc5e-ece7-478d-bf1b-670090241884"
      unitRef="usd">1481000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjAtMy0xLTEtMzAzNTE_40451592-a9fb-4165-9af3-3aa7b9abcd57"
      unitRef="usd">2591000</us-gaap:LoansPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjEtMS0xLTEtMzAzNTE_be559129-a09b-4814-a45a-390462aa3027"
      unitRef="usd">1190000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjEtMy0xLTEtMzAzNTE_ba1b1891-8057-463f-a192-9e57e8cafa88"
      unitRef="usd">1148000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjItMS0xLTEtMzAzNTE_e5271e1f-e370-4550-93e5-28ec391f8d12"
      unitRef="usd">32105000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjItMy0xLTEtMzAzNTE_e640380e-55bc-4a15-aacf-a658cf4e0b9e"
      unitRef="usd">34017000</us-gaap:LiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjMtMS0xLTEtMzAzNTE_59eea6c8-601b-467d-989b-a04a16ecb048"
      unitRef="usd">17229000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjMtMy0xLTEtMzAzNTE_d25211dd-1220-4468-8a06-a8f8f188cf07"
      unitRef="usd">18413000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjQtMS0xLTEtMzAzNTE_16d46831-eeb0-4bde-8691-97ba3bb635d1"
      unitRef="usd">1004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjQtMy0xLTEtMzAzNTE_05c123c5-26bc-4841-b75c-935077436b47"
      unitRef="usd">1322000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjUtMS0xLTEtMzAzNTE_4f4b6ab4-6bf9-496b-9b0a-86cf51c829b0"
      unitRef="usd">50338000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjUtMy0xLTEtMzAzNTE_b295fd02-b113-4341-bfc8-43fa6d2d7a03"
      unitRef="usd">53752000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjYtMS0xLTEtMzAzNTE_bb54ff32-3b52-4956-b9b8-f3852310dfc3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjYtMy0xLTEtMzAzNTE_ba465a02-1b38-4bb9-9121-c26f07fa6951"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8yMg_17e63a39-17e2-468f-a78d-8c0bdf28ba73"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8yMg_913586a8-3037-47ce-b923-7c0b1ee5243b"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8zNg_6d7c0e02-0d2f-4ad2-b2b5-6c066992e6c9"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjpkYmFiYmEzZjM0NWI0MTQ3YmQwZWJjYTg2Mjk5MDIzNF8zNg_d08600a8-f01c-4ed5-b764-983f24cd1511"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMS0xLTEtMzAzNTE_b84e5f52-e6ba-4c53-b930-3bc9ad4b863c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjgtMy0xLTEtMzAzNTE_ef0939b3-6307-4ad8-8f28-4bcd299eaf6d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV80Mw_31585d79-6243-4eb4-931f-68608afa4692"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV80Mw_f1a756a0-b22b-4d18-bca1-d15371abedaa"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV81Nw_909fa249-6047-486e-b101-415737f4c5a9"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV81Nw_d19122d3-7b00-4772-a86d-fde3b6f836c1"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85Mg_1ad696a3-a2a1-4ed4-92bb-507acb278854"
      unitRef="shares">1870713</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85Mg_c084c67a-3d6e-45a0-af99-221a0948d269"
      unitRef="shares">1870713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85OQ_6b2b6d45-2f14-428b-9cb9-49baf025e80c"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjo3N2IyOWY1ZDY2Yzc0ZDZkOWRkMWMzMTc0YzdkODAyZV85OQ_def10892-c6ff-4887-bc72-3b4379966082"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMS0xLTEtMzAzNTE_16dd5a22-1b7c-4a28-8942-5304ca30324a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMjktMy0xLTEtMzAzNTE_ab21dc09-ac25-4710-9ea4-6c9ea9ed1074"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8xOQ_8b478aae-549a-4e2d-a19f-5136389dba24"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8xOQ_d12bf858-1794-49fb-9a77-0ab91deae01e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8zMw_5a169051-9e96-448d-9425-f5c0e111b370"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl8zMw_9679fbbf-a0fa-4913-a38b-edc2a8e0534c"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl82OA_2add9378-913f-47da-b591-b73708de97b9"
      unitRef="shares">69049247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl82OA_72fd81c9-9fbb-4a8c-a347-53dfc48af7d3"
      unitRef="shares">69049247</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl83NQ_f76bbf6d-f964-4b18-82f7-b7efb0e57048"
      unitRef="shares">67863674</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMC0xLTEtMzAzNTEvdGV4dHJlZ2lvbjozMjE2MmE4ZjY1ZmY0NDQ2OGFhZTlhYWUwZDY0OWQxNl83NQ_f9ed5a62-e3e2-4dad-b9c4-85226773871a"
      unitRef="shares">67863674</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMS0xLTEtMzAzNTE_fa1ca59f-a7f0-41ff-8bdf-00ed81934ff5"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzAtMy0xLTEtMzAzNTE_25bbc6d7-eade-4f4a-a503-46551b8d0810"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzEtMS0xLTEtMzAzNTE_c0950811-ecc5-41b4-8a74-232dce5b6b92"
      unitRef="usd">400398000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzEtMy0xLTEtMzAzNTE_997d83b7-daaf-4846-a1f6-89f4b496216d"
      unitRef="usd">398733000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzItMS0xLTEtMzAzNTE_89bfc192-e3e5-4324-8114-acbbfb62cd9f"
      unitRef="usd">-395448000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzItMy0xLTEtMzAzNTE_29476c60-d760-4069-822c-ba121e6efa62"
      unitRef="usd">-377167000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzMtMS0xLTEtMzAzNTE_c2414242-914f-42de-a06b-92c840337b86"
      unitRef="usd">4957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzMtMy0xLTEtMzAzNTE_a428e279-62c5-4645-ac63-178e4faf53be"
      unitRef="usd">21573000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzQtMS0xLTEtMzAzNTE_daaf0b7d-b94a-44d2-be64-6925143cc24d"
      unitRef="usd">55295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xNi9mcmFnOmQ5MjA1NzdiNDVlYzRkZmZiYmQyODE5MmM5MzkwOWQ3L3RhYmxlOjc1YTkxNjc4YWE0OTQ0Y2NhZTY2NGQ3MzA5ZGFhMDQzL3RhYmxlcmFuZ2U6NzVhOTE2NzhhYTQ5NDRjY2FlNjY0ZDczMDlkYWEwNDNfMzQtMy0xLTEtMzAzNTE_696f99cd-5433-4480-880c-8ae5286c276e"
      unitRef="usd">75325000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0xLTEtMS0zMDM1MQ_66937767-38b5-4c67-be75-3be7c6d36a35"
      unitRef="usd">7109000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMy0zLTEtMS0zMDM1MQ_c9e7d640-1deb-482f-87df-052652e89340"
      unitRef="usd">2408000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNC0xLTEtMS0zMDM1MQ_baffd04d-ee02-441f-9341-a21c4d97cd33"
      unitRef="usd">7109000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNC0zLTEtMS0zMDM1MQ_4657bf7d-5e90-47e8-a4a0-108b0f7bf3d7"
      unitRef="usd">2408000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNi0xLTEtMS0zMDM1MQ_3f3d9598-88a2-433f-bfdd-57c5f260f350"
      unitRef="usd">20166000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNi0zLTEtMS0zMDM1MQ_fc55a4e5-d299-498f-84c0-05aab262dfcb"
      unitRef="usd">15849000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNy0xLTEtMS0zMDM1MQ_413dcb96-fbfc-490f-aeab-d103e03072bd"
      unitRef="usd">5204000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfNy0zLTEtMS0zMDM1MQ_b6f101c1-9cf4-4300-93ba-3285a0249a69"
      unitRef="usd">4781000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOC0xLTEtMS0zMDM1MQ_185cf0d6-41ce-4056-8d4a-14ed25a91b26"
      unitRef="usd">25370000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOC0zLTEtMS0zMDM1MQ_983dfd23-4fe3-4c4f-b9ef-d67edeece30d"
      unitRef="usd">20630000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOS0xLTEtMS0zMDM1MQ_29199a91-ad38-4178-b708-c47354a6d32f"
      unitRef="usd">-18261000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfOS0zLTEtMS0zMDM1MQ_c6c3a76c-71c6-4eee-b09c-9ad9b5cb14e2"
      unitRef="usd">-18222000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTEtMS0xLTEtMzAzNTE_859507f1-06a2-4230-88b5-4f1445a05e45"
      unitRef="usd">-20000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTEtMy0xLTEtMzAzNTE_aa14abc4-9838-447c-b6b1-aa1c0fcf8bf6"
      unitRef="usd">-70000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTItMS0xLTEtMzAzNTE_135d041c-9ae9-4bb9-ab63-7f69c0348411"
      unitRef="usd">-20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTItMy0xLTEtMzAzNTE_717c1d59-e7f5-4d17-b16f-adcd9ff24b4e"
      unitRef="usd">-70000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMS0xLTEtMzAzNTE_51db5670-4bba-4313-b03a-ac51ae48c873"
      unitRef="usd">-18281000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMS0xLTEtMzAzNTE_54909531-7527-4e9c-b1cb-539b0ec1e5a2"
      unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMy0xLTEtMzAzNTE_157277cf-f89d-4f37-828e-5f38b4a34b97"
      unitRef="usd">-18292000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTMtMy0xLTEtMzAzNTE_bde72121-5ba7-47b4-8ceb-271961e2a5bf"
      unitRef="usd">-18292000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTYtMS0xLTEtMzAzNTE_0c2e77f7-f373-4472-8415-eb725a0612fd"
      unitRef="usd">-18281000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTYtMy0xLTEtMzAzNTE_2fbff7cc-1add-4c9a-8ff4-50dacc8e1d09"
      unitRef="usd">-18292000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMS0xLTEtMzAzNTE_0a7034a6-1bc6-4947-bd40-0910e8493e5c"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMS0xLTEtMzAzNTE_6340991b-2429-48e6-98fd-3f8a41c64d34"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMy0xLTEtMzAzNTE_187783a7-0f23-4aae-a139-55ef757802ab"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMTctMy0xLTEtMzAzNTE_508a1484-ade5-40a8-bd3f-7513e9d128de"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMS0xLTEtMzAzNTE_1addc553-431f-4df7-b127-ea43cf78adf5"
      unitRef="shares">68138116</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMS0xLTEtMzAzNTE_dc32eb76-0761-4682-b33d-fe3c8c48115f"
      unitRef="shares">68138116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMy0xLTEtMzAzNTE_b480c608-8bea-46f5-8461-59a2b1d15af4"
      unitRef="shares">46967213</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8xOS9mcmFnOmMyODg1NWM3ZTRiNTQ2ZGI5ZTkwMzVhMGM3YzRlOTIzL3RhYmxlOjdkOGE3YzViOGMwYTRmZWU5NTE5YmMxZTViNWI3MTNhL3RhYmxlcmFuZ2U6N2Q4YTdjNWI4YzBhNGZlZTk1MTliYzFlNWI1YjcxM2FfMjAtMy0xLTEtMzAzNTE_f6714fc0-6ea7-465d-b3b6-de72099b8804"
      unitRef="shares">46967213</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMy0xLTEtMS0zMDM1MQ_f4da75b4-6268-401f-af2d-d23b4bc4608f"
      unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMy0zLTEtMS0zMDM1MQ_956f127e-da52-4511-8523-c5658e8f307c"
      unitRef="usd">-18292000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNS0xLTEtMS0zMDM1MQ_614a6a77-881a-4c6d-b84c-726068ce42c4"
      unitRef="usd">1338000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNS0zLTEtMS0zMDM1MQ_43a0dbd4-5488-48d5-bb78-27106d662202"
      unitRef="usd">879000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNi0xLTEtMS0zMDM1MQ_5d881fcc-52a4-4f6b-a5e0-86f3f5e62d7e"
      unitRef="usd">39000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNi0zLTEtMS0zMDM1MQ_05ae4f35-77ca-4df3-ad20-d46c077999dd"
      unitRef="usd">57000</us-gaap:DepreciationAndAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNy0xLTEtMS0zMDM1MQ_2d9db758-b38b-49c6-91d6-ff91ab2aaee4"
      unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfNy0zLTEtMS0zMDM1MQ_ee214758-3f8e-4354-b4e3-f5d9f5aa41b9"
      unitRef="usd">3000</us-gaap:PaidInKindInterest>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOC0xLTEtMS0zMDM1MQ_3516d714-443a-4efa-8313-91a63e0e1683"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOC0zLTEtMS0zMDM1MQ_1f510071-5800-472f-a87c-eb0d097bd40f"
      unitRef="usd">1000</us-gaap:AmortizationOfFinancingCosts>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOS0xLTEtMS0zMDM1MQ_f07ba777-d9fa-46f0-a909-8eb5b0bb746c"
      unitRef="usd">258000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfOS0zLTEtMS0zMDM1MQ_76fd1fe1-0ab9-40fb-8133-f455a70e2652"
      unitRef="usd">206000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTEtMS0xLTEtMzAzNTE_bf579bdc-192b-48f9-8d11-47c964cf08e1"
      unitRef="usd">3427000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTEtMy0xLTEtMzAzNTE_58431fa1-e4a0-4ab2-8f33-ee4c30c3911b"
      unitRef="usd">-11164000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTItMS0xLTEtMzAzNTE_fef56929-b4f3-400b-95b4-8e61446775b5"
      unitRef="usd">1120000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTItMy0xLTEtMzAzNTE_e8564112-627c-4632-9afd-9036e5e897fd"
      unitRef="usd">-461000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTMtMS0xLTEtMzAzNTE_c412ddd5-7fd6-435e-94fe-d5360a4939d0"
      unitRef="usd">657000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTMtMy0xLTEtMzAzNTE_8ed7e0a2-a88d-4b55-9cac-38f534b8b3b4"
      unitRef="usd">-253000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTQtMS0xLTEtMzAzNTE_dbf9102c-8f56-4e08-9908-19c9c52afbc9"
      unitRef="usd">-1953000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTQtMy0xLTEtMzAzNTE_3bfed273-ce34-4ea3-a9a6-4a7426385038"
      unitRef="usd">1451000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTUtMS0xLTEtMzAzNTE_447724dd-07be-4064-b336-0275059063cb"
      unitRef="usd">-844000</cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTUtMy0xLTEtMzAzNTE_c8b88573-8a4d-4464-adb7-29f4a1d597ad"
      unitRef="usd">2753000</cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMS0xLTEtMzY5MzE_a1930488-a88d-45ae-836f-66075646c0de"
      unitRef="usd">-276000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMy0xLTEtMzY5Mzk_3b55bfba-356d-426f-bf69-30143f58c2f2"
      unitRef="usd">-223000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMS0xLTEtMzAzNTE_c629d86f-00fa-487d-8a2d-5acc5e6d2ef8"
      unitRef="usd">-23608000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTYtMy0xLTEtMzAzNTE_3f4ebe65-8b23-4179-94f9-c5dfb37ecda1"
      unitRef="usd">-1793000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTktMS0xLTEtMzAzNTE_adfc583b-23a3-4be3-9ea1-7e4d7980917e"
      unitRef="usd">84000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMTktMy0xLTEtMzAzNTE_0566bf82-5bb2-425b-b8ec-69ba5759b117"
      unitRef="usd">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjAtMS0xLTEtMzAzNTE_ec6ec63c-52c3-4acb-b2b3-a52376aafa18"
      unitRef="usd">-84000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjAtMy0xLTEtMzAzNTE_ead83b2f-e8e0-4ee1-b04f-63aa447f1986"
      unitRef="usd">-12000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjQtMS0xLTEtMzAzNTE_fc5f0b4e-7a14-49d3-b7ab-de4108fd7a86"
      unitRef="usd">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjQtMy0xLTEtMzAzNTE_c916b134-da60-46b5-9026-0b365f6a92cc"
      unitRef="usd">8755000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjUtMS0xLTEtMzAzNTE_93a904da-cf93-4f06-8689-19852c4d4742"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjUtMy0xLTEtMzAzNTE_9d6ab3b1-91c8-4177-bfe4-34a676ada022"
      unitRef="usd">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjYtMS0xLTEtMzAzNTE_2a4d08c8-c23d-4259-807e-f031245772c6"
      unitRef="usd">1111000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjYtMy0xLTEtMzAzNTE_03e39a9d-b59e-41bc-8d7c-d85fb09eee1e"
      unitRef="usd">1111000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjctMS0xLTEtMzAzNTE_4efacc6a-a5b7-4e2b-8ffd-a7a26f37e33b"
      unitRef="usd">-611000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjctMy0xLTEtMzAzNTE_7a11bbeb-a8b1-460c-b9d4-d38a16ccc667"
      unitRef="usd">7645000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjgtMS0xLTEtMzAzNTE_9d14d3fe-eb1a-4faa-abc7-9816b42e7b65"
      unitRef="usd">-24303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjgtMy0xLTEtMzAzNTE_741206ea-66aa-4f21-b687-6b5fd9980189"
      unitRef="usd">5840000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjktMS0xLTEtMzAzNTE_66dce5e6-f92f-4b70-b74d-4addb1f5372e"
      unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifed4d780fa7c4657ace1ca39915c5db9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMjktMy0xLTEtMzAzNTE_95b7ba49-1e70-49e1-aa51-b2a3793a988a"
      unitRef="usd">42949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzAtMS0xLTEtMzAzNTE_0cf8295b-3bdc-4781-bb85-1f7c4e63b73c"
      unitRef="usd">37970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i594ac01243ff48a294a5691f8bb16ec7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzAtMy0xLTEtMzAzNTE_5de310a3-923a-4f1f-b091-dc4db7b243b2"
      unitRef="usd">48789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzMtMS0xLTEtMzAzNTE_18bf7b8c-b1b9-4bab-9430-8f619da9adb4"
      unitRef="usd">25000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzMtMy0xLTEtMzAzNTE_3388f4b8-b1d2-4f2e-b1af-74c8ba95c5f8"
      unitRef="usd">75000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzUtMS0xLTEtMzAzNTE_57a62f04-94ad-41f5-9184-596d7374aac6"
      unitRef="usd">16000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yMi9mcmFnOmU0NDA5YTljYzVjOTQ0MTJiOGQyODA2NmIyMzIyNWEzL3RhYmxlOjY1YzAzN2E4ZjZhNzRkOTlhMDA5OTcyYzk1MDRmMTg1L3RhYmxlcmFuZ2U6NjVjMDM3YThmNmE3NGQ5OWEwMDk5NzJjOTUwNGYxODVfMzUtMy0xLTEtMzAzNTE_4fc2d7fe-8fb3-43a0-a404-fa15e4c73e28"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:SharesOutstanding
      contextRef="i7ae401fe1ec94508a4c3bc1de6b123a7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0yLTEtMS0zMDM1MQ_03c3238e-9b50-42e8-a63e-99662b19bf4f"
      unitRef="shares">1818472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7ae401fe1ec94508a4c3bc1de6b123a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy00LTEtMS0zMDM1MQ_d40e7920-5288-40dc-809d-35600867ce22"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="id29d0679e5a849fd8f0b328b0047051f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy02LTEtMS0zMDM1MQ_b54666b0-6535-4b45-8056-2540ba2567d8"
      unitRef="shares">67863674</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id29d0679e5a849fd8f0b328b0047051f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy04LTEtMS0zMDM1MQ_6650019d-016f-43ba-829d-9ae25c076a87"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01e075b04cda432ea3e0bb290da8aa76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0xMC0xLTEtMzAzNTE_4b95bf4c-bdfc-410e-ae36-5ae1118d3ed9"
      unitRef="usd">398733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb5be7deff5c45d58b2dabd268641ffa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0xMi0xLTEtMzAzNTE_f3c63198-6897-4a19-9277-30265d9bbc0a"
      unitRef="usd">-377167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMy0xNi0xLTEtMzAzNTE_a47eaf69-27ef-4cdc-946f-8cd3017f6d69"
      unitRef="usd">21573000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie249caef64f94171b3f97f31b1702323_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfNi02LTEtMS0zMDM1MQ_07205ff7-732a-4f78-b677-dd3f0001c942"
      unitRef="shares">644265</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iffef7cfce9f74e188e663bb9b9e5a2b6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfNi0xMC0xLTEtMzAzNTE_9b6cc98f-b1e3-42c2-a85c-3a9977dd3f10"
      unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfNi0xNi0xLTEtMzAzNTE_08995a6d-b4b8-4d63-8ca7-584581812ab6"
      unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie249caef64f94171b3f97f31b1702323_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfOC02LTEtMS0zMDM1MQ_d087f106-244a-4f6c-8424-d9d111a29127"
      unitRef="shares">541308</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="iffef7cfce9f74e188e663bb9b9e5a2b6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfOS0xMC0xLTEtMzAzNTE_db523a2a-aba5-486c-95c9-2c7236083c04"
      unitRef="usd">1165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfOS0xNi0xLTEtMzAzNTE_60f2f8b0-3e6e-4017-a31c-ce2e158b587e"
      unitRef="usd">1165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="ie90d7c5734cb4948aae78ef94bf77084_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTAtMTItMS0xLTMwMzUx_eef10547-07b8-4065-9c13-3d62effbc746"
      unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTAtMTYtMS0xLTMwMzUx_f37735c6-a4eb-44a4-a2f3-762a49d6d065"
      unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i078bfa49848346d5a1e3ebef80a9bf83_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMi0xLTEtMzAzNTE_69bbd421-afa5-4175-bf91-71d2fc72ca6b"
      unitRef="shares">1818472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i078bfa49848346d5a1e3ebef80a9bf83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtNC0xLTEtMzAzNTE_72246a7c-d38a-4f16-9b2c-e988d0e2e430"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ic98e2da648634bd2abb09e30b07febad_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtNi0xLTEtMzAzNTE_17e74f8a-94c3-46e7-9fc1-f52bbeb69091"
      unitRef="shares">69049247</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic98e2da648634bd2abb09e30b07febad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtOC0xLTEtMzAzNTE_ebc6bd74-bf65-4b91-a662-bb702cfaaad9"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idfbfbe505a42456b8b907a1ce48ce8f8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMTAtMS0xLTMwMzUx_11874c97-f915-47ab-b2f4-c92ce2b2280c"
      unitRef="usd">400398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a2d9cef5eea4c869286d364c1fc6da0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMTItMS0xLTMwMzUx_0a091087-001f-44fb-acb3-8fea1c2c7990"
      unitRef="usd">-395448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjkwMGExNjRmYmYzZTRmNzk5MTNhMzRkNzAyNzZiYzRlL3RhYmxlcmFuZ2U6OTAwYTE2NGZiZjNlNGY3OTkxM2EzNGQ3MDI3NmJjNGVfMTEtMTYtMS0xLTMwMzUx_a7a0cc15-57de-4e97-b592-4ae143ee1375"
      unitRef="usd">4957000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i75db0cf998d34c4f90645b2615a44ae4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0yLTEtMS0zMDM1MQ_b6f04a7c-3763-4de7-a64b-50e48c009455"
      unitRef="shares">1044278</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i75db0cf998d34c4f90645b2615a44ae4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy00LTEtMS0zMDM1MQ_86591ffe-01e1-4107-82c9-753fcc9b35d9"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy02LTEtMS0zMDM1MQ_35ecec31-bfc5-44d4-a5f6-e0e1fefc10e6"
      unitRef="shares">44876408</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy04LTEtMS0zMDM1MQ_6727d183-dcfa-4e8f-958d-f196c959c271"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib20007356f9d4ba5be34c0e5c7493ff3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0xMC0xLTEtMzAzNTE_f0783746-c939-41d6-a115-07db97f12c60"
      unitRef="usd">345411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f61e4e8ab114e4e8fa4705c380ffc10_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0xMi0xLTEtMzAzNTE_9b21c427-8f68-46e7-b750-7d300dd6e8eb"
      unitRef="usd">-334700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifed4d780fa7c4657ace1ca39915c5db9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMy0xNi0xLTEtMzAzNTE_c271efc0-dafe-4e47-9412-2d89746ee8eb"
      unitRef="usd">10715000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi02LTEtMS0zMDM1MQ_3dcd6481-89ae-4f96-8243-63219f6065a0"
      unitRef="shares">3327706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi04LTEtMS0zNzgyNQ_6c550e9f-4993-4aa7-967e-e1e772866477"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi0xMC0xLTEtMzAzNTE_e4cea129-7d57-4888-93d6-5b97e381034a"
      unitRef="usd">8588000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNi0xNi0xLTEtMzAzNTE_3d9e4aad-a879-488f-b59b-63d934892013"
      unitRef="usd">8589000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNy02LTEtMS0zMDM1MQ_b5aff5b6-39fa-405f-b95a-39ee19146dd8"
      unitRef="shares">486</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNy0xMC0xLTEtMzAzNTE_1e425a64-d00e-43f8-8105-6446edeeacf4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfNy0xNi0xLTEtMzAzNTE_1e20f11c-09f5-4188-bfbc-2311b2e1a2ed"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i52015336fa754888b0567c048a6a08cd_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfOC02LTEtMS0zMDM1MQ_789b9347-1e77-4617-8d12-63b4ab9cb33b"
      unitRef="shares">84070</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="id45ba10d7b514f129d2a1566440e0d66_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfOS0xMC0xLTEtMzAzNTE_e0718acb-d991-490a-9847-d7800479e7df"
      unitRef="usd">879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfOS0xNi0xLTEtMzAzNTE_50f41ff0-6c34-49da-a221-814db82bec7e"
      unitRef="usd">879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="ic51fadbb95d64d119839876c70af802f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTAtMTItMS0xLTMwMzUx_7711c982-0c52-42c6-807a-b14d54ba0ad8"
      unitRef="usd">-18292000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTAtMTYtMS0xLTMwMzUx_7e98223c-9a0f-47bf-a73d-971ee8216180"
      unitRef="usd">-18292000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="idf01e9ab4d5447ae8695372ee5c96045_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMi0xLTEtMzAzNTE_11e775cf-dedd-447e-b1cf-dc4b7deec952"
      unitRef="shares">1044278</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idf01e9ab4d5447ae8695372ee5c96045_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtNC0xLTEtMzAzNTE_b3bc3530-b42e-4d6a-88d9-7ce1485241e2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ie313ed150dbb4af980047e1f2ca2e27c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtNi0xLTEtMzAzNTE_6d9442eb-d59a-4119-86e9-ff325f0ff1ac"
      unitRef="shares">48288670</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie313ed150dbb4af980047e1f2ca2e27c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtOC0xLTEtMzAzNTE_3cde04c4-6c1d-4b3c-bf89-5e62d5f0518d"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3325f5645b9b4b7f988048d9368cbd44_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMTAtMS0xLTMwMzUx_6140e809-8f6e-4832-823c-b974e03de178"
      unitRef="usd">354879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i570e663b09344feb9ff09e6ddb45fead_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMTItMS0xLTMwMzUx_7a59fb2b-0eec-42d5-9604-7efaf29ad8ed"
      unitRef="usd">-352992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i594ac01243ff48a294a5691f8bb16ec7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8yNS9mcmFnOjM4OGE1ODI2Yzk5ZDQyZDc4MGZiZGU1ZGQyODdkODZlL3RhYmxlOjFlYjEwZWJjNzk4NjRiOWQ4ZWI0MzBhNTE4ODNmNDVkL3RhYmxlcmFuZ2U6MWViMTBlYmM3OTg2NGI5ZDhlYjQzMGE1MTg4M2Y0NWRfMTEtMTYtMS0xLTMwMzUx_ebeb4718-5bc1-462d-bfab-03b9614d9535"
      unitRef="usd">1892000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzcyNg_432cb031-2b07-45cb-8594-693849d50e7d">THE COMPANY AND BASIS OF PRESENTATION&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. The Company is focused on infectious diseases and oncology. The Company&#x2019;s lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections. In addition, the Company is using its Cloudbreak&#xae; platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. The Company's initial development programs target influenza and other viral infections, including respiratory syncytial virus, or RSV, the SARS-CoV-2 strains causing COVID-19, and human immunodeficiency virus, or HIV. In addition, the Company has expanded the Cloudbreak platform to discover and develop DFCs to treat cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2022, the Company had an accumulated deficit of $395.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the Company had cash, cash equivalents and restricted cash of $38.0 million. Based on the Company&#x2019;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s obligations for twelve months from the issuance of these financial statements. The Company&#x2019;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#x2019;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to estimating the fair value of the Company&#x2019;s stock options, estimated collaboration expenses and incurred expenses related to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement (each as defined below), certain accruals, including those related to nonclinical and clinical activities, and the Standalone Selling Price of performance obligations associated with license agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzc0MQ_3b548f3e-98c7-4480-a67b-716629383253">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2022, the Company had an accumulated deficit of $395.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the Company had cash, cash equivalents and restricted cash of $38.0 million. Based on the Company&#x2019;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s obligations for twelve months from the issuance of these financial statements. The Company&#x2019;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#x2019;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, &lt;/span&gt;&lt;/div&gt;including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfMTgxNQ_84c9364c-bd1c-4e33-a989-fb6f5784c0b7"
      unitRef="usd">-395400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfMjEyNQ_008ada1f-ae13-4450-8765-0630b0ba02fb"
      unitRef="usd">38000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cdtx:UnauditedInterimFinancialDataPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzczNw_85694dd8-d0e4-48d7-b29c-28c617e0768c">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</cdtx:UnauditedInterimFinancialDataPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzc0OA_3d7244ec-2a5f-4ef7-b53c-ac633cdc3640">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzczNA_0fbe53c8-1722-4029-a4eb-6dc76fad3633">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to estimating the fair value of the Company&#x2019;s stock options, estimated collaboration expenses and incurred expenses related to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement (each as defined below), certain accruals, including those related to nonclinical and clinical activities, and the Standalone Selling Price of performance obligations associated with license agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzczNQ_456bb799-ace6-4720-b584-b44f7be4fb0b">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zMS9mcmFnOmUzZTZiMDA3NzA5OTQwNzdiYWE5Mzk5OWZjYzg2NTcwL3RleHRyZWdpb246ZTNlNmIwMDc3MDk5NDA3N2JhYTkzOTk5ZmNjODY1NzBfNzcwMQ_da2de6b8-6507-4f4f-888b-c1aabbb40571"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzQ_44e94ea9-bfd6-439c-9841-06977ae0dd60">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Restricted cash represents cash that the Company is required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 4 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTIzNw_5527d6f8-bbd7-4b20-ac44-ff096fb03762"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the FASB ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue is accordance with ASC Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three significant performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. The Company concluded that there were three significant performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#x2019;s estimates have no impact on the Company&#x2019;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments and estimated reimbursable research and development and clinical supply costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#x2019;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,442,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,847,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,648,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,550,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31,608,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described in Note 3, the Company believes that the fair value of the term loan approximates its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzE_e4afda8d-4ebd-49fd-80e0-93bfec6e905a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Restricted cash represents cash that the Company is required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 4 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NjY_390aa4da-59a2-4df7-b8fa-c23f6f6b3648">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NTQ_b6540413-248e-48d3-b6f2-d0db957700a5">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated &lt;/span&gt;&lt;/div&gt;using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTIzNw_5527d6f8-bbd7-4b20-ac44-ff096fb03762"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i21169da961a642269defd386e1909c8e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTI0Mw_76115f46-ef89-4fb8-828b-684e2c002539">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NDM_6416d935-2fad-46e2-904c-987b5a3202f7">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the FASB ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzY_d7237cdc-7535-4295-9af9-e809fba2059e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue is accordance with ASC Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three significant performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. The Company concluded that there were three significant performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#x2019;s estimates have no impact on the Company&#x2019;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments and estimated reimbursable research and development and clinical supply costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5Nzc_432e1f43-82c4-455d-8a39-740739ed2e21">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5Nzg_4203836a-244e-4108-ada0-d420cd3f6c41">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future &lt;/span&gt;&lt;/div&gt;periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NTU_af808914-513a-4f96-aa63-51e5f638fbcf">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTQ3Nzc_575ed202-d37d-49f5-b211-c4a8e9d8c972"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NDQ_f7da15af-83ad-4bf5-9d05-997da0b73a24">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#x2019;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NzM_5c6ee533-3cbf-4025-8db2-c782cd7b6dd2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,442,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,847,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,648,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,550,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31,608,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i95f5fe2a729b4d4b88d79c8b9f71926b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMi0xLTEtMS0zMDM1MQ_baad4d6b-59d7-40d1-af92-01c34e046c97"
      unitRef="shares">12517328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i31a37a66cd6249378b32ab50166895a0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMi0zLTEtMS0zMDM1MQ_69cc27de-5007-4339-9618-db9f109ad0ac"
      unitRef="shares">12517328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4aa023587c32497cbf47ee68d3cbfb01_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMy0xLTEtMS0zMDM1MQ_dc73394b-1ab2-4a0f-a859-f1c5f015d641"
      unitRef="shares">18184720</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i900152b8dae048ce8a4acda17d7bcb77_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfMy0zLTEtMS0zMDM1MQ_5ea4b966-403b-4b64-a879-9b61bb424aa7"
      unitRef="shares">10442780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1c94bb11270499696b1406f63c1b83d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNC0xLTEtMS0zMDM1MQ_db580017-48f8-434d-9dfe-617306369b2e"
      unitRef="shares">10847996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1b5153e1e8ab48e49acff0d1756e5388_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNC0zLTEtMS0zMDM1MQ_53a72c2b-4577-4829-8d33-649f776bc931"
      unitRef="shares">8648708</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNS0xLTEtMS0zMDM1MQ_7bca099f-2708-4c4c-abef-f3248970a8d3"
      unitRef="shares">41550044</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RhYmxlOmM3ZDJmNGJlMGE5MTQ1NmM4YmM1OTFiZWRhM2M1ZTBjL3RhYmxlcmFuZ2U6YzdkMmY0YmUwYTkxNDU2YzhiYzU5MWJlZGEzYzVlMGNfNS0zLTEtMS0zMDM1MQ_a3298095-5f4c-4c78-90a9-a54ce754a1eb"
      unitRef="shares">31608816</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NDU_732687aa-55e6-435c-8153-49376320831f">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described in Note 3, the Company believes that the fair value of the term loan approximates its carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNC9mcmFnOjQzYjk3MmFmZjlkNzQ5OWJhYzk0ODMyOTEzYzhhZTQzL3RleHRyZWdpb246NDNiOTcyYWZmOWQ3NDk5YmFjOTQ4MzI5MTNjOGFlNDNfMTg5NjA_f7260a32-9de4-4ca5-bff4-f1444bb3fee0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RleHRyZWdpb246NWVmYmMzOTU0MzhkNDM3Mjk2MjU5OGVjOWY5YjU4MzZfMjE0OQ_885c6245-dbf2-4361-9d92-8f698d9e81e5">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RleHRyZWdpb246NWVmYmMzOTU0MzhkNDM3Mjk2MjU5OGVjOWY5YjU4MzZfMjE1Nw_2ffc2870-631f-44c9-b435-8a297c7fc77d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy0xLTEtMS0zMDM1MQ_5fd18848-7a6e-4f20-81f2-b35a80d2bab8"
      unitRef="usd">36488000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i16c6cdf33b80446aa3a77138caa526a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy0zLTEtMS0zMDM1MQ_32d8783c-f9e4-4ad9-b9b3-c09c91b5267c"
      unitRef="usd">36488000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i041a511ce516484886b5ffe0acef8f8e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy01LTEtMS0zMDM1MQ_bca230da-6877-4c75-9e48-d01bc5801e8c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa38f920be7245f686abc0a371da8a87_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMy03LTEtMS0zMDM1MQ_bffda14b-9702-49ec-a343-39d3ee9611d3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCash
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC0xLTEtMS0zMDM1MQ_5f598415-b468-4251-8142-3701419b9360"
      unitRef="usd">1482000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i16c6cdf33b80446aa3a77138caa526a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC0zLTEtMS0zMDM1MQ_853295b1-9ae2-4bff-9c4a-62432a818d1f"
      unitRef="usd">1482000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i041a511ce516484886b5ffe0acef8f8e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC01LTEtMS0zMDM1MQ_51eb015e-0d50-49d6-a4f1-4d8dae9f12a3"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="iaa38f920be7245f686abc0a371da8a87_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNC03LTEtMS0zMDM1MQ_39650a03-71ca-4e45-b292-d1485aedd97d"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS0xLTEtMS0zMDM1MQ_2ce801fa-ce03-44dd-be7a-bdb2b3121293"
      unitRef="usd">37970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i16c6cdf33b80446aa3a77138caa526a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS0zLTEtMS0zMDM1MQ_58a6d082-668a-4ff1-87e3-00171f329f94"
      unitRef="usd">37970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i041a511ce516484886b5ffe0acef8f8e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS01LTEtMS0zMDM1MQ_a87491c4-a7c4-439b-aa39-c8d427570f45"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa38f920be7245f686abc0a371da8a87_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfNS03LTEtMS0zMDM1MQ_71f578b4-c941-4682-921a-7c05472d7807"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtMS0xLTEtMzAzNTE_e38d3470-143f-4461-8f70-1b3f1db89710"
      unitRef="usd">59680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i28b73da715794f18af42e513a2842fb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtMy0xLTEtMzAzNTE_9dc9508d-1041-4223-897e-b0d28b5bcc86"
      unitRef="usd">59680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtNS0xLTEtMzAzNTE_5cd45946-9353-483f-ac21-6a4e1bddb04a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic713e533dda046afa29b8024f40c66d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTMtNy0xLTEtMzAzNTE_5549cdf5-2655-481b-93f2-bb31d1e56da7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCash
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtMS0xLTEtMzAzNTE_a7b1f529-c9d0-4b40-a18d-b904d8af7bb0"
      unitRef="usd">2593000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i28b73da715794f18af42e513a2842fb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtMy0xLTEtMzAzNTE_0e6be76f-8033-4694-9624-d8f0d5448dc7"
      unitRef="usd">2593000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtNS0xLTEtMzAzNTE_ae1fa413-e455-4937-b8c6-041a164c1254"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ic713e533dda046afa29b8024f40c66d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTQtNy0xLTEtMzAzNTE_9e3dee3e-8f9c-47aa-99bf-c69de4be6519"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtMS0xLTEtMzAzNTE_a5fa4b2f-1358-43b9-8f30-48d521f609a8"
      unitRef="usd">62273000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i28b73da715794f18af42e513a2842fb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtMy0xLTEtMzAzNTE_f894975c-d4ad-44f6-b6e7-e2a0f870d636"
      unitRef="usd">62273000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i19c62f6b54434cbaa6c9fb2b03fcc16f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtNS0xLTEtMzAzNTE_1164dd84-bfa1-418c-b9c5-f8e841d42dcc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic713e533dda046afa29b8024f40c66d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl8zNy9mcmFnOjVlZmJjMzk1NDM4ZDQzNzI5NjI1OThlYzlmOWI1ODM2L3RhYmxlOmRhZTdmNDkxMWY2NzRkZTI5YmMwMmVlZGY5ZDEyNjU2L3RhYmxlcmFuZ2U6ZGFlN2Y0OTExZjY3NGRlMjliYzAyZWVkZjlkMTI2NTZfMTUtNy0xLTEtMzAzNTE_13e435f6-d081-44d6-902e-38989566245f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMTUyNg_80b81c5a-dbdd-410b-88b8-113e985fd15b">DEBT&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $10.0&#160;million&#160;from the Lender, or the Term A Loan. At March&#160;31, 2022, the Term A Loan bears interest at 4.5% and matures on July 3, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 4, 2022, the Company and the Lender entered into a Fifth Amendment to the Loan Agreement, which modified certain debt covenants under the original agreement but had no impact on current or future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of certain events, including but not limited to the Company&#x2019;s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement or the occurrence of a material adverse change, the Lender has the right, among other remedies, to declare all principal and interest and other amounts due to the Lender under the Loan Agreement immediately due and payable. The principal payments due under the Loan Agreement have been classified as a current liability at March&#160;31, 2022 and December&#160;31, 2021 due to the considerations discussed in Note 1 and the assessment that the material adverse change clause under the Loan Agreement is not within the Company's control. The Company has not been notified of an event of default by the Lenders as of the date of the filing of this Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future principal payments due under the Loan Agreement, as amended, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total future principal payments due under the Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i795c9fa22a224d2bbd52d8f2fe81648b_I20161003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMjQ3_3df28e5e-86e1-47fe-86da-4e3241636ac4"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i46940802d05a44c78644bacf035f8ab4_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMzI4_4389dfc8-2876-4fa5-9b66-8615b8bf2180"
      unitRef="number">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RleHRyZWdpb246NWZhYzNiZTczMmNhNGEzOThjYTIzNjczOTY0N2Q1ZTJfMTUyOQ_434a95d5-7498-4ea1-8499-34a288ae99b6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future principal payments due under the Loan Agreement, as amended, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total future principal payments due under the Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i46940802d05a44c78644bacf035f8ab4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RhYmxlOmU2ZDBlYmFiYTcwNDQ5ZjI5NDlhMzgyYWYyNWYyNjg3L3RhYmxlcmFuZ2U6ZTZkMGViYWJhNzA0NDlmMjk0OWEzODJhZjI1ZjI2ODdfMS0xLTEtMS0zMDM1MQ_cb7a6a78-ba07-453c-b96f-95c0952471dc"
      unitRef="usd">1482000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebt
      contextRef="i46940802d05a44c78644bacf035f8ab4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80MC9mcmFnOjVmYWMzYmU3MzJjYTRhMzk4Y2EyMzY3Mzk2NDdkNWUyL3RhYmxlOmU2ZDBlYmFiYTcwNDQ5ZjI5NDlhMzgyYWYyNWYyNjg3L3RhYmxlcmFuZ2U6ZTZkMGViYWJhNzA0NDlmMjk0OWEzODJhZjI1ZjI2ODdfMy0xLTEtMS0zMDM1MQ_a9fe83b0-352e-4ee5-a355-fa9ca318c3aa"
      unitRef="usd">1482000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjkyNQ_b201d015-1138-4ddc-97bb-3f0a5d6f3f8a">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Controlled Equity Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp;amp; Co, or the Sales Agreement. During the three months ended March&#160;31, 2022 and 2021, the company sold 644,265 and 3,327,706 shares of common stock, respectively, for net proceeds of approximately $0.5&#160;million and $8.6&#160;million, respectively, after deducting placement agent fees. As of March&#160;31, 2022, the aggregate offering price remaining under the Sales Agreement is $48.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On October 13, 2021, the Company completed concurrent but separate public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common stock, at a price to the public of $1.55 per share, and 774,194 shares of its Series X Convertible Preferred &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock at a price to the public of $15.50 per share, for aggregate gross proceeds of $38.5&#160;million. The Company received total net proceeds of $36.6&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the amended and restated certificate of incorporation, the Company&#x2019;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On August 12, 2020, at the request of certain holders, 52,241 shares of the Company&#x2019;s Series X Convertible Preferred Stock were converted to an aggregate of 522,410 shares of the Company&#x2019;s common stock. As of March&#160;31, 2022 and December&#160;31, 2021, shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The specific terms of the Series X Convertible Preferred Stock are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Conversion: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 10 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Dividends:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company's common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Liquidation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Upon the liquidation, dissolution, or winding up of the company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Voting:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company had 200,000,000 shares of common stock authorized as of March&#160;31, 2022. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#x2019;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#x2019;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, warrants to purchase 12,517,328 shares of the Company's common stock were outstanding with a weighted average exercise price of $6.82 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The warrants had no intrinsic value at March&#160;31, 2022 and December&#160;31, 2021. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,847,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,470,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,232,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,436,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,170,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;680,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,953,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;43,289,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6621b987d56742bdb57725ac1faabdbb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTY2Nw_ecb2c339-7ce5-417d-ad13-f65abc4eec01"
      unitRef="shares">644265</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i35c8f58bd982422a986ef78bf58fc3ed_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTY3NA_a58a1b96-29f8-490b-a200-accc1b1ebbb6"
      unitRef="shares">3327706</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6621b987d56742bdb57725ac1faabdbb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTc0OQ_7bf57142-4e17-4ebe-bcc8-9f95d2bb6051"
      unitRef="usd">500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i35c8f58bd982422a986ef78bf58fc3ed_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTc1Ng_bbe8858d-c098-4343-97fd-ae82ac1af80c"
      unitRef="usd">8600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cdtx:SaleOfStockConsiderationRemainingOnTransaction
      contextRef="i0195058d79fa431882538deea9d40134_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODgxOA_e9667471-83a9-4ca7-b858-9782a171a4ee"
      unitRef="usd">48000000</cdtx:SaleOfStockConsiderationRemainingOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ifbc4656677c945bea6a7f93277e0065d_D20211013-20211013"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODcwOQ_52136f82-53e3-469e-bd6d-5abcd13da86f"
      unitRef="shares">17064511</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie51f2518f48844149c35fadeee45c717_D20211013-20211013"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODcyMQ_c088179b-a4bc-4485-b471-119676e71a88"
      unitRef="shares">2225805</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ifa0b0517b28c459d84c79bff7bdcb54e_I20211013"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODczMg_a4720fc9-c15e-4424-a1c7-d755325d7cc9"
      unitRef="usdPerShare">1.55</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0df47124083a4f99a0e151684e8f154c_I20211013"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODczOQ_c697f979-b9df-4acc-b360-72cba9b68a4e"
      unitRef="shares">774194</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0df47124083a4f99a0e151684e8f154c_I20211013"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODc0OA_850fc90a-9229-4103-a6e6-5932653e9661"
      unitRef="usdPerShare">15.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ib1eb42daf54d4b668a360dcc81934f30_D20211013-20211013"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODc1Ng_0455175c-ef23-4f8a-9058-696638f0588a"
      unitRef="usd">38500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i55bdd2d5589d4fe7b0309fed8211b8a8_D20211013-20211013"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODc3MQ_2434931f-7fa0-4b14-aefe-e8b270721f15"
      unitRef="usd">36600000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjA4Mg_6b34ee58-b4fe-4455-aebf-d87c2a38ee7c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjUyNg_187e4c7b-59e0-425a-a021-dbc7b03df472"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i69448e0c7d0b4165bc50aaf98eb14d71_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODg2Mw_580a387c-e6e6-4695-982e-ea4534066b51"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i69448e0c7d0b4165bc50aaf98eb14d71_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjY5OA_30c39358-0923-4e47-8ae6-80dc478ac673"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i280b1d43fcd44cc3b820c5ccce18586b_D20200812-20200812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjc2Nw_e9eecf55-4cc7-4867-a057-fdba4ba9d921"
      unitRef="shares">52241</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="idc285ca9fc0947889305e6be663b5ce3_D20200812-20200812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMjg2NQ_e9862d56-7746-498a-8a77-5dc123324954"
      unitRef="shares">522410</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5ca662309536454c8fc2ec20aa598bfe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODk4OA_909fa249-6047-486e-b101-415737f4c5a9"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMTA5OTUxMTYzODk4OA_d19122d3-7b00-4772-a86d-fde3b6f836c1"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i8b6a39ac194e4bdfbf136edfa309899a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMzA5Ng_7cb3cc20-6d03-4697-b4e6-84924dc6e3f2"
      unitRef="shares">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion
      contextRef="i2b1567b76bf14270856d0e77828b3edd_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfMzQ2NQ_981e797f-a5bc-4f8b-8cec-01ffb123ab89"
      unitRef="number">0.0999</cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNTYwMQ_bdf3c669-5675-4d31-92f8-a5bc4e5f638e"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <cdtx:NumberOfVotesEntitlementForEachShareHeld
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjkyNg_024f318e-b746-458e-a91c-ea4e74f457ce"
      unitRef="vote">1</cdtx:NumberOfVotesEntitlementForEachShareHeld>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1202dce605be4c82a0a70d95af7a8593_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjY4Nw_9852fb81-694e-42f8-9760-b27f4a591ed4"
      unitRef="shares">12517328</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5971b45c3a7c412c88e46aa2b80a5a6e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjY4Nw_f7ea5052-39b5-4493-a3c2-b91ac1231949"
      unitRef="shares">12517328</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4f8aa79b2a034ff484490a0f9ed5005a_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjc3MA_883c1077-2fbc-4ea5-99c6-f4a10c389aea"
      unitRef="usdPerShare">6.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic27040cee9f64227942f86974dfc7e07_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjc3MA_f2fcfd65-52e1-4aea-a1d8-711194c95190"
      unitRef="usdPerShare">6.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding
      contextRef="i1202dce605be4c82a0a70d95af7a8593_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjU5NzA2OTc3ODcwOA_28f60326-1d62-490e-bf5e-f7a20d7d0cf4"
      unitRef="usd">0</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding
      contextRef="i5971b45c3a7c412c88e46aa2b80a5a6e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjU5NzA2OTc3ODcwOA_b9ac724e-1e07-4412-b7d3-29ac9c10b52f"
      unitRef="usd">0</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RleHRyZWdpb246Y2I2MWM2NWY2MjY5NDE4MzgzODE2ODUwMjM5ZWU1N2NfNjkyNw_6a2d842d-305f-4cf8-a009-b8035804d164">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,847,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,470,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,232,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,436,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,170,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;680,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,953,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;43,289,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i67507a3641814df4b10e074a32b49c2e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMS0xLTEtMS0zMDM1MQ_6a25c959-9887-4446-8229-60577476423f"
      unitRef="shares">12517328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8bd0f0932ef8490bb6c1d6b126581749_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMS0zLTEtMS0zMDM1MQ_64add0c8-8cfb-4019-8434-a684654ed514"
      unitRef="shares">12517328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8a0d4f2214a74513a73c71607fd17646_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMi0xLTEtMS0zMDM1MQ_3be13d4f-f2c2-470f-a1cd-bfe0e635acc1"
      unitRef="shares">18184720</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id49a49faa40b4317b2251637999b3844_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMi0zLTEtMS0zMDM1MQ_0148870c-c15b-4d3f-8e32-11fa20947c15"
      unitRef="shares">18184720</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3394b2a276ce4f24a740ba07a69873e9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMy0xLTEtMS0zMDM1MQ_42894f14-2858-4b9d-9ab1-287d6778a8e2"
      unitRef="shares">10847996</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ieef9aeb2eaab46cf8f2dc459329f1dab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfMy0zLTEtMS0zMDM1MQ_74179735-6627-4681-bc5a-c424b8952349"
      unitRef="shares">9470178</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6500728b40904350a970627b377ddbb0_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNC0xLTEtMS0zMDM1MQ_aac696d5-c7a0-47db-92cc-4f376afe9186"
      unitRef="shares">3232404</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ieab45868d7b34980921f34867b165abc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNC0zLTEtMS0zMDM1MQ_9edbf104-bda1-4c55-bfce-71a043d78cc8"
      unitRef="shares">2436984</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib71eefcf9d68457782ef30c211def3a7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNS0xLTEtMS0zMDM1MQ_88209cf3-4cc7-4a3b-a7ad-fe6f3f892b3f"
      unitRef="shares">1170564</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i378b0ff196374173acefdb91629cc588_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNS0zLTEtMS0zMDM1MQ_db45ec69-dfd7-4924-931a-da4640f8c65e"
      unitRef="shares">680228</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNi0xLTEtMS0zMDM1MQ_6be2c67d-eccf-4e05-8334-7411fac2821a"
      unitRef="shares">45953012</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80My9mcmFnOmNiNjFjNjVmNjI2OTQxODM4MzgxNjg1MDIzOWVlNTdjL3RhYmxlOjdiMzBjZDY4ZjdhOTQ5NGE4NTdiYTkyMGFiMmM1ZTRkL3RhYmxlcmFuZ2U6N2IzMGNkNjhmN2E5NDk0YTg1N2JhOTIwYWIyYzVlNGRfNi0zLTEtMS0zMDM1MQ_4ef06de9-6022-46bd-b056-ea8654acebc4"
      unitRef="shares">43289438</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYwMg_7295d76c-b117-4a98-996d-7e0a70718b32">EQUITY INCENTIVE PLANS&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Inducement Incentive Plan and 2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company's board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company&#x2019;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by 4% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTQ2NQ_7675637d-1608-4a23-aa34-7b6bb8a8e302"&gt;three&lt;/span&gt;- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company&#x2019;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;1%&#160;of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31, (ii)&#160;490,336&#160;shares, or (iii) such lesser number as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The ESPP allows substantially all employees to purchase the Company&#x2019;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#x2019;s payroll deductions under the ESPP are limited to 15% of the employee&#x2019;s eligible compensation. During the three months ended&#160;March&#160;31, 2022 and 2021, no shares were issued pursuant to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, total unrecognized compensation expense related to the ESPP was approximately $0.4&#160;million. This unrecognized compensation cost is expected to be recognized over approximately 0.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PRSU activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs and PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,174,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,466,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(749,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(48,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,843,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of RSUs and PRSUs granted during the three months ended March&#160;31, 2021 was $2.56 per share. The total fair value of RSUs and PRSUs vested during the three months ended March&#160;31, 2022 and 2021 was approximately $1.0 million and $0.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, estimated unrecognized compensation expense related to RSUs and PRSUs grants was approximately $2.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Contractual Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,296,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,804,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,096,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,004,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,004,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,609,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted by the Company during the three months ended March&#160;31, 2022 and 2021 was $0.53 and $1.51 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, total unrecognized share-based compensation expense related to unvested stock options was approximately $4.1 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.5 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage
      contextRef="i1a0dd60e595d4d90b99db4dfcc03e925_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTA2MA_097ab02b-7006-454b-bf56-6309064cd054"
      unitRef="number">0.04</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2b6dd61a92f24717a10f0e25c4e1a31f_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYxMQ_b4e5395b-7f99-421e-b93e-d756eee87446">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTY1OA_b7a06134-e728-495f-9639-5e9ee46a5311">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTc5NA_c1b9fbba-7eff-49c1-b5af-1a1c7448fbcb"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold
      contextRef="ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMTk3Nw_fe63f4ee-9ea3-4700-8a2f-08f49126adc5"
      unitRef="number">0.10</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i720b8558f3114a66b3afb7ddb6acfbda_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjA4MQ_0631f915-7917-4822-ba2c-650e7c43f996"
      unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage
      contextRef="i0b84d00a866d4c51b68551b7e95373d5_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjQyNw_7d397e7d-de6b-47e4-aa36-24d0bf991376"
      unitRef="number">0.01</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i3fbce54647a341fba1a08f3e3d01f687_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjU0Mw_b0de8393-7bf1-4c96-8281-a44bb0ee9ddf"
      unitRef="shares">490336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i0b84d00a866d4c51b68551b7e95373d5_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjc2NA_2a199300-900e-4ed9-9d91-65104e80d5a4"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ib71eefcf9d68457782ef30c211def3a7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMjkzNw_ff259235-cc21-4bb6-840a-d3f9c7e2562d"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i64417209e6a7431e9641d70ebaa9d805_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzAxOQ_67eabd9e-9462-44c7-9481-d54a3f4fffe3"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i720f7ca4cb4d47c797738cd1efd27be0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzAxOQ_a49c6f30-379d-40e0-8a25-b00263bd02b2"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ib71eefcf9d68457782ef30c211def3a7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzE4MA_444669c5-fe56-40e1-aa7d-1a62d073bcac"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i64417209e6a7431e9641d70ebaa9d805_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzI2OA_66e2fb83-40c1-4b30-98aa-ab5fe90c6500">P0Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYxNA_e13cc207-3d53-4801-b835-5da1a5cf7207">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PRSU activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs and PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,174,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,466,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(749,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(48,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,843,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7725d535d6df481ba4eb64e1f9497bb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMS0xLTEtMS0zMDM1MQ_9c3dcc1b-98b4-4133-a054-5561e38b7a98"
      unitRef="shares">1174087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7725d535d6df481ba4eb64e1f9497bb5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMS0zLTEtMS0zMDM1MQ_32a39488-60be-4989-8e59-0b9923927b27"
      unitRef="usdPerShare">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMi0xLTEtMS0zMDM1MQ_da6618d7-52f5-4347-b6c1-eb7463854dc5"
      unitRef="shares">1466954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMi0zLTEtMS0zMDM1MQ_15dc7d7b-6fe0-4782-aed2-399d5c78431f"
      unitRef="usdPerShare">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMy0xLTEtMS0zMDM1MQ_3bd72751-e4e0-4eed-9406-1b4f44207a3c"
      unitRef="shares">749254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfMy0zLTEtMS0zMDM1MQ_df7155e4-7bbc-4bed-ad53-75db0c733a9e"
      unitRef="usdPerShare">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNC0xLTEtMS0zMDM1MQ_60ed4d0a-e715-4de2-99e2-e480eea963c3"
      unitRef="shares">48159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNC0zLTEtMS0zMDM1MQ_53d1342b-8f49-4d2f-a60c-75fd711c9024"
      unitRef="usdPerShare">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i36320806fa3c4b5f9432d569a7254fb3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNS0xLTEtMS0zMDM1MQ_d3ad8c5d-25b9-4fa9-b90b-9cd3c67837aa"
      unitRef="shares">1843628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i36320806fa3c4b5f9432d569a7254fb3_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOmM3ZTVhYzIwYTRiMzQ4ZDk5MjFkOTY1MmFiZWI0MWNhL3RhYmxlcmFuZ2U6YzdlNWFjMjBhNGIzNDhkOTkyMWQ5NjUyYWJlYjQxY2FfNS0zLTEtMS0zMDM1MQ_1f954461-b21d-4634-8c07-f605c2d087fa"
      unitRef="usdPerShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4d982e5d0cc6497c854d56be2b7a9838_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzQ5OA_8675d3cd-53d8-478f-86f8-10d92c40ebf3"
      unitRef="usdPerShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i52857d65c7254f2c8007a2219d6f0a6b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzYyNw_4dddd0e7-f823-4e04-89d7-462551675646"
      unitRef="usd">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i4d982e5d0cc6497c854d56be2b7a9838_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzYzNA_b86b9f37-2096-4ac0-9330-b62607d6dc5d"
      unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i36320806fa3c4b5f9432d569a7254fb3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfMzc1NA_87c39849-cd7d-4df9-9b0b-8e0d9637b9cb"
      unitRef="usd">2700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYxMg_26f6d826-e5b8-450a-bc04-c44092bda9d1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Contractual Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,296,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,804,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,096,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,004,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,004,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,609,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS0xLTEtMS0zMDM1MQ_3d8aead1-5004-4334-b17f-80e9555d128e"
      unitRef="shares">8296091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS0zLTEtMS0zMDM1MQ_194cb8ce-543e-4fde-88a2-e34f2b1188bd"
      unitRef="usdPerShare">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if93aa19e1f944c0c881474a93809cb2c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS01LTEtMS0zMDM1MQ_405f7100-e1c6-4caa-8297-e56ee3cab2a1">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic36326a3df014b8d992c03bd0101de68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMS03LTEtMS0zMDM1MQ_acbbea26-c778-40d8-962e-ad6dca31c754"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMi0xLTEtMS0zMDM1MQ_c08fc83a-a3f5-4d1a-9020-257c68b2033d"
      unitRef="shares">1804700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMi0zLTEtMS0zMDM1MQ_b3949582-524e-4d30-a793-67938015a848"
      unitRef="usdPerShare">0.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMy0xLTEtMS0zMDM1MQ_ff0a7bdb-dbb0-4b51-903b-29ad5853e246"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfMy0zLTEtMS0zMDM1MQ_84c41fbd-aaa6-417f-be2c-9643ec933242"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNC0xLTEtMS0zMDM1MQ_b9429a8c-7d8c-46d2-9e0a-135c17c89ebf"
      unitRef="shares">1096423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNC0zLTEtMS0zMDM1MQ_1f810185-44e2-4830-a0d5-31af12c565cd"
      unitRef="usdPerShare">3.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS0xLTEtMS0zMDM1MQ_b4bceee0-a57d-46c8-9de0-fc9d6e6fd12c"
      unitRef="shares">9004368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS0zLTEtMS0zMDM1MQ_ebf3a1cb-a6bc-45bf-ae71-c04fa84458f9"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS01LTEtMS0zMDM1MQ_b4ef2d13-d445-4903-ab68-2c37e14359dd">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNS03LTEtMS0zMDM1MQ_6a0f8551-9453-4f9b-868c-1c5d655d9796"
      unitRef="usd">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi0xLTEtMS0zMDM1MQ_f5451163-bf3e-4232-a408-848a2f3801ec"
      unitRef="shares">9004368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi0zLTEtMS0zMDM1MQ_fbb5743c-b4e6-4086-b44a-8843dc5d8b33"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi01LTEtMS0zMDM1MQ_0e53bff5-c65b-4a5e-a00f-0dad84d005ac">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNi03LTEtMS0zMDM1MQ_9d793cdd-d97a-42d8-a6aa-cda7a56ac41f"
      unitRef="usd">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy0xLTEtMS0zMDM1MQ_a4d63223-2b5a-4e31-9722-55e163ed88b2"
      unitRef="shares">4609717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy0zLTEtMS0zMDM1MQ_d096ac31-2df4-4665-8f76-e0b465b5ec21"
      unitRef="usdPerShare">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy01LTEtMS0zMDM1MQ_246f260b-c0a2-4235-9e09-2a6b335fc9a9">P5Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjA0ZTM0Njc0NTc2MjQwNTY5ZjljYjgyNWQ1MThmNmU2L3RhYmxlcmFuZ2U6MDRlMzQ2NzQ1NzYyNDA1NjlmOWNiODI1ZDUxOGY2ZTZfNy03LTEtMS0zMDM1MQ_9f27fafc-7428-432c-86a0-dc7cf6ee71b9"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDE0NQ_1441d193-d486-4a6e-9720-87c0b79d0d4c"
      unitRef="usdPerShare">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDE1Mg_70d14e77-fa34-4006-aa7c-778e4cc2393f"
      unitRef="usdPerShare">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDYwNw_f32779dd-3900-4efa-b624-de196ad864f8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i228ae513e4d048c1b3d1b4222fab3750_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMi0xLTEtMS0zMDM1MQ_2deb20f4-0b66-4236-9cac-5beae404aab3"
      unitRef="usd">455000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f64292f9a6949a8b73b0d21cbeefa6a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMi0zLTEtMS0zMDM1MQ_f506ab67-c8a6-473f-88fc-521ddbdb6fc8"
      unitRef="usd">391000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0284b9283584c6a98c2cf36c7b67635_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMy0xLTEtMS0zMDM1MQ_6ac687ee-aaf2-4ac8-9943-c598825de86f"
      unitRef="usd">883000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a4d20a797ca4520be3b7156f337e50f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfMy0zLTEtMS0zMDM1MQ_d6f39eab-99a0-4ba3-9098-57b199324630"
      unitRef="usd">488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfNC0xLTEtMS0zMDM1MQ_6fc806e3-54b1-4a85-9ab7-37a1c8f43163"
      unitRef="usd">1338000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RhYmxlOjg4ODdiYTQzYjgxZjRhYThiMGM5ZTI3ZmI3Y2ZjMWJjL3RhYmxlcmFuZ2U6ODg4N2JhNDNiODFmNGFhOGIwYzllMjdmYjdjZmMxYmNfNC0zLTEtMS0zMDM1MQ_9256432a-fb0d-43a0-8204-6f8e5b6490b7"
      unitRef="usd">879000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDQ4MQ_40234606-3e7c-464d-aafa-cb46d0f88a36"
      unitRef="usd">4100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4b2950f3ff64498ea4482c1111550256_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80Ni9mcmFnOmE0ZGFjNDZkNzRkYTRjZmZiYmQ2MWIxZDRkZDhkMjk1L3RleHRyZWdpb246YTRkYWM0NmQ3NGRhNGNmZmJiZDYxYjFkNGRkOGQyOTVfNDU5OA_f5b81b1f-2bed-4d2b-96a2-d621e487cb51">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjE2OTk_526699c2-62b7-4427-86c7-07ff75eca05b">SIGNIFICANT AGREEMENTS AND CONTRACTS&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Licensed Product for the treatment and prevention of invasive fungal infections.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#x2019;s ongoing Phase&#160;3 pivotal clinical trial of the Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#x2019;s planned Phase&#160;3 pivotal clinical trial of the Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#x2011;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Licensed Product in the Mundipharma Territory, at Mundipharma&#x2019;s sole cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#x2011;bearing license to develop, register and commercialize the Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, subject to the Company&#x2019;s retained right to lead a global development program for the Licensed Product in both the Mundipharma Territory and in the U.S. and Japan, or the Company Territory, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#x2011;exclusive, worldwide license to manufacture the Licensed Product and rezafungin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Until the seventh anniversary of the first commercial sale of the Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#x2019;s territory. However, in the event of the acquisition of a party by a third party, this right of first negotiation will not apply to any such anti&#x2011;fungal product of the acquiring third party prior to consummation of the acquisition of such party, acquired by such acquiring third party from another third party after consummation of the acquisition of such party, or developed internally by the acquiring third party, either before or after consummation of the acquisition of such party, without the use of, reliance upon or reference to any technology of the acquired party that is licensed to the other party under the Mundipharma Collaboration Agreement, any technology of the other party that is licensed to the acquired party under the Mundipharma Collaboration Agreement, or any technology jointly developed by the parties pursuant to the Mundipharma Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company retains the exclusive right to develop, register and commercialize the Licensed Product, Subcutaneous Product and Other Products in the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#x2019;s Global Development Cost share of $31.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible for double-digit royalties in the teens on tiers of annual net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSPECT Trial and the ReSTORE Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company's patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million plus the research and development funding of $31.2&#160;million, plus milestones achieved of $2.8&#160;million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that require judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$17.9&#160;million&#160;in September 2019 as collaboration revenue in its condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Licensed Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company's initial obligation to supply rezafungin for ongoing clinical development in the Licensed Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company determined that as of&#160;March&#160;31, 2022, all the potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In November 2020, the Company achieved a $11.1&#160;million milestone under the Mundipharma Collaboration Agreement, which is recorded as long-term deferred revenue as of March&#160;31, 2022 because the rights to consideration is not expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. In December 2021, the Company achieved a $2.8&#160;million milestone under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;No&#160;royalty revenue was recognized during the three months ended March&#160;31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs (previously called Antiviral Drug Conjugates, or AVCs) based on the Company's Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or the Phase 2 Study. Unless otherwise agreed by the parties, the Company will be responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company will be the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget. In addition, upon the effectiveness of the Janssen Collaboration Agreement, Janssen will also reimburse the Company for certain costs incurred by the Company in independently performing certain research and development activities from the execution of the Janssen Collaboration Agreement until its effectiveness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Within 90 days after delivery by the Company to Janssen of results of the Phase 2 Study and all then-available data from other clinical trials of the Development Candidate conducted under the Research Plan, or the Election Period, Janssen will be obligated to notify the Company of Janssen&#x2019;s election to proceed with further clinical development of Products, such notice, an Election to Proceed Notice. If Janssen fails to deliver an Election to Proceed Notice prior to expiration of the Election Period, the Company will have the right to terminate the Janssen Collaboration Agreement upon written notice to Janssen. If Janssen provides an Election to Proceed Notice prior to expiration of the Election Period, then the parties will continue any then-ongoing Research Plan activities to completion, and Janssen will otherwise be solely responsible for the development, manufacture and commercialization of Products, at Janssen&#x2019;s sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#x2019;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Compete Covenant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#x2019;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#x2019;s DFC technology more broadly. The Company&#x2019;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Terms&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company is entitled to reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting Research Plan activities. The Company will also be entitled to receive up to an additional $695.0&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales of Products at rates from the mid-single digits to the high-single digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. In addition to the Company&#x2019;s right to terminate the Janssen Collaboration Agreement for Janssen&#x2019;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;prior to the completion of all Research Plan activities and the Company&#x2019;s delivery to Janssen of all Research Plan deliverables, upon 90 days&#x2019; written notice to the Company, provided that if any clinical trial under the Research &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;after completion of the Phase 2 Study and before expiration of the Election Period, immediately upon written notice to the Company; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;after delivery of the Election to Proceed Notice, upon 90 days&#x2019; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million plus the research and development funding of $59.9&#160;million, plus milestones achieved of $3.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that require judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $27.0&#160;million in May 2021 as collaboration revenue in its condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The research and development services to be performed represents a distinct performance obligation. The Company records payments due from Janssen as collaboration revenue. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company's initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company determined that as of the latest financial statement date all the potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In March 2022, the Company achieved a $3.0&#160;million milestone under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement during the three months ended&#160;March&#160;31, 2022&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Opening balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Closing balance, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred revenue, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, aggregate transaction price allocated to performance obligations that are unsatisfied is $15.5&#160;million and $48.9&#160;million under the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively. These amounts are expected to be recognized over 1.75 years which represent the remaining research periods under the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company recorded $0.1&#160;million and $8.6&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents our contract revenues disaggregated by timing of revenue recognition and excludes royalty revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Point in Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Over Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Mundipharma Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Janssen Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Janssen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Point in Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Over Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Mundipharma Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost
      contextRef="i8d1f47cfaf864b5b8449cf27f8903001_D20190903-20190903"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNDMzOQ_0948c7c4-f45e-4214-bcf1-882439988b70"
      unitRef="usd">31200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="i8d1f47cfaf864b5b8449cf27f8903001_D20190903-20190903"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNTE0MA_d5000e16-447c-4722-a029-2dcdad675e9e"
      unitRef="usd">568400000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNjQ1NQ_a034a72c-29e9-4427-a9ff-7105d9db30aa"
      unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost
      contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNjUwMw_e0abfbfa-b969-424d-a1b5-18ae9491e48b"
      unitRef="usd">31200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i7a1b832c3bcc45ec9f16fa3306e87d89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY2MDQyMA_a661fbc2-3c6e-4957-83f6-655ca1b03336"
      unitRef="usd">2800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i59db54d089334f80bfc2bf1d019c720c_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfNzk0Mg_5440f401-da26-4ebd-895e-1e676231ad8a"
      unitRef="usd">17900000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
      contextRef="i68f5f47ae533474f9d58f357b7560076_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfOTczOQ_531b73be-6c9c-414e-90e5-3b8ed3bf387b"
      unitRef="usd">11100000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i7a1b832c3bcc45ec9f16fa3306e87d89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY1MzcwMA_a661fbc2-3c6e-4957-83f6-655ca1b03336"
      unitRef="usd">2800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i5b2c214fd2d34166a98231e78e89cb57_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA4NjA_193484ea-0d46-4c0c-9278-587fcdb6f629"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ie4961bcc2a42459fbdcff0f5d4ffbff3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA4NjA_c8e9319b-7cd6-4267-9009-91084d6263df"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults
      contextRef="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTMxNzc_0fcd154a-ee6c-43bc-bb15-4c7c0788f378">P90D</cdtx:CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="i857d96ec633a44e1b0ea653816686201_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTU5NjE_66db1af3-d4ad-47f7-9be6-036663fabd90"
      unitRef="usd">27000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="i1be4c76c948d42acabc01f60c0e15d14_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTYwODY_c3de1781-ef59-4ff4-b3e5-05045df4694a"
      unitRef="usd">58200000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="if8dadaa504524767be44ca25b519478f_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTYyMzc_968b5ffc-9862-478d-b4cd-2e1fdc91d41b"
      unitRef="usd">695000000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice
      contextRef="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTY5OTU_1af3596f-9916-488d-81e4-66ba7d37d881">P90D</cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice>
    <cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice
      contextRef="ic9b311ebe0c2403faa873d2c8e9c3559_D20210331-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTc0MzE_1af3596f-9916-488d-81e4-66ba7d37d881">P90D</cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="i41dc4db26c7d45a799666fc33080b4f5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTc2OTk_e3199a3d-f66d-4ef8-908b-30120ae11bd2"
      unitRef="usd">27000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost
      contextRef="i41dc4db26c7d45a799666fc33080b4f5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTc3NDc_11d40495-bdde-4c03-8a6a-f6184071996c"
      unitRef="usd">59900000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ia37c7f2020504762b3c04bc8f40f0ede_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY2MDQ1Mw_1ea45ade-60b8-405c-b7b7-bd7ba28261a3"
      unitRef="usd">3000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ifbcdd3cc2a2e4827a4681f970f6d7389_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTg4NTE_f0598002-7b7a-489d-adfc-826e43e33dd6"
      unitRef="usd">27000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ia37c7f2020504762b3c04bc8f40f0ede_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY1NDY0Mw_1ea45ade-60b8-405c-b7b7-bd7ba28261a3"
      unitRef="usd">3000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i58b63e51f2fb46699aee3fdf1e54a345_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjA0MTU_d381383d-5e84-4822-9e0d-abf5a601ea9b"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjE2OTE_de66183a-0106-49f2-b76d-13cc481ce132">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement during the three months ended&#160;March&#160;31, 2022&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Opening balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Closing balance, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred revenue, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents our contract revenues disaggregated by timing of revenue recognition and excludes royalty revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Point in Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Over Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Mundipharma Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Janssen Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Janssen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Point in Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Over Time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Mundipharma Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="i79dab98a8e3e4d89a66719d5a46c5f73_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMC0xLTEtMS0zMDM1MQ_9a8c88e6-4ab0-4c7e-8260-5d2b2f129a72"
      unitRef="usd">32333000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance
      contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMS0xLTEtMS0zMDM1MQ_9d7c8fa5-4a8c-4a9f-b02d-6117bb856d24"
      unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable
      contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMi0xLTEtMS0zNDkxMw_3c8b7755-eff7-40a5-b963-af5d8d6beb3a"
      unitRef="usd">1508000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib6ad281cf98043f397abe2529a87e175_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMi0xLTEtMS0zMDM1MQ_4abf076d-aa7a-430a-ac4a-edbbe18e05f4"
      unitRef="usd">2352000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="ie02b09de693048bc9accc5d0a7f832d4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfMy0xLTEtMS0zMDM1MQ_8df23cf0-97ab-46f7-ba8e-d56841659ee5"
      unitRef="usd">31489000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfNS0xLTEtMS0zMDM1MQ_21d25af4-ab06-4dbf-ba44-2f417f6e4a72"
      unitRef="usd">14260000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfNi0xLTEtMS0zMDM1MQ_43275ab1-3198-4251-bf2a-9d13e3e8640a"
      unitRef="usd">17229000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOmJiYjljODU4Y2RiYzRjYzY4ZTkxYTczMWI3MDVjNjU0L3RhYmxlcmFuZ2U6YmJiOWM4NThjZGJjNGNjNjhlOTFhNzMxYjcwNWM2NTRfNy0xLTEtMS0zMDM1MQ_94898f13-a870-41c8-adf7-ff196b034e96"
      unitRef="usd">31489000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia4458c0ab6aa4e3aa31bee9f21e043b2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjA4NDg_92965b85-d846-48e7-9029-c061b0bb43ef"
      unitRef="usd">15500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i443dc61676d64544abd994b78e8e6267_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY0OTUzMw_6aa3ec45-4f54-47d3-b4d6-e52943d40285"
      unitRef="usd">48900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ia4458c0ab6aa4e3aa31bee9f21e043b2_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY0OTY3Mg_ca4947a4-976e-4fbf-873c-1b6ca16c1923">P1Y9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ie02b09de693048bc9accc5d0a7f832d4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMTA5OTUxMTY1OTQ0Mg_16db4746-aebb-4582-9ca7-309291871b8e"
      unitRef="usd">100000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i78a1639fe6204e6f9c15a4b4242bfe9e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RleHRyZWdpb246ZTJjYjE5M2FlYjdkNDc2MWEwZDcwMWVjZTdlYWJmMTVfMjExNDg_62efef2a-bb19-42dd-87a7-50a3b93031a7"
      unitRef="usd">8600000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i0c53ce77870a41f5beea59ecd239000c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNC0xLTEtMS0zMDM1MQ_ad1738fb-f5cb-40c6-a99d-5e82015fab41"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3dad60c0f2e040f5b0673a6393394e63_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNC0zLTEtMS0zMDM1MQ_cf32723d-6059-47fa-bc29-1c0387872f81"
      unitRef="usd">2274000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i87caf4dd1d234587aa8a86b0e5f01f6c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNS0xLTEtMS0zMDM1MQ_f3ae2959-10d4-4af1-b931-d138d064bc79"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i837f36bd31f84edca1439985d38c4717_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNS0zLTEtMS0zMDM1MQ_39942dc3-4b6c-4892-9f69-68dccd5c0aa0"
      unitRef="usd">252000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i10c225bd22cb4a8094a6e4710a63e69c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNi0xLTEtMS0zMDM1MQ_3b35d8c3-dfb4-479b-af63-433ae0ed5851"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iba15d9175213445a9632cc6854819319_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfNi0zLTEtMS0zMDM1MQ_ed4c5c02-2de7-46cc-a7cc-47813b8319ce"
      unitRef="usd">2526000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3ce9e60ff6584997b9bbb0384ed6d8f2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfOS0xLTEtMS0zMDM1MQ_20bb0ca7-b307-4e7d-ba58-eb79a35ddc8b"
      unitRef="usd">816000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="id2edbac57ce84f7b9906d418d840a9f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfOS0zLTEtMS0zMDM1MQ_b34e2897-215c-464b-bf2d-b905438b7495"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i57264f734480431092220a6ede4796c9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTAtMS0xLTEtMzAzNTE_40e6e75e-dfb6-4c46-b321-cc218a37b443"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i615ceceeaed5466fb85286d706d29b85_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTAtMy0xLTEtMzAzNTE_74ebdd82-916d-49dc-8df6-11e9ab276241"
      unitRef="usd">2356000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i716d135486924cee81e022c6ac2e5d44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTEtMS0xLTEtMzAzNTE_3184b778-085e-403c-be0d-cbf6b2a43ea7"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibc5e6adc3fef490dbca284a3b1c6289d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTEtMy0xLTEtMzAzNTE_29df149d-ee85-49ff-9704-997b2c1518a8"
      unitRef="usd">1411000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="if2ba2d8537d1401aa4d567fbd40f5201_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTItMS0xLTEtMzAzNTE_b83cef52-9043-4f89-8c30-90a74ffeb544"
      unitRef="usd">816000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ie796a038ce0e48ce994e533569bf1dff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjE1YTcyODY5NDZiZjRlNzNhZGZlMTJmMjVmOTYxMWEwL3RhYmxlcmFuZ2U6MTVhNzI4Njk0NmJmNGU3M2FkZmUxMmYyNWY5NjExYTBfMTItMy0xLTEtMzAzNTE_3b245769-cdbe-48b8-8bfe-c9f3588fabc5"
      unitRef="usd">3767000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="idc1fea76ca9d480da5ec1b4279d7de92_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNC0xLTEtMS0zMDM1MQ_be993971-a249-4ddc-8157-df4bf61b350e"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ic368059479da424f931465560c9ec6ae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNC0zLTEtMS0zMDM1MQ_6d39c3c8-0024-47c7-a294-e1133bc2f9cf"
      unitRef="usd">2331000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i8326f1cfdd2e45bda044cbe96cfa6825_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNS0xLTEtMS0zMDM1MQ_8b6842d3-ba0c-4192-b915-6114820ac999"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i0a7f4f7d381047d6b390662bf856366c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNS0zLTEtMS0zMDM1MQ_76f5fec7-d714-4803-a0ce-86487b771eae"
      unitRef="usd">77000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i38c0da6f182649489b0466ee3d5e1e90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNi0xLTEtMS0zMDM1MQ_f9f3668a-4ca9-48b1-973a-1da8578ffd56"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i80e055b607f746a7bb4d400492c18aae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl80OS9mcmFnOmUyY2IxOTNhZWI3ZDQ3NjFhMGQ3MDFlY2U3ZWFiZjE1L3RhYmxlOjJlOGI1YjM3NTFiYzRiZTZhODczNDgzOGZjMDAwMDU0L3RhYmxlcmFuZ2U6MmU4YjViMzc1MWJjNGJlNmE4NzM0ODM4ZmMwMDAwNTRfNi0zLTEtMS0zMDM1MQ_0c14fdcb-ea8b-4875-b5fd-6bd05b1486c0"
      unitRef="usd">2408000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYxMQ_b9c4ce2a-011c-4630-acf5-01f196790d04">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 14, 2021, the Company entered into a sixth amendment to its lease with Nancy Ridge Technology Center, L.P. which extended the term of the lease by an additional 24 months and increases the base rent to $103,733 per month effective January 1, 2022, subject to 3% increases every January. The lease expires on December 31, 2023 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of March&#160;31, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. The incremental borrowing rate used in measuring the Company's lease liability was 10.8%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of March&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company's operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the weighted average remaining lease term was 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the present value of operating lease liabilities was $0.3 million and $0.2&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $0.3 million and $0.2&#160;million for the three months ended March&#160;31, 2022 and 2021 respectively. These costs are primarily related to the Company's long-term operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ida2575eac8b54cbd9b8d91895a8f0d63_I20210714"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMjI1_c17dcef2-d8e0-4aaa-af90-bbba41e924d6">P24M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cdtx:LesseeOperatingLeaseMonthlyRate
      contextRef="i4d38d95a623e4c7db64c6031f9fbdbde_D20210714-20210714"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMjU5_bd30beca-db7c-4b5b-81e4-6665c97073f1"
      unitRef="usd">103733</cdtx:LesseeOperatingLeaseMonthlyRate>
    <cdtx:LesseeOperatingLeaseAnnualRateIncrease
      contextRef="i4d38d95a623e4c7db64c6031f9fbdbde_D20210714-20210714"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMzEw_59f1f2e7-6532-4f4a-88ac-0d9f1c1bca02"
      unitRef="number">0.03</cdtx:LesseeOperatingLeaseAnnualRateIncrease>
    <cdtx:NumberOfOperatingLeaseOptionsForExtension
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMzk0_65706300-ed17-401d-8681-ff258819d07b"
      unitRef="option">2</cdtx:NumberOfOperatingLeaseOptionsForExtension>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYwNg_bf86aeae-bb7d-4578-b2f2-fe73bc0c4f09">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cdtx:LesseeOperatingLeaseIncrementalBorrowingRate
      contextRef="ida2575eac8b54cbd9b8d91895a8f0d63_I20210714"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfNjM5_63f6522f-ded7-4b00-b016-f133efff628e"
      unitRef="number">0.108</cdtx:LesseeOperatingLeaseIncrementalBorrowingRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYwOA_88d5d57e-8c54-4617-84d6-bfc3a6e0add1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of March&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfMS0xLTEtMS0zMDM1MQ_d2487ffc-85a0-4511-97bb-e2778db125e5"
      unitRef="usd">1020000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfMi0xLTEtMS0zMDM1MQ_f0182190-6490-4dbf-a41c-35b05525fc32"
      unitRef="usd">1400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfMy0xLTEtMS0zMDM1MQ_03728353-d822-4458-b3f3-8f87f7079bcb"
      unitRef="usd">2420000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfNC0xLTEtMS0zMDM1MQ_593b8c6e-6c16-4d3d-8ce3-d8a8645d30b5"
      unitRef="usd">226000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmFiNjdmMmNkNjBjMTQ2ZjQ4ZmU2MTQ0M2MwZmE5NzU2L3RhYmxlcmFuZ2U6YWI2N2YyY2Q2MGMxNDZmNDhmZTYxNDQzYzBmYTk3NTZfNS0xLTEtMS0zMDM1MQ_3b09184d-394b-4a7f-a15a-286617d9b79c"
      unitRef="usd">2194000</us-gaap:OperatingLeaseLiability>
    <cdtx:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTYxMg_23a4065e-c350-4f67-927f-7b4cdf432715">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company's operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdtx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfMS0xLTEtMS0zMDM1MQ_0430da2c-d7c6-4066-957a-28b8e7b71517"
      unitRef="usd">2030000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfMy0xLTEtMS0zMDM1MQ_8cb80639-c3e2-474e-9cbe-cb38847fd5a0"
      unitRef="usd">1190000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfNC0xLTEtMS0zMDM1MQ_06e03780-8709-4740-b711-1cd163a274dd"
      unitRef="usd">1004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RhYmxlOmQ5NDE1ZjY1ZDBjODQ1OTU4ODAzYjkwZjdiNmZlNWJiL3RhYmxlcmFuZ2U6ZDk0MTVmNjVkMGM4NDU5NTg4MDNiOTBmN2I2ZmU1YmJfNS0xLTEtMS0zMDM1MQ_becc5def-94b5-4ad1-be7d-34eb6ebc364f"
      unitRef="usd">2194000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2191d31021fb49a59ba0e5e2e38662fa_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfOTYz_e3dd4e90-ef86-4d48-b4fb-38a195a8217b">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePayments
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTA1NA_6cba11a0-9788-4eea-805d-76a460f06905"
      unitRef="usd">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTA5OTUxMTYyOTkwOA_bac33516-b48f-4d61-a8fc-8bb7b8b7b8be"
      unitRef="usd">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseCost
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTExMg_dcbfcf57-f092-4954-b335-d02bd08b2311"
      unitRef="usd">300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i154ed7a422d24dae9b7f7d47764e3bab_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTA5OTUxMTYyOTk2MQ_0ad4717d-c244-4b95-afa0-ff1a8a4e9131"
      unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81NS9mcmFnOjgwOTZiNWQxYTVlNjRiYjg5NTFhMjY5ZjFhOWJiMDAxL3RleHRyZWdpb246ODA5NmI1ZDFhNWU2NGJiODk1MWEyNjlmMWE5YmIwMDFfMTMyMw_efbdc555-c3e4-4edc-824b-9774fb6cc882">P30D</cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81OC9mcmFnOjFhYjZlMGMyNDRlMzQzZDlhOTQwMGRiMTdiYWJiNWI1L3RleHRyZWdpb246MWFiNmUwYzI0NGUzNDNkOWE5NDAwZGIxN2JhYmI1YjVfNTYx_72ab6694-be89-4dcf-8db9-fd2bea30e534">SUBSEQUENT EVENTSOn April 20, 2022, the Company entered into a Letter Agreement with Mundipharma, which amended the Mundipharma Collaboration Agreement, under which the Company is eligible to receive prepayment of one milestone payable pursuant to Section 5.4 of the Mundipharma Collaboration Agreement as reimbursement for the cost of the Company continuing or conducting certain rezafungin development activities, up to a total of $11.1 million. Any such amounts prepaid by Mundipharma will be deducted from the milestone anticipated to be payable in 2022 to the Company by Mundipharma pursuant to the Mundipharma Collaboration Agreement. If not prepaid, the remaining portion of such milestone will be due upon achievement of the applicable triggering event as set forth in the Mundipharma Collaboration Agreement.</us-gaap:SubsequentEventsTextBlock>
    <cdtx:CollaborativeArrangementPotentialPrepaymentMilestone
      contextRef="i7ab61c4680194901bbce5f08a8fd1c4c_I20220420"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyOTI4ZDU3MDg0ODRiMDFhM2NlNDYyYTk5MjE2ZWViL3NlYzoxMjkyOGQ1NzA4NDg0YjAxYTNjZTQ2MmE5OTIxNmVlYl81OC9mcmFnOjFhYjZlMGMyNDRlMzQzZDlhOTQwMGRiMTdiYWJiNWI1L3RleHRyZWdpb246MWFiNmUwYzI0NGUzNDNkOWE5NDAwZGIxN2JhYmI1YjVfMTA5OTUxMTYzMDYzOA_78b84767-c92d-491f-9b12-bec1f4492de4"
      unitRef="usd">11100000</cdtx:CollaborativeArrangementPotentialPrepaymentMilestone>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ME>^V5)A$$T48]MP!_>3QG%#JK$G5*%<DMZ-5ZUY_FP=@B!;CJN$2PRF:."'
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MPB"- <ZOA=#/'5-LU<7U_"]02P,$%     @ QX"K5"6[LM!F!   1A   !@
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MQ+JZ7#$*W*,%X/E2"/6\T-\4#Y^UI_\"4$L#!!0    ( ,> JU2A3VET>@T
M -PC   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK5IM;QLW$OXKA'OH
M"R#++W';M$T"R([3N+W$1I3D<#C<!VJ7DEAS297D6E%__3TS)'=7MN0VN'ZQ
M)2TYG)=GGIFA]&SM_&U8*A7%I\;8\/Q@&>/JQZ.C4"U5(\/8K93%D[GSC8QX
MZQ='8>65K'E38XY.CX^_.VJDM@<OGO%G-_[%,]=&HZVZ\2*T32/]YEP9MWY^
M<')0/GBG%\M('QR]>+:2"S55\</JQN/=42>EUHVR03LKO)H_/YB<_'A^1NMY
MP4>MUF'P6I E,^=NZ<U5_?S@F!121E61)$C\NU,7RA@2!#5^SS(/NB-IX_!U
MD?Z*;8<M,QG4A3/_TG5</C]X>B!J-9>MB>_<^K7*]GQ+\BIG O\5Z[SV^$!4
M;8BNR9NA0:-M^B\_93_\E0VG><,IZYT.8BU?RBA?//-N+3RMAC1ZP:;R;BBG
M+05E&CV>:NR++]Z_OA07UV]N)F__+29O7XKSR?1J*JY?B9MWE]/+M^\G[Z^N
MWSX[BCB*-AQ56>QY$GNZ1^P3\<;9N SBTM:JWMY_!!4[/4^+GN>GCPI\(_U8
M/#D9B=/CT]-'Y#WI['["\I[LD7?M%]+J/R1!8R0NG W.Z%HFI-A:W'@5E(WI
M S<7K[25MM+2B"D^5(!E#.(_DUF('L#Z[R,:G74:G;%&9W]W)/X&L>*E"I77
MJV+M>1L@)@1Q 9]X*=XOE9<KU49=A9&XLM5X))P7<:G@NF8E[68DUC+@,[V
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MC@R$V^8Z\JYL-1*:**U6Z.IKHH1VQ;WQ4JL[=@D* E$X#&#N:<F;M?J]I:(
MV:%=H:C'G>&K7(B4[@ 7*_@7W$>Q&:4(X0Q]!\A0]:/XP>#H=45>Y>?LTJ?C
MX]ZC@&I?L1\HTWI/]G68 AV /, VF#68#&?*P&C8%Y=(?_4)\"4/\&%<Z.]K
MM<;!J'"T$WZ8)[**Y!44E'JG%FYF]"*[G3-SK0P@V:3FF.%(VW0(+=%/3HQ
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ML\$(@LJ*\;>[]@N/\,(8GEMP_*X&Q?.Z&[!">IIO.^@F%TF1OD,C*^#ZPAW
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M^'  )IR_PXW3E3_S+K6C$[1?YO27!0UOH/>9IC9O;MA!]R?H_#]02P,$%
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MR4X.8+^T2+YA(@[&I^SYOU!+ P04    " #'@*M4GMJG>&D+  "I'P  &0
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MAC3B7F8-EP.Z#X2/>J 8$'Y?-VN01#&*6=4APQIG!EHTHL2PAU70,427XU.
MXR3$YD.E=9J>"#VU!AK H,,H''0NK!5'D]'PORP6(O/AILCI]1;HQMG@G^+W
MN*^#T)SJ=@9-W$VBRPFHP_32)1.U=:H& ;3,.QM. W[X!ZNO4&WEMK[R8PE)
MK\0M5S;I3R)/$J?KUMO\VL?:-T.OEPLSZI#AZTC[&XB?73:PAE1Q2"O4N(^B
M7^1$I0J>$3!&O6I[2]+9&P7*1=PYY6JE,XT ^:9"]>0:"W2I(0P@!>Q8JD+!
M^1KMK-P6>+/1U5<<=5LVH'_+@#:EKHCZ1;^ON;&"+U1E[3RR\%O#T?AY^H(
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M=,XT >,SK<O-"RFHK_S/_P=02P,$%     @ QX"K5%SP,9#=&   LF(  !D
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M*=F^!-O(!3NS@:[K\KBDWT?H> -]+ZT-VQ=VT/_B.OL74$L#!!0    ( ,>
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MGD2VP0#[E3'^/ D!ID=V^S=02P,$%     @ QX"K5+:HEK,M(0  ^6T  !D
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M SWA1BZOXUA@,P;Q,8+X.A#$UT=Q><7)!_R;O8S1+"'VMS'[@ %3A/(O6WP
M'DAFHIS6L27IMJ1!3A%"(H3<&6]#[@GV6V9Q%@X<LB&]TVD<A$2$3S$0852
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MQ$#U,KM>!W()8;V=,<PYUL7CBKF^,C6YK9TNF3*3\W<I)?NJ%*CCB0&]_XY
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MNB&1D+<UMS7YL%-H2XG[(U=ZIVGQ&94[ON"AE@OE^U(K@?UBU^(?/=^KR=B
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MT/=XM-G_@@W"7WO[X7\ 4$L#!!0    ( ,> JU2SG-1?4@,  +X&   9
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M+.@'@\HZT/E>4D=U&TO0_[)F_P-02P,$%     @ QX"K5!9[48$) P  # <
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MA@XO/EU&8+NI[1QGFC IF7$\=\&L^*%#ZP-XOS3&[1V?H'\ZTS=02P,$%
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M*@IM0/MKSM5NH@&ZYG?R#U!+ P04    " #'@*M4'C,^+UD$   4"P  &0
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MA\<B3*RJ_06]59:N>S\LZ7U%[0+H>Z&4/4Q<@N[%GOP'4$L#!!0    ( ,>
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MWB3\EH6Q#7 >OS.ZT7MCL%*>I'RVDVDQ\@++B'*:&PM!\.^%9I1SBX0\_FU
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MF2KK@.L+*<UV8C=H._#Q_U!+ P04    " #'@*M41,SW<UT#  #7#0  &0
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M;]HP$/XK5K1)K;21D "=JA")ETU#ZC14VN[#M ^&',2J7YA]0/?O=W9"Q"1
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M(@U\V:5:P!))OD.[HSY%]O.! M@,0;E?5^BSECX+]+T+]&-C"0$E6UNC&%;
M).@2[#GA-=,@,/F+N"^Z2?WE\?Y,#KTVA][5'%ZX%7PI@7&M=W38EB.<.[?K
M++U./WE_KB+Q22/Z1X .>".T(Z%K(DHZ=_V(V?IBU0Z:;>C-I4'J]&!6]!:!
M]0&TOC8&CXYO]_9U*_X"4$L#!!0    ( ,> JU3R(8 (*@(  )4$   9
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M6#CZ<A^ ZBY!YQA9^\';26/'V)NE?3=0N0"[7TAI3HZ;Y>$E2M\!4$L#!!0
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M7(2H()I&L9DHOC*]UCU7V+F988;--0AM@,\7G*O'B6[?NG9]_#]02P,$%
M  @ QX"K5.)_!OKU!0  2QL  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&ULS5EAC]HX$/TK%FIUK=1"$@,+%8O$LE2'5'K<TMWJ=+H/)C%@-8FI[<!R
MNA]_XR3$@0:GE>XJONPFP3-^,_:\-TX&>RZ^R VE"CU'82QO&QNEMN]:+>EO
M:$1DDV]I#+^LN(B(@ENQ;LFMH"1(C:*PY3E.MQ41%C>&@_397 P'/%$AB^E<
M()E$$1&'.QKR_6W#;1P?/+#U1ND'K>%@2]9T0=7C=B[@KE5X"5A$8\EXC 1=
MW39&[KM[W-<&Z8@G1O>R=(UT*$O.O^B;:7#;<#0B&E)?:1<$_NWHF(:A]@0X
MON9.&\6<VK!\??3^/@T>@ED22<<\_,P"M;EM]!HHH"N2A.J![W^E>4 =[<_G
MH4S_HGT^UFD@/Y&*1[DQ((A8G/TGSWDB2@;@I]K RPV\<X.;"P8X-\#G!NT+
M!NW<H)UF)@LES<,]460X$'R/A!X-WO1%FLS4&L)GL5[WA1+P*P,[-9S\_CC]
M] >:?AQ//GZ:/DW0_,/HXP*]1:,@8'IE2(BF<;:_]#J]NJ>*L%"^AB&/BWOT
MZL5K] *UD-P0025B,7J,F9)OX"%<SU@8@I4<M!1@U3.V_!S778;+NX#+13,>
MJXU$DSB@087]V&Z/+?8MR%&1*.^8J#O/ZG!&1!-A]PWR'+=3A>>[S3VOPOS^
M^\U=2S2X6':<^L,7_"WT<KW5!1.@,8^ 162VOB,A2+RF4-D*+0^H/&Y.#NGC
MT9Z( /WY 5RBJ:*1_,L"J%T :J> VA< ?:(B0K#-$.QX_POB6XU&(L71DJ(U
M8%*5N^#.[M5UT($2(2T .P7 CM757#"?(KXZ 8B(1%LJ?$@+D*3^E4K%H%0@
M72O"!-J1,,FLLOH DP!^U4_2H*I"LN-P':?I."\M$76+B+I63T]<L7B-MGQ/
M!5(;@+?A8662[7[<.D W!: ;JZ//*4G3X"W94:'SF:8H2]AI-FFT#?F!TK/=
MDN\3] JH)^!A""NOER=+_NNJHLT ]5) 6B)W0Z?9P8/6KER:WPYRFQVW&'02
M:Z^(M6>-]3$6U.?KF/T->&6IROQR-=)G?4W?'".L"B&;IU]"UVY> -<OP/6M
MX":+^=RRGJYCQ,6Y#IIQ2WKG6F,;)2"I ,)')(X34#<6^] P2:KU*J]2DJ@-
M%^G2:$IB4B8D]M,1]&O"U$$; 4;H6- V)'&EO-EAN#4UXWHF(.]*B*D&2*]3
M%Y-1)Q=;77U@$5,:T['0?X%PR$% 34-3%R1^5N\0)#D/,V1KM@SI21U5M@]V
M!&YM,$;97+L(38_;!^ !J@C"RI8J@=9$H,F1RQ;IPWDB_(W>CG/86"F392M4
M25_YS)TR?YV1EW7(:41&"EV[!DV*O93\"(U51M#YAKZ<9OL"0*-LKEV2OE$2
MV"2,![J=*/">8C_!ZW-950#CFEEO4)3UG%VHI8.MZ7"-)+IV37R NH4"U[G.
M]D?:7@-W 5%2D?;EL+7RI%</MN$P<N7VKH3)C4BY=I5Z6#SFB4BO?ES\<_^G
MZM\[5_^*45ZSTZW>HIZ11L^QHG]_PL*GL50>+S)WW7(7<H8T'W):2_@"4".8
MGEVI_L-BSV?JGZ3RY@) (X">77=^J^J-3GT9X?&NY%SD&?GP[/+Q/W%9S:Q>
M=G "*LLXS1:*T0W/KALS+BB<-$#77.>EWO:[TA'$-H,A?J][)>MG&-RS,_C/
MZ\]J@+BU!S7/R(%G/[[,6,RB)++Y,CSN]:]CS; A9VPGYR>]&GICIJ56E>L:
M![CVO0,V!(SM!#PCSS6YQH8KL7<EN2Z]B;)WVM^1:[N#=GVN#=EB.^WEN4;_
MH)HS,#:DASM7DG+#DMC>J)HS</GP&R?1$OHEPSED1UA(]&'JY!1L/Y/<Y7.7
M#QSMOH/QA8X)&R+%=O[2+U[19&I=%4-@^$KZ66QX$-O[V9_U9J(&1ON22+1*
M7QDB*M;IUQH)#482J^P]>O&T^"(T2K^#G#T?N^_NL^\ZQDWVF6E&Q)K!P3ZD
M*W#I-&]@%XGLRTUVH_@V_9:QY J2E5YN*(%CM!X OZ\X5\<;/4'Q_6SX+U!+
M P04    " #'@*M47]@@#&<#  !?"P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6RMEFUOVC 0Q[^*%>W%)JWD.80)D"CKMDI;Q\K::2]-<H!5QV:V
M@>W;SW;2P$I"*=H;XAC?/[^[\]G7WW+Q()< "OTN*),#9ZG4ZIWKRFP)!98=
MO@*F_YES46"E7\7"E2L!.+=&!74#STO< A/F#/MV;B*&?;Y6E#"8""3718'%
MGTN@?#MP?.=QXI8LELI,N,/^"B]@"NIN-1'ZS:U5<E( DX0S)& ^<$;^N[$?
M&0.[XI[ 5NZ-D7%EQOF#>;G.!XYGB(!"IHP$UH\-C(%2HZ0Y?E6B3OU-8[@_
M?E3_8)W7SLRPA#&G/TBNE@,G=5 .<[RFZI9O/T'E4&ST,DZE_47;:JWGH&PM
M%2\J8TU0$%8^\>\J$'L&6J?9(*@,@J<&48M!6!F$UM&2S+KU'BL\[ N^1<*L
MUFIF8&-CK;4WA)DT3I70_Q)MIX97W^ZNO_]$US?CJYOOU_=7:/)Y=#-%%VA:
MYA7Q.;H%J03)%.1HJGCV@.X841)AEJ,)"+N56 87)IIYV^*121=1?]#K]Z P
MH?*-_L;_$+Y KY"+Y!(+D'U7Z9 8Q]RL<O^R=#]H<3]$7SA32XFN6 [YO_:N
M#F4=S^ QGI?!4<$O6'10Z+]%@1<$#3SCT\W](SAAG=[0ZH4M>C?K8@;")G%Z
M5T76C(Y(1[5T9*6C%NFO:R65%B1L\1;-8$$8TT-=4]0D#;TFK,K*FZ:TE-JQ
MU39'S6;H^]W(2[M]=], %==0\5&H?[U$"X&9V3#/P,2',%&2].*H&2:I89*7
MP&ST!GZ>)3E@N>A&O:"-I5NS=%_"DID<T>=INH<T4>K'O6:8M(9)3]\Z8)^G
M[IOT,%5I%"9!VDS4JXEZ1^ODASWN=3Q&&Q#Z^D(?S<Y!^D@%] $3@>XQ7<.1
MJO&]W8'KG5,WND17( @O4Y)S2K&09JJ,1F,PJB^E>]$(.G'8' I_[TKPSRVB
M$[FJ.\?; _,ZZ0ZL/ JK94_PDQ;\8(<?G%EV)]('A_1^)VPI0']W%/OAV25X
M(EEX2!9TTK:([4YR_P5'N:['\S9C=)!-OY/$3]C<O5:E +&P'9P.!E\S5=ZR
M]6S=)8YL;_1D_M)TC[8%VLF4K:>^0W51241AKB6]3E>?%J+LYLH7Q5>V(9IQ
MI=LK.USJ#AB$6:#_GW.N'E_,!^J>>O@74$L#!!0    ( ,> JU17[)R,?P0
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M#X#_EYRKPX5^0/'59_('4$L#!!0    ( ,> JU0)U^[T[ (  (0(   9
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MMWL5YL/=9W<JS$<OF:],V"]VP(ZMK=@O7X?]\\&!;T'EY.7CY.7CI/[P%G]
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MG?=LA2Z=<HOC]4RDCC6I8S.IO[)]R+P7=G_'U#Y@3=C83-BCYR?2@"@6W*<
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MLA/@_5)*\]RQ :I_(<.?4$L#!!0    ( ,> JU1<F?7/D04  ),F   9
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;-5:77/:.!3]*QJF#^U,-U@?!I(A
MS!"@73I-R@2Z^["S#PH([*EML9* 9F9__,K&L?BPE> D&_<E6+:.='7OT3WV
MC=H;+GY(CS$%?H9!)"]KGE++BWI=3CT64GG&ERS23^9<A%3IIEC4Y5(P.DM
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ QX"K5+4M,''$ P  =QP   \
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M;%!+ 0(4 Q0    ( ,> JU0 )MJD[@   "L"   1              "  :\
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M2P$"% ,4    " #'@*M4053@$O\"  !H"P  &               @(&V$P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ QX"K5"6[LM!F
M!   1A   !@              ("!ZQ8  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( ,> JU1D>RP+)P8  ",8   8              "
M@8<;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #'@*M4
M\/OZ6%X%  #B%@  &               @('D(0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ QX"K5*%/:71Z#0  W",  !@
M     ("!>"<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M ,> JU2':4JM&AH  .U/   8              " @2@U  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #'@*M4U T.EU\%   0#0  &
M            @(%X3P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#
M%     @ QX"K5"%H3;B?!   U@H  !D              ("!#54  'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #'@*M4GMJG>&D+  "I
M'P  &0              @('C60  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;%!+ 0(4 Q0    ( ,> JU0ITE4Q- @  /X7   9              " @8-E
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ QX"K5%SP
M,9#=&   LF(  !D              ("![FT  'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6Q02P$"% ,4    " #'@*M4-L:OI>(%  !]#0  &0
M    @($"AP  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M ,> JU1F2&&G/0,  ' '   9              " @1N-  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ QX"K5+:HEK,M(0  ^6T  !D
M             ("!CY   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #'@*M4LYS47U(#  "^!@  &0              @('SL0  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,> JU06>U&!"0,
M  P'   9              " @7RU  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ QX"K5%K;@!1H @  1@4  !D              ("!
MO+@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #'@*M4
M29B+LQ #   I!@  &0              @(%;NP  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,> JU25ZV.=@@0   @+   9
M      " @:*^  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ QX"K5!XS/B]9!   % L  !D              ("!6\,  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #'@*M4767<(& #  "]!P
M&0              @('KQP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( ,> JU0U)9$2!@,  -0'   9              " @8++  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ QX"K5+2DZ,.3
M @  >0<  !D              ("!O\X  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #'@*M47(I^4%P#  "-"P  &0
M@(&)T0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,>
MJU1$S/=S70,  -<-   9              " @1S5  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ QX"K5*DKMD N @  Z00  !D
M         ("!L-@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #'@*M4\B& ""H"  "5!   &0              @($5VP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,> JU3RI>+=* 8  '$;
M   9              " @7;=  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ QX"K5 :A\.)N P  N@L  !D              ("!U>,
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #'@*M4XG\&
M^O4%  !+&P  &0              @(%ZYP  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( ,> JU1?V" ,9P,  %\+   9
M  " @:;M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MQX"K5%?LG(Q_!    1(  !D              ("!1/$  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #'@*M4"=?N].P"  "$"   &0
M            @('Z]0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( ,> JU1]GA'HQ08  (8F   9              " @1WY  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ QX"K5-/^'WGG P
MD0P  !D              ("!&0 ! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #'@*M47)GUSY$%  "3)@  &0              @($W
M! $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,> JU3K
MO./0<@,  #@*   9              " @?\) 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ QX"K5,UU_!FA @  ) 8  !D
M     ("!J T! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M" #'@*M4B**0;:D"  "-!@  &0              @(& $ $ >&PO=V]R:W-H
M965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,> JU3)NM,$/P(  (P$   9
M              " @6 3 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!
M A0#%     @ QX"K5+@2 P@; P  ,!(   T              ( !UA4! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #'@*M4EXJ[',     3 @  "P
M        @ $<&0$ 7W)E;',O+G)E;'-02P$"% ,4    " #'@*M4M2TP<<0#
M  !W'   #P              @ $%&@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ QX"K5+[+,T&9 0  =1D  !H              ( !]AT! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ QX"K5"/5;@VH 0
MN!D  !,              ( !QQ\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #( ,@"5#0  H"$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>236</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - EQUITY INCENTIVE PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANS</Role>
      <ShortName>EQUITY INCENTIVE PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/DEBT</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSTables</Role>
      <ShortName>EQUITY INCENTIVE PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/EQUITYINCENTIVEPLANS</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - DEBT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBTAdditionalInformationDetails</Role>
      <ShortName>DEBT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails</Role>
      <ShortName>DEBT - Schedule of Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cdtx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cdtx-20220331.htm">cdtx-20220331.htm</File>
    <File>cdtx-20220331.xsd</File>
    <File>cdtx-20220331_cal.xml</File>
    <File>cdtx-20220331_def.xml</File>
    <File>cdtx-20220331_lab.xml</File>
    <File>cdtx-20220331_pre.xml</File>
    <File>exhibit3112022-03.htm</File>
    <File>exhibit3122022-03.htm</File>
    <File>exhibit3212022-03.htm</File>
    <File>exhibit3222022-03.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="417">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cdtx-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "cdtx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cdtx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cdtx-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cdtx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdtx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cdtx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 379,
   "entityCount": 1,
   "hidden": {
    "http://cidara.com/20220331": 1,
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 12
   },
   "keyCustom": 30,
   "keyStandard": 206,
   "memberCustom": 19,
   "memberStandard": 25,
   "nsprefix": "cdtx",
   "nsuri": "http://cidara.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://cidara.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - DEBT",
     "role": "http://cidara.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - EQUITY INCENTIVE PLANS",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANS",
     "shortName": "EQUITY INCENTIVE PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://cidara.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - DEBT (Tables)",
     "role": "http://cidara.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - EQUITY INCENTIVE PLANS (Tables)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSTables",
     "shortName": "EQUITY INCENTIVE PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)",
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i795c9fa22a224d2bbd52d8f2fe81648b_I20161003",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - DEBT - Additional Information (Details)",
     "role": "http://cidara.com/role/DEBTAdditionalInformationDetails",
     "shortName": "DEBT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i795c9fa22a224d2bbd52d8f2fe81648b_I20161003",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i46940802d05a44c78644bacf035f8ab4_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)",
     "role": "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
     "shortName": "DEBT - Schedule of Future Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i46940802d05a44c78644bacf035f8ab4_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i55bdd2d5589d4fe7b0309fed8211b8a8_D20211013-20211013",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i55bdd2d5589d4fe7b0309fed8211b8a8_D20211013-20211013",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ia9826f2bc1b746e58123e9f3f7f9aeab_D20150301-20150331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i7725d535d6df481ba4eb64e1f9497bb5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i7725d535d6df481ba4eb64e1f9497bb5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ic36326a3df014b8d992c03bd0101de68_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i8d1f47cfaf864b5b8449cf27f8903001_D20190903-20190903",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ic36326a3df014b8d992c03bd0101de68_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i10c225bd22cb4a8094a6e4710a63e69c_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ida2575eac8b54cbd9b8d91895a8f0d63_I20210714",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ida2575eac8b54cbd9b8d91895a8f0d63_I20210714",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i2191d31021fb49a59ba0e5e2e38662fa_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i7ab61c4680194901bbce5f08a8fd1c4c_I20220420",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cdtx:CollaborativeArrangementPotentialPrepaymentMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i7ab61c4680194901bbce5f08a8fd1c4c_I20220420",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cdtx:CollaborativeArrangementPotentialPrepaymentMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTax",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (unaudited)",
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "i4b1dc55c0b024ab9b76a4a45d166b6b2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION",
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220331.htm",
      "contextRef": "ibf93d87f62d043f08388507ef12e1da4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "cdtx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdtx_AuthorizedSharesForFutureStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized Shares For Future Stock Awards",
        "label": "Authorized Shares For Future Stock Awards [Member]",
        "terseLabel": "Authorized for future stock awards"
       }
      }
     },
     "localname": "AuthorizedSharesForFutureStockAwardsMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ClinicalSupplyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Supply Services [Member]",
        "label": "Clinical Supply Services [Member]",
        "terseLabel": "Clinical Supply Services"
       }
      }
     },
     "localname": "ClinicalSupplyServicesMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_CollaborativeArrangementCostSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Cost Sharing Percentage",
        "label": "Collaborative Arrangement, Cost Sharing Percentage",
        "terseLabel": "Cost sharing percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementCostSharingPercentage",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results",
        "label": "Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results",
        "terseLabel": "Election to proceed notice, period post delivery of results"
       }
      }
     },
     "localname": "CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Third Party Share Of Cost",
        "label": "Collaborative Arrangement, Maximum Third Party Share Of Cost",
        "terseLabel": "Collaborative agreement, maximum cost share"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumThirdPartyShareOfCost",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_CollaborativeArrangementPotentialPrepaymentMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Prepayment Milestone",
        "label": "Collaborative Arrangement, Potential Prepayment Milestone",
        "terseLabel": "Collaborative arrangement, potential prepayment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialPrepaymentMilestone",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice",
        "label": "Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice",
        "terseLabel": "Termination provisions, required period of written notice"
       }
      }
     },
     "localname": "CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdtx_CollaborativeArrangementTransactionPotentialValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Transaction, Potential Value",
        "label": "Collaborative Arrangement, Transaction, Potential Value",
        "terseLabel": "Collaborative agreement, potential transaction value"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPotentialValue",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant [Member]",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common Stock Warrant"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]",
        "label": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]",
        "terseLabel": "Controlled Equity Sales Agreement, Cantor Fitzgerald and Company"
       }
      }
     },
     "localname": "ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion",
        "label": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion",
        "terseLabel": "Maximum ownership following conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development, Regulatory, And Commercial Milestones",
        "label": "Development, Regulatory, And Commercial Milestones [Member]",
        "terseLabel": "Development, Regulatory, and Commercial Milestones"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercialMilestonesMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer",
        "label": "Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_JanssenPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Inc.",
        "label": "Janssen Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Janssen Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_LesseeOperatingLeaseAnnualRateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rate Increase",
        "label": "Lessee, Operating Lease, Annual Rate Increase",
        "terseLabel": "Percentage increase in base rent annual"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRateIncrease",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_LesseeOperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Incremental Borrowing Rate",
        "label": "Lessee Operating Lease Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_LesseeOperatingLeaseMonthlyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rate",
        "label": "Lessee, Operating Lease, Monthly Rate",
        "terseLabel": "Base rent per month"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRate",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost",
        "label": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost",
        "terseLabel": "Variable lease and short-term lease term included within operating lease cost (greater than)"
       }
      }
     },
     "localname": "LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdtx_LicensesOfIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses Of Intellectual Property [Member]",
        "label": "Licenses Of Intellectual Property [Member]",
        "terseLabel": "License of Intellectual Property"
       }
      }
     },
     "localname": "LicensesOfIntellectualPropertyMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement [Member]",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone Achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "More than ten percent voting rights classes of stock.",
        "label": "More Than Ten Percent Voting Rights Classes Of Stock [Member]",
        "terseLabel": "More than 10% of voting power"
       }
      }
     },
     "localname": "MoreThanTenPercentVotingRightsClassesOfStockMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_MundipharmaMedicalCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mundipharma Medical Company [Member]",
        "label": "Mundipharma Medical Company [Member]",
        "terseLabel": "Mundipharma Medical Company"
       }
      }
     },
     "localname": "MundipharmaMedicalCompanyMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_NumberOfOperatingLeaseOptionsForExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Operating Lease Options For Extension",
        "label": "Number Of Operating Lease Options For Extension",
        "terseLabel": "Number of options to extend"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseOptionsForExtension",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdtx_NumberOfVotesEntitlementForEachShareHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes entitlement for each share held.",
        "label": "Number Of Votes Entitlement For Each Share Held",
        "terseLabel": "Number of votes for each share held"
       }
      }
     },
     "localname": "NumberOfVotesEntitlementForEachShareHeld",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdtx_PaymentsRelatedToCollaborativeAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Related To Collaborative Agreements",
        "label": "Payments Related To Collaborative Agreements",
        "terseLabel": "Payments related to collaborative agreement"
       }
      }
     },
     "localname": "PaymentsRelatedToCollaborativeAgreements",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]",
        "label": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]",
        "terseLabel": "Preclinical and Clinical Trial Accruals"
       }
      }
     },
     "localname": "PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock In Underwritten Public Offering",
        "label": "Proceeds from Issuance of Common Stock In Underwritten Public Offering",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_RDFundingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D Funding",
        "label": "R&amp;D Funding [Member]",
        "terseLabel": "R&amp;D Funding"
       }
      }
     },
     "localname": "RDFundingMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Services [Member]",
        "label": "Research And Development Services [Member]",
        "terseLabel": "Research and Development Services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units and Performance-based Restricted Stock Units [Member]",
        "label": "Restricted Stock Units And Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units and Performance-based Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability",
        "totalLabel": "Total deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "order": 1.0,
       "parentTag": "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current",
        "netLabel": "Current portion of deferred revenue",
        "periodEndLabel": "Closing balance, March\u00a031, 2022",
        "periodStartLabel": "Opening balance, December\u00a031, 2021",
        "terseLabel": "Current deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "order": 2.0,
       "parentTag": "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue",
        "verboseLabel": "Long-term portion of deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance",
        "terseLabel": "Payments received in advance"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Revenue from performance obligations satisfied during reporting period"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability",
        "terseLabel": "Long-term portion of deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable",
        "terseLabel": "Payments receivable"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_SaleOfStockConsiderationRemainingOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Remaining on Transaction",
        "label": "Sale of Stock, Consideration Remaining on Transaction",
        "terseLabel": "Consideration remaining on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationRemainingOnTransaction",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_SeriesXConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X Convertible Preferred Stock [Member]",
        "label": "Series X Convertible Preferred Stock [Member]",
        "terseLabel": "Series X Convertible Preferred Stock",
        "verboseLabel": "Series X Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXConvertiblePreferredStockMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Number Of Shares Authorized For Issuance Percentage",
        "terseLabel": "Automatic annual increase in shares authorized for issuance in equity incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold",
        "terseLabel": "Voting power threshold"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A [Member]",
        "label": "Term Loan A [Member]",
        "verboseLabel": "Term A Loan"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]",
        "label": "Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]",
        "terseLabel": "Total Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdtx_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "verboseLabel": "2015 EIP"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_UnauditedInterimFinancialDataPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial data.",
        "label": "Unaudited Interim Financial Data [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Data"
       }
      }
     },
     "localname": "UnauditedInterimFinancialDataPolicyTextBlock",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdtx_UpfrontPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment",
        "label": "Upfront Payment [Member]",
        "terseLabel": "Upfront Payment"
       }
      }
     },
     "localname": "UpfrontPaymentMember",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_WarrantsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Aggregate Intrinsic Value, Outstanding",
        "label": "Warrants, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Warrants, aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "WarrantsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://cidara.com/20220331",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r284",
      "r399",
      "r400",
      "r401",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r46",
      "r89",
      "r90",
      "r200",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r199",
      "r236",
      "r286",
      "r287",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r459",
      "r461",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r199",
      "r236",
      "r286",
      "r287",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r459",
      "r461",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r153",
      "r272",
      "r273",
      "r419",
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r153",
      "r272",
      "r273",
      "r419",
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r199",
      "r236",
      "r276",
      "r286",
      "r287",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r459",
      "r461",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r199",
      "r236",
      "r276",
      "r286",
      "r287",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r459",
      "r461",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r45",
      "r46",
      "r89",
      "r90",
      "r200",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r411",
      "r413",
      "r416",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r404"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r21",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r20",
      "r88",
      "r400",
      "r401",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable, related parties"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r321",
      "r322",
      "r323",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r289",
      "r313",
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r60",
      "r71",
      "r219",
      "r386"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r87",
      "r139",
      "r147",
      "r151",
      "r166",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r344",
      "r347",
      "r367",
      "r402",
      "r404",
      "r436",
      "r447"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r43",
      "r87",
      "r166",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r344",
      "r347",
      "r367",
      "r402",
      "r404"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r290",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r92",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "THE COMPANY AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r29",
      "r73"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r11",
      "r74",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r73",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "verboseLabel": "Cash, cash equivalents, and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r376"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r84",
      "r87",
      "r114",
      "r115",
      "r116",
      "r119",
      "r121",
      "r127",
      "r128",
      "r129",
      "r166",
      "r185",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r234",
      "r235",
      "r239",
      "r243",
      "r367",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r260",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r339",
      "r340",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "SIGNIFICANT AGREEMENTS AND CONTRACTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r180",
      "r440",
      "r454"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r181",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r404"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "#REF!"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r57",
      "r442",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]",
        "terseLabel": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]",
        "terseLabel": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r234",
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series X Convertible Preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r17",
      "r18",
      "r246",
      "r252",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common stock issued for each preferred stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r213",
      "r220",
      "r221",
      "r223",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r86",
      "r91",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r387",
      "r437",
      "r438",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r196",
      "r225",
      "r226",
      "r385",
      "r387",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Borrowed from the lender"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Variable annual rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r86",
      "r91",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r37",
      "r86",
      "r91",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r252",
      "r256",
      "r257",
      "r258",
      "r384",
      "r385",
      "r387",
      "r388",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r71",
      "r173"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY INCENTIVE PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r58",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r111",
      "r114",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r360",
      "r361",
      "r443",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r58",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r114",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r360",
      "r361",
      "r443",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period to recognize unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Estimated unrecognized share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "Awards available under the ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r53",
      "r54",
      "r55",
      "r93",
      "r94",
      "r95",
      "r98",
      "r107",
      "r109",
      "r126",
      "r170",
      "r251",
      "r259",
      "r321",
      "r322",
      "r323",
      "r336",
      "r337",
      "r359",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r464",
      "r465",
      "r466",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r211",
      "r225",
      "r226",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r363",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r211",
      "r277",
      "r278",
      "r283",
      "r285",
      "r363",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "LEVEL 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r211",
      "r225",
      "r226",
      "r277",
      "r278",
      "r283",
      "r285",
      "r363",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "LEVEL 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r211",
      "r225",
      "r226",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r363",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "LEVEL 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r211",
      "r225",
      "r226",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r70",
      "r394"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets, and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r66",
      "r68",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r87",
      "r148",
      "r166",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r345",
      "r347",
      "r348",
      "r367",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r87",
      "r166",
      "r367",
      "r404",
      "r439",
      "r451"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r87",
      "r166",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r345",
      "r347",
      "r348",
      "r367",
      "r402",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "terseLabel": "Current portion of term loan"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r210",
      "r224",
      "r225",
      "r226",
      "r438",
      "r448"
     ],
     "calculation": {
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total future principal payments due under the Loan Agreement"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Year ended:"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of fiscal year"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails",
      "http://cidara.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r47",
      "r49",
      "r55",
      "r56",
      "r72",
      "r87",
      "r97",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r117",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152",
      "r166",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r361",
      "r367",
      "r441",
      "r455"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r111",
      "r112",
      "r118",
      "r121",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r104",
      "r110",
      "r124",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r184",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r334",
      "r335",
      "r336",
      "r337",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r398",
      "r420",
      "r421",
      "r422",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r146",
      "r149",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r393",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease payments",
        "totalLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability",
        "verboseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r391",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash financing activities:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r290",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r404"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from right offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r316"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r174",
      "r404",
      "r444",
      "r453"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r174",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r284",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r284",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r284",
      "r399",
      "r401",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Principal repayments of Term Loan"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r327",
      "r418",
      "r480"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r79",
      "r435",
      "r449"
     ],
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash and money market accounts"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r11",
      "r79"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r259",
      "r324",
      "r404",
      "r450",
      "r468",
      "r473"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r93",
      "r94",
      "r95",
      "r98",
      "r107",
      "r109",
      "r170",
      "r321",
      "r322",
      "r323",
      "r336",
      "r337",
      "r359",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r338",
      "r341"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue from collaborative agreement",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Sale of stock, proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r289",
      "r312",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r289",
      "r312",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Instruments Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r290",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r295",
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r84",
      "r127",
      "r128",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r243",
      "r249",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r231",
      "r232",
      "r233",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "RSUs and PRSUs canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs and PRSUs canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs and PRSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs and PRSUs granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs and PRSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "RSUs and PRSUs vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of RSUs and PRSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs and PRSUs vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Limit on employee's payroll deductions as a percentage of eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Automatic increase in number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of employee stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r297",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r288",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r290",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Term for stock options to be granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Price of stock option as percentage of estimated fair value of shares on date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r84",
      "r87",
      "r114",
      "r115",
      "r116",
      "r119",
      "r121",
      "r127",
      "r128",
      "r129",
      "r166",
      "r185",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r234",
      "r235",
      "r239",
      "r243",
      "r251",
      "r367",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r42",
      "r53",
      "r54",
      "r55",
      "r93",
      "r94",
      "r95",
      "r98",
      "r107",
      "r109",
      "r126",
      "r170",
      "r251",
      "r259",
      "r321",
      "r322",
      "r323",
      "r336",
      "r337",
      "r359",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r464",
      "r465",
      "r466",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r126",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Common stock options, RSUs and PRSUs issued and outstanding",
        "verboseLabel": "Stock options, RSUs and PRSUs issued and outstanding"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r41",
      "r214",
      "r251",
      "r252",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r251",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r251",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Public offering of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r251",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for restricted share units vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r251",
      "r259",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Issuance of common stock for exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r251",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r251",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r87",
      "r162",
      "r166",
      "r367",
      "r404"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r250",
      "r259",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r383",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r383",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r383",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r383",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r405",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flows:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service [Axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service [Domain]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred at point in time.",
        "label": "Transferred at Point in Time [Member]",
        "terseLabel": "Transferred at Point in Time"
       }
      }
     },
     "localname": "TransferredAtPointInTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]",
        "terseLabel": "Transferred over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r113",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used to compute diluted net loss per common share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r111",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used to compute basic net loss per common share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r484": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r485": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r486": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r487": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001610618-22-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001610618-22-000042-xbrl.zip
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MZ9RV.C+\0\F^Z5N?^[PRZK;&<NV.,G*7KLH:"Q),8M%Z++FWSA$J.'4.!\U
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M%TM7%):_=-<?'8.[4CWUMA*YPJ69>F/)BA"_U@4_[%BX[0RB#E2L<"Q^/>I
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M93F02"TP.Y$QNL]JZ>*:@_ZWB,Y^1*X?[1&R"51IU;9/[-E@Z=75AD&K)OW
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MCVLU[G\!"=F\N2<BICEZEW3T+.CHU_9[*NGHZ>GH_!H=:1*UUL8A3*Q G*F
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M&B,T5@5P]3PE5LU+W.+I4C)^9$C,=DYV7A;<W+L^P-U?>]'Y>+K9)B4!3X^
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M>+U6\+J9 R\M+#,Y38#46(4H)PYQYI,1923/B.4BI<G6#NG2Y-$)!9X<O#;
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M,L0IH$<F)%'8X$PZNJ;B$CG)2PB,RQFF3B<HMSX\/L\,;#(J1SYJ/A%"<9Z
MP-"\*W+6)3C=P$WFU=F5Z]?AU](R3.P_0[0S_-?TONS\-_Q3/W$A1V>]0?!4
MY(%5/,\.3OP./J<UW^Y:6^RU]4FQGK>S)]9VI/8^ 3FX]F5>!L.Q+;;OV/NJ
MKSO_K4;_W+GUF>H+J>_1Y;#H>6SY>63[H0;4+U<],SZOR4_KJ0H_DNDC4A5#
MO['<^LAZ32V=G9#VO[[/88_#1!!N,I9PRJE*L$RUI3F10A"<6ZL^$K)5/W3>
MN"LO8:]%:F3E9R0=C.MGV;^2U\76/V=G Z:B/?5WF[5O+.G:B#);.M][!V]V
MW^]V3O^U_W[WW?Z?IP=[)]W.P='>[<+\TAT>#HQ/YF(Z\%,(%Y3>#7<RAO_X
M,K%%9^@Z>[(X[[SM#Z^*=1W&3Y.!G)@>=/T?G<>BWG>09-ECY867!C0"]X 1
M]^5E87^N?_BEWD)Z@S" \- O5:<JI/&CG>,<X?O*CZ?JLYV4*E3MZM4W5Q]O
MAX_FJ%+Y&2/;++W]XV0;W_K9MUZ+\7:.Q8->^^W/LB?J++E;A[[#G+[K-A +
M39>8_:44/:_=OZ!%9>J]\Q%LQ8?0[KSH[ ,PF* *A[YZ="?%W1D6?L>Y68M#
MB>7#_>E@T!F?#R?P$E,LG! O\Q_=XUK)>JZP=]JN:J!W.<7;A G#]Q'[UW&-
M<_E8F^H3'6][?P'":XM'I;!?F1@]TX'R'3OYW.>T+?)1O0+Y]C_G(2']RUSU
MG6/E#TC1NUF1E:\\=C)FMKK5%WM]V*M]L7\F1V]VLP^G_4\?;O[SZ?CTC^3P
M]-\]>,_U\9M=<G1Q<'UX<W!]]-=^RQ?[ 7_POE&R3__^]/?YT<W[S\>G_?-#
M>,_QJ;[^</,9'[YY?W%X>H87?+&?_O/I\,UA^N'T_.+H8C\]^NV/[/BO_:O#
M-Y^SHYM_P_?_>77TVX>OQV_^XPX7ZZ<[:B3+%$4YR3FB"79@J!.##$D559KF
M"7<KN'&[?BGS(PAM!@C%?$FO#X06:IAF.>P9S"(C,X)HAC'B&4F1SO*,6^[2
MA.D5W'Y=(0@]-[]?)W*W:SY-BG'I]AL/.R,+^JA[?3N-RH._^I^U=PB&8+[>
MH%6>?9G9,,,/GYO;/]D[UL4$P.GVLTM)2"" E/3+[P]M[* (562_L^0;5<#F
M>;GT[.Y57S&Q9J\U^W$;6]4V=K18)C;'5.:2,<0YEHCJW"#%J4:,Y$G.M:5$
M4]C&NFG*5Q3 L$9\^H?7X!40T;MI<%32^RCI/->DJ4R,,A1EE(/!RTV&E&+<
MI^9,<I/G@*UD:X>SQ>MB+Z>BZ\(V7X)'O+&7P#![0?;#'1!Y,81>WSR63"R9
MHHV!HI63B?8B[ [,;FL)(A[=!X]Z"Z0A,\ 6G-8H(Y(BZG*%9&83Q'.7NLS"
M$C*[M;/D]NH]X6@Y)+R6@DT;J:8K9PQ135>FIO.T(<FDI2[-$&-:^FM4*9*&
M),C07">,"2&,V=K)%O.IO)R:_LC>AZ/A  7W4V^NZ'5T/SP/8W@G>^9@\']Z
M U/7SXT(=!\$6CRI(T88Q3*.5,H5HD+G2&"3(^<$EHI(::WW+JR1V1(]"VO*
M$Z)R/E8YY^F!M013KYRIXQ;1-*-(P>(@EQGA,BDI5@)8_!HIYX_L4V@38Q^Y
M;JP:=WI%,9$#;6$VBO$MD4L_O,FR<I[07HIC][8W@"6 6=OS:S![6.%Z7ZU!
M-W8TC&!U#[ ZWEM@$FF&<\,P192F8,M8)Q'W=0Z!1^2I32S.>>HOAW&"R2]K
M9-!$O\.:\HEO*W%4UOLHZSRSP"Z#!68893Q)$&7$(<F91E8E)A',I_=U*Z#]
MT>_P),QB&O72M[*PG3!]:.C0!'Z116$?Q30VV>A9&=/09OSUYW>C(0BX*=Z.
MAA<'%=$[=JU2%P>#/P?&CJY&O?'8#MY-5+^GCYV#<?ID$!'"[@YABW$1+F%*
M,L80V$(A/TB"I$@$XE9E*E&*T5QO[9 L1D5LGAJOC&M$-7YN-9YG(BQW!CN+
M42*50$ [%.(X39&C62998DF>$7\5;C$G6/1RO 07V3N7@S-;^.#;DFF$\(E^
M3ZI>/X;?/B,1)>S9::C6,"Y8\9'5MO?%IQ#XD6CF,U]BFS6&#P9ZY+G^&UO^
M]V!0K\;[9C%B&.[*;I.4>]1L/CJ7,:&,1E@0A2AW0#4-QF \:Y%3#6ML\=9.
MVJ5+RI^\YBMMFZG,:W$7+"KULROU?)T'[A,82XPLE0FB4A'$';!/:ZE.$YT*
MC-76#L9=G--(0-> @[P;V4O9,W7@3='M#,?G/EW[9#2R@W'%2;N!E):?/-H?
M]NJ<]FM&5*HE>V/!8!Y9LU^NW.[ '/OUV0W+$U%N=2AWL$!=G'59+HA BKH4
M;.Q$(>%OYW.;8TISQC*5^2M$F"2/+P,;S^1^3.IR-S6/FGP_39[C*Y9G.<68
MH)PPC6B>$B2D,T@D:6XSRP7SI>QI'D_NUH&L- Z32WD=LC2&FT9:CR9VQF7V
M(WE1UHN;U"OTKEP@?[VA7)[?IZL30>M>H'6X0#\TQ<08DR$ I]R',5HDJ+/(
M9&F>2"I289*MG?SQUQRB\V3]#(R7\)Y$;5ZE-L]1$ [+:1-)D.3<(*JR# DM
M-4JYRU*JN$H5]>?NBV')/W1.G1=A'X%HM/.D! :B[,"Z7O2)/'\&PD7(VK^X
M[ ^OK7WORP', 55TB:P*Q?Y8K$@&BXP3HA&@%G 2FW D!/R#A18Z(](I+;Q+
M1#P*QZ)+9.V,BI6'*4>=?C&=GF,FJ7+6$)8B;5,*.BU3)(4$[9:,DCP%#$^Y
MUVF:1??(.A"4VE78&=DO=C")P23/QD="V.,B<+TOU\''0>[YPB%J. HUBG9'
M(Q_TY9,S[G_5_8F?XYFV@[$?QE^]\?G>I("YM*,(9O<"LS\7" J%+0DV*(,2
MIBRB24Y]R=0<)81E22:2/-5J:X?3Q6/I&&RR;LK^8I'-3ZSBD<RL4/_GR(SF
M"E >R R7U"!*0?^E40P1X:C$)A-,FJT=TF5+#)17'Y@2OIOP]4R-?CQW^VK9
M0<Y&6UOKZDMI%N9W_WMM=EU'*+H7%'UH49$/V>'-_D>)19KXO):EQS>3%O$T
M=RC/$Y;E/E65L0!%;/&*1O24O&;=?<ZCFZB[*]+=Z[;N?OZ8JBQ33DF49CGH
M+@&U52X7*$TPP''&-7'^>A59$R_GVCA#DFWR(O6MOEO=X/%.DEN+CFTHC#UI
M02E?GO;=:/BE9ZSY]?I/6+@6ENTVJQ9MI:<A*)6ME!-A.$!;DOBKX)P9L)J(
M09G4.K.Y(=9Q +FTFR>+M\'O[2ZYF_Z\(D?*CP8(3UK<*0+"B[*>ZB3(4:ML
MGB&N2(HH9L)'G FD,^-4RJPV$ON3("96$*7RM'A0,:*Z%[70TZ#MZW(G>EW>
M\=ST\4D ;GF!W(/!%UNLI$#N77>.EWS'ND1MO42&A7>3D3X'([CPJ9XN1]X(
M&%^'P"W[/Y/>I7?1Q\BM9TLX?1U*TIT.=S5,_LB^J];C75\.QKL#LU\O2=RS
M[[5G?UX@\=(XG?%4(9)*V+.539&P$B-FJ6&")P+[DA7\,>>=T<FX?BK[!&FH
MH\H^E<K.T>PDRW/E.$&94@11DBFDN-4H%TIF+!,*8P8T^S'55:-O\8E\B[TE
M?/()?8N;ZTUX=O=B8PFTO0D1R>Z.9)]V%\B'U3G\?^KK96D@'U(#DA&5(IF1
ME.52.HGY(\G'?35D$QR(FZOUS^Y#C%J_ JV?OTTO#1@<Q"'+;8*HM1BIA#J4
MIU)2RAP6/'\D?WDNK5\W-^&=!OS2/L3[=W*#'8Q-@OWH8/S_MDRON.S+:Z_T
M]MM?^UPMU\4CFF^SY_>(5@F:.VXTO.A<AOS+G6&5@-E[277(U0R]&>K/W<X
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MC:-MM#JT6KS5020U"0>@TB3U5]<R@3BL(G))B@G-&",Z#UG+\2)BQ9BPUZS
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M:=N6GC"R"[^5>H@96,\]I'?6G \G_1F \9]/!H%U?'MFUY,BM(F:AZ<%FA8
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M;S\G%2P1-B'-,AVP@QW-! P_#+R!G6*6\D<4/=B-@\;?W7Z_ :O<*,N\DB
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M%<:!Z2(BC4Q+29.]<H'\,M=MLWJ@[VOW[0*0.=[DX+=+QW)FID8.X!_\=B$
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MY@A)JU,=X4U&4,X/P3)#D["*L_W6E5FR?[;(_=WZS[ 5R@GI3S'1QKS=[<E
MFCG-I63REC]@4P& +8H^/!WA0TT.T:R"".5HN#;+KKK.9ZU,<CVUN/!["WZ
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MH222#(.%P'W N7/UXIG)N)G<-(WA,J']44?K44^RZ3YS62-CN>(4@4#A9,X
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M*3WL;I+-\YDYFOIYU)OT#3B,R/6B_8)L@C'^8=MG]KS_[/?9)X/'FI[&J\U
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M>(>LS!V?A$O(1D60QSQ9S;G0R11JJ57J^/030X6/P):Y-X:L=47 (U/V^8H
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MT8O]?"#8^AK;YW, _5!=Z[=.3MO=\QC?Q]Y7V#0ND*-VN^O+;WOI7?3=PPZ
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MJBLTN\9@U.8R0WBT5O:_\^RTHPVC&FG0TS)KV7Z%^<[7"(W#=M?!K$PE5C?
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M/^-VEKFA'?"8.W&2Y'Z<//D]=99:EL"6U;J:27OKKX;7"/160^=4H4'[;VY
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MTG4SX=TF[//UNHW<+]5LNXW<(P7Y\/U[UQ6!$Z2AG0DAL3S>MQ,6,2 H-PG
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MR:/H!Z/LPY-=]VCW?<0SYKK,L=,X2>Q 2F8G3BCL.&)!Y.1.E#KAD]^=G14
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M #,\/D1;OV.]@8O,KM10Y/P$":.58)7!0?N@)JE:#I2T!-@&17#$4<:E;A&
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MSC@1"L8&%L2.*-1'K$T]W,P7-!D2WYW'E'2;<EKCCG4,5V6,!@"P>O1QP/O
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M!$+AUG6L <QOP,.#1:">J-Q\I/.L4!X8Z=)-MZ=Q\4'"_V <MM$G*A+$/0]
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MMD50W]!*OVO:Z78!K\BE_U.ZXPP:=)D4L9J-I6&4>JN!%'ITQ:R??&<XP/
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M&Z/V37F\>/2Y#BBM%^[&5,?\NB7K:-0D;9(*/P+N#CK2M%$+U#OF9T4E;-R
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MI0TXA=FLJ61MAMIU>&QZ4.SQ+M%Q9Z7]U-5Z]UN<[B4^,\ !%<R9#<=%$\<
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M;A!-QW$>$=T)OB&'MG-*6JT,F(2A-6%1C'L>0 1T(R"DA,SSN,)'20$**^#
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M$BV*&_/=>L_@FS)TA.93$#UBID,:XSHLQXGOV-$""17))76N$Z$^IC^9 O)
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M2K^="F8?#1KN'E<E%< 4)X(@AH;/?7/6^B:ZY26'G5)RF]?NM_/6]\#-1&[
M-L^6<ZF"K-8-KN&^>.GMKKVYFZ?4K*EY2L0)-,N99A=IDW9FV70"!TH @WK
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MWWB;6Z(0:"1"ZVBZ<4[DM-DH3C3%NRW+6A[_R<F#B"C#ZW9^<];W9I;;PLN
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M]"EC_<W2GQ K)F4;+P4!Z&F!$,_,-4!RXX$JZ8?)M__^9YU@S[RA!?G<[6[
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M<%FV8%-<=B./7Z VF=(T@M.U?<"[J4FK.1^*?>=;F_#2G.372'ZZ[;Q=TS?
M$+B1P]0\ 9];V[+QJ8Q '&>F^]K#PEBR&&A[3AJ([Z4_OZ8X&B.\KD#8;E]W
M$PIKDL:05T57C^*M6@,4[DD/Y2XQULM;]?*SNUHO/PK3Z'<;K7LBP5PQ[R'T
M/5U<&!T('?R0.%:>AC(R> G.?0I$&3R3&\%8;)2!#4YUR8314C$-8%M0UWJ"
M,)(M-]"Z@)2ZXMR7>&H0[MC_/'#CU!)6MJ:=)%@N20*CS>W1S6VJ](V!4"5#
MV5L!?-(A#'T-8_8[!W.B:C9X"7E+?UB#6MG2\K)-WCN:_PK+]!,)%EL9W1B;
MUH]O2V((L8XSW"KCYS5%P-$2X8I9'KR\;==O+'6W)N&1?,8+WB@P5!GJ.$R(
M#ZS:3<+1^SE9#WY[0_(.D?!%+'?*2)$^F:Y$AS2)6Z5;DH%(1ET+BN^*G%C"
M_3G[Q-X[Z*:V/._X3W@<M#M_.7E[DN"WAF9VF5WDM1"& -L8^;KBE1LG:1DI
M2(+3BB2[3!Y&F@@C 6_?(\#,ND'%+.3 C5H9$$2!-TM9LOT3^&!55J$4VF >
MI:B1;Y1:7"OX&(85L][*E1.)ZW0=(Z/ *F.L@%:+RIQM3] M<B^PQ_H'<SZ0
M\RH+O1O4GNAQW)@J+5@2@17;B?GP+"N4'VU:A&,@^C2 C=AP ;2.1#T_KHA+
M]!6K[!-V6.MIZ>XJ=('#%Z,,%7-S/NFJFS9PNX73W3\[3U)G*W#;90X%G59_
M93(1?2FF75R"8V/+@:_HP/&I4607J;1M&[=?^R5:EM#3*/J@'FM(DTCR9KJ6
M>?-H)*E38VG%T$"0^V*C.>7:-G<>[JW/QD&Y"97[K'(F)GVPECDP6<=9/WBU
M>Y!Z@=<13A<Y#DL["7D2RL*QB4-(@R6GCL&-E!-:DJU;^$2?3?1,5A[G%+*>
MK.D7L']\KADF?H7[R0=N3SNCR^[5)KO@VIG;!FX!@ZEI0]HW%CG8);E%8VZ;
M^):\31=#21]"9E4BLJW@X5B3HH49C(<"-*2$9HL\7&*XF6O2C X1>WRKQ@U?
M=UEGUZKW049?R?;HZB>3OQF0I*F)<]*X\TY,&+#99*NU9'75U/%Q,MWR7N1:
MI)EGG%8KVK^ O:9;/\W&8IE!(EL-C+J[$J42^HB%*Y52R%4CFYUQ7ZVD;4=3
M0*I.&I_.N?NC 72'5HH;\HT0U?ERASMBEV3>@E &/F:Q* :D*8EQH&8_'_8/
M3!>66:?2"*G[2Z."CID">#Z^8&ZP>GQB>K;:P3L;'I@!*NR;7L$8\[D[#%F=
MPFAG\:F?]%N-N U_V$A2Q+3#U<JYZ3X,(T5(%KE8%DL8,M4[X/W3;H;3TV>'
M?N=GO<5O!Z\[\QP2$I99L]'GY.UKCYV3NNPA?]1 42YBY8=T"H"*P!)I*N="
M".0F:"3J*.?U$-VG8LH'$#S$^4$;W1O#G]SM2^B\.#M^D<OQMF@3'L4OZ1D=
MW#I?"G3 +@(]:M9ISC: /"Y"#::2*H4@3\4J#'!7KM !C9QCO6G%[S< OP'#
MD@JL;48-U8&^8R*.1)0NVGG%;"A\2:)K$F#*K\1I"K&!V3*K= X_SSTC3HX=
MQJ+R:0'$0NEL5G("1<H21K(.)EM/"$_?GU>S9E4CM5Q#0K,*(@]NE324/Y65
MYI.IO>.1+MTA,J?V,%[$JL)8;X)GP?&#%J9" ZN;+4$.<YM5.2'X+-,0\ %6
M&QVH0(OR<^8/%/J8@T*O_>/NR<N;#"@OY7 BH25@*@S_HA+DOMKQ9F:LK2BB
M(V5;H9[!1%O;9T^NTT>?-U^FUT&8KN8.**A'DV(LI_4#]MX&L>AKNV0M35$9
MH'54+HW&I;R[Z+^%37D>3IR>X[Q<;%!Z=$_2K-U3_H2U@!JSK+-UN<Q]$X>Z
M$-;UIQIDMMG(J9US\VPKXR'78%1AQ$_AAM-Y-4N/](LLA5&/T3OS(L?8@)HG
M3-*]18-^@Y8J3#1#0Y1)W>YN(Y2:AE2^5^T#;--W"W=S:ZT@J$HII2G".=#
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M'V=T"G#*3L@<0C-LE!#OAL]M3N_\*D>3SZS"T"W%'J#\J ;A.#>Y/;K]44+
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M(?;H((CGU+WXDL)*60$<W)15;81O_+1J\T*- G.&:"Q?]!L3F['&A6JL5=J
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M*98DR%U%_&0!]-#.:NVI0Q0C/J%+J]947JWV+XLG]&)_;>*,?&&J(697FUP
M563 #VUT##0;..*,6CBC[T><T7XCM5OU*\I*9C>*?IG^C$'")O[$BOB81YAF
M*"S2T>6%')$?%8D07TLF-RAKR[/O(\M]E";RE>J2"LW2:;?X<""!TEL5%?BJ
M<3VAMXS@+W[H$H)4+^BN<H];EA&.N.CT[F9>J$\O%LB%QT+!,1<* G!LH!+,
M>M/M0C#]C4O5X^Q^J21_##%(VXG]7B&P0(I?CXG_,?&_?^+_0)"0T1S<P7J
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M6&*CH^"K3+@69ZD,?(.6!'-W99!BK6Q4KH^T.!?C#['2O0 WK-PHXJQ\\'U
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M]:]L__DJ<!PUZ'U?]*$18;J]Z@6;UX:\J["^W\842&&$_,@)[@;GCP,L2&C
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MWUH8,S*$Y=DF&*(#W%N:6 .UCJ0W1K*H A\M[>"?Z!1)1(/XMA#7 N?Z[>A
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MW^Y[>]T; L.\X[].1-<!IG>UA9X*F1!3D($:1%J 8C8C:R%G#KDG" L*R$L
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M>1"DD-MS =3^0'FZB/8IIVTR)%:*7/;+\JXE63D]:D[-GEZ;'PO>\^?(_^1
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M !'S9<35 E>D:5;YX<+M\I,Q,23"V*.X%ZIR*[$2^E56@E(NJ75(\[P("R*
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M0D7VVND=B:89LD?\V8E2TT8;Y-&M_H[>T'5J%Y!CF,UF&.AI8TU,GT)O3*D
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M[MT X:(&)+[I)FI@SI#]9 1COJCTX\I[Q7DF(8\',6GHU=%F "DS%UH"8C/
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M%#(^A_8B'*52YS%8H#CI@E/0:1TB1W!I>=J"DH/WM]M-,W.%EY2-+*F,#[%
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MCBG><]?U6O15ML3205DDK$]W_)W:1_P5@QZ+5>CW=@VW%0 P&YI]HUVF8>9
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MIZL+JL"Q9F O-FL8^/<IP>_50B9W83V9!!&1?R(+J94U36=7;<XVN.P\!6/
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M<SG;8E@%K._2/GJ,Y>2@PER0<RJDW1F;J:=D8N"=EB#N'8"0+)G\>^%]\_'
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MW:I)-Y(%'X8VU%K6L8@#Q/""NS88$^KD6VS+_-F?$")X&I,G\M!@82@LR@!
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M,6U/WK"^TM9?.?U"Q:3N<>%.Y96;RE5ZQ"3T2?8JUH2'%9K%J/YW0S]5@TD
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M#AD65P[BZ?+2*\S,"90,D7E8G[ G2"L)$[=TM'F(78=8&.L!(\!2[HS$&^C
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MP"0ZBTPSJ#89W8.B]8F2U?)?=>UQ R9_V[XY4N_P]TH'+8]F^'-Q6&>2S[7
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M!X@#&X7WA'//2SZ* G%,(K+PF$MDGI5OLY?R Z%66L"D/Q>>:MFH#GU';2-
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MK$',EYHJT70U"-;Q&%P *Q(E29R<$P.%SM)9'2Q/A+#5)+ :U:/.)7HS=X-
MX2TA"S.*67_%,,7W=<?^;?F=)J<Z_('FF44;-&!( I1*"(X;"59;B2D*)TR;
M]_]>6(^:#/T9O$&0<&T]>C,>I8O9JL8FJ0@/13**9:4T$$)T$$Q 'F6QSLHV
M++@+SN/V_M8&;K;F#VRP<_S A:'EC0=&*.I?2TYH><PNMG'SXOF/VJ\;F+#!
MNO[K,,3A*5D-I[3,?)B-TW]]'I_29T_KDC/[=C54P[@J(18PM/R $IR&6F(
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M4+U7N3B'KWJ;,)Y+H5=[_8->X/.23^>FM]?F38Y)F*2*<ZA]*U-(7,:0DI!
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M9S@X/9=[T_.N97JZ%(8_?YX<0LH'G:^!PL<]?%:GY\TM4-P;S*U!X>>/,EP
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M?;AQ>P!<5/NDUO_E.ZYMY%?$AO[T^F[!-IM]]PP)*6140I#E,C9F)#*\H:
M2!.8V*J*N?:+J^\>;VKDT6S3UBP>;4.PU?K%'NQ:/]2SC:&-ZA#[OEWUSL^
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M.,PIP%*9+6J:F\UJGIM=1)HC3?T*]+:/-34*:HA:Y"2)IK#^YT9M"+L?(07
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MYR_HN?#8#;#Y?WN"^<(69=!3<W=\NY2'OVA<.=.0XQSE""3"UH:)H2U\3!(
M$\A2H@A5HD?AXZMD\GG'QZM87+IXK <L4GM9;XKB2NM#%UG$MN=J&GLN=U=-
M:Y)D"B5"@#31*<"$"%NZ, 8"YXI)J56*I6_5X9$G=?ARP9Y3>E!0>,S)% (A
M'DL&5)[E $,66X]S#/(8,D((A9FB,T,H?.5L0HXUE4VI_O^)=#14QYJ<H0V$
MTBEN0;]KSLJ1W[R8I>/?-6X(:/.& #:L77R51./:SB' .[&O@SRT9Q3WEFV+
MD+#*R"]B$XK]I&344"[/0*:E #B+<T!2;JPC2@44:29R[>4:;!UILAOV0L)>
MN_1V5-W(+PA68^W2G6#RCZ6]!$'8J-;6T<:-+[VD]$FDY\4;_&A!R.T?9E^V
M,#^O;$+)BVI$C=I,W/FR"#1X7*]>YC98R3"5X:)UW13G0?]M/=]NU?+C:FO;
M0FN$&!8, YP8NQM3B &G2(,$412S)-<2.Z7*!99K:I33T"#ZOE/AQIAMI1)U
M_P[SM?U>ZA$M"T7<:"GTK':3V!O.U>#.GH92AY6[FC/XV)C!6K6Z)=J#CBKM
MHH]O.(-R)8H [^*F*<[D@8#_16;4>0T<"/=RQ;0/M\L@BI-J$0P]W"A+YD 8
MU0OL4(_O::4;6[]:W#\^VU[+YA^-^.'[Y1<CVX:)XFO&BF":R]@NLM;K!0D@
M(C=6CV0BQ81BB!(OP]UC\*DMK%5D_6:UD/US&KS0=S3P!\)TX 70BKTS^6^B
M4O3B%P<9# ;HAOP!]P0]4 N[3? 18-R=0P]H3C83?9YQ=;/W1[9^6!?[&%DD
MCAG^+$:=I4F*,(D5T IE ',F <MMZ6TI%!$JYT1Z%=EU&'-J]-7,V;J)OK-U
M]%(DKX;HX^<R!8ZNVK# #F[$-SO,&X%M>$$I<I4:;(0N"6V0CO.7(!JJ"7WK
MN&_5E_X2$!VMZB_>VH^5OIC;'G3#T"M<=G'&::P1!VD2I]:1P0#-&0<Y(5KF
M4J2IS'UXZ.PHTV.>EHU1<5#1_'<C'?_PICZ.T_,SX$9#5^/Z5MZ#8)!ZTU(G
M9$&)Z/Q(HU)/I[+'9--]<0^GZB_SA3+K^%+=BF]S]5(\\Q=EK:P93"FGG&N@
MTE38>F(YX(IHD&L(4R%EG$*G#=N%<:9&,3M)HX:H'NZP#D0=')1A<!J8,LY"
M%/U6RNE(K9>P\G %AL%L)-=>3^S\G'27$>ETNG7</IX3[;(.!TXQA\M[)JML
M-FJ[J;+8=J&AFF.,I48@59EM\Z@R0"!B0*=IHF*H-"5^&2KG1ID:-=:%1EDA
MK&?'MO,XNME05Z,S,"&6\NV23 >IXM2)0=B4DK,CC9M'TJ7L2?)(Y\4!,T8>
MGK>;K;&*Y\NO,YEH0I#(02(Y IAC#;AD& @4XR1A<8:3ZQ-'&@-.C0LJ03?1
M:B_C%?5Y+L'MZ/()".+0VZZV;)*;J"'PP#DE9Z 9/K6D.>C;9YB<@< IT>3<
M?0.4?/[5C+ INEHK>?>',)?>/ME_S6">:XI0!F1BH,=90@#/8P;B.,XI215F
MB,^6ZJMU1GT)5/2Y31BGSXJ6G]6)2,-]8E:7?X[NG[X_;XO3'T.+QD0,6 BZ
M=7+<V&HXK*=3_KFI1E3J$96*C%3T^1*.X]5[;I5D.J6>+X'E5>7YXL.N/J-[
MQ[[/MVQ1G@9^4ANU?E'RY]7ZY^?M\UK5A:!F4C,*59H!F%!CJNE$V10-#7#"
MH*2(9X9'>Y[8N4DP-=NMZ)!Y33%%WQGP/K +C^NHQW>5^'7\0:U 4=BR5&%7
MIFR0PSP_^(8ZVG.4XJT.^OQ ZCCV\WQ0/]J[K\R7^Z58/:FJJ>?'U7)5D^]'
MM9UID=IFW]IL2I5-B4@08+:L8IZFFE.1P51YU5%T&71JY%;+'*E2W)MHJ3R-
M/B>LW3@M-((#T]@.O%+>Z$^5Q'\N:IGOA#;_ZL#4F[E\0 I*5DX#C\I//E <
M4Y+7O5='?+Y;+3=S63QYM?RDA)H;UGLX"#K,L>00"@UHGAAS"RH,&(2V"P;$
M-G]=VOSU?B&?ET>?&B\9\&T2A5!*>A9T]0/=C9<&@W)@@CH*]3R0/:J%CU;#
M1WJZHS94J*>#!&\5Z^D.3D>PI\=#^II4EB>_L#\>5XNY>/VB_MC^9!3ZCUF:
M"843&@.%8MMO.&6 V#+]<<P3!6$B8N+4?O'20%.CJ&K1-X(J3XIJA=+52KH>
MH,$MHQJ;FZB4,OJM^J\5-RKD#7C<=PF2P'90RV CVS[=*I_:.Q>N[Q$/54>8
M'_JTJC8C9D]W]\?66%5%/DM"B8JS'.0XAP#+7 (68P)2+0T],(G3V"D"P&_8
MJ5'&/M=B50IK&_XI*ZUC\0Y/U+OY9#@L!V:7"L8'?>Q,KWM)14;P:"?Y(-!Z
M1%P- O%( 5BAH/:+R/)&K#- R_UIX\5K>6MX$+[E?W? "@*/*_/P[9PM'M?J
M>]EW:A=.-J-0)QAJ#*ABUJ>6"D SE@*4FO=+)BR.8Z>>3;TEF!KE'\9^LV9R
M\O=:#=NYJ=(C6A>FNVVK'B"IO'.J'!:'H2=@\&.&UL3PG0;17H5HI\/0T ?(
MW \U!6^?H]]S*L(DXKO V"OEOO/!;Y]<[Z*W4QJ]TX/ZEP.]71[7RMHU)WP_
MWXC%:O-LLTRE2ED&,4 J3P'.-0-,)A2PC LLLEQ!Y-<IT'7DR:TV=16Z)P/_
M:_3$UO^AMI%^7OIZ4=VQ=_-9#(+HT,M'#>9IX;]&#]J]Z&'+^WFA%;R4G]OH
MHY?M\P+E7(D^OP?XE\2^,URX?;V5TKR(F\?59LL6_WO^_=U*JEDN<@H51B#.
M90ZPSG/ ,.$@%DE"4JV1<&O3T3W,U!BIE#2J1+6KO14V,M)&5EPW5KJ ;#<%
MA<-K8+[I"Y575?++2/0N4=[QZ-'JE5]6KUF\W.'JODWW7M3R6?UL9'NW6A8I
M%G^;;[^]>S9VT9-:GQRAY!C3A&M LHP#S.,$$%MPCPFME*:0(K<*>_V&GQIE
M5-+; \K5U^6\\U R!/IN%LQPF Y,*S6<]D.):M&CWXWL42W\L(<S_9 +W!30
M2X21NP7V@>>TC6"OI_0M.&R>4184>O^\GB^_EO72RIB^XH^5+_+N#[46\XV2
M,Y8HFN<8 LYU#' F#-E1R8&,J<R03AG/_*);O$68&LWM6N^N="2:?=V+ANZ5
MU/:/Y6_K$Z/^%=#\)PU#;';5YHM"1$F 8[M"I8*!F(F8(YZ*/,_KM)DWG;;#
M=)F!)ZX^^:CGZ)JJ=/YSXK9:#?MY#+QB%5("SBRT[U9/-C*O#%EJUE?AKU'S
MNL?*<7C[.UO+F_ITZB:J]=O8@G:/W7T2>M2W[HMRX,+7WF*,7!&[+TRGI;)[
M/ZG?2E=X->>R"@^]7<JBK,]!#O5,(9C*3-A#+I4 C U+\@PJP! FBNN,9LRK
MNH'#F%-;RRJ1ZRCR3>$V6Q45D,1!&00_>G1!WXT/ V,Z, '6<%;B%FB6]:2.
M:B>$HS(/@()RE\NXHY*5!Q#'[.1S:S\Z^INRV=1*WKZH-?NJZCB ][89J*IH
ML%D( .>0(<T(X*G* $YR#!BF!&!$.:)QKFGN54;8<_RIT5258?9L#8;MREK=
M-MLYDJ7X-O4E6JPV93G.VB2WM_0W\'PGS(W-!IR&@9FMECRJ1#\M/]R0^R:J
M- I'<SV1"TIYOC*,2G\] 3JFPKZ/Z5EU2HBU,0GK9.JYVED'.M,$)RH&2.:&
M !'BP# ? QK3!,8DT0GUJC_<.M+4J*X2-%KL)?6L0-6*J1M'!4%J8#:J06H(
M.8!I=1&)L/6H6D<;MR;5):5/ZE)=O*$?-SS8_K2+Q6IKW0/E[K JFL@SSF&N
M-,B* UFE.> ,(8!9;'9L**7F7S[<T#K2U+C!"@IVDE:^$C]V:$?5C1V"8#4P
M.YR%*6#Q26<L@O)#^VBC\L-%I8_YX?(-?8]J%]9G_,C6V]?WJR<V7\ZT3B!7
M(@.2)=(8#3@#+-<02(Q)G"B$2*K]CF./AY@:(U021H6(T6^ED)YEO\\ Z7JR
M>@T\@Y^>>B'3XW"T3?G !Z GPXQ\R-FFYNE!9NN5/2O&K99?S3?T]%[QK:T(
M7E2C)T(9XU\Q(+7YL+%@%!!!<@!S"CG31!O;P.<3/S?(U#YR*R.P0D96RIO(
MRMFKP/]91-V^]6MQ&OAK[P.1?P6V#@S"%E@[-]"X]=,Z5#TIC]9U;<\X!?%-
MR><B1]YZ''ZR)X7- \7FB=&MV,Y?YMO7+S;WIA&:)3C!*8T!T8GMH PE('FN
M0$91#*%,<(R(5]S"U2)-C58^/S\]L?7KOHMP92C7TGN>B%\_98XGY*-.Q(@G
MYKN3\&:23:G(S6Y2HM\*788)^ H';=AC\NO%&O?8/!B,)\?HX9[<LTF3+4NB
MU7JMY.WV<35?;N^77^9/JO(A($II$FL.<FW+A>=2  :-L<8SQ85$,1&<>75K
MZAQN:H3:D#9BVZB0MVC':"3V[,34#;,;488#;V 2[,)M +>-&RYA&S!U#SEN
M)R8G]4]:,KG==458ZK?5PMRQL1D^V]>/JVTCKV=O(NA49YEB BBB-,"4<6/?
MH0SD<6[^0!#"R*OTH_/(4^.:SU\>WOWKOSQ\>'_WZ?-__P>"8/X_HKM_^_7^
MR[_W"&1T@M[1.AL"T*&-L(;,_QB54MMVXLT<06-W#6)Q^<(5/O[0:?3QPPY]
M0#D;;>CU@!YE-LY5!;]?BG5AN+/%3ZOU>O6[^<,GME4S)9&"N=;&U,\3@%.L
M ,50 (D2I#-;S5:YEU'R&7EJO-60,^*UH)%1Q*=V@Q?TW;PU**!#.[T*L4\*
M_#0AWHD>?1H08H^R&$-!/5(YC'"0^Y7!Z -;9_D+KP>.5_:BCYX'Y2YZ/:"?
MU7KW]'VQ>E6JL>FN]F>92#35E %"-0-8)CF@""J@"9$ZPPF3"OI8J:TC38W=
M*]>#GPG:CJ.;R1D$G6GX^0;8[5Y$)ZA%V3[:J!;D1:6/+<;+-UQ[D'&[W,Z+
M>.7YB_JLQ/.Z")6Z^T,LGJ629?JGC6HN%K '?<?62T-3F[JY^GX?!C/.19QR
M@$1J.Z+K&#!M[,E<2:(0CCG"7N027L2IL5+CH*,1NKJO7[5X+>.5;86KO=Y1
MK7B5@,T6XGE1IK.9!U4!L;9#P*Z+P(?59O-GFZM6AD3W/3\)]J;XGJ>\Q?P/
MS;N5<G;*FNIUS/->17M3K>1^6D<Z@0D]&0.=R 03\XU.:$+#W'YB$WRDGE9K
MX0_9=29&>:Y0FF,@LY0 K#D'-$DS@ 7E*H4XUM@KGN;P\5-;"2K?GD/C8A?L
M',W3WH@,S(WN8/@;G6=U#FMI'@XQKGEY5KT3F_+\5?T^VUVULY]>=S_^R]SL
M<M?BV^L']6+TM<%<.8Q91F *,B$XP%";G:?$,> <QI3$*H^UUP&LV[!3^\SW
M5?YNHIVT?I^Z(]YN%! >Q8&IH5$F<2=GD<S\\?:OP</J_- )2B*.0X]*+GYP
M')..Y]W^A1+?5X[6?WMF:_,M+UX_J>^K]7:6,D4@M$>Q&3;F0VRVI1S1%"2)
M%@PE#$&1N59);!EC:C13BQGMY(Q*0=V+([:AV<TK@3 :F$3\X?$JB'@!@-[5
M$-N>.UHIQ N*->L@7KJTQ[%F>VLJ&])O=B2'?=@@$33CTGSGF3(&!^,I( D2
M !+,TRS/4>R6I]MC[*G1P6&7MG4MLVW3MG5HTW;U5#@<= X'\-!^G.Z&> VH
M73KB70VUQX'G<)"/=.09%GJ_8\]^X'4>?'H^<KRCSWZZ'AQ^]GQ$WZ ]MBT.
MKQZTK<S]\V+U^V;O5DIB%9,D 41R#3#)4L"@61L$Y0DQ2X8PZX)?G%[[8%-;
M!W:RVJ^F*$%?B-O;Z]0)M*.//Q!\0[-\?^1Z1-Y=AB1PL%W'@"/'UUU6_32D
MSN&>?D32[-U\T-1Y]Y(S9+:/.*& :Y4:-B$8$,B$^8GJ%",NN/2J07MQQ*E1
M2EE#KBK2]\]^]'$97C<."0K:P$32E/6DR?L@=.*,3E!.N3SJJ,3B#,(QN[C?
MV&-'6\7;;*H$]2^KPY9(7]>J(+;-+$\SGG*D <J1-5I$#+A-82)*Z%RSE$KD
MY#SW&G5J5%/+;3:P90&%HM[>02^\6G:/_97S'#AL8H= =F ^VH%:5Z7XLHJ.
M.JOMQ!X"58_]ZA#HCK13#8*RWP;5%ZW.K:GSP\;;E/KJ=[ =];ZY9[NY!=ML
MJFWOA_E2W1M#U9!YSA.,<@K2W-J,2&> Q!J!+$MUICC$0G@5=SX[RM3(NQ!R
MG]#_FQ4T*B3UW'.>Q]3-4+P:J8')N ](_IW@ND (V_7M[$CC=GCK4O:DFUOG
MQ3UK@:U>V6+[6H6-YUP03C$VVT6H )8P 8Q0"EC,LP29SU\G3D>19Y\^M4^^
M$LZSY-<!7FZ?=6\4!OZ<*[D&")T_JW'8ZEX'(XQ;V.N<<B<UO<Y>U&,/]F6U
M98O;KV;)MXU>[I?;]7RYF8LB/*'B@BIWY"]KMK3UAVOGA-14844A8$*:CUF3
M%##.4D#33*8BSM(<.E5"OTZ,J7WUA2+13I-HITH5M6/KGF^_K9XW;"E=2Y]?
M.5$..[=1X!^8;BXA_W!836D35:IXN_^O_6[<MWRC3,M(>\ AI\=O:W@UJIU[
MQ?Y/'V_S>#4"![O)ZY_6<WM9]),HGE]7.2(IMF4H 1=2 ZQR#*A.<L 5QB)-
MM*#4J^OGR0A36VU* <L/QW,?>0*>XQ[R&DB&WC\VT!C ZFQ5/>RN\624<7>,
M;4J>[!9;+[RRQW?U'[L#A3.&D-"$:)"Q6-I.8)G9.R(,\CC6,9-8);ES\&KK
M*%/[JH_;5E<_1(4_Y&'9M\7W ;#=7WLPN ;^XGLCU;_#]SDDPC3X/GCRV_3W
M/J=<:WOOLQ?WC#106QN\\+A>O<REDC^]_KI1\GYYOWQ1&WOT6)5,G*O-+*92
MISB/0<(3!C#,S?)N&ZKF(F&92G0:(SG;6I/$;8UW']J+)G8"#'B6KK:1L+$X
M1?<MLZ^<US)';">T9TB"^SRXF0O#H#LPJUA@BR"G6FS;&O5/OY8H_SG:"1_=
M7H;9/U[!&[&P@0ONPX\;P> -RTDH@_\3PEDR:(8H$9R*&$A*;>=GK %/A 3F
M;<RR)$Y2C)W*7G>.\D-9,E]^7UUOR: K+!DON-[2DNE"*H@E@P:S9-#;6S+(
MQY)!5UHR14DKME'O5?G?^^6NY-4[]GUN/26U(Y#G<9K F .E)3>,P 2@L6V*
M0QD5FD/,$Z^F..Y#3XTFWGVS]9:*AN)E4^,BI;71:,\SLM)C$MS,F&&@'9A2
M:J&C/]5B_]DBO"^15XD^2-BE/V)!S1B/X4<U8_QA.39C>CRA9YN_P[A/6T-I
M)DFF2"8)0(PG !/#5@RA!- \R?)40IR*Q&?S=6:,J>VRK$QE :(J$-:[C-XY
M(-UHYTIX!N:7AY- [J+.5L V?NWJAVW@=V:<<5OWM2MZTK2OX]*^QRC-V+]]
MZ<-&0MK?YMMO1?NPXTC!_=7U"8R0*F5* TH2#7"N("#*_ ]3%&>93'@JO)K[
MA!1N<E;/801LL^AD0[WH=Z-?U2QO>Q(VN[_)]_@GX*2[GAR]S50.?N@4<A8'
M.;8*CWO@$Z^  HY\6!8>VM-SM@'&Z)E8?+:U46.4GU[WEU0QYK>_L[4L"V[=
M+XU=6H2:;(JTN2]FUU<%!OQ5;;;6&?>HUO.5/&IU7T0-O&=;M:N;,Y,I3SF6
M @BSV "<,0)X'"O 4I02G;"<^<603T:SJ:U1GS[_6F[&'XN?7@IMBB V:=^T
M]28R]DBTL=@X!K--#G+73.VIR#NAM:]9/+N)RL&*QE^CLT6V+38W=5.7!CQ1
MF5.[-0#5L6 W48F1=5^4*-U$-4Y1!509+Q99J*)]E;2 :>E3F_^P.?"3T6[<
MA/O)J-VR^D]/P'ZFPU_4TCQX<;N4M_)IOIQ;#Y4U4:ILXCH_)$UCGMLJ=3(6
M  LE (LS#@1-9)83A-+4*:3<:]2I+;F5T,6JRP[$]EM@W2!W6_R" SGPPM3$
M\%#BJ!)Y@(V6%TA!V=MMY%&9U0N,8];SN[FOVVNY62WFLB#41_.3>-T7Z$\0
M)RQ&,:#2;"TPSQFPQ_< 0BV1B#.84:_BVUV#38U_S%(R+[(P#X3V=2]U@.OJ
M+@H#V>#NGX:8-U$I:/1;]=]!6A&X(!/80=,QX,@.E\NJGSI0'.[I&^GS^9M:
M+*QIQI:OLY1BC*!,0))Q"G"24<!0BD%,N,R93'F>>08K-Q\_-9ZH(E8*$:-*
M1M]XG@/XNGGA>E &9@(O/'I$[9Q3^\IPG8-'CARG<TZ=TP"=LU==>9Y=M)[[
M4 67O+Y[7J_-_F@&<XTT$1AD)*'VY H!JK1U+O)<YB2SS4!]EOSNX:;V,5=B
M1;9(<=5@9U'$CM1!.)YY[!? CG-,-$L2P+D-?:)9"DA*,Z 3S$3"M8AC.#-;
M4;X:'^[FL/]E '>SN<*!.##7'K7YO(EVLMY$E;0#A"%THC),1,+Y(=\F.*%3
M_=8XA>Z[PH8LG.N.GB9"4)U)("G, 48J!T0E""B8PYPCF6'B5?#68^RID?SG
M^[]\O/_Y_MWMQR_1[5\^W=W]<O?QR^?H]N/[Z-W#QR^?;M]]^1PFC*!_F_J!
MX!U\%]AVGC]XH_H>@(UR>O_FS>I[ .-Z]AZN87T]TH=]K'.]9&<XA4+'.4@0
M-C:2S+2QD1@&-,$H347&D5^LY>D04PNU+$M$B,HR:H1_^Y'2&2S=N.<ZA :F
MF(9P ]@X[:H')8LSPXS*">UJ'G_Z'5<&:$I>1TM*F6>*YP!F*0(8&BN%)!D$
MN3(V"R-,88;\MD%G1IG>WJ<XH-Q$[(7-%T7'UN>E+$[\573W^?'QBB;E%:ZQ
MEC&!J3'W%$$VLP8!3@4#4##(&%,QUJIWF_=IGAJ& <Z-)Z^$8V@_7"7=8'5
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M2S P:P<+R!R&XT>8A(D':;Y1G-$(P \?MADJ>JG!@#,-TPQG" $$LQS@+*6
MY9H!E!*="93%-!8^R7^-9WNM#:-E^BWV GK6R&V@YD:Y/;$8F"(_. #@7_OV
M5-6P!6\;SQ^WRNVI8B>E;<]<TM.H?.8;]?=G>X9G[(UM=4J4H!@SDFD >9+8
MZM8"L"R5@*0TAAK"!&;4RQP\-\KT#+E:R*B0TM/<.@NDHZ%T+3Q#NZ..D!F@
MQ5(G!&$-C+,CC6L:="E[LJAW7MPC_.Z7YZ6<?__&UD_L%R6MC]&ZM-GRM7IG
MF9924?NUYQP#G/(8<,0H0!)JSABU?<6=(^@N##8U#FB(&U7R1I7 'A%1EQ#N
M9H70N U,#AV07>8)?^P\ L("8CA23-=56/J%8SF"TQE1=>D9XP5%.6IS$-?D
M>D_/JG*VC*5M.U">WG&NA8PIX!)R8U"1'/#49BWG4! FM$+0J\[_P=.G1J*%
M<%7+BQZE]0^1<[.@>N,QM$O?&0K_RFKG5 Y;-^U@A'&KHIU3[J3FV=F+>J97
M&>#4>JUDT1.W6FN0=80C94P?I#. 8X4 $Q0#FUQ%&2&("B^O^+E!IO;Q[F2,
M"B$]4Z/.H>CV!5^+S< ?\A$L ^R N@ (F[YT;J!Q$Y4Z5#U)2>JZ=J"F"YL+
M9:G_8J[<;NZ798_LOZGYUV^V3/6+6K.OZNX/M1;SC7I<SX6:"1CC3.<42$QC
MLYE"L5WX8R RQ42:PI0F3INI-Y!]:LQ4*1!]M1J8#_%/\V4DK2-[O8F^JW79
M?Z^]"MB;OPJ.OJ!I3O#0'B:'/@H;UT8*)0*1>3U*#&ZB&H6H@B&J<8@*($9L
MFQ!^]L9ME!!0_FFU1@@_,=[-$ 80X6VZ$C7Z,QQUEN$Q1QG#!*1F*018VW"Y
M--<@3E*=Q$BAF.@QNPZU2CJYQ6\OZ+A=A-KG,M!Z-L8,36#U<EV\#AK]3+:]
MS\59F53[GG9II[4&70MZZ/8[EP?L&0VB-ANE'NI"L1^4&;\^TG[]A6V?U^:_
M1R%G$(F<("T S%(!,$KCLK(\4E2++(LYE%XK1P\9IK8FU.$^-ESP]LF&G-[4
M 80V].Q7\U*NMVR^W);!B6SS+?IYL?I]$]E7,]JI'A6Z>T:F])A!M_5BX'D9
M>"4HI;\Y!O=F%P+Z>A/52@P:]G<%C&&C:'K(,6ZT37^@3J)RKGA4CW/\Q_5*
M*"4W-MG>5O4K.IC:]+0GVZ/4//Q^^>O2/.MW,^Q6+1^?^6(N'K0VNX?EUUF2
MBP0E,@$\(39AGMO46T1 )J@2<8;2-''R;5\ORM1HU5#I>CO_S]*",\2YKSB_
ML#,:K>V^"ZPT>#;_8&;*MXYA?0%FS2%R8+2Y&-SC7NI1KE:U)F68O=6E<L3?
M+Z.F.E&I3U0K--K,>,0EC#9#(T4M##Q3?G$-0<#MC'JX;H3Q8B*"('$0,1'F
MB7T[0)CG?ULMS!T;6X5N^SK+(4T5% +(--$ ZX0 $I,$4)8AJ7*6Y9GR"20_
M'<)K:1HMGGS3D/,?BRJ66\?HM XPB8%.Q#&RI4)3 R;5@.-4 Y0Q+C*:)(CG
ML^^%Y[%H@#X&I,?##0?L3VQA7^:;B*NO\^72W\MV"JB2*!<:4H 5LAM6S "7
M2-F4.I1FB.2:X@K0NZ5C'=80<-:#C0"FZN.O/$72T=%X%39#>P@//ME2O.AV
MNUW/^?.VV 5N5]$C6W>%G??H9]*&2.">)B?#C-S7I$W-T]XFK5?V6Y0:2U_A
M2-N4U=5G+)%86S)%N253"A%@D$@@,RH8H3%5<3Y[46N^<G57M8SD\XHWQQON
M3:],OF*-NBG/Y#?1O"PZ;T_LR]]X'M.WX>S&# &P&Y@>FG;R37E,L+FI2O6'
MXX,+. 0EA;:Q1F6&"PH?T\.ERT-$%AZ\OA"GL3"6%4@PEP!GQE@PW  !XB*A
MC*J,I%[!0>U#3<W'L@^G"TL4'6"[<448" =WC1P$(]:,$9PP+H,Q8&#BV]'&
M9;6[@Q0#D$?1[M[8)[=KQ=ZMI)J1',$XM=LSE!B+0BJSFZ!Y O*4QR+.(.'0
MJ;'R\8.G1@SO"L/8"!=9Z=P^_A.PNC_U:R 8V@YPT][Y0VY3]<QGNU'BG[ZN
M7OY?<TOQQ?X=VQ]!^6/QF9X\;)2/LDV%^A-L_7N_U?I^*=;6R_]>E?^]7];5
M?![9J]VHW2ZE^<W:?-K-[/R8,R5PF@,9)V:S'V-J/E3)@/EB&5))0B3/?5;R
M?F),[6/>%;3Z7@I='$NS4NS^51%Z3I';^C\\\ -32*U ]*=:A3_;2-C=5#PV
MIJ)2)!JD/L-U2 8U+'J*,JK1<1U<QP;)E4_K<1K]1:V?/JS8\K;.(H<(82DE
MR#DU>QNM-2!29""C2L<HQBDCV,T%<N[QT_-[6 &CV\C*Z''F>(R:P_GN%4@,
M3#T%!%8T@T./S.]C+#Q.5*_ 9*0S4B]L_$X\6Y3O/,,\OF>\4\D6:0_.&=NN
MN2*:G5^.@N0M49!59+UES<,H2#C+"$](G-A3LA0#C)0$7#$*XEBP'"94)KG3
MKFQX4:=F&C8D[1'//LQL.IXS36*.ACZO"AC1WE!XZ(CV0:<E?$C[,.*.'],^
M*.QG@]J'';%GQ0_Y?YXWVZI_HBW;NA3SA?JHML887SVI#ZN-^;V-PGY<KU[F
M4LF?7G\U(MXO=Q&CMV([?RDL\5W'#<XSQCA* +/E0K 4&- $*<"4S+-<I[EF
MB5?AD &$G-K:TM#1'JNO:RVCI=I&"Z.A_:W]6=B0^&?+76:'O _S9#L-_]FS
M<LD0;X#;JO36\SKP>G0TI3L%(Z-A5*H8_<DJ^6?[YR+5H5;4+E-_^K6<Y#\W
M O/W^@[2QV7("0E;Y64(0<<M%C,@U"<U9X8<*T@)SUWEI)SE4B%!@((: 2QP
M"AC'$$"M6$*@PD)[^:1;QID:^Y\4J^Q=B*H-6,=]PO5P#6WD]T'JVLJ>@U:L
M:AOK+:M[7JIB=>GR'K[8MNK?C?+>CZNM^<6<+<I<;IHP 77" 8^AS0;*-6"V
M2)V"(N-*0\6X<,X&\AY^:A1R6)V?U7T<;J+OM=C1=J]+]-*YDPTQ/0YNX4%!
M'_K8N[U[<4/\FVBGP 7G00C(/;S/@T(_DG\Z]!3XN;![(]CIY/9_ZGAN\-X:
M'SC*^S^EGZEYF-MJVQ[.6"P)A)P!HG(!<(:5^0F;E0-Q!A%+)85>#HK3(::V
M.A2"1<)(YF=.G@'/S9*\#I*!N?LDT_U=%S#>UF.[[D$-QS/#C&HSMJMY;"YV
M7.D?8GAGF&'[>BNE>2,V-HKJ8?UE]?MRACA-4Z$Y(,@V&\T2!EB<89#G*<*,
M:DIA[!IMV#+&U+[J4LRHDM.\QO9?JW5D974/0VP#M/M##P33P%]Z+X2\0A4O
M8- [:K'MN:,%,%Y0K!G+>.G2ODD(UKV]?7TT,[J]74J;_?3=6@J_;I1^7GR8
M:UNJ5,.8* B*>J48P@10Q&UO=O,7FJ="::\:Y0YC3HT$2LFBA1'--^_@,KYN
MBWU@U ;FA%I:LS&P\A91A3N);Z(*SP]=>/;(2G!&*'!ZPN5Q1\Y3< ;B-&'!
M_=90^?J[$ZV$QC'/,P:R),T!U@0"QK,<$)9P)37C"21>CNG6H:;&+X=IP&7F
MON<98P>NCG[I(&@-[9IVSY<>Y/3N,D@#IU"_S4G:9;4OIU1?>:I5^#6JYK>V
MSDB;B^/N#[%XMN4%#JY=%D/_;;[]]NYYLUT]J?6N %<5"E)U9;9'<K?RQ=8I
MF)%,D#C+$Y#P++,'91QPA#(@TS3+A,PAB9U*"XXO^M3XK1;4QEP4DMK "E;*
MZN&M'7?Z'9SKDYW4@6FX;D)ME3GN;MUT$>^4CX[N*/6/+ !1C<!!,<3=&U/#
M8,M$W4[\C?$X&YCLFS/2N<)$WR"_XXDWF<3.HXUQ)1KO6.1-D#XX4GD;"?J6
MG[FZR_>'^5+=;]739I8A@F <$Z Q,[LR3B1@3%&0JH1 *'@LD%<QBI#"3<W.
M:26R,JVR\>^'[3>UCK;?V/*(_7ZSRD6%=IYA24%GW6W/^%9S.;!Y,]8T]JC4
M$Q[OP.5] @HX<DV@\-">%A(:8(RW27[[J]K8'C-+>??'=R7,CU]6]E>-S@!'
M?6@^J2<VMP44ZQ7QF2UL/A^<)3R/>0ISP'/S3N$L8X!#B #1*4QCRC--G&+,
MIJ?:U):G4K."Q%2EF_67O2C?D(7I0#Q2<M[;O!-#.U,#)O,U7JV[QJME?WW4
MN^:DY]H.JJB!563!FDX68/CYGU368$#U?J@LP_#3&CHK<0 )KPL<7RVKW:U[
M98KVNR=$A@="[IQ-/<I5=&#5+W;X"LS&#Q+>8Q<^!+@%"-=8W^/;WR2HMT6'
MMNC=MLO;ON$FZ&:K\!__\[_5OS'_8SGF?_ZW_PM02P,$%     @ QX"K5,43
MK/>+;     L% !4   !C9'1X+3(P,C(P,S,Q7W!R92YX;6SLO5ES6\ER+OKN
M7]%WG]>;NVL>'+9/L#78"JLE'4F]M_=]0=20)>&: F0 5+?\ZT\6P'G$L(JK
MJ.V.:(H$0:P<OLK*S,K*_*?__<>7XY^^X6(YG<_^^4_\S^Q//^$LS?-T]NF?
M__3;QY?@_O2__^4?_N&?_A^ __CE_>N?GL_3R1><K7YZML"PPOS3[]/5YY_^
MFG'YGS^5Q?S+3W^=+_YS^BT _,OZCY[-OWY?3#]]7OTDF!#7?[OX1V>$33$4
M,,484%$*B)$K4,%G#-KFQ/G_^^D?!<\RV.3 8BJ@6.00F$_@10ZN".XRX^L/
M/9[._O,?ZY<8EO@3,3=;KG_\YS]]7JV^_N///__^^^]__B,NCO\\7WSZ63 F
M?SY[]Y].W_['C??_+M?OYM[[G]>_/7_K<GK;&^EC^<__\>OK#^DS?@DPG2U7
M89;J Y;3?URN7WP]3V&UEOF#=/UTYSOJ3W#V-J@O 1<@^9__6.8__<L__/33
M1AR+^3&^Q_)3_?>W]Z_.'YFF.2S"G]/\R\_U5S\_FQ,0WH5/E=#U'ZZ^?\5_
M_M-R^N7K\?EKGQ=8_OE/*:_^@*I1)C>/^U\7?_SSQ9._+G!)8%ES^II>./V,
M^K1=J< _5CC+N.'K[/./Y^G*FXZK5.>+L[\\#A&/UZ].,DXGZT\^BLO5(J35
M)&LN%=,.BHX$*9TS(<\%B)P75 )=CNXJTY7@)5&\5L(2TY\_S;_]3!],RA#\
MOU3]%C;?KB5RXY$;R>Q'^]FZ^TCOG43&?. V 0N.%@U:6@W<6;"IY!22+]K:
M@TF__,2KE%_6ZM$B_31?9%R0\3A[9%BD*QJ^"=S3=_S\-2SH@R!]GA[GL[^N
M5F0(G:WF TAOHQHB]T\_$=<%%PO,KS>:N9.Y-6<K,JFX?N<06O\_)V%!GWC\
M_3U^G2]6$Q6%4U%G$"5Q4$E86'-D6"DV<<>55(,!X-K#M\*"Z!\+A\BT$UB\
MP\5TGE_,\G/:BB="&\XC)UDHZ4%9[\#KF( 'BUYGETN1@X'BRJ.W@H3L'Q+[
MR[,30'Q<A-ER6@5_"FK,#H./ C(* 2J3F0LY&<(XU]HQ;M /AXGK3]\*%JI_
M6!PDU9&1\6*VFJZ^OYP>XYN3+Q$7$Z=<\CQ$$H8@,X>*@_-6@[/6>%0L1%L.
M1L3UIVZ%!-TO$@Z28A<(>(^?IE4(L]6;\(5LF]#<)([ G,N$8&LA4BP%1CAI
M9%#,,S80"JX^>2LDF-Z1<( TNT##*PKQ%V3*UH+_0/+'9_.3V6KQ_=D\X\06
M&T@L#(2,Y" +F\%+BKT9@;XX2YY1.#R\V(*0K;!B>\?*<++N CH?PQ^O,HEO
M6J:;#,:I1=3.N"@S$B-(0D*6P&',H#U7C"F3DHX#@>8.$K:"B^L=+D/(MPN@
M'.5,*EB>_O-Z.D-.3 3&">104HZ@C&0042O@#)TIPJ >P!V]\_%; <3W#I!#
MY=HI.,3$Z6!+H"@+,]:\3$K@F>502I+)6JZ</SPA=^?CMTMQL:>'CMT$VQ,Z
MGM&W;Q<?Y[_/)L@33R$+0C27M$TJ$DH6Y&]+GRE,=]F&,"PV+AZ^'3(ZSGX.
M(=2><+%VHMXNWBWFWZ:SA!/.%0\E*0C.4#@N#'TGBP9C!1<9<RSL\&SH?11L
MAY".<Z*#B;<GF+R;+U?A^/^;?ET[VKPPYJ5)@(J<*)59@6A4 :XI4G-83,0\
M+$BN/'\[B'2<(QU(M",#I%J_HP6&-=TFJ6BLXZ!+/CU[#BXJ,,XGS2V7+AV>
M!+G\Q.U T'%&=&_QC:SV>MI^_.[S?':6OPL\2A4,.<RQ>!) 4."\SR"S\LFK
M6*+C!ZO^^E.W4W_':="#Q#@R!#Y@.ED0?+F('Z>K8YPHSB/*%"$JZ4"YH,&3
MV0(FM6;<60+UX5[#]:=N!X&.\Y\'B7%D"'Q<A%K7].'[ES@_GB2IBV"Z@- F
M@RJ<$^&:@PG2!('&6G^X";CRR.V4WW%"<W\!=K+X7_R1/H?9)UQG[9WPP@I/
MQDMY3FY+RA!4)@SS$FQ*3(EX>$QYVY.WPT''F<J#Q=E%F/#L9%'%M3G3K; F
M'9PL)UXJYU2.4+BB/4UQ"XXY8LLSEZ2/R.Q0T>3M%&P'C^[SE .(MPN8O)K1
MIY$XIM_P>5B%4[8F,1H4S"$P$2/!75D(-I/W:X(UDN<8DAD()K=3L%T=5O<)
MRP'$VP5,:G' XEE8X:?YXOND\, 4*Q%D,$2^=Q*<RP5\B?0;(R.3:< JB_,'
M;P>*[G.5^PNS"RQ\^!*.CW\Y64YGN%Q.&&>"Y9#(.[*"1,%3]941=$(32Q+.
MN*$LQ94';X>%[K.2^PNS"RR\^(*+3[3]_>MB_OOJ\[/YEZ]A]GVBG98RVP0B
M94:[H%+$AF?@I1=.2,Z1#W76=2L!VV&C^W3DX<+M B,?/N/Q\1GUR0=C92D@
MC462"'WQUD=@47MTBD*K/%2B^O)SMT-$Q[G) T79!1"(\"^U2&B>_O/#9Y+;
M\NW)JMX=JE'W1!O&K>4&+*<ORM8*$"L#F.BUBT51U#U46=9]=&P'E(ZSF .+
M>F3@''W!6:Y5RB^/PZ=)0,N%"1IJ^5AUE4@<&A5Y3B(F%K+"B =CY,HCMX-#
MQQG-_0782='_R^DRA>._85B\I%>6$X,\Z!@"Q=7D,RM&49.S-<*.R4H*LI,<
MX&SCCH=OAX:.4YQ#"+4K7&SNM&R8*,IP(:4&<I9517@&)X4!V@:33($5BV)@
M9%QZ_';8Z#CM.8Q@^W TB(U%.'XUR_C'O^/WB?7<(5,%"DO$ &,:/ 8+5O@2
M @_1AJ'R%=<>O1TJ^L]V'B#0L6LB-BFW"XMW=@$.A9#(G +-.=D\72CJ3EX0
MJCD+IF1IY.%7A>YZ^G9W"CM.;PXBUL&@\4\_WY#C:WIAGR8!!/'9$C-]LYP?
MTV]7F'\)Q[7! 05?N%I>I7W;[@$/?NK!;05VH_O ?@,G2_@4PM?)NIBN;AIO
MR\OIC!XVI9UCOKE-> XQC%P[71AXYL1I;;\5$834#+DS"?E]^W()R[A6_^E#
MUZOM9SQ>+<]>62\Z8/RT-\3_VH6Z?4W+C6=\#/$8)SSG[()UH*(B] >!$$TF
MKFLY45:T'.)]15<#\+JF8YR.!LU0<69X!A#ZB+O1#>J?'8?E\FU91^E'?TR7
M$U44LQ2$0]*UYBR'2.$9[:U&*<85C]GP^_R4 =!SG:1.@+2'GN^"S$%"[P ]
ME^E_/O\2IK.)1<EH5^6010Z@K*I;+L5Q-FOTM,:"+_>%Q/O#YB8MG>#E,"7/
M!Y7XB)BIGLCD T5RN/P/<@S([UM-:2&].R-CS=*ON"YVS"9[E;4 XJU6+M!W
M3MD"+.DHK,Q2ROB0G[/#\\8%RJ$JG;>5[]Z0(0KB?"!#<]E[?'W:SVN]EFRT
MI63N0&N;07F&$!*GX(\[)4IF[OYKCON;F[LH&J=G3X--:A"1=[!'W<;'Z3)S
M+*9DT4!&S:%6S4&(FI:!XRJ88)D.;8*!NVD:UQ0-H_,M@+2' CJ TOGJHD@8
M7]&WRXD36@2;:'%%) X")@C<&Z#U1J95^1R#;^LEG],R3FNHEN[Q?F+N "A'
MRR6NEN?AI11"!TW<>U'[;296P F22"A9(4I=9&SC$U^EHQ-_>$^MS@<3<3<
M.<U;GC/AR:0R1:+P69/;%\CMB\(GP.10IAQ*<?>5*AV*DVODC N70_1[*U0.
M$78'B'D6EI^/9KG^\^*_3J;?PC$QLSQ:/0N+Q??I[--?PO$)3HRVID@C0#I!
MMK=6]09:1, B:ENLC#'<=XYP0/2]#7D](.H@&%P/Q@?720= >X\DF6E:X9JO
MLR+Q%'R4.GE P1DH^@JN:(I(&;.:U4J_1J;I5G+&#;*&!]+A,N\ .$<IU6Y;
MR_>8D-8">8%O<'7&BS;9YAA3;=QHR'Y+"X'%#+*P++ED7-O[JJ4.V-KNH6I<
MCWEX& VF@0[0]&Z!7\,TO_CC:SU*)"O[=O49%U=D-C$I.AV4!.Z(+Q52 8],
M0[0R<(ED7--]UPKW!]46Q(W3D;4=MH;61P<0NTJ\4%+0MBQ!65V_<**[. O"
M5):TD1S;G'?M#IO!*WX;FJ2]9;P_0.:K<#R0#9I_Q<7J^[OC0.*8Y>KD?:TA
M+)G52;".Q^ "6%&;F'-2; P4EDAG=; \$4>MC,_=5/7@& T2LPTF^@[LS%OB
M)-1[N:\Q+/%]'='RMOQ&1K2*:Z)Y9M$&#1B2 *42@N-&@M568HK""=/&[MQ+
M5@^NT2! &D[X/2#I8L]],Y^E4ZM:?;=4A(<B&<4)4AH((3H()B"/LEAGVYR!
MW4I.#X[/,,@Y6-@=(&9#_\0&N^87ZHT+LIB!$=7UQY(36AZSBVT@LGE^#U[-
M@*G$G<39@1_S>AKB]'BZFN*2MM)U(<#G^3$)?5FWU=7W<]$8QE4)L8!9']T(
M3J(I,0!#PYG1UHE&Z<-M*>SD='V8(XPF:NG YESBZWHH$:1'-+6UMA#U'-E%
M<(RLI_4:;=0<M6X.L*Z..=I@X&Z@':*0#J!UEN%Z%[[7]-997.F-B5Y9LL(F
M57N,9,T]J_T1@XU6HU!XWWW=P[.+5^GI!E(':?N.Y.(!HN\#0(L3>NH-&4UB
M()*U<B D<:/J4G,V<#!:<)FC"#'<UXSJ( S=3M*XFUT[& V@@ Z0].++U^/Y
M=\3W>%SOM]S"D.(B,H[K1IV^#ASQX%&0F)S,@D5MBVA37O8@:>-&]XV0-:Q"
MQJZ4?H_?<':"+TEZS^;']-OU6)MO>+18U#Z U0M]\4<Z/JE-%*Z\=[:6Y%^G
MJ\_/3I:K^1=<G$GBK$_<!*TK3N1:[UM$K>:S$*/2X!*3CB7%E+I6M'9'>75#
M(L=-(PP,T:XTVH'M?#T/L^N.1"PV2*DR,,W)P4U.@3>6@U"N*.$D2M4H-+A)
MS+CYBD;V\5"A=X";J\G<&ZO &)^2UAF<"0J4JHWKLDR0BY#H8Q'FHN5WPU3Z
M7J9L\+8MC=$TH"HZ -8MSH+@/#&;'"!7MH[RD>0V1 5<>A8,K]-\VGAO>[IK
M@W=Z:6V.#A/YB&G59KOYY6.&H$F&T8)!5^J9>X$H5(*0Z1>*)V^OGPH^HHNV
MXV'/8X2HPR?/>M-R!U;R#IM_B2&N7.8R!+(%/)&@,QD$$PU(2U]S<B8WNC3^
M(&G=A+SMTKS#JJ<#O%V2VB2%$GUU(Z)SIG:Z1XBY3L#0,@8EHTG^OJ&G@VS'
MW<2DCW)4L)/(.SCEK&TFIZLOZQ+\6>T]4Y<"SE)E193@O#0> KD0H*(C+B0&
M<+PDE;6-5K4I7[^'J&Z"S'9H&DHE'=BB>R3$ D^BZ  V10E*BP(!#2.>BF2)
MOB*V,4T'GI,_1LC9#EL#*:0#:%UMT;"Y-*1,EJ'8 ,'EVJ&!8BR'V@"FHJ5@
MQL=[!VT>5-I^G9BQ[XT.H^>;]>P'";T#W%SJJ[RA7POI:PL]<'6(AY**.#'6
M@$XA2UM8BKS-)9OKE(Q=IM,$,0>)NP.X'.6\[GH6CM^%:7XU>Q:^3LGWNL36
MQ)E4I-'D\>&ZFLD0;\)8B@]$X!JST?*^AO@'G($_2-O8W0V:0&I@E70 LO>X
M"M,9YA=A,2-?;WF4TLF7D_6![',LTS1=3:(IM&ITK,-,26 L(I ( _ 0C'?%
M!)W;6*F':1LWP&L$LH%5T@'(;@IJ4M"2NZ@3!!4S+1,G(%91U=,L)#P@2VT"
MO)NTC!O7-0+1@2+O(#WP4% R"05#<-&!E/4L5*"G6)0V=JZ-BSJ+I%CS Y];
M*>OF^.=1TDZ'*Z<#L%V-+C933XY.5I_GB^E_8YZ([!A3+-<!GH'6G^40F2V0
MBT(6-/,B/T9T=YVNL7VL0:OK!U3!4VP-_FXM\\^XFJ9P?)61H?J$7WU$\Z;A
M]W#TF!W$R>WFV1M3FW$2,%-2$(J@357G6C]HG1%MUNX('<1U<E*YVI"_:(IP
MBQ7@74K ;#3*99_UO5-,_HXZB.^"B@<ZB.\B]"Z<\;OZ'&O'')>Q1A6L%I?Y
M6AUB-(6N3C/GD[2IS:V,I]%!?"<];]U!?!>A=X">VYH?)R%0"EF;']=-OR X
MYY'"TL"EL](PT>8XY>ET$-])R5MT$-]!XF/7Q6_9X=K%'##2NA*!EI22JL:Z
M<=U^31@ME)5EN_JII]I!?!>5[M%!?!?Y=F!F;HLMI-(V&P5%)$UT(P,G4@;$
MXI@.4OC4)@VY9^?>Q^H9/LBVM)^8.P#*5;!3R/%VL68JKX]\WN%B'4A.. 6)
M+%I&%E>2NR<$&6!G+4AR]T2(R;A&EP6WHZ^3?6M/%-P;R ^BDNZ =B,]80US
M6"B*$)IDM;E6:QT#S1(:)C./H<WLI@$R1(_:?V$P8!VD@DX!]6JY/"%.I!=*
M:RDABLI)J-_%1)Q@XBQB1&G:]!^_FZ;^4HT# VD/T7<*HJO3NA7W3AO(T1MB
MAP<(61B(F2N?N"B6/9Y9VG52>L.#V^9PVE<)'6#J4C7#W9NW\1:=)@O+7-BP
M%.OF+2PC;D5)IE7?\H>)&_L\=U!L#:V,OO!U8P\G*6&13)%3F&M:UD0(H<[5
M<K2Y!ZU$;C6-[FZBQJW-;8>G@X3?(XY.M_#,,3+E!7#R^D IERBP(',;G(HY
M&]K$>9NBN#L(&K<<H#5^]A!Z%Q/J;C!R><?V/BJ>LR;R10(5M0(?F0 ,SODB
MG"BQS4G(?51MA2/W5'&TK_B?R%G_N?B6\W)Z[X]^&^HEFR_TR,_T!]-O^'I.
MJVD63O*4_F2P(H!]GMVB.N!@&0Q4-O!J1G3B.37G9\+.VR)\I'69L4[QK.WP
MM?%@N>;T#4<*!YNL^CL(.M3$?:3WO2VGUYQ?5-DMZ_G Z^FR-N\J/J5$3F*,
M@GS&VH#&ZPR9.1ZR9E:K-KS>0]2X6= A4''=R@VE@0Z\K0%OUD]*SJYH+"3-
MP.B+U!"#XJ!0<E>$D=RWR<8/R,2XF=468!U+PUVX@^=W\4\'IERTG\XB:FVR
M(C@Q!*4#@C<Z0!WJ5 <]"<_;@/5.DL;-Q;: WC#2[\)*+I$(J%/FGM,2.9Y_
MW2R;-5<3SHQEQ3,P*J=Z05^ )]& Y@$9\U*PTF8$R;UDC;OM#J3ZFP/:!M)#
M!Z#Z5YR1C(Z)EZ/\93J;5OE4PWS&3HJ16Q(5L)1)4%$R"$HH<*H(1B$3-Z6-
M+_< 8>-ND6V -:0N.H#6#2%-F#,N&1<IBJ]7C52IMT(HO,_DCQ9:)#FQQCWY
MSD@9=YMK Y_#Y-W!19ES!C9N0 W6)RD[FR,Z*$Q7%I(!GYD&)7R)W!@M&LT:
MO868<0\6F_I&>TJ\ ]"\F<_F5[DX&TMXOJ988CSE>IU'4C!<L@>O2.'>(/)4
MK'&RS3GU@Z2->YK8 E##:J.#3>S5C#X+EZLKS%SFLLZ@8X$[%@0#+4P]W$(%
MGL@%)8-6)LI2?)N3Q6VH&]<%'Q@0\\;:Z0!QZU%C=XIMH@6/*5D!26HRRLE&
M"#%'2-X%D530V;0Y/KJ?KG']\;8H&U C'6R85PY$-IS0*GE;/H8_)E*@L++N
M_9RX4$4Y"([LOY8J9R9I)95F9Y-W$36NJ]X664/IH@.S171?<B*]-;HX,K*!
M5@&YCM%"+,: \;FF;D6VC0ZYKY QKL/>%CK[R[L#&W2%^*-O87I<KYM\G%\Z
MN3]M^?!+6$[31'C#7=$&9$X*E"$9!70"C++<*)3)Y39E-SL2.FXY5Q.'OJ&F
M.@#B61^DLWK'#1,I!241&: OOEY[2K2CAP#2%4G6F$L4;9(.MY(S;HU7"U =
M+O4.-KSK3#R?'I^L:K6:X"XS+4&;S$ Y^LY[4>H7J\A,>\?:!(-W$#1N:==C
MP&<?R7< H+]B'4".^>@;.0F?\,U)O4S[MMPH6=NL#J\M=U$94.@S?3$)HA :
MHBG1*NY$:N11[43F5F#S3PEL[;34+P1/%]3-XDD2E"C&.@IU8PUU:9D%+@3(
MX+*TF0M>VK1CV)'0[7)>[ ? X2"J>H)UKL_"\O/+X_GOC4M:;WE,Z^K5AS@;
MOK_5^1//@4JA* IN)%@,M8C!*O+BZ^PNJQ/*R#D/K;K8WTW5 $%G_<QWB_FW
M*<GOE^^_D19>S<[/P([2:OIM,X-J/9S@A%Z[*"6^Z.Z4(Z8@/'"?L'8?I(6E
MA04I,&:G,"7OF\AF&/H[:0=P*.INB5,?6[D=[-]7DT ,,9.;$2!S1_*KG5BC
M(>)]%H8EDXWR;3JT[9YT:W?>- (.[LW,[:*4W1'E-XB:X6J@MO#__\ER,Z/E
MX_P]IODL38_Q"D,?YUO*]U(OV"3K-3_(M76YLA'!2<] 9(K(HN!<RC:P;,'-
MR.=<XZ-[=(AT8';/DE:XOEU$WMQ:OI/H:0-C2D)F]8ZK"1(B.E[O2CO.%19O
MVM1*WD[/N(9X?)Q<[T=UN-(Z@-YSI">GZ4:-LWST9;Y83?][PXI%&Z*4>M/.
M73F5P7&*^TS1)B0EE99MRBOO(6I<>]D="(=27P=(W$PI^??I+)]5X4PD1H>>
M.9"Q-HLPM1&@B!P\-]K8PHNV;=KHW:1EW*J![G!WH+(Z@-OEI7+>?'GVZ=E\
MN5I.DM5%1(H7%><>E/?$B\4:0Y)U=ZS8@&W.7.ZC:MSJ@^X@.)@"Q^XZ2P)+
M%-0MZP7%VJ&B=J5_6RX=B+^:_38CY?Z^F*Y6.'MW$H^GZ6TA0FM>5G%-% 5>
MASO;.LM 0XC1@K.R<.X<(P?\H;3EX62,6WG<#38?69\=F%&2\*).A'Z.FW\O
MR?1TX-BY0$,DCR-G!5Z2+)6I$Q 39Z!+1!*TS4*:)D9U>QK'K;?I!L:-E=LE
M;(]2FI^0Y$GN./VV[E9<4)MLI  A*)XC![H.$+8:+,LD/4T+-;:YZ+$-=:,W
MH&B"C <!>*":#LB(?JH':XW ]VZ!7\FC?GY*T5E=YRRO2\6/EDLDGZ8X)5D(
M'B1*$B265-M]1E L%5T4D[2E/Q(<MZ%W]*83XP!T<%5V"MFSA?@N?*^KL"8?
M4EJ<T/,NQJU-C'$JNX2@57*T^2@*!R6+D ,&9P*/R3S6EK\-O:,WJQC7I@ZF
MRBXW^!=?OA[/OR.^Q_5XTLN\*1OJM%M!RU$)\KE%J'?@*6Z4-MN<<G(^/1),
M[Z9R]-O"XX!S(+6-'>3?9&S(%D:N-K$4M#B#J=?\N;"UA9&H(\.+C;54OESS
M5.]( C0E<_3KR2T1W)F6NS3!YP)_77\^6\K?)SKYY'.LEVDM+60E:TU#CA X
M,BZR22FUN8ZS-8FC7\09Q_@.H; .D+A]F<.ZE$&HG"$(+FM'. >1!4OR4S%&
M2;\6;<[<MZ=QY NLXY>,-%)G!]?'[N#LU>P;+G<0;O2N7ARH-6)&@W*2PLN<
M$A1MM3(BU;L#CPGB'>GO9!#0(Y64ME1N![:7@LK3C/91^J^3Z0*)?V)J]?W=
M<9BM*-:L0]C7'>\F7NHL(DJR!-6+CX$VE.P\.&^0IZA9C&W<@.UI[+(8M2F"
M;AS\-U%G%TFN[<4[<5QX89PAF>EZODPF(*PG-$MOF7(\!M&L'\&6-'996?J8
M4&VDSG[=A/,:B"V%FS57D1<#K/A:2EX">,<+",&9SS)8S]K<RAF&_D[&O#V2
MF]!2N3VX"0\534PD:F0A%8BAU-FQ&#>1;3#)"UF8UK$-6A\DK4NGH"E>;@R5
M&U)YG:%QS<#;KVMIO?@#%VFZK+T!"B\UPPQQW2#'90.Q#JJV&BFDU#Q8TZ8]
M]H.D=;GOCX7&PY77 1K?X]=3K_MM>3V???J(BR_/,=9DG\9UGH^9%$#E@A =
M\5%\<%RCTCFTZM%^.T5=IJ8>$WN#J.K08.ACZ\3I+1*=1"Z9U2X#RYX\=8^.
M+'S($%S!VD1%.-7LLNB6-([<OFU\=#929P<1466K_E^S#]_",:XKQ$ABTT3K
MH?[B:):OOG#IG>]P,9WGFZ<?I\=R+_Y(G^M9W7M:6R]*P5I4*9@3CJ13DJ1X
MD7$)T:,$41CZNK-HU<87?5P^.YE\/'2$U3%8GOI2FAB,-KF4P3)7NXQF#B$*
M,D\6)?J8='1MKFP=1'8G8YB[ OI.JMP;MU_7RXDDL!BFX\!A+-.V)B66#%EI
M4>\.98A((8(($G/R7G#1:%1X<_2V'_K<%WIW4>6!Z'TQ&^;\X</)UZ_':U&&
MXS-1OIJ5^>++1IEG0O7%RI)00XHBT\(D[R]R92 ;H:T+.H;<QL9N26 G0Z2'
MQF,+]72073B[P%NO]-;Q!E*GDD)A(+ V>LO90>#U*AJ3(5(4*UQJ5;-]A9"1
M&TNU4/8=TR;VD7P'P#D;8Y!(/!>':K-\'DZN)V^?2\JJR'0PI:I?4D19:]0L
M\2D%UUZ%$(-J@ZO=Z.QD<OG0QJNALCJ XFD5Y/JR39ZN3DAK%)&=5$I^.5F]
MF:_^ANM5-C&\,.XD0G;U',)+#4%FXK F-:SDQNM6X<EV%(X\X+(A2FYX=PU4
M]A0;CZ[3!<OIC-[P#1>K.G/[W1GMZ^.+,,N7^^)7)W?UO7&;TD.):M[4=%"I
M#=\"]>:C+YKV2D\^ 84C,K$Z6D/3+E\'JHO $BT:FZUO4SJT%7D'QS!G#_FX
MOIN;8XP,$X/,@P%EC "GO06.DE[QVB!KL^E?I:.;)J4#X>)&:+*_U#O8O<^I
M?W8<ELM3(1W],5U.4@Q1Q&R B7K/P#B$:+!ZQ&@<#TKY1F5V=Y+4"9+VT/-=
MD#E(Z!V@YS+]S^=?PG0V01,UK2(+M'1H*4F7:2EY!<6S@$5&9AH59]RDI1.\
M'*;DZZ[;81(?^RKF!UQ,<?D?=WH.OV)MA3^QB;$DF01CZ[&-)0_7.5N@1*T$
MC^M8["%':X?GC0N40U4Z;RO?#LS,^5+:;-NUY^=\5IW1]7+"$$WB%)]8AK&.
M4L\0,^W@MHXX#M*ZG-JTBKF7K$XNT@RX61TL_ Z0=(V'T^6FZIVW0/1KKA2H
M$F7MG.C!>E>'#7F?>9O++[>2T\FV=;BZKX]Z.ECV'0#H5G,J*&J0F2DP&#*%
M#T5"#"C(>B/)A0>GL(VKW-]F-H"2;Y24'BCQ#E!SJ1S[E $E92Q"9R!_CQA(
MR8*3,8%3*:(F 3G69O+(#5+&W:B&Q\MALNX +$<Y3ZOXP_&FT^]IMO;,=<M2
M:_+=0(I0&U$H#QY-@8!>AY11E4:=R.XE:]SBX^%!-)P..@#4>UR1/#"?S5H\
MY4)S9YS("HAJ2<O"4!A:NYW:Z'-.IO:,;G-3_79ZQBUX'!Y" TB] ^R<NX.O
MB9?U"=2DH#3!^ 39UY,GI1RX2!%%LD0Z6H7%-1XH=DY+)]<0!PRR]A-S!T"Y
M695[,]_^?GY\_'*^^#TL\B3P')01'G01)*U8+Z<;QT"S0DM$%&3NL3IJWDMH
M)]'8GKAXL,O0<$KJ (,W)V=:J[VI"=9D3=VI,QEPY!0V4/00G?#H&GE+>XXQ
M;86CIHJ_;3C/WEKHIIKYIH F6OEBC=(04]*T]#0'ARCK?'/,*4EE&PWEN4E+
M;QU^&\+I,#WTA:=Z0QOS\Y,Z;F!SFV6S6M[@[^M?+2<4.[C(N(.$-36?N8!@
M,X6M4G'O4/'H6AV[;D-?;VUZ&^-N6'WUL$7>SM5?PO$)7C!5K!6R& ;<*U[3
MO B!^0A8+-.\*,\:A89;D==;-]Y'Q^ !VNH7@IN%=7O3 (&6A>(RH+;U.A2+
MX&LQHM#1.J^"<]AH&N/.M/;6:'<D WFX'OM%ZGKYW<Z@-)YC\062JFVQE0D0
M1&%05#TY8YH9VV9XV<ZD]M95=QPC>K@6^X7I9B%>W-+;%"!5<;[!U=M"HBVX
M*?ZN[0*EC@7!^=JYN!#7/C %*081C>/D5C_J?K\]Z>/>=^L QHVTW &LKXSD
MNN- YO9!P)=7]7LD+2RG*_R BV_3A!NIU0E?GV;3S=3@(FWA&" K6SUXK\%9
M3NI)13FC%8O-3M0>A<%Q;U4]YA+I$3$=+*0K4^PF/.2<A8S@@A/U-)Q\,&X#
M:,R2"U5[)+DF<+]"QE:@]#\"*/>7_M[0^8:+.&^64S>*:R:-@Q*= J6-AE!=
M))V\$IJEF&V;1@U[YM39CX"BP]302Y.%6U*Y)3DNI8+@? !%+@C)Q#(P1J,1
M,:'%5L6[>Z74^8]Q1'.8(@:%TV#7/3_^VXMG;W]]=_3F;T=OGO]R].'5A[<O
MW[U_\>'%FX]''U^]?7.5^NUN:S[XF0=>MMR-YH'N2KY=? JST^G=%Y<\*\YG
M^=TE)LXG>Y/7='[_\]*->&%R5!F,#K61)S/@F8D04O+5!AD3VE0P#D+^H:;L
MEY/E=(;+Y7-<IL7TZ^GCR:^<+M^6RU1\)*7]<ES[\.J"23"EP:3"03'R&GUM
M329U3E)D+AEK<[*S.ZTCWX1_='Q>MX^-M=O?5?F'[-#S6LQVO&QA0L\^NK$E
MO96#K@PJUEZB)3N0R1)@3>WX&;0"6?N].9ZMSVW\ZBX,ZO5RR:.43KZ<K.=.
M/L<R3=/5A%'H5++W4)LZUMB)01"TK+GS.4<CA--M"@\?INU',)B[X.^A8M<#
MM==!TN2P#G@Z<F>+\02FVN4\8@*7$T*2(:NDK22.VUSO:-[,L%E1T?@H?CR=
M=Y':>7-2*]+?EO/A?1_PTUJ8DR!XB%D&X %U'1^%X$WFD 3W,F<TG#7*$=Y%
MTKAU1^-#<QA=]>=X?OCMUU^/WO_M[<L/K_[US:N7KYX=D;_V[-G;W]Y\?/7F
M7]^]??WJV:L7'_;Q.[?\Y /=SGWH'\CK/!T=7T\""8]IBA=(,UJS8)F$+)'7
M?C8%G) )F- Q8;;&FS:>TMTT'9P[G'Z:3<F3J)/N;CSD(@R3A'<*MB(D4Z.^
MDAQ%?4+64N/@DHPZ-NH.OQU]X_J) R'F1C9Q>-4\54-UQG4[@W7^A$<Q7+?S
MT]Z <9[#^K* B%81''. D)!V-AM84!0P%-LFN=C.@)UFCZX]X/OFZ\4J$?0?
M<G2@<7V]AY9D$$82YU(+4T1VH@WGV]'7K0';!3$WTGW#JV;L1DN_G75;7#<Z
MGGXY]TN?AU6XSAB&@DYS"Y$I!&4I? G:9)!&RJ *&:D<'K)>.S]UW&!S8"2U
ME7D/Z9#+4<]U7KRUNI8U0.*,0I"0(BT,GX 77>B'HJ1L4SYX'U7C1HR-+-5@
M:N@ 4K\M\6UYL5Q-OU"DO)PP<@%15W_0L#JE3=?KT]E L*'X4K2(C;*[5^D8
M]W))(]@<(.H.@'*:ZGB/7^>+NW=GXHG)(!%LQ%+[LM>60%*#3)IAJ7V">*-*
MDFW(&_=:2"-8#:^8#M!VFN=]* ]\?339FNE)X#86Y FB413C<EI>,14#!1%S
MMIZ'T.:BTB%4CWL5I-5.^5AJ[ "R'Q<A(S&S'B%P*D]B-2&Q55N ;IB*G/NB
MF ?+P_KR50*?2:Y<\T VWR9AVM2Y;T7>N!<Y&H%P>,5T@+9WB_E77*R^OSNN
M";]9KLOG:]T';H0XW A3KZ065TZ[JCOIB"_)"C/&Y.S;%#1L2^&X-R,:8:Z)
M>CJ W::(_F/XXSH?'*5RC&<P<7T;(WEP-::V/MJ06?$YIB8PNXNB<>\V-(+5
M(.+O $;O\1O.3K .J*^SGJM<_CI=?7YVLEP1?XOKW#G-;/!DFY5$^J*]AV!,
M@!2",-H&P4J;"[V[T3GR38A&F&NHJRZ0N$0BH'JASXG1X_G:2J^',BW/7(.<
M,3)-EIFQ.G;)!0->TUJK=\Z81Z>\;K.%;D'<R/<EFF%N6*V,?1#P;H&)?C%-
MX;B&.Z???EQ,Z>>4%B?U'N3R+/"YY!QDKT)M4^E4JN/%* )RRB5("DFF/&27
MKV53[C@2V._YVV'K29T./((B.C!JMU^O?7M60D]>!(E_^@VK=WH>;7NA \?:
ME;D6SM6QUVLS7ER6DGQ4+5NU5=N=V.V ^=2.%5IKK0-@GE4FO\/%FMOKZRPJ
M:4+F&CBKG>2\C.!1U(FRW"1,G'AKD[E[@+#M /?4#B2&U$8'X'H9IHMU/YE?
M,2Q/%G@1;E]GK 1A,X768 5/M4EP!E<2 _2B8) ZV^N3C0:"V=8D;@>XIW94
MT49#'4#O#?Y^262+^8R^39O"X]OY"XFI5&_#.1W);@>A(&8RWI&Y; R)V/$V
M:>!=*=T.B$_M7**IOIYJV>2Z@7K#HLG3SW^4DLG;>&E?,,F\8JD(\L%2G5HO
MM8904<*0(_ID2PIMAFLWK/A.GS&?'./;<D2?GZ?')]4%_8#I9#%=T7->_)&.
M3TBHF_30EZ\G9W<PKCL7ETJ0BTPRQ +:&;+M(G!PO"1R*Q*/11<6&XT@'YZ7
M;@LQ=T'BC3AD7)4_5?-YT>KJU:S,%U_6#SS@RO8 3WT44[L]W^T-L$8EE:=(
M6$9:_LK6ZZTQ*2"\)VVYQ)R>VI6;>UR5MXO-%/A7L\OOF,[2E."U&8?"/1;R
MGAFMM%R;M!<+T<H 0DEK6$;R9-H4LA]$=K=F=1=\[>!S#JS($0.BY6(U>5]9
M60^JU-[R%).$H"+M0JG6ZL=LP7"&UBE-(MOJ!BM]ZB7DT4_747?EL>.BYQ'5
M/#]4YCT Y70B5_&!Y^0B)*\+*)T2>&<CL$1"<-[+K+>:_KH]5,8<U'F RJXK
M?0_YC:SV7Z>SZ9>3+Z>$U]N(TA/?B)F1:\@4^"01N+:><R]--%L5CFRE^"N/
M'EGU^RAN/H04QU9_^.,2X0JYKWLG(3[6!GK907!:0$DV29%BX=M-6ME._9<?
M/<[5I\'4O[<4^TZ7WKM'OCZ?OY984#:B AU8J0,<+7@N%12O.#=D2W-L,RS\
M8-+'O7'W^-[).#KO .1WEH#^ML1R<OQZ6G!")INC]QHH*J9X(A@!41>RW3%[
M,@#6A!B:P'@+XIZF&[TG7+8MW]U3=QW \?;J@J/%HHJRLO;+]XNWO O?ZTOK
M"0;GAW9'R^7)E[,I'5^QWM]X/OTVS3C+[\,*)UB"5HHYX,*3&ZN+!B^4@\)H
MBW.2]C?;IMU6<]:>ILT>9BGTA9LGFQR^G$E?=Q%OGQF^\Y&/DQ;>CN/V.6%I
M<M3:6<C"9%#6<? J)ZB>3!UUQ75J4U/T% [E-FZ="['4&339*8H>N*>=C.D
M'JT1"7UPI8T7,BP?W6:-=T%@N\.XG57=@=-R(,^_?+_] ]99-Y]065Y'B]6I
M8K0_%@B6.U)2#-F$'&PC=Z4A4R//21\1J]>'$'4"G&[7T)OP!9_/OX3I;&*]
M",JH!#%EW'0L\:+.L-"1,>=L2JE1FZ\'*!O9H/<"H:V@O:<^.\#G7T.-)5:G
MF<R4?7$A2>"V>% *$2+60CN#-G,C3?)MKB%<(:-'Y.VKX?E0XNX *\_FLV^X
M6$WKM?TS$M9C=$[9B=8C.5,16#T_4R5I<-HG"$'29I$#<Z9-8?<#A(W<9JTE
MGH9420<(6Y-^.=-14X"GK'A;DD/.(48D/YXL-7@9).A<5$3MK2R-9J[=3=3(
M#=9:(FLH572 J@-]B8M,'@;'M;)DH#DCGS@7"<YD!T7*&D8&&5.;_EI#<3"N
M)?QQ(I3](/'TE\+1EYIEF6B3%5<R@RY8)9\\N2S!@(C2*>NC]Z7+=; AOT?W
MLC7RAH7_'C#H[^C@Y=&K]W\Y>OW;BU]?''WX[3W]\^;C7E,6;O^@ ]/\6U W
M4/+^_*3H^729CN?U9N!%\E3P7*PCUQ%+JC<92@&'4@++Q3"-NBC?IJ3[/JH&
MNZIZZ;,OM9#E3F3#,B3A:H_^0*A6F0,//ELAC2RV32^E>\D:UV@-AI$[[Z0>
MK(HG8F#VO^9WW\>U,#8-+_'="R?-.6?.2TB!UQ%!VD-PA(%HH]3&*&=,FPMJ
M+4W.A>M[^6 >5\NC67X]#7%ZO-Z!3V]FY[>S]W577M"FNV[,O];%Q;K(3'EO
M=8)4*Q:55Q352U'+3U5Q6$)I=7]Y4#8Z-FF[8/#N,\/'5O43,8$?3KY\"8OO
M\XM!8:]F)/>3=4W-F5C"ZEQZ\VL2.J!VHRD]+8QP$UD]AA5G2JO +2.T&D&Q
M@:/%4VCK-E$&'X-+P;4I$7X4QW'+!4UO>#.?+6ZN[TE"SE)Q!K+SGCR;;,BV
MI *27!K4V5D?VB0S!V.A8^N]"_;N=$@?5<4=9(;.&?_E^_FW_S;%16T$^/UU
M;0.XN2V%6+<<!%/J?J0C[8S"<4A>%.VCXK&TJ=O8CKY.4/FXX+D+PL-ILB=\
M7NI>M+S)W^G)1W11";[N6X0*%'J$P(A7*4J)@L=H&I4=[D1F)V@=$"=;M)P:
M1FD](?+5[.O):KF6&#\](4/%#?/)0M&1@4J^SE&0$;C&@$%&;1H=5MY#5"=H
M&QX*=X'N0+UT"C%QRHHD/R9X02)2]?C+(H-@10+M>3;<..38)@EP#U'CGB^.
M"[%]]-(IQ.0I*X*3H?<R@"&.0)F8P7-O(49;HB\NZM1F!OH]1(U;<C$NQ/;1
M2T\0.\ MOCCWC#%(Q8P![IBJ]?R1Q&LLI"P+<G)/2FH<@0S!1B>6LH] Y=%Q
MT<&BV/!\2Q[C8AXY<L\9:A"Z5F^5NL"M=5!\PL021Z7;'$0^2%HGGN3CP^9Z
M&<6@.NP E+=/A+N%P8F6*CEC"D1I BB1&'@M'86&+!C&HXJF30G0UB2.7.8S
M+#2VFNQWJ)XZ .#5X823Q I7* D'A6A6202(F@O@Z".)S7B6M^I/LS/*KM(Q
M<@%Y4R@=(/$.\'*G;"9&>J=$]A#TND;9*(B.C+M5TK+L$YGU1MV [R)IY&+Q
MIB@:1@_[ VJ^"L<M#K"?O_CEXSX'S>N_._! ^.:S!SJX?8YQ=8O^,0<GDW.0
M3*KM-:.BK<))<$DF[TNQTK0QMK?3<ZAIN/JI%Q45C"N7F!,0%0IB4S&(11L@
MW:D2"\\4M#\"FYV4P0R A>NV8 C!]U?*4E?C_L5[E_YZ *O0L#3O#CP4H71.
M64,P! 655( @-0/-,WT?=,G8YCRMC6VXJ-'Z-:Q.J]_?EM?SV:>/N/A2GWFM
M#(NK4@=B&V)=1U".U62;2J!+T<DXQTQJ8S1VI;1+:[(+>NXNIVN@JC[-S-"]
M[!_\S %,TJ/WH;\+:A)]\%F E):T;YF!@-[7T0LR&XZ,;=?)N!-#53_UHN+O
M-.7JA!0Y,D!5-%"PIB H$X&",ZMC=$SJ=G[:-6+Z-#<[8. VY^40@7<0$U?;
MN#JSC?0WFYX7PEM%EA:$R_6V&"O@96(@8DE6F&!Y:M/9X39JQD?-02J>#RSO
M#C%S>H!)L3E&[RAN%P)!>:?!9<GJ (:0.*+)V[4'/Q@U/=1+':[G!X"SA]#'
M'JU<?;#7\_/& $I89#I80!EYG314Z@BD#,XB1YU\QNNSNN\8F7SU<_O2^SYJ
MF@\CLPXLQ57KN5X#R:HB:^-0S2-)(L4(T>0"O/;$3U)@X&U.Y&_2,FZF?NB=
MY4!9=X>62ZU)4HZ$]%I02@*B+YR#%]R#R3:9(KALU7O[+HIZ\DEVU_2]P-E3
M[+WL+4=GAE(Y'Y$+R-XX4$PDB%FKVK@X&,>\MLKOM+D<];"[#*.JV_:7?>2V
MM\Z_X2+.FQB-U^>E&CK2CFN+ 7*KR)2*.@J!>04)@Q2N]IO(;6H.[B!HW .]
MMIO-?E+O;L=Y&=)9MQ*47L6B)42GR<^*+D"@G^L43%L8=R2X-B7Y=U'4D]W9
M4]WW0FA/V7=H@E[-")^X7-6&^1](19C?X2)5;7W""6?2"E;G4K.:;6(R@V>T
M!'-*1G)KE%?M,H[;T=B35]P":8/I9T#L#7HB<'8(,B\O3U8G"SR=,A&.3T<^
M''(G?J?/'^"D8#]>VIX:Q"RDT2Z!X;+0OLD$.,8+6,N"M=(EY]KM#8]S:E"2
M49JC!U]/Q!0W$KR. :(R]*]AY&G^?9\:[(*!;4X-=A%X=W[3.@(5@7O%@Z*X
MTQM04M8)=T+4-K*RB((VJL?PM_L\,=A)O0_G=7:1=7=HN12UAJB#$#X"QWK!
M4LD(SF8%Z)2P-D61TF-X0QWG=7;2]+9YG5W$WEM>QV==&%(T8$*=:\BSA."D
M X<F6^Z9N-$+Y4GG=792U7UYG5WDUD50=>L!6F;:69,0M"D9E,<,SGE>[Y,E
M%YPN0K=)!.]],/VHQP>';#,'R[N#C>:.P[>,)HD<"J"W9#I])',:O"#?+0AN
M8PH4U_U]'TSOI.?M#J9W$7HOF\RIK72&6^:< )$L)Z/K-80D/60I=/*19:]W
M.SOH88L90DWW'$SO(K,.+,5=::94;(RZ'J&I.N R"4T+(1O(ONA@N<B9/<;I
M=,>G!L.%,OM)O0/P7*XG_N7[::7Q]XL9@EPX=(+(-Z8N!97 E[)N"DK^FPC6
M-CJMOI^NGCS</55_R\XSD!XZ0]5%]?I[_'J:Z7Q;SI.?[[':;E+8V_)RNDSA
M^&\8%A/-"[-H)8BL$ZAJQ8-+B8"20BG6"LG;3%0ZE/+Q-\:A4'0/0)NKM#,(
M3XI61EB.4&]L >T9!4(T",6(X"T:$V6[(N(S*L:-T1X)6CN)NK]KLQ\^OGWV
M[__V]O7S%^\_O/@_O[WZ^+=]3J9N^91#AV<_0-= ITRU)\-E4+#@9# &@K35
MOV(&7,H.C+1,)2^E:311XBH=@PQG^SP_I@6VW'SRF_D*;[WI&= GM#4S)6M/
ME<(@NAA!)\&328$L7QN&MR9QW/WI 'S<.J9M<*7T=R_NYLK=_S+NG9\UN'5I
M>%'W&H8B5X$)IR!%52<6)(2@R;>0I#TN"[K"VK3J&]C&G-_V7 /[E^_/CL/R
MTD28F+3)/#FP,M#^ZJ*#H*P' J]-VIEZ:;V-9;F?L*[LR2Y8N/NZ[>$*> I6
MY$T=R%O'H!U00;/%IPYN6>ZGNXV-T6BRB[: $"G4MI.T3WE7P$D5R<DE8(DV
M9[N/8F/6J3"#PI5L#=B<!"CI+80<!!2G!2M"2M:(Q7N(ZLJV[(*!+6W+SH+O
M("S^<!*7TSP-B^\?PCE#ZW.7DK2,N7! LI2@BJL'LE9!49$QD\C/PS;IYCM)
M&A<_@RG].I@&T4 /4+H@OU8)O"T?%V&VI+56&RAL3G2,"YGS$*$DAJ!BG;?L
M. .E@]2T&TO;J W>P[2-#*YA0' =6L-J9.RCT&?SV8H^[QCSQI97]I9'GQ:X
M[E[]+,SH;U].5__]"1?A.->VDO,O7\/L^^DQ('&3BK4(NH3:5,63L;<J0-$B
M"6$SJNM#K^\X.CV,CI&!-C DYN/H9VPHOCN)Q].T%N/;0H^?SCZ=<F$<-]YC
M 6T%<>%Y;18D&)BLC0D<@^1I*Y3=^8B19Y\W!- P4NU@*WS[#1='Q\?S507^
MVZ]5-J>,A*P4DN6NV?0$BGXBD,<"'EFP(5GG?9O^8W>2-.XQ?B,X#:N($1&U
M7*PF[\/LTZ86RF7:[966U3K6D1PA@!<HP5@?A--1"[/5]0[ZU$O(H9^NH^;*
M8T<V. /[W?M+M <8G**719=1!@8)3;WC011[05PD)Q/*F(2+6S4%WAX(8SHO
M!ZCLNM+WD-_(:O\K3C]]7F$^(E,6SAG0F)G7T8&(ALR7R(1\7P(X4VN?ZJQ=
MMM65EJT <"L)(T-A'T7.AY1J!V[&^HKHVK>N)O%JU.BBL#* (&>:]DRK(2;E
M@<RBD2R@4+;-C:<[21K9S6B5O!E$ QU Z3+]IWZ7=M)R1AP4C+7AN4+PD1E@
MSNB(G+,L&TW&N$'+R#'S,$J^/OKB,(F/'0%_H/ ,E_]!,3]9T-64%M*[,S+6
M+)WU;+&*"VG)/LM .[8*=8!'EL"TBD*3I\UQNZ3+=L\;%RB'JG3>5KX=F)GS
MI;3)$-4$T'Q6RPW7RXD'HV+D)!V49(F9LN E5[2PBI-2Z<@PMMVU;B-K*TRI
M)[MS':R)#F!UC8?3M<>MT,@-@I$^U@N*"B)*!(N&O#I.CE[38]YKY'2RAQVN
M[OG0LN\ 0$3^E_GLLF&5Z#F99PO%>PZ*2U/ODDC( :,T6K&HVXS=N4%*#\?F
M!ZGWNN-SD*Q[ ,MFF_]KK5R9K=XNWM=0<K..T!NF66V!ZFDW9K%0_(BDY:P%
MDF"<5&U&&=])TE;@T4]M\QI& [U"Z72-6952J&.LI&:R7K#PX)2SM?I-!!8M
M^7EMMJ][B.K"OSY4[=N :0\=C!V17;*KI[R<FM<BG)(: P3AR%C'4 ]0E 1'
M^WRFL,0;>^VVRYT'W[<_H4-4[*._^=#"[,? K!EY?7ZST:*+(M8Q=CG3AHL4
M/]8.AD"K1&?,+#C>IDW8K>1L!1_S1/>H R3? 7PN'\^>5/S3#Y])K,M7R^4)
MYE>S2\>U$T9>G$CUOJRNI4K"!/!&TMJ+4=ABF,!& ^EVH;(+6W4(*.ZI\1I4
M0WVA[]E\MIR2;M::>H\)I]_J;.S+S"E'T8)=W_GW=>PG4^ 9!2:.<Y^Y+RF)
M1MFC7<@<]S"]*?X&UM'8_M3=G%778CK[=)6UE)A6Z#+D.J1-"=HF J>U%0N)
M5GBG6>1;>5F[/7?<<[7A\-1:Y'V9LW>+:<)WN%B;ZDE1"A-YJJ>U2#(;B"Y$
M8++0*X75T<.M+=<5BL9->3<U4OM+O@,$73T"NKS/3R(W3BL9@%GA0%FCP1DL
M@/0Z2UG+8-JT-+B;IG%S3\.C:"#I=X&C>4+,RY<DM<I!F"5\N]BLDDW"=V*2
MC)EC!",% V7(RGI,!ER.7C+D(<8V(>+#M(T;+[; U:#:Z !?#SF%9'\O[^,B
M"[2V>.!:69)@". $#R"$5YB=XYGY43SWJW1NA3O[='#74$L=8/ V:WUTLOH\
M7TS_FRRV+S)Z:R4$R24H5_O2U",H%1//N:"E>.31]LL+NK;"F'LZ&!M0"]UA
MZEU8D)E>C^GX2S@^N? J)6/"US$@6M2Q5]9S6BDV02'?,DA3<GH4;-U%WU88
M\T\58X-HI0.LK9G9N)?/3^I5*&)D.L^;);0I"UN2RMZ62R5B'S"=-G*;<.XM
MJX=A+M51]25%B%9H8,:J4.JXF-CH^O9!=&^7GF5/!YR/J,8.0'MGN>+E:.FW
MK_/9!><3[Y \VU# Z3IY.,1$;JT/$!/SW!59BF_3DW0/8K>#YQ,Z/FBML+&3
MN'?7SX8_IE].OKS]?48/^CS]>C%HZ^7\^'C^.ZW42RR'7#B3VI.(+<7W7IEZ
MX%L/@=&AECF6ZY6I=]\='X">[6#X!$X1QM)1%Z;RO,+@AEML259.1@N6R^H,
MYSK^4BHP1>J0E='&M-F\[R%J.\P]@9.&H14PMHD[._;]RWR%RQ>SU71UO*[T
M?3E?O CI\YJW?\/C/!',<:.$A&CJ%$$G!3G VI$#7(HKZ+3"!UN$[?3$[2#S
M!,X1VLFY!T-T6_W4VY/5<A5FF4SL)#M?D%D#O!Z-*%=HJ_?*02BF^%@2)FS3
MM><ARK;#UQ,Z81A4%;U"Z\4?M(U/E[@^B3O_Y?+TMTL^,4*Z8-$#$ZFV/#)(
M_B7MYLP*P8O7P9DV/3+V(G<[$#ZAXXCV2AM[QSRC_NC3IP5^"BM\-5M1:+Z<
MIG7&Z/*"*SDCJ\52G*T/]IB 0"_5F?.:>$PQN^WN+V[_S.T ]03.&5K*^BFT
M9+T8$'S)U7Q/SUE\PUSFB\W8X+,3OT'[MN[WZ,&;NPX@@38=8%DD+&=GP=7V
M(<JE#,Z( $QSKFR4!1N-77N\#K \Y1BYRK1.><W2< 8^:8IH@I#!>2S.M$FK
M/94.L+M@8)<.L+L(O@,?[>CWL,CGT_:DLQ)1%-!>YEJ@&<!Q[R!GH:UTQ237
MIHSH"AG]=GK=2;GSH23= 4S6X>TO88GKKHTX6YZJ8U&;\:PG!OWR_>(][S93
MA-8<7[ ]R^^.P^S2"%E+8;%!"I)-G1ZKDA+@C4"0Z'5.Z$(H;0Y*6W S+F@/
M -=UVS:VICM ^]4[7\EC1*$2)&,E*$[QMY=H(2EKF*@W@D*;!$A'M^S&1\5\
M*!6-'7YNV=I%E&"#3QQ*<0A*I A>*P6R6"E<LO3J=NG: 5OGM.ORV N\6FFH
M Z-V6NEW(=XJKK,^0@6](I'4:A@2E6$% F,1F TN\!"=\XWF1=Q-U,@MXWI!
MY-#JVQN)M!;B? @#>''0MCEX>WF6"=AT5JOB6YZU!HF1H2.>(@NV7M"H#7N9
M!\OM^K37^>OCH.XP@ML_<^1^3[W KJ6F.C"&+[Y\/9Y_1[QLSX.(RCB6(:&D
MX Y%!H>A "?Y1)><9*E1PZB;Q(S<N*47% ZEKE&-WOVI]<2-2UIQR#[7$C^9
MP%M=_5?+%?*BK&]ZO+I',X91FGT?DGHY7/(=F*Q+.?1GX>MT%8XW1ODLH?[R
M>D)]8I67)>D,0D5/#.8Z4B,;D(8GGD,)F3>"UJZD]MB682=XW%U<U$!7_9U^
M;<Y[7KUY]N+-QU=_>?'N]=&;#_L<9=WZ.0>>2SU,VT"'3!?3:FLY]\6^^1Z/
MZW6$9_/E:KF&0;RT:R[/#R1XTC%%84&+=7%'<+0_:@3N!"\8'&>Y3=7?870?
M:M:V?OIE7^/2)$]K:X]V<CS1U>+/Q!&BC[0YH$[18\!@V_3].)#P<4W>(V+U
MNFU\3(4_#4NY_PCH>SZM@=5L. ;Z0#PJGVA;=@((?0@JBPBA> 7942C@?6;"
MM3GM'M=V7O*7SY]QE0IZSC2M3O.6%)-=>^6WV92H2:OIM^GJ^UJ]%^M,&^UE
M"AZ,,-7A3A2O!;3DH)B4&%*\+YO/J!Z<JR=M=7=!^3TE"^-"I8-(ZIHL;B0Z
M-B/HUN/"[N*8]C@LWB%D%M9]("/$:!5HF10FS[ARC8ZN#Z9]W!"_GR706NU=
M ?T\@4;AYS3A'0F^X_5'KN^COL<T_S2KJ=_-C=6U8BX)0E&TBD*!#;$FWPP'
M[YF@P#5H;:+D)37JMM>*I7&/F[I8%F."Y&EXZD<Y3^LGAN-7LS)??%E__ &E
MNSL_HX%7OSU/??CZ1?(L1$9@NEA0W'F(BO#EK1%>:F>3&CG@?PQ??Z_3F4TF
MW3&)N=0+:NA"+9;1X(LO8'.,1@?IA6\SIF P%IZT%[\+?G=U8=J H -/YNPL
M<3-W323A(\]05-04;F0/(64+,?NBA4K>ZS;G&I>IZ*9(^3&!<+WUSKY:Z0A1
MIZ?3F1=A4R#/7JCJ03&B/CH':'263.BB39ML1T]5Q/OK\PY@["'<L<LS/_X^
M__AY?K(,L_QR6E:(L\W%D5>SVGQB^@TOU5UAT@S1:2AU K$*+D.4+-%WUB09
M=&(V/.0"[OK0/A"RCV+GCR#E40L]K@ZJSCXIGR.M'^E,;2*1( 169UMEBYH%
M$?A6E\R>Z+3V$;:E_>7?T6QW+9.(TI"=]:Z<WO$7U@.S6!QW%,[+K8XRGN)L
M]YU4=L=L]UWD-[+:?YW.:H.CLW)RXP*S9->*K9=VDDG@G<C$/.?2\:RS'LY>
M7'ET'[/<=U+<? @ICJW^37^KLQINP[P+EM7K[[25^I#!>1/HB[;1("\F;)76
MV$[]EQ\]SI8QF/KWEF('0<CE#I"G)8^_S:;_=8+/<9D6T_59Q-HR&I6#KA46
MWGM%VV'.$!1QJ*,M(F0K1&IS8WU;"D>^K=%%.-Q$FSVB]%($8')DCI&45+U^
MIXH2X'01D%+RS!53#&_5J^Y.HD:N)FV"@H>@MJ=*QHZV?YTO\./G,/N(L]/V
MCG^9KZ:S3YN^0NO"7#PKS3VK^]>Z8$U$6$Z;NW))0JB-Z+UBQI7, I/7Q@7<
M$73O_NS.@+6OSN>/IX .K-?5J_%(*$@^<O(/&2TZEPM$ZS0(FR0+GM.7-H.]
M=^]PT>Z261>[Y?YZZ0!436Y(!<:L*4J#3LA 25J_ZUOLU:?-0@CTK29H_N#]
M,'8"UV/TP]A%TQV@_;;K=RD5KE*A78#5.\>.U<%[QM,N@"E)SI77K E8][TM
M^;1Z8^R$D"UN2^ZBKK&=PELK3V>UQFA=GS)+&TG>]K93;IU065KO@?FZX(LE
M[X2SFA7PLD@G13;;-6P_F)0?L*_&/M <0:^]V<U-9>G9<J0-24@N0*IZFS4S
M R[6#4J)F)7FW.O4WGI>)ND';+<QF W=6W4=8/!!R=XEV-?G-V%E*)XDZ, +
M5D %R2%@[?Y:LHPF""-2HUZ2!],^<A^%+@*M1T; V-[#WNP>G:SFM?HUO9JE
M!=)O7\W.FOY?GQ#Q<KXXN[E],95DHK*URB4/!6LF1JL 3MEJ(WP(&)06>LN6
M76.QT+DC/3!0YT\.-4]Y/UE_^0OY=N=3T/A$1\^2C0Y$JK,R4&@(67$P,0>5
M R^BC)3QV(&+SEW\-HMF=#CTLA1NW*2\R7N\SON+/[Y.-\-V-YQ/1/:"F$?@
MLM;1.>W .<\!C9/UEIGFHM&XQJ%8Z#Q\>(1%\.A >,HKX-W)(GT.YP-%+O7+
M.=T9)[+6E2J;0#I-'J^I11S,(8B2+)>&9<;:Y!?;\=1Y:\%.U\BP4'FRT<DM
M8Q _$NZ7G^?'>6*$L<'7V@$I/"DF4'C(K(#@C)+),)W%=OG.)N1UWLRPQZAB
M,&WWLDGL(X2S..KBANJ-28U)&">XK&U'59T[Q10X:2VPR )MHXR1B/H*(!YF
M:JOETFRB6 _;1 =@><KKYK0D]CR%?1+/"\_>AQ62:4J\>.' 2$/V0]H"/OD(
M+&?CO2BVJ#8U,*TXVFK%-!N9]E17S) PZ6&Y5)=P,['\^<GB/*NPL0)7CG/.
M/<KC,%M.N'8*LY6 BJ(MQ13MIL0Z&,[09,FD;=0E=4^"MP*[^U'!_@A*[@'+
M^TKY[!;E<K4X61\KO5U]QD4M\#QM;/2OZW&,KT[S#7_%6N:)^>@;+LC%7/_R
M.:W]EV&Z6 ]HG @3,"89:OL6!BJB!Y<1@<*&1 :@:(EM#JJ[$<%6Z\W_J.NM
M%RWL!,0?>@77G#GF,\%]G*_"\864*/8K)24)6F $92U") ,'&I/FQ2EO<*21
M:DWXW>Z\DOW/XAP+8QVLQ*VZFKVI=RLJSYNA)FN.+_^^-O5Y,U_]#5<7/<\N
M/FGS1]>%.(G9JK29PR,L*/*9P6OZ,2FIN'(^"-7&LQR-Y>W6XX]60#"ZV'="
M6@=+<O^TZ'Z^@S-1%2$DY'J6IG0DB\6+ ,D"9[98+-OU5'B\7;&AJ\K_IQ3A
M\5'5P:)K9YTN]<V=1.&8]Z% ,62$E"@&?)#U5C\C.Z22XZ5-)<.CL+?= OM1
MRQSZ0]"/O*PV9NCE?''Z4GT?GW 3M#?:@<ZD1!6C@QA"!(Y9NQR=2:SQD+I'
MX7.[A?:CUDITC*FGT:?YP\F7+V'Q?5YNNTL4KEPYBG==.3IK 3]P>^<6I#7H
M"MU<@GTTDTZ*8>"&W#?/ZN0*C1!D\6!1N.!M+.Y_FDG?>S'%Z"R$KM.80KV1
M%\G_C3HP0&>%0N>"+HW*]/ZGF?2.^&W73'H7$'3@LEUM#J",RJ+>$K2":U"I
M-@<P/(-)/DIT2J-MXU'MWA'D";23W@D*]W8$V44O'8!J?\'=<X.5Q61#<:9.
M2J8UGLA'"\DRB!BETL8$E<HXB:LGWA%D)W ]1D>0730]=@WSX??X:=M*R68.
MKB:ME2?)QZPH[&!1!1:#8LP\Y%P_8G^&I]4Z9"<H#=N?81>]/@6;_7"8SQS6
M+J,:&+.2.$ZRME2I-7-%:ADY"5V/8Z&'N1O_!%J%'^)R/#("GC+F'RP:.$](
MO9\?'[^<+^H?38KC-@B*2'+R)!TN P1D&I)25B25I;!/K2#E-CX[WT8&1O&C
MU:$<#*F_CP6WN?LP2<4SJVR$X$IMGZ\E.$7N;50V):;1YSQ2M# 4BT]TF3T"
MSA]_2>X!NKU7X]=-E?<J+%:=K\FK10238D..DCG0@C2G,@O@2T@0BY<9778Y
M/NWRZ2?:_.)'6I$'0.Z'WAZO%K%.ZMBR0*8*A-.U&UPT)))D29?&&!F4DKZS
M6V\[<OA$6W#\2$OQ ,CMOA3]9BG.\%,]*?KX!%8D*:_@]+*$E,C*!>E 6.=
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M6_WA$P\ZIAUT%^P,SNPI N=LN;P,BTK*RV5:UW=FP6FL;0JA<HQ(DK6Q;C+
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MS!QY?=NV"%<;2QLFA[0[4]=JO"6XV\*@+%<9P$3;.A2&4C&K@*WV8YY">4D
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M?03SX(=+Q5_W&97]H.OT3U!+ P04    " #'@*M42;FPB$H(   3)@  %0
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M6@X:N_0=H2DC09,5=]?GW=Z ##_VR%6O<SWH#_N]*]+[O?.Q??YKC[0[0W1
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MS4&R5$@%(H ^IT02&(=,DI3EBOM9!4X2WX*R5MG=.? \I],7<4J2N7ER.WN
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M%V2+[^*ZSEP<'OX#4$L! A0#%     @ QX"K5&ZO[12M;P( U&43 !$
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M &5X:&EB:70S,C$R,#(R+3 S+FAT;5!+ 0(4 Q0    ( ,> JU2E1^(=_P4
M ),<   5              "  1H0! !E>&AI8FET,S(R,C R,BTP,RYH=&U0
52P4&      H "@"6 @  3!8$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
